*

mánudagur, 22. október 2018

júlí, 2007

 

DUBLIN, IRELAND--(Marketwire - July 31, 2007) - The SMS Forum, a non-profit organization with a mission to develop, foster and promote SMS (short message service) to the benefit of the global wireless industry will disband by July 27, 2007, and take down its web site by the end of 2007. Originally founded as the "Short Message Peer to Peer FORUM," the organization changed its name to the "SMS FORUM" to involve all sides of the mobile telecommunications industry in 2001. The SMS Forum fostered and promoted SMS for the benefit of the global wireless industry, facilitated easy development of SMS applications and services and provided access to the SMPP protocol specifications. The SMS Forum served as a useful tool for the industry through its workshops and its liaise with other industry and standards organizations. Since its inception, the SMS Forum provided operators, solutions providers and developers with an important platform to exchange ideas and present solutions to the challenges that the industry faced. This process has been very effective, and the maturity of SMS means that the need for further promotion of the standards is now no longer necessary. Members in good standing are encouraged to login to the web site (http://www.smsforum.net), and download valuable tools such as the SMPP v5 protocol specification, the Mobile Message Application (MMAP) protocol specification and the SMPP client test tool, prior to the removal of the web address. NOTES TO EDITORS The SMS Forum was established to foster and promote SMS to the benefit of the Wireless Industry, and to manage/enhance SMPP with the intent of providing a robust worldwide standard. The Short Message Peer to Peer (SMPP) protocol is an open, industry standard messaging protocol designed to simplify integration of data applications with wireless mobile networks such as GSM, TDMA, CDMA and PDC. The protocol is widely deployed in the mobile telecommunications industry. Contact press@smsforum.net for additional information. Contact: SMS Forum press@smsforum.net


 

Aachen (Germany), 31 July 2007 - The biopharmaceutical company PAION AG (FSE PA8, ISIN DE000A0B65S3), which specializes in the treatment of stroke and other thrombotic diseases, today announced its consolidated financial result for the first half-year 2007. The revenues of the first six months 2007 in the amount of EUR 2,285k (prior year's period: EUR 2,868k) resulted as in the prior year's period exclusively from the reimbursement of development costs by Forest Laboratories, Inc. and H. Lundbeck A/S. The reduction of the revenues is primarily due to lower reimbursable costs of the DIAS-2 study in the first half-year 2007 and to the fact that since the direct inclusion of Lundbeck into the contractual relationship with the contract manufacturing organisation of Desmoteplase in the second quarter 2007 Lundbeck directly bears the proportional cost of production development. The research and development expenses of the first six months 2007 increased by EUR 775k to EUR 9,632k compared to the corresponding prior year's period. The research and development expenses of the reporting period contain a milestone obligation towards Schering AG as the original licenser of Desmoteplase. The milestone obligation was proportionally captured as expense and did not have a cash impact so far. The whole milestone obligation amounts to EUR 3m and is recorded as provision. Due to the out-licensing of the development rights of the substance Desmoteplase to Forest and Lundbeck EUR 2,632k thereof have been recorded as expenses. The remaining part of the milestone obligation in the amount of EUR 368k was capitalised as intangible asset. Compared to the prior year's period the general and administrative expenses in the reporting period increased only slightly and amounted to EUR 2,452k (prior year's period: EUR 2,277k). In the first half-year 2007, with EUR 10,932k the net loss for the period was comparable to the result of the corresponding prior year's period (EUR 10,777k). Special items like the milestone obligation towards Schering, present value adjustments and restructuring measures, have affected the net loss of the first half-year 2007 by EUR 2,326k, net. Mainly due to the net loss of the first half-year 2007 the balance sheet total as of 30 June 2007 decreased by EUR 9,018k to EUR 61,032k compared to 31 December 2006. The equity ratio as of 30 June 2007 reduced to 57.3% compared to 31 December 2006 (64.9%). As of 30 June 2007, the cut-off date for the period, PAION remained at a solid cash position of EUR 49,055k. PAION employed an average of 86 employees in the first half-year 2007 (fiscal year 2006: 77 employees). The current reduction in personnel due to the results of the DIAS-2 study will have an effect on the average number of employees only in the coming quarters. Development in the first half-year 2007 At the end of May the results of the Phase III-study DIAS-2 with PAION's drug candidate Desmoteplase were presented. The study showed no statistically significant difference in clinical improvement 90 days after treatment between stroke patients which received either Desmoteplase or placebo. Thus the primary endpoint of the study was not met. However, with respect to safety, Desmoteplase met the expectations. In particular, the unusual high clinical improvement in the placebo group is not consistent with previously observed patterns in the Phase II studies previously conducted by PAION and large-size, placebo-controlled acute stroke trials. The absence of consistency with previous findings is surprising. Currently, PAION together with its cooperation partners Forest and Lundbeck are conducting in-depth analyses to better understand the data of the DIAS-2 study. As a first reaction on the unexpected outcome of the DIAS-2 study an action plan was established which, among others, includes a significant reduction of internal and external costs. As part of these measures taken, 25% of PAION's employees have already been notified about their dismissal for operational reasons. In addition, the preparations for the additional confirmatory study with Desmoteplase in acute ischemic stroke, which PAION jointly planned with cooperation partner Lundbeck, were put on hold. Since the first quarter of 2006, PAION is conducting a clinical Phase IIa study with Enecadin. In the second quarter 2007 patient recruitment for the first dose group within the study was completed. An analysis of the first dose group is currently being conducted. For Solulin, PAION currently prepares a Phase I clinical study with this substance which is anticipated to start in the fourth quarter 2007. Outlook The future development of the PAION Group and the financial outlook for fiscal year 2007 largely depends on the results of the detailed analysis of DIAS-2 data, the decision of the cooperation partners regarding the continuation of the development programme with Desmoteplase and on the strategic positioning of PAION afterwards. At this point in time, PAION expects a net loss for 2007 on a comparable level as in 2006. However, deviations could occur in relation to events and measures taken. ### About Stroke Stroke is the third leading cause of death in the industrialised world and a leading cause of serious, long-term disability. In the US alone, 700,000 people suffer a stroke each year, and around 20% of them die within four weeks. For the US, the American Heart Association expects the financial burden of stroke due to in-hospital costs, long-term care programs and productivity losses to be approx. 63 billion dollars in 2007 alone. About Desmoteplase Desmoteplase, the most fibrin specific plasminogen activator known today, is a genetically engineered version of a clot-dissolving protein found in the saliva of the vampire bat Desmodus rotundus. It has received fast-track designation from the U.S. Food and Drug Administration for the indication of acute ischemic stroke. A recently completed Phase III study with Desmoteplase did not reproduce the positive results of two Phase II studies. PAION and its cooperation partners Forest Laboratories, Inc. and H. Lundbeck A/S are currently conducting in-depth analyses of the study data. PAION in-licensed the exclusive world-wide rights on Desmoteplase from Schering AG in 2001. About Enecadin Enecadin is a substance which may increase the survival time of affected brain cells and therefore may serve to reduce neural damage within the course of an acute ischemic stroke. In 2004, PAION has exclusively in-licensed the neuroprotectant from Nippon Shinyaku Co., Ltd. for territories outside Japan whereas Nippon Shinyaku has retained co-exclusive rights for Japan. About Solulin Solulin is a thrombin modulator which may act as an "intelligent anticoagulant" with anti-inflammatory potential and which might be useful in preventing arterial re-occlusion related to ischemic stroke and other thrombotic diseases. PAION acquired this substance from Schering AG in 2001. About PAION PAION is a biopharmaceutical company based in Aachen, Germany (listed at Frankfurt Stock Exchange, Prime Standard, ISIN DE000A0B65S3). It aims to become a leader in developing and marketing innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need. Please also refer to the PDF-version of the press release, which additionally includes a table with the key financial figures. The complete half-year report will be available on 1 August 2007 on www.paion.de/reports. On Wednesday, 1 August 2007 at 2 p.m. CEST (1 p.m. BST, 8 a.m. EDT) PAION will host a public conference call during which the results for the first half-year of fiscal year 2007 will be presented. Participants may dial +49(0)69 2222 2221 (Germany), +44(0)20 7138 0840 (UK) or +1 718 354 1362 (USA). The conference call will be conducted in English. No pass code is needed but please state the name of the conference: "PAION AG Earnings Call First Half-Year 2007". To allow for smooth processing we suggest that you dial in 10 minutes before the beginning of the call. The conference call will be recorded. A replay will be available starting approx. 2 hours after the call until end of day 3 August 2007. The dial-in details for the replay will be published after the conference call on our website www.paion.de/investors. Contact Dr. Peer Nils Schroeder, Investor Relations / Public Relations PAION AG Martinstrasse 10-12, 52062 Aachen - Germany Tel. +49 (0)241 4453 152 E-mail pn.schroeder@paion.de www.paion.de --- End of Message --- PAION AG Martinstrasse 10 - 12 Aachen Germany WKN: A0B65S; ISIN: DE000A0B65S3; Index: Prime All Share, CDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Amtlicher Markt in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;


 

LONDON, UNITED KINGDOM--(Marketwire - July 31, 2007) - Barcelona and Portugal playmaker Deco created some of the most striking football imagery ever produced when he recently took part in a photo shoot for Umbro with specialist underwater photographer Zena Holloway. Deco was flown to London, where he spent two hours showing off his best moves at the Pinewood Studios Underwater Stage usually reserved for big silver screen productions such as James Bond. The idea to shoot Deco underwater was based on the fact that the new Umbro Ultra SX boots, which he will be wearing in next season's Champion League, the first Umbro boots to feature new Outdry technology - letting the player's feet breathe whilst creating a barrier against water entering the boot. The finished result is quite simply stunning - the water allowing movement and lighting that simply could not be created on ground (images attached separately). Deco Shoot - behind the scenes: http://www.ccnmatthews.com/docs/deco1.jpg http://www.ccnmatthews.com/docs/deco2.jpg http://www.ccnmatthews.com/docs/deco3.jpg http://www.ccnmatthews.com/docs/deco4.jpg http://www.ccnmatthews.com/docs/deco5.jpg http://www.ccnmatthews.com/docs/deco6.jpg Editors Note: A photo for this release will be available on the EPA picture wire via Marketwire. Facts and figures: - 1,200,000 litres of water were used in Europe's first specialist underwater filming stage which was cleaned especially prior to Deco's arrival - The tank is 6 metres deep and 20 metres long and has been used for many of the water scenes in the famous James Bond series - The water was heated to the temperature of a bath to make sure that Deco did not suffer from the cold - 4 trained safety divers were on hand in case Deco got into any trouble underwater - The ball used in the shoot was filled with jelly to maintain neutral buoyancy making sure it didn't sink or rise to the top - Deco used an eye bath full of milk to stop his eyes stinging after 2 hours in the water - Between each shot he returned to the surface to get a breather and get instructions about the next photo to be taken - Over 50,000 watts of lighting was used, the same amount used on underwater blockbusters such as Titanic and The Abyss. - One member of staff had the crucial roll of sitting on the side of the pool for the whole shoot bobbing a float up and down to create the waves! Zena Holloway is one of the countries leading underwater photographers and has a deep understanding of her medium as she has been diving since childhood. She delivers remarkable images, combining highly technical aspects of underwater photography with superb creative direction, more information can be found at www.zenaholloway.com. Contacts: Jonny Fozard 020 7907 7269 jonny@exposure.net Jack Lamacraft 020 7907 7267 jack@exposure.net


 

Pennine AIM VCT plc Voting Rights and Capital 31 July 2007 In conformity with the Transparency Directive's transitional provision 6, Pennine AIM VCT plc announces the following: The Company's capital as at 31 July 2007 consists of 13,907,160 Ordinary shares of 10 pence each and 2,836,269 D shares of 10 pence each. The Company does not hold any shares in treasury. Therefore the total number of voting rights in Pennine AIM VCT plc is 16,743,429. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Pennine AIM VCT plc under the FSA's Disclosure and Transparency Rules. ---END OF MESSAGE---


 

Chrysalis VCT plc Voting Rights and Capital 31 July 2007 In conformity with the Transparency Directive's transitional provision 6, Chrysalis VCT plc announces the following: The Company's capital at 31 July 2007 consists of 33,165,988 Ordinary shares of 1 pence each, 536,072 'D' Ordinary share of 1 pence each and 601,376 'E' Ordinary shares of 1 pence each. The Company does not hold any shares in treasury. Therefore the total number of voting rights in Chrysalis VCT plc is 34,303,436. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Chrysalis VCT plc under the FSA's Disclosure and Transparency Rules. ---END OF MESSAGE---


 

Hamilton, Bermuda, 31 July 2007 - At the Annual General Meeting of Shareholders of Dockwise Ltd on 30 July, Mr. Adri Baan was appointed as Chairman of the Board and Mr. Rutger van Slobbe was appointed as a new member of the Board. Mr. Adri Baan was a member of the board of Philips Electronics N.V. and after holding various positions, amongst others he has been director of the Board of PSA Corporation Limited (Port of Singapore Authority), he is currently Chairman of the supervisory boards of Wolters Kluwer N.V., Hagemeyer and the Authority for Financial Markets in the Netherlands and a non-executive director of Imperial Chemical Industries Ltd. Mr. Rutger van Slobbe was a member of the executive board of Royal P&O Nedlloyd N.V. and currently he has various additional functions, including a position as supervisory board member of the Port of Rotterdam N.V. Messrs. Mark Dickinson, Bert Bekker, André Goedée and Brian Francoeur were re-elected to the Board of Dockwise Ltd. The appointments have immediate effect. About Dockwise Ltd/the Dockwise Group Dockwise Ltd is the parent company of the Dockwise group of companies (the "Dockwise Group"), one of the world's leading integrated heavy lift services providers. Following the recent combination with Dockwise Ltd (then named Sealift Ltd), the Dockwise Group currently owns a fleet of 22 vessels, of which 17 are semi-submersible heavy transport vessels and the remaining 5 are due to be converted into semi-submersible heavy transport vessels. The Dockwise Group is able to transport the heaviest cargos over vast distances. In addition, the Dockwise Group provides its customers with high value added services such as engineering, project management and front-end engineering design, particularly in the transportation and installation of offshore structures business. This capability has been further enhanced by the recent acquisitions of Offshore Kinematics Inc and Ocean Dynamics LLC. The Dockwise Group employs about 800 people worldwide. With a global network of offices in Bermuda (Dockwise Ltd's headquarters), Breda, (the Netherlands, being the operational headquarters of the Dockwise Group), Houston (Texas, USA), Shanghai (China), Shenzen (China), Busan (South Korea), Lagos (Nigeria) and Fort Lauderdale (USA)/Golfe Juan (France)/Genua (Italy) (Dockwise Yacht Transport), as well as 8 representing agents, the Dockwise Group provides an extensive service network to its clients. For further information: www.dockwise.com -------------------------------------- For further information: Jacqueline Lenterman, Investor Relations Tel: +31 (0)6 29 39 39 69


 

Odfjell SE`s second quarter 2007 result will be released on Thursday 23 August 2007. The results will be published on Oslo Børs at www.newsweb.no as well as made avaliable on www.huginonline.com and on www.odfjell.com. An open presentation and a conference call will be held with details mentioned below. The results will be presented Thursday 23 August 2007 at 09:30 CET by President/CEO Terje Storeng and Senior Vice President/CFO Haakon Ringdal. The presentation will be held in connection with the "Hordaland på børs" arrangement at Radisson SAS Royal Hotel/Kongesalen at bryggen in Bergen. The presentation will be in Norwegian. There will also be an English conference call Thursday 23 August 2007 at 14:00 CET. Dial-in numbers are 800 193 95 from Norway, 0800 694 2370 from the UK, and 1866 966 9444 from the US. Conference ID: 6285677. There will be an opportunity to ask questions. A replay of the conference call will be made available on www.odfjell.com, `Investor Relations`,`Webcast`. If you wish to participate in the presentation in Bergen, please confirm with an e-mail to: Ellen.Skagen@odfjell.com or call Ellen Skagen at +47 5527 0000 within 21 August 2007. Press contact: Anne-Kristine Øen, Information Manager, ph. +47 5527 4548 or +47 957 71549, E-mail: anne.kristine.oen@odfjell.com Additional information about Odfjell is available at: www.odfjell.com


 

Moscow/Oslo - 31 July 2007. A-pressen has sold to ESN Group a 25.05% minority stake in Publishing house "Komsomolskaya Pravda" ("KP"). Publishing house "Komsomolskaya Pravda" is one of Russia's leading print media businesses. Komsomolskaya Pravda, its flagship national newspaper is Russia's largest daily, with a circulation of 800,000 on weekdays, and a weekend edition, which is printed in almost three million copies. Sovetskiy Sport, Express Gazeta and the tv-guide Teleprogramma are also products of the publishing house. A-pressen became a shareholder in KP in 2002 in partnership with Prof-Media. In 2007 ESN Group acquired Prof-Media's interest in Publishing house "Komsomolskaya Pravda". KP has experienced tremendous growth between 2002 and 2006. "We are very pleased about the financial results achieved in Komsomolskaya Pravda during these last years. We have had a long and fruitful cooperation with Prof Media, a leading Russian media group, and it was natural for us to consider the sale of our stake upon their exit from the business. We got a good offer, and we are happy with the solution that now has been found, where ESN Group is also buying our shares", says acting A-pressen CEO Even Nordstrøm. ABOUT A-PRESSEN: A-pressen is a Norwegian media corporation with 2,700 employees. Its business activities in Norway include newspapers, printing, TV and electronic media. A-pressen is the largest owner of commercial television in Norway. In addition, A-pressen is involved in newspaper and printing operations in Russia. ABOUT ESN GROUP: The ESN Group is an investment holding company that manages assets in energy, media and transport sectors. ESN Group is a Russian partner of Italian energy major Enel on several projects. Since 2003 Enel ESN Energo has been performing management of North-West TPP. By November 2006 the management company completed all the tasks set by RAO UES which include construction of 450 MW unit. ESN Group launched an electricity trading company "Rusenergosbyt" that by 2005 became the largest Russian independent energy trader. In 2006, 49.5% of "Rusenergosbyt" were acquired by Enel that made the latter the first foreign strategic investor in Russian energy sector. ESN Group owns an oil-loading facility at the railway station Uyar (Krasnoyarsk region) which is in operation since 1 of April 2006. In January 2006 ESN Group set up a media holding that by now owns the most commercially successful publishing house "Komsomolskaya Pravda" and transport-focused media-assets "RZD-Partner". Press contacts Even Nordstrøm A-pressen Tel.: +47 411 89 012 Marianna Belousova ESN Tel.: +7 495 139 54 93


 

ISK 16.5 billion (EUR 189 m) profit after tax 24.2% return on equity Financial Highlights * Pre-tax profit in Q2 was ISK 11.3 billion, up by 34% from Q1 2007 * 45% of pre-tax profit was generated outside Iceland * Net interest income in Q2 was ISK 9.7 billion up by 22% from Q1 07 * Fees and commissions increased by 22% in Q2 and amounted to ISK 8.9 billion * Earnings per share for Q2 amounted to ISK 0.66 as compared with ISK 0.46 in Q1 07 * Total assets amounted to ISK 2,335 billion up from ISK 2,246 at the beginning of 2007 * Assets under management increased to ISK 913 billion from to ISK 541 billion in Q1 07 * Strong capitalization with CAD ratio at 13.2%, and Tier 1 ratio at 9.4% Operational Highlights * Glitnir was the 3rd largest brokerage in the Nordic equity market with a market share of 6.16% in 1H 07 * Successful alignment of the Finnish operation: consolidation and alignment in the final stages * Management board strengthened with experienced Nordic executives * 500 new employees join the group in the first six months * Strong performance in three global niche sectors, seafood/food, geothermal energy and offshore supply * Deposits increased by 11% to ISK 552 billion by the end of Q2 Lárus Welding, Chief Executive Officer says: "We are very pleased to report strong financial results in the second quarter. Leading the quarter's performance were strong profit achievement in Capital Markets, good results in Corporate Banking, and a substantial increase in fees and commission income. In addition, we have moved forward on our strategic initiatives, doubling assets under management with strong underlying growth in our Investment Management business. We are in the final stages of integrating FIM into the group and at the same time we are progressing with the consolidation of our Norwegian operations into one banking platform. The international management team of Glitnir remains confident that earnings will continue to increase, adding value for our shareholders. We have good momentum heading into the second half of the year and our goals are to maintain sustainable growth across all our businesses." For further information please contact: Lárus Welding CEO Tel: +354 440 4005 Alexander K. Guðmun CFO Tel: +354 440 4656 Bjørn Richard Johansen MD Corporate Communication Tel: + 47 47 800 100 brj@glitnir.no Vala Pálsdóttir Head of Investor Relations Tel: +354 440 4989 vp@glitnir.is For Lárus Welding's video comment, please visit: http://www.glitnir.is/Media/video/Q2Results-2007.wmv


 

Drug Development Veteran to Oversee Clinical Development WALTHAM, Mass. -- July 31, 2007-- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, has named Patricia Walicke, M.D., Ph.D., as Chief Medical Officer and Vice President. "Dr. Walicke's scientific expertise and extensive drug development experience span the entire drug development process, from IND filings, translational medicine, and Phase I work, through Phase II and III studies and approval," said Richard Chin, M.D., President and Chief Executive Officer of OXiGENE. "Dr. Walicke will be a tremendous asset to OXiGENE as we continue to advance our drug development programs." "Vascular disrupting agents address a common pathophysiologic mechanism and therefore have the potential to help people with a variety of diseases. I am excited to build upon the strong foundation of basic and clinical research already established at OXiGENE, and to work with the company's talented team," said Dr. Walicke. Most recently, Dr. Walicke served as Vice President, Clinical and Regulatory Affairs at Avidia, Inc., a subsidiary of Amgen, where she was responsible for development of an IL-6 inhibitor based on a novel protein technology. Prior to Avidia, Dr. Walicke served as Vice-President, Clinical Development at Rinat Neurosciences, focusing on translational medicine for an anti-NGF antibody for pain and an anti-beta amyloid antibody for Alzheimer's disease. Avidia and Rinat Neurosciences were initially privately-held companies which were acquired by Amgen Corporation and Pfizer, Inc, respectively. Prior to Rinat, she served in clinical development roles at Genentech, where she played a key role in the successful development and registration of Raptiva® and in the initiation of the Rituxan® program for multiple sclerosis. Her experience also includes work on the multiple sclerosis drug, Tysabri®, while serving as Director, Clinical and Regulatory Affairs at Athena Neurosciences, and provision of clinical research services while serving as Director, Medical and Scientific Services at Quintiles Pacific, Inc. Dr. Walicke has held full-time and adjunct academic appointments at leading medical research institutions and is a board certified neurologist. She earned her B.S. degree from the Massachusetts Institute of Technology, her M.D. from Harvard Medical School, and her Ph.D. from Harvard University. Dr. Walicke is an inventor on two patents and an author on over 90 articles, book chapters and abstracts. Concurrent with Dr. Walicke's appointment, Dr. Peter Harris will step down from his role as the company's Chief Medical Officer. Following a transition period, he will continue to actively serve as a consultant to the company. "Peter has made innumerable contributions to the company. Most notably, he oversaw the design and initiation of the ZYBRESTAT(TM) pivotal registration study and led the team that secured the Special Protocol Assessment for the ZYBRESTAT pivotal study from the FDA," said Dr. Chin. "We look forward to Peter's continued contribution to the company as a consultant." About OXiGENE, Inc. OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients. Safe Harbor Statement This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, including with respect to the timing and results of its clinical trials involving ZYBRESTAT and OXi4503, may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's Form 10-Q, 8-K and 10-K reports. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2006 for a description of these risks. CONTACT: OXiGENE, Inc. Shari Annes, 650-888-0902 Investor Relations, 781-547-5900


 

Dear Stakeholder Last year, Glitnir organised for the first time the Glitnir Capital Market Day, with great success. Much has happened since then, and 2006 will long be remembered as the year when the spotlight of international media and analysts was on the Icelandic financial sector and economy. In spite of the tempestuous climate, Glitnir performed extremely well, and 2006 will go down as one of the best in the Bank's history, when both earnings and income doubled from the previous year. Glitnir began the year 2007 with the acquisition of the Finnish financial firm FIM, which has now been fully consolidated into the Bank's accounts. In May, a new CEO was announced, and new executives have also joined the team to take the Bank even further ahead, after the rapid growth of recent years. This year, Glitnir will host its Capital Market Day next 1 October in Oslo, Norway, where the bank has invested extensively in recent months and years to the tune of approximately 530 million euros. It gives us great pleasure to invite you to join us at the Glitnir Capital Market Day of 2007. We look forward to seeing you in Oslo Monday, October 1st. Best Regards Lárus Welding, Bjørn Richard Johansen CEO Managing Director, Corporate Communication Glitnir will post the agenda of the Glitnir Capital Market Day in mid-August. For further information please contact Vala Pálsdóttir, Head of Investor Relations, ir@glitnir.is, or tel. +354 440 4989. Glitnir is a proud sponsor of the Oslo Maraton to be held on Sunday September 30th. Glitnir encourage everyone to run one of three distances: 3km, 21km or 42km, a full marathon. To register please visit: www.oslomaraton.no About Glitnir The financial group Glitnir offers universal banking and financial services. Glitnir is a leading niche player in three global industry segments; seafood/food, sustainable energy, and offshore services vessels. Services include retail, corporate and investment banking, stock trade/brokerage and capital management. Glitnir considers Iceland and Norway its home markets. The Glitnir group has operations in Iceland, Norway, Sweden, Denmark, Finland, the UK, Luxembourg, Russia, Canada and China and plans to open a US office in New York in the fall of 2007. Glitnir is listed on the Icelandic Stock Exchange. For more information: www.glitnirbank.com


 

Leiden, The Netherlands, July 31, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that it will release its financial results for the second quarter of 2007 on Tuesday, August 14, 2007 at 08:00 Central European Time (CET) (02:00 US Eastern Daylight Time). At 14:00 Central European Time (8:00am US Eastern Time), Crucell will conduct a conference call open to all, which will also be webcast. To participate in the conference call, please call one of the following numbers 10 minutes prior to commencement: 1-888-495-6450 for the US; 0800-358-3476 for the UK; and 0800-265-8593 for the Netherlands. Following a presentation of the results you will be able to ask questions during a question and answer session. The live audio webcast can be accessed via the homepage of Crucell's website at www.crucell.com, and will be archived and available for replay following the event. About Crucell Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com. Forward-looking statements This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on June, 13, 2007, and the section entitled "Risk Factors". The Company prepares its financial statements under International Financial Reporting Standards (IFRS) with reconciliation to the generally accepted accounting principles in the United States (US GAAP). For further information please contact: Crucell N.V. For Crucell in the US: Leonard Kruimer Redington, Inc. Chief Financial Officer Thomas Redington Tel. +31-(0)71-524 8722 Tel. +1 212-926-1733 Leonard.Kruimer@crucell.com tredington@redingtoninc.com Barbara Mulder Director Corporate Communications Tel: 31-(0) 71 524 8718 barbara.mulder@crucell.com


 

31 July 2007 - Aker Kvaerner will publish its 2nd quarter results 2007 at the Oslo Stock Exchange on Thursday 2 August at about 8.45 a.m. Central European Time. The results presentation will be held at the company's premises at Lysaker at 9.30 a.m. the same morning. We invite investors, analysts and the media to Aker Kvaerner's results presentation: Date: Thursday 2 August Time: 9.30 a.m. CET Location: The Auditorium at Aker Kvaerner's headquarters, Prof. Kohtsvei 15, Lysaker Language: English The presentation will be broadcasted live on http:// www.akerkvaerner.com and http:// www.oslobors.no/webcast at 9.30 a.m. CET. It will be possible to ask questions via e-mail during the presentation. In addition, participants can listen in via telephone: Country Number Norway Free Call 800 193 95 UK Free Call 0800 694 2370 USA Free Call 1866 966 9444 International Dial In +44 (0) 1452 552 510 ID 6276444 The complete 2nd quarter results 2007 report and presentation will be available at www.akerkvaerner.com and www.newsweb.no ENDS For further information, please contact: Investor relations: Lasse Torkildsen, VP Investor Relations, Aker Kvaerner, Tel: +47 67 51 30 39 Media: Torbjørn Andersen, SVP Group Communications, Aker Kvaerner. Tel: +47 67 51 30 36, Mob: +47 928 85 542 Career opportunities: Visit http://www.akerkvaerner.com/Internet/CareerCentre AKER KVÆRNER ASA, through its subsidiaries and affiliates ("Aker Kvaerner"), is a leading global provider of engineering and construction services, technology products and integrated solutions. The business within Aker Kvaerner comprises several industries, including Oil & Gas, Refining & Chemicals, Mining & Metals and Power Generation. The Aker Kvaerner group is organised in a number of separate legal entities. Aker Kvaerner is used as the common brand/trademark for most of these entities. The parent company in the group is Aker Kværner ASA. Aker Kvaerner has aggregated annual revenues of approximately NOK 50 billion and employs approximately 23 000 people in about 30 countries. Aker Kvaerner is part of Aker (www.akerasa.com), a group of premier companies with a focus on energy, maritime and marine-resources industries. The Aker companies share a common set of values and long traditions of industrial innovation. As an industrial owner with a 40.1 per cent holding in Aker Kvaerner, Aker ASA takes an active role in the development of its holdings. This press release may include forward-looking information or statements and is subject to our disclaimer, see our web-pages www.akerkvaerner.com


 

31 July 2007 Angus & Ross PLC (the "Company") Total Voting Rights In conformity with the Transparency Directive's transitional provision 6, the Company notifies the market of the following: As at the date of this announcement, the Company's issued share capital consists of 141,377,203 ordinary shares with a nominal value of 1 pence each ("Ordinary Shares"), with voting rights. The Company does not hold any Ordinary Shares in Treasury. Therefore, the total number of Ordinary Shares with voting rights is 141,377,203. The above figure of 141,377,203 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules. ---END OF MESSAGE---


 
Hitt og þetta
31. júlí 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |-------------------------------------------------+-----------------| | Company dealt in | Homeserve Plc | |-------------------------------------------------+-----------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |-------------------------------------------------+-----------------| | Date of dealing | 30th July 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 2,5017 | 1,681.30p | 1,710p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |------------------------+---------------------+--------------------| | 2,5400 | 1,687.70p | 1,707p | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +-------------------------------------------------------------------+ | Date of disclosure | 31st July 2007 | |---------------------------------------+---------------------------| | Contact name | Seema Soni | |---------------------------------------+---------------------------| | Telephone number | 0207 992 1565 | |---------------------------------------+---------------------------| | Name of offeree/offeror with which | Domestic & General Group | | connected | Plc | |---------------------------------------+---------------------------| | Nature of connection (Note 6) | Connected Advisor | +-------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | AXA Investment Managers UK | | | Limited/AXA Framlington | | | Investment Management Limited | |-----------------------------------+-------------------------------| | Company dealt in | Reuters Group | |-----------------------------------+-------------------------------| | Class of relevant security to | Ordinary shares | | which the dealings being | | | disclosed relate (Note 2) | | |-----------------------------------+-------------------------------| | Date of dealing | 30/07/07 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------------------------------+ | | Long | Short | | | | | |---------------+--------------------------+------------------------------------------------| | |Number |Number | | | (%) | (%) | |---------------+--------------------------+------------------------------------------------| |(1) Relevant |12,901,349 (1.02%) | | |securities | | | | | | | |---------------+--------------------------+------------------------------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+--------------------------+------------------------------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+--------------------------+------------------------------------------------| |Total |12,901,349 (1.02%) | | | | | | +-------------------------------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +--------------------------------------------------------------------------+ |Class of | Long | Short | |relevant | | | |security: | | | | | | | |---------------+----------------------------+-----------------------------| | |Number |Number | | | (%) | (%) | |---------------+----------------------------+-----------------------------| |(1) Relevant | | | |securities | | | | | | | |---------------+----------------------------+-----------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+----------------------------+-----------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+----------------------------+-----------------------------| |Total | | | | | | | +--------------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | Buy | 25,000 | 6.24p | | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short (Note | Number of securities | Price per | | name, | 6) | (Note 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------------+------------------------+------------| | | | | | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 31/07/2007 | |---------------------------------------------------+---------------| | Contact name | Maria Mauro | |---------------------------------------------------+---------------| | Telephone number | 0207 003 2812 | |---------------------------------------------------+---------------| | If a connected EFM, name of offeree/offeror with | N/A | | which connected | | |---------------------------------------------------+---------------| | If a connected EFM, state nature of connection | N/A | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

New Hong Kong subsidiary creates regional hub and strengthens service capabilities to address new customer demands VENLO, The Netherlands / HONG KONG, China, July 31, 2007 - QIAGEN N.V., the leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics today officially opened its new subsidiary in Hong Kong. The location will serve as the Company's hub for its further business expansion in this region. QIAGEN is hereby strengthening its regional service capabilities and facilitates access to the full offering of the company's leading portfolio of sample and assay technologies throughout this region. "Hong Kong is a focal point for science, healthcare and the fast developing market for biomedical research", said Dr. Frauke Ehlert, General Manager of QIAGEN China & Hong Kong. "Our new local team and infrastructure will allow us to increase our support of our customers for our sample and assay technologies in research, pharmaceutical development, applied testing and molecular diagnostics." QIAGEN's Hong Kong subsidiary is a further step to expand the Company's presence in the rapidly growing Asian markets. With growth rates of over 60% Asia today is the Company's fastest growing marketplace. QIAGEN's strategic expansion into the region began in 2005. Today the Company maintains 12 Asian offices with approximately 300 employees. Including the subsidiary in Japan, they contribute approximately 15 per cent to the Company's overall net sales. QIAGEN's business activities in Asia address in particular the growing demand for solutions in diagnostics and life science research. Demographic developments and the further growth of middle classes in many Asian countries are spurring the demand for diagnostic solutions and also catalyzing increased investments in science. QIAGEN is the leading provider of state-of-the-art molecular diagnostic and testing solutions for infectious diseases. Asia is significantly investing in this area to protect from human and economic impacts. QIAGEN will also target the strong potential for HPV testing in Asia by providing its leading HPV testing solutions as well as new developments to this region. Sixty percent of the world's cervical cancer patients reside in the Asia Pacific. About QIAGEN Asia QIAGEN Asia, headquartered in Shanghai, was established in 2006 as one of the company's regional organization. It today encompasses 12 locations in China, Korea, Malaysia, Singapore and Hong Kong, employing close to 300 employees. Products to customers in Taiwan, India, Thailand and Vietnam are sold via local distributors; Japan is an own entity within the QIAGEN organisation. Last year, QIAGEN received the Frost & Sullivan Award for Competitive Strategy Leadership in recognition of the company's strategic initiatives in the Asia Pacific molecular testing market. Asia is QIAGEN's fastest growing regional market. About QIAGEN QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such pre-analytical sample preparation and assay solutions in research for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and target specific assays. The company's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 2.600 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. Further information about QIAGEN can be found at www.qiagen.com. Contacts: Dr. Thomas Theuringer Dr. Frauke Ehlert Manager Public Relations General Manager China / Hong Tel: 0049-2103-29-11826 Kong Email: Tel.: 0086-21-38653811 thomas.theuringer@qiagen.com Email: frauke.ehlert@qiagen.com www.qiagen.com


 

BRUSSELS, Belgium, July 31, 2007 - Delhaize Group (Euronext Brussels:DELB) (NYSE:DEG), the Belgian international food retailer, confirms that it will announce its second quarter 2007 results (ended June 30, 2007) on Thursday August 9, 2007 at 8:00 a.m. CET. The press release will be available immediately after its publication on Delhaize Group's website at www.delhaizegroup.com. The Delhaize Group management team will discuss the second quarter 2007 financial results during an investors' conference call that will start at 03.00 p.m. CET (09.00 a.m. EDT) on August 9, 2007. To participate in the conference call, please call +44 20 7162 0125 (U.K.), +1 334 323 6203 (U.S.) or +32 2 290 1411 (Belgium), with "Delhaize" as password. The conference call will also be broadcast live over the internet on August 9, 2007 at 03.00 p.m. CET (09.00 a.m. EDT) at www.delhaizegroup.com. An audio replay of this webcast will be available at the same website starting at 06.00 p.m. CET (12.00 p.m. EDT) on August 9, 2007. Contacts: Guy Elewaut: + 32 2 412 29 48 Geoffroy d'Oultremont: + 32 2 412 83 21 Amy Shue (U.S. investors): + 1 704 633 82 50 (ext. 2529) DELHAIZE GROUP Delhaize Group is a Belgian food retailer present in seven countries on three continents. Its sales network consists of approximately 2,500 stores. In 2006, Delhaize Group posted EUR 19.2 billion (USD 24.1 billion) in net sales and other revenues and EUR 351.9 million (USD 441.8 million) in net profit. Delhaize Group employs approximately 138,000 people. Delhaize Group is listed on Euronext Brussels (DELB) and the New York Stock Exchange (DEG). Certain statements contained in this press release and related statements by management may be deemed to be forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including those described in Delhaize Group's filings with the Securities and Exchange Commission. Delhaize Group undertakes no obligation to update this forward-looking information except as required by law.


 

Cairns, Australia (6-10 August 2007) - The Vaisala Group, specialized in electronic measurement technologies, will be attending the 33rd International Conference on Radar Meteorology as a Premier Sponsor of the event. Vaisala is also one of the main exhibitors, and can be found at booths numbered 5 and 6. Vaisala will be showcasing the Vaisala Weather Radar, officially launched by the end of August this year. The radar has been developed in cooperation with leading international research institutions and partners. New technologies have been investigated thoroughly in the R&D process. For example, the radar's dual-polarization technology enables more precise information on the quantity and type of precipitation. The Vaisala Weather Radars carry world-leading Sigmet signal processors and application software. With the acquisition of Sigmet in January 2006, Vaisala ensured that its customers receive the most advanced processing and display capabilities with their radar systems. Vaisala has already received its first weather radar orders. Oral and poster presentations by Vaisala personnel include: Aug 8th, 8:00 AM-10:00 AM, Hall A, Session 7: Advanced Radar Technologies and Signal Processing; Evaluation of FM pulse compression for weather radars - Pekka Puhakka Aug 9th, 8:00 AM-10:15 AM, Hall A, Session 9: Commercial Operators Talks - Pauli Niska-Pudas Aug 9th, 1:30 PM-3:30 PM, Halls C & D, Poster Session P11B: Polarimetric Radar and Applications II; Real-time hydrometeor classification for the operational forecasting environment - Reino Keränen The Vaisala Group is a successful international technology company that develops and manufactures electronic measurement products and solutions and related services. Application areas include meteorology, environmental sciences, traffic and industry. The Vaisala Group employs over 1,000 professionals. In 2006, Vaisala achieved net sales of EUR 220.8 million. Vaisala operates and serves its customers globally. In 2006, operations outside Finland accounted for 97% of net sales. Parent company Vaisala Oyj, domicile in Finland, is listed on the Helsinki Exchanges in Finland. For further information please contact: Robert Ireland, Regional Manager, Australia, tel: +61 4383 55145 (Melbourne, Australia) or visit www.vaisala.com


 

Prosafe announces that the FPSO Umuroa has commenced production on the Tui field in the Taranaki basin offshore New Zealand on 30 July 2007. Prosafe converted a Suezmax to the FPSO Umuroa, and was responsible for the engineering, procurement, construction, installation and commissioning. Prosafe holds an initial five-year operating contract with five additional one-year options. Australian Worldwide Exploration Limited is the operator of the field with a 42.5 percent working interest. Partners are Mitsui E&P (35%), New Zealand Oil & Gas (12.5%) and Pan Pacific Petroleum (10%). The FPSO Umuroa is capable of processing up to 50 000 barrels of oil per day, 118 000 barrels of water per day and 120 000 barrels of total fluid per day, has a storage capacity of approximately 773 000 barrels and a gas compression capacity of 25 mmscfd. She is turret moored in a water depth of 120 meters using Prosafe's in-house developed turret/swivel technology. After good cooperation with Australian Worldwide Exploration Limited, Mitsui E&P, New Zealand Oil & Gas and Pan Pacific Petroleum throughout the project phase, Prosafe looks now forward to conducting successful and safe operations at the Tui field. Prosafe is the world's leading owner and operator of semi-submersible service rigs and a major owner and operator of floating production and storage vessels. Operating profit reached USD 150 million in 2006. The company operates globally, employs approx. 1 000 people and is headquartered in Stavanger, Norway. Prosafe is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com. Stavanger, 31 July 2007 Prosafe SE For further information, please contact: Arne Austreid, President and CEO Phone: +47 51 64 25 81 / +47 900 77 334 Bjørn Henriksen, Chief Operating Officer Phone: +47 51 64 25 30


 

For immediate release 31 July 2007 INTELLEGO HOLDINGS PLC ("INTELLEGO") AIM:IHP TOTAL VOTING RIGHTS For the purposes of the Disclosure and Transparency Rules of the Financial Services Authority, the Board of Intellego Holdings Plc (the "Company") is required to notify the market of the following: As at the date of this announcement, the Company's issued share capital consists of 100,927,485 ordinary shares with a nominal value of 0.5p each, with voting rights ("Ordinary Shares"). The Company does not hold any Ordinary Shares in Treasury. Therefore the total number of Ordinary Shares in the Company with voting rights is 100,927,485. The above figure of 100,927,485 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Service Authority's Disclosure and Transparency Rules. --ENDS-- Enquiries: Angus Forrest / Ranjit Roy Choudhuri Tel. 0870 428 1250 Intellego Holdings Plc www.intellego-systems.com Maxine Barnes / Nick Farmer Tel. 020 7562 3350 Bishopsgate Communications Limited intellego@bishopsgatecommunications.com Roland Cornish Tel. 020 7628 3396 Beaumont Cornish Limited ---END OF MESSAGE---


 

Zug/Munich, July 31, 2007 - The Partners of Global Life Science Ventures (GLSV) are pleased to announce the appointment of Stephen J. McCormack, PhD as a Managing Director of GLSV AG. Dr. McCormack (age 42) had joined GLSV in their Zug office in May 2006 and became Partner in November 2006. From the start Dr. McCormack has been active in identifying and assessing investment opportunities, which have already led to two investments where he represents GLSV as chairman or director on the supervisory boards. The companies concerned are IMI AG based in Zürich/ Bonn and Coapt Inc, from Palo Alto/ USA which develop retina implants for the blind, respectively bioabsorbable implants for use in aesthetic surgery. Dr. McCormack's additional responsibility as a Managing Director in Zug will also allow him to draw on his previous operational experience as a co-founder and CEO of two US-based biotech companies. This will benefit the GLSV partnership, which plans further expansion of its team, and its portfolio that has grown to 34 investments throughout Europe and the USA. Dr. Peter Reinisch, Partner, stated: "I welcome Stephen on our managing board and am convinced that he will quickly assume and share those additional responsibilities in running our operations. His strategic expertise will also be of significant value to GLSV as we manage the growth of our firm." Dr. Hans A. Küpper, Partner, added: "With this appointment, we install the same co-management system as in our Munich office and keep pace with the growing activities of our group, and particularly of our office in Zug." The GLSV team today consists of seven investment professionals, including five Partners, who bring a wealth of management expertise in the pharmaceutical industry and operational experience as entrepreneurs of biotech and medtech start-ups, as well as venture capital know-how. The team is ideally positioned to exploit the attractive investment opportunities in the life science industry. About Global Life Science Ventures: GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Switzerland and Germany, GLSV is dedicated to supporting early-stage companies originating from universities, scientific institutions or industry, but also invests in selected later-stage companies, including buy-outs. The group currently advises and manages funds totaling more than ¤200 million. GLSV has now financed 34 innovative life science companies throughout Europe and the USA, thirteen of which have completed an exit through IPO, trade sale or M&A. Since 1996, GLSV has built up a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology. Global Life Science Ventures Industry-born team - Proven track record - Global perspective Switzerland Germany GLSV AG GLSV GmbH Postplatz 1, P.O. 626 Von-der-Tann-Str. 3 CH - 6301 Zug D - 80539 München Tel. +41 (0)41 727 19 40 Tel. +49 (0)89 288 151 0 Fax +41 (0)41 727 19 45 Fax +49 (0)89 288 151 30 www.glsv-vc.com mailbox@glsv-vc.com For additional information, please contact: Rochat & Partners MC Services (for Germany) Jonathan Leighton or Christophe Lamps Raimund Gabriel Tel. +41 22 786 54 55 Tel. +49 (0) 89 210 228 30 Fax +41 22 786 54 58 Fax +49 (0) 89 210 228 88 E-mail: jleighton@rochat-pr.ch E-mail: gabriel@mc-services.de clamps@rochat-pr.ch


 

The Swiss real estate portfolio is sold to Delek Global Real Estate, Delek Belron International Ltd. and Igal Ahouvi's Blenheim Properties for CHF 3'400 m. Jelmoli Holding Ltd has completed its review of the Group's strategy. The Board of Directors has decided to sell the Swiss real estate portfolio to a consortium comprising Igal Ahouvi's Blenheim Properties, Delek Global Real Estate and Delek Belron International Ltd. at a price of CHF 3'400 m. The consortium has also been granted an option until the end of this year to acquire the Jelmoli House of Brands, the majority of Jelmoli Bonus Card Ltd and the Jelmoli Service Ltd. Within the framework of its strategic reorientation, Jelmoli intends to restructure itself into an investment company. After reviewing all the options, the Board of Directors of Jelmoli Holding Ltd is convinced that selling the Swiss real estate business and working together with the new owners of the real estate to find a suitable long term solution for the Jelmoli House of Brands in Zurich as well as the majority of Jelmoli Bonus Card Ltd and the Jelmoli Services Ltd, provides the best possible chances of creating added value for its shareholders and simultaneously securing the workplaces in the individual divisions of the Group in the long term. The sales price is CHF 3'400 m including financial liabilities. Execution of the transaction is subject to various conditions, including approval of the responsible authorities; it is planned for the second half of 2007. Blenheim and Delek Global Real Estate are internationally well known real estate investors and have a long-term strategy with regard to investing in Switzerland. Blenheim has to date participated in transactions totalling approximately CHF 12 bn, of which CHF 1 bn was in Switzerland. Delek Global Real Estate is an established real estate group which is listed on the AIM London Stock Exchange. Delek Global Real Estate and Delek Belron International Ltd. are subsidiaries of Delek Real Estate which has to date participated in transactions totalling approximately CHF 13 bn. Recent investments in Switzerland include 5 WTC office buildings in Lausanne, a building of the University of Zurich in Oerlikon, the Credit Suisse Building in Dübendorf, a building of the Swiss Confederation in the Luna Park in Berne and the Matran Shopping Centre in Matran. The current transaction is a follow-up to the disposal of the retail business (Fust) to Coop as announced on 29th May 2007. Jelmoli Holding Ltd will continue to manage its investment in Tivona as well as its real estate development projects outside Switzerland. For the other investments Molino Ltd, Beach Mountain Ltd and Fundgrube Bonne Occase Ltd, a suitable new owner will be sought in due course without any timepressure. "We are convinced that in Delek and Igal Ahouvi we have found the right buyer for our extensive Swiss real estate portfolio", says Walter Fust, Chairman of the Board of Jelmoli Holding Ltd, "The internationally successful real estate investment group provides assurance of the careful further development of the first-class properties". The current disposals represent a further milestone in the development of Jelmoli. Having successfully transformed itself from a chain of department stores into a company with a focus on real estate, Jelmoli is now making use of the favourable market conditions in order to realize the market value of its real estate and other investments for its shareholders. As part of the new strategy, it is the intention that the proceeds will not be distributed to the shareholders but reinvested with a focus on generating superior returns for shareholders. The Jelmoli Group will thus become primarily an investment company. In connection with the change of strategy, the Board intends to convene an extraordinary General Meeting of shareholders at the end of September 2007, at which the shareholders will be invited to approve the new strategy of the company. The Board members Prof. Dr. Christian Belz, Daniel Bürki, Carlo Magri and Prof. Dr. Hugo Tschirky will resign from the Board of Jelmoli Holding Ltd as at 31st July 2007. Walter Fust, Chairman of the Board, comments "The relevant gentlemen have contributed substantially in the successful implementation of the Jelmoli Group's corporate strategy in recent years. The company is extremely grateful to them". The structure of the Board of Directors will be simplified and reorganized. Walter Fust remains Chairman of the Board of Directors. Gustav Stenbolt, until now President of the Executive Committee, will remain on the Board. Harald Pinger will newly take over the executive function within the Board. Proposals for the election of new Board members will be submitted to the shareholders in good time prior to the extraordinary General Meeting. --- End of Message --- Jelmoli -----------------------------------------<Br><b>Jelmoli über WAP:<Br> wap.huginonline.com</b><Br>----------------------------------------- <Br>St. Annagasse 18 Zürich WKN: 851225; ISIN: CH0000668464; Index: SMCI, SPI, SPIEX; Listed: Main Market in SWX Swiss Exchange;


 

KYOTO, Japan, July 31, 2007 (PRIME NEWSWIRE) -- Pursuant to Section 203.01 of New York Stock Exchange Listed Company Manual, Nidec Corporation (NYSE:NJ) (Stock exchange code (Tokyo, Osaka): 6594) ("Nidec") announces that its annual report on Form 20-F for the fiscal year ended March 31, 2007 was filed with the U.S. Securities and Exchange Commission on July 27, 2007. Nidec's website address (in the English language) from which the Form 20-F can be accessed, is: http://www.nidec.co.jp/english/ir/lib/index.html Upon request, Nidec's shareholders (including holders of its American Depositary Shares) may receive hard copies of Nidec's most recent audited consolidated financial statements (F-pages of the Form 20-F) free of charge. Such request should be made at: http://www.nidec.co.jp/english/ir/lib/20f/form.html The Nidec Corporation logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=1734 CONTACT: Nidec Corporation Hiroshi Toriba, Senior General Manager, Investor Relations +81-75-935-6140 HIROSHI_TORIBA@notes.nidec.co.jp


 

31 JULY 2007 LSE ANNOUNCEMENT MONTO MINERALS LIMITED (the "Company") FOURTH QUARTER ACTIVITIES AND CASHFLOW REPORT 2006/2007 FOR THREE MONTHS TO 30 JUNE 2007 COUNTDOWN TO PRODUCTION.. * Dry commissioning under way * Commercial production and sales expected during the current September quarter The Goondicum multi-product industrial minerals project in Queensland entered the production phase in June 2007 with the commencement of dry commissioning of the processing plant. Wet commissioning of the plant is expected to commence later this week, subject to the integrity of the water pipeline which recommenced pumping this week after the discovery of initial leakages earlier this month. Assuming no further delays to the completion of commissioning, the project is scheduled to commence commercial production at the end of August with first sales deliveries expected during September. The project remains within budget. Construction and commissioning Construction at Goondicum progressed significantly during the quarter with the completion of the tailings dam walls and the processing plant. Outstanding pipework and electrical installations at the plant are expected to be completed in August. Electrical and other dry commissioning at the plant is also at an advanced stage. Pumping of water from the borefield at Mulgildie was suspended in early July due to the discovery of 15 small leaks in the pipeline. The Queensland Government owned corporation SunWater is responsible for the development of the water pipeline and the supply of water. These initial leaks have been repaired and pumping has resumed. The operation of the pipeline is being closely monitored to confirm its integrity. Further leaks have been identified however the Company is advised that they are not expected to delay water delivery for wet commissioning of the Goondicum plant. Assuming no further interruption to water deliveries, wet commissioning of the processing plant is scheduled to commence in early August. Commercial production is expected to commence in late August, subject to any further repairs, successful pressure testing and commissioning of the water pipeline. Mining continued during the quarter, providing stockpiled ore for commissioning of the process plant. The sand-clay ore is easily accessible and being mined by excavator and truck without the need for drilling and blasting. Construction progressed on schedule at Dakiel, 25 km by road from Goondicum, where a washing plant to upgrade the feldspar is being built. The plant, together with storage facilities for feldspar and ilmenite, is due for completion in October. Upgrading of the road from Goondicum to Dakiel continued during the quarter with further bitumen sealing scheduled. The interim diesel generators were installed and are operational at Goondicum. Construction commenced on the power line which will bring mains power to the project. All 30 employees required at Goondicum have been engaged. The application made in April for an additional Mining Lease covering 2900 hectares within the company's Goondicum exploration permit area (EPM 9100) is proceeding through the various approval processes. Together with the Company's existing Mining Lease (ML 80044), the mining lease area sought covers all known industrial mineral resources within the Goondicum crater. The Company has finalised a road transport contract for conveying mineral products to the port of Gladstone for an initial period of up to 12 months whilst continuing to evaluate a longer term rail transportation option, the terms of which will be subject to expected volume levels and applicable rail freight rates. Completion of commercial arrangements for stockpiling and shipping through Auckland Point at the port of Gladstone is pending finalisation of environmental and community impact plans by the port authority. This is not expected to affect the Company's shipping program. Marketing Marketing continues to take high priority in the early production phase of the project which has the unique benefit of having five industrial mineral products to sell - ilmenite, apatite, glass feldspar, ground feldspar and titanomagnetite. First deliveries of Goondicum products are scheduled to commence during the September quarter. As previously reported, the Company has secured contracts and letters of intent for more than 40% of its first year's production and is negotiating with additional customers. Ilmenite (paint, paper and plastic pigment) - Global demand for ilmenite is presently strong and Monto expects to contract all of its planned production to large pigment manufacturers following initial customer trial shipments. The Company's sulphateable ilmenite is very low in contaminants and suited to Asian and European markets. Feldspar (glass and paint/powder coating) - Marketing of feldspar for use in glass manufacture and in finely ground form for paint and powder coating continued during the quarter. The Goondicum feldspar will be upgraded at the Dakiel washing plant which will initially operate on a restricted basis to process sufficient product to meet current domestic sales commitments. Subsequently, production from the mine and through the plant will be demand driven in line with the development of export markets for both ground and glass feldspar. The Company expects to finalise contractual arrangements in the September quarter with a global glass manufacturer with whom it currently has a conditional agreement to supply 5000 tonnes a year for three years in Australia. Additional sales of Monto's feldspar as a high quality source of alumina for glass making continue to be pursued. Ground feldspar continues to be the subject of negotiations by Monto with several companies in Europe and the United States. A US company is currently conducting an evaluation of the product Titanomagnetite (coal washing) - A 10-day trial of the Company's titanomagnetite under supervised operating conditions is now under way at a central Queensland coal washing plant. The product appears to be performing efficiently. Installation of grinding equipment at the Goondicum plant for the preparation of the titanomagnetite product has been deferred pending the successful completion of the commercial test and further development of the marketing strategy. Apatite (organic fertiliser) - A fertiliser company has contracted to purchase the whole of the Goondicum project's production of apatite for organic fertiliser. The company, Ausmin Australia, announced this month its plans to construct a phosphate fertiliser processing facility at Dakiel to service the region's farmers and graziers, commencing in October. Funding On 28 May 2007, shareholders approved a $35 million fundraising that will take the project through to full production. The use of the proceeds include $15.7 million in guarantees required by the infrastructure providers to the project and $6.5 million for the capital cost of the power line (the Company will achieve long term benefits in lower power costs by building the power line itself). The fundraising comprised a $23 million ordinary share placement to Australian and UK investors and a $12 million convertible note. A further $6 million loan facility will provide for planned expansion to 2009. Board appointment During the quarter the Company announced the appointment of Chris Barrington as a non-executive Director. Chris was until recently the Managing Director and majority owner of Raw Material Solutions Ltd., a UK-based distributor and merchant of industrial raw materials, representing a number of international mining companies, including a major Australian producer of mineral sands. Chris' knowledge of the natural resources and raw materials markets and extensive experience of business development strategies, marketing plans and contract negotiation, will be of great benefit to Monto as it establishes itself as a producer and supplier of industrial minerals. Outlook The Goondicum project is on track to begin commercial production during the current September quarter. Mining is continuing and the process plant will undergo commissioning during the quarter. First sales revenue is expected to be received during the September quarter as sales and initial deliveries to customers commence. The power line is scheduled to be completed and transmitting first grid electricity in October 2007. Construction work will continue on the washing plant to upgrade the feldspar at Dakiel and is also expected to be completed in October 2007. Enquiries to: +-----------------------------------------------+ | Geoffrey Moore | | |--------------------------+--------------------| | Monto Minerals Ltd | +61 (0)7 3034 3100 | |--------------------------+--------------------| | | | |--------------------------+--------------------| | Richard Brown | | |--------------------------+--------------------| | Ambrian Partners Limited | 020 7776 6400 | +-----------------------------------------------+ For further information on Monto Minerals and recent photographs of work at the mine site please visit the Company's website at http://www.montominerals.com ---END OF MESSAGE---


 

Venlo, The Netherlands - July 30, 2007 - QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) announced today the successful completion of its acquisition of Digene Corporation (Nasdaq: DIGE). QIAGEN completed the acquisition through a tender offer and subsequent merger of Digene with and into a wholly owned subsidiary of QIAGEN. At the completion of the merger, Digene will become a wholly owned subsidiary of QIAGEN's affiliate QIAGEN North American Holdings, Inc. Peer M. Schatz, Chief Executive Officer of QIAGEN said, "We are pleased with the overwhelming support from both QIAGEN and Digene shareholders and believe their commitment is a testament to the significant benefits this combination creates. We are gratified by the vote of confidence of Digene shareholders who tendered more than 94% of all Digene shares in the tender offer. That 90% of the shares tendered expressed a preference to receive QIAGEN stock in exchange demonstrates great confidence in the upside potential of the combined company. We are excited that this transaction has been completed as we believe it represents a great opportunity for our shareholders, employees and the future of our Company. On behalf of QIAGEN's management and Supervisory Board, I would like to thank both QIAGEN's and Digene's shareholders and our now combined Company's dedicated employees. We look forward to a quick and smooth integration and to maximizing the value of our leadership position." As a result of the merger, each outstanding share of Digene common stock not validly tendered and accepted for payment in the tender offer was converted into the right to receive, at the Digene shareholder's election, either US$61.25 in cash or 3.545 shares of QIAGEN stock, subject to pro-ration so that the total consideration issued for Digene stock consists of 55% cash and 45% QIAGEN stock. The merger consideration and election procedure are the same as were offered in the tender offer and will take up to 60 days to complete. QIAGEN will announce the proration calculations for shares exchanged in the tender offer when such calculations are completed which we expect to be on or about Thursday, August 2, 2007. Shareholders who continue to hold Digene shares at the time of the merger and who fulfill certain other requirements of Delaware law will have appraisal rights in connection with the merger. Effective after the close of market today, trading in Digene common stock on the NASDAQ stock market ceased. In connection with the transaction, Goldman, Sachs & Co. acted as exclusive financial adviser to QIAGEN, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., De Brauw Blackstone Westbroek, and Freshfields Bruckhaus Deringer were legal counsel. JP Morgan acted as exclusive financial adviser to Digene, and Ballard, Spahr, Andrews & Ingersoll, LLP were legal counsel. About QIAGEN QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such as pre-analytical sample preparation and assay solutions in research for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and target specific assays. The company's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 2,000 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. In this press release QIAGEN is using the term molecular diagnostics. The use of this term is in reference to certain countries, such as the United States, limited to products subject to regulatory requirements. Current QIAGEN molecular diagnostics products are 34 EU CE IVD assays, six EU CE IVD sample preparation products, one 510k PAX RNA product, nine China SFDA IVD assays and 98 general purpose reagents. Further information about QIAGEN can be found at www.qiagen.com. Forward-Looking Statements This communication contains certain forward-looking statements, including statements about the expected benefits of the acquisition. These forward-looking statements are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the integration of the technologies and businesses of QIAGEN and Digene, unanticipated expenditures, changing relationships with customers, suppliers and strategic partners, conditions of the economy and other factors described in the most recent reports on Form 20-F, Form 6-K and other periodic reports filed with or furnished to the Securities and Exchange Commission by QIAGEN and the most recent reports on Form 10-K, Form 10-Q, Form 8-K and other periodic reports filed by Digene with the Securities and Exchange Commission. Additional Information This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Digene. QIAGEN has filed a Registration Statement on Form F-4, as amended, with the Securities and Exchange Commission in connection with the exchange offer and subsequent merger. Digene shareholders should read those filings, and any other filings made by QIAGEN with the SEC in connection with the Digene acquisition, as they contain important information. These SEC filings, as well as QIAGEN's other public SEC filings, can be obtained without charge at the SEC website at www.sec.gov. and at QIAGEN's website at www.qiagen.com. Additional copies of the prospectus, which is a part of QIAGEN's Registration Statement on Form F-4, can be obtained by contacting QIAGEN's IR department at QIAGEN Strasse 1, 40724 Hilden, Germany. # # # --- End of Message --- Qiagen N.V. Spoorstraat 50 KJ Venlo Netherlands WKN: 901626; ISIN: NL0000240000; Index: HDAX, MIDCAP, Prime All Share, TECH All Share, TecDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;


 

* Committee of the decentralised approval procedure (CMD) refers decision to a central body of the European regulatory authorities (CHMP) * No impact on the overall result for 2007 expected Martinsried/Munich - July 30, 2007. MediGene AG (Frankfurt, Prime Standard: MDG) has been informed by CollaGenex Pharmaceuticals Inc., that the decision about the European marketing authorization for the drug Oracea® for the treatment of the skin disease rosacea has been postponed. The committee of the nine countries involved in the decentralised procedure (Coordination Group for Mutual Recognition and Decentralised Procedures, CMD) did not reach a unanimous decision, and therefore refers the procedure to another committee for decision-making. The Committee for Medicinal Products for Human Use (CHMP) which is responsible for centralised approval procedures in Europe will decide by simple majority vote on the marketing authorization for Oracea®. This process usually takes about six months. MediGene does not expect this development to have any impact on the forecast for the company's overall result for the financial year 2007. The annual peak sales potential for Oracea® in Europe is expected to be about 20 million Euro. Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, comments: "We believe that Oracea® meets the criteria for marketing authorization. Our partner CollaGenex Pharmaceuticals Inc. has committed to use its reasonable best efforts to achieve approval and to close the procedure successfully." So far, marketing authorization applications for Oracea® have been submitted by the US based company CollaGenex Pharmaceuticals, Inc. in Germany, UK, Italy, Austria, Ireland, Sweden, Finland, Luxembourg, and the Netherlands. MediGene acquired pan-European marketing rights to Oracea® from CollaGenex Pharmaceuticals in 2006. In the US, Oracea® is already approved and is successful on the market since 2006. MediGene's first drug, Eligard®, is already available on the market. Another drug, i.e. Polyphenon® Ointment obtained marketing authorization for the USA and is currently undergoing the European approval procedures. Furthermore MediGene has several drug candidates for the treatment of various types of cancer and autoimmune diseases in clinical development, and possesses innovative platform technologies for drug development. About Oracea®: Oracea® is the first drug for systemic short-term as well as long-term treatment of rosacea with inflammatory lesions. By the innovative and low-dosed administration form the antibiotic doxycycline is relased in such a way that it should have an anti-inflammatory effect without affecting the body's normal bacteria. Development data suggest that the characteristic side-effects of antibiotics as well as development of resistant bacteria can be widely avoided. In clinical trials in the US Oracea® showed an efficacy superior to that of placebo, and it was well tolerated. About Rosacea: The skin disease rosacea is an inflammation of the facial skin, especially in the center part of the face. The onset of the disease is usually between the age of 40 - 50. It is a chronic, episodic disease. The cause of rosacea is still unknown. Both genetic predisposition and outside influences seem to be involved in the onset of the disease. In Europe, about 15 million people are affected by rosacea. This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGeneTM is a trademark of MediGene AG, Oracea® is a trademark of CollaGenex Pharmaceuticals, Inc., Polyphenon® is a trademark of Mitsui-Norin, Eligard® is a trademark of QLT, Inc. - ends - MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company with a drug on the market. Another drug obtained marketing authorization for the USA and is currently undergoing the European approval procedures. Furthermore MediGene has several drug candidates for the treatment of various types of cancer and autoimmune diseases in clinical development, and possesses innovative platform technologies for drug development. Contact MediGene AG: Email: investor@medigene.com Fax: ++49 - 89 - 85 65 - 2920 Julia Hofmann/Dr. Georg Dönges, Public Relations Tel.: ++49 - 89 - 85 65 - 3317 Dr. Michael Nettersheim, Investor Relations Tel.: ++49 - 89 - 85 65 - 2946 --- End of Message --- MediGene AG Lochhamer Strasse 11 Martinsried / München Germany WKN: 502090; ISIN: DE0005020903 ; Index: Prime All Share, CDAX, TECH All Share, HDAX, MIDCAP, TecDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Geregelter Markt in Frankfurter Wertpapierbörse;


 

Antwerp, 30 July 2007 - The public property investment fund Intervest Offices announces that the half year results as at 30 June 2007 will be published on Tuesday 7 August 2007 at 12h30. The results will be available on the website (www.intervest.be). Intervest Offices SA Uitbreidingstraat 18 - 2600 Berchem T 03 287 67 67 - F 03 287 67 89 E-mail:intervest@intervest.be


 

Pursuant to article 26 sec 1 WpHG BB MEDTECH AG, Vordergasse 3, 8200 Schaffhausen, Switzerland hereby declares that its wholly-owned subsidiary Medhealth N.V., Snipweg 26, Curaçao, Netherlands Antilles increased the holding in own shares as of July 27, 2007 to more than 5% of the proportion of voting rights (730 613 bearer shares / 5.04% of the proportion of voting rights). Pursuant to article 22 sec 1 clause 1 no 1 WpHG 5.04% of the proportion of voting rights need to be added to the voting rights of BB MEDTECH AG, Schaffhausen. BB MEDTECH AG did not hold any own shares as of July 27, 2007. For further information please contact: Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht/Zürich Adrian Brüngger or Dr. Christian Lach, Tel. +41 44 267 67 00. --- End of Message --- BB MEDTECH AG Vordergasse 3 Schaffhausen Switzerland WKN: 898194; ISIN: CH0000428661; Index: IGSP; Listed: Investment Companies in SWX Swiss Exchange;


 

London, UK: 30 July, 2007 - In conformity with the Transparency Directive's transitional provision 6, cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) notifies the market that the Company's issued share capital consists of 446,334,177 ordinary shares with voting rights. Antisoma does not hold any ordinary shares in Treasury. Therefore, the total number of voting rights in Antisoma is 446,334,177. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Antisoma under the FSA's Disclosure and Transparency Rules. - Ends - Enquiries: Raymond Spencer, CFO +44 (0)208 799 8200 Daniel Elger, Director of Communications Antisoma plc Background on Antisoma Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information about Antisoma. ---END OF MESSAGE---


 

30.06.2007 30.06.2006 + / - Sales (TEUR) 21.873 9.933 120.2% EBITDA (TEUR) 5.261 2.443 115.3% EBIT (TEUR) 3.537 1.706 107.3% EBT (TEUR) 3.118 1.711 82.2% Net Result* (TEUR) 1.873 1.013 84.9% Earnings per Share* (EUR) 0.38 0.27 40.7% *after profit distribution to third party shareholders The strong growth of the Impreglon group continued in the first half of 2007. Compared to last year's results sales rose to 21.9 million EUR (+ 120.2 %) and EBIT after 306 TEUR of good will write-off increased to 3.5 million EUR (+ 107.3 %). Profits before depreciation, interest and taxes (EBITDA) rose by 115.3 % to 5.3 million EUR. Earnings per share before one-time expenses due to the 28 % increase of the share capital climbed by 40.7 % from 0.27 EUR to 0.38 EUR. The strong sales increase can be attributed to 11.2 % of organic growth and the contribution from new strategic acquisitions. Plant expansions, cost cutting programs, new coating processes and the trend to Impreglon's environmentally friendly surface technology are the main factors for continuous growth in the second half of 2007. IMPREGLON AG Hohenhorststraße 1 21337 Lüneburg Tel. 04131 / 2260091 Fax 04131 / 882-250 investorrelations@impreglon.de www.impreglon.de --- End of Message --- Impreglon AG Hohenhorststraße 1 Lüneburg Germany WKN: A0BLCV; ISIN: DE000A0BLCV5; Listed: Entry Standard in Frankfurter Wertpapierbörse;


 

MONTREAL, QUEBEC--(Marketwire - July 30, 2007) - Pixman Europe S.L., a wholly-owned subsidiary of Pixman Nomadic Media Inc. (TSX VENTURE: PMN), and its partner Promomarketing S.R.L are completing these days a successful tour in 119 Italian cities for 3 Italia, an important mobile telecommunication company and subsidiary of the international holding H3G. Since July 14th, Pixman brand ambassadors have been the main characters of the promotional campaign Doctor X-Series Contact Tour 2007. Upon completion of the program, they will have toured 438 venues promoting the first complete offer dedicated to third generation (3G) mobile phones in Italy. This new solution enables users to access several Web applications, thanks to the support of major companies such as Skype, Yahoo!, Google, eBay and Microsoft. "The granting of this contract demonstrates the capability of our company to make national promotional campaigns and positions us in a unique way to meet the requirements of other similar campaigns," said Philippe Gribeauval, President of Pixman Europe. The awarded contract value exceeds 115 000 euros. Pixman Europe S.L. is currently discussing with many other clients who wish to retain Pixman services for their nomadic and tactical marketing campaigns. "With our company deploying across Europe an increasingly growing range of applications including Wi-Fi and Bluetooth transmission as well as data acquisition, we anticipate that the telecommunications and mobility markets will be important sources of future contracts," underlined Cristina Romero, Vice-President, Sales and Marketing of Pixman Europe. "We make it possible for these companies to reach targeted customers where they are, by using means that bring traditional marketing campaigns further." About Pixman Nomadic Media Inc. Pixman Nomadic Media Inc. (www.pixman.com) is a Montreal-based tactical marketing company. The foundation of Pixman's business, through its wholly-owned subsidiaries Pixman Corporation and Pixman Europe S.L., is the Pixman® patented wearable multimedia system worn by brand ambassadors. Pixman creates innovative technology-based marketing experiences that bring new ways to promote brands, products and services. Pixman provides turnkey media services throughout North America and Europe, and licenses its products to partners active in over 25 countries around the world. Pixman is listed on the TSX Venture stock exchange (www.tsx.com) as "PMN". Forward Looking Statements This news release contains forward-looking information. These statements relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management of Pixman Nomadic Media Inc. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. These forward-looking statements are made as of the date hereof and Pixman Nomadic Media Inc does not assume any obligation to update or revise them to reflect new events or circumstances. The TSX does not accept responsibility for the adequacy or accuracy of this release. Contacts: Pixman Nomadic Media Inc. Isabelle Gregoire +1-514-845-9669, ext. 223 Toll free: 1-866-703-4887 igregoire@pixman.com Investor Relations: Evolution Group Inc. Sylvain Archambault +1-514-448-4887 Toll free: 1-866-703-4887 s.archambault@evolutiongrp.com


 

RUNNING FOX RESOURCE CORP. TSX-V "RUN" OTC "RFXRF" Frankfurt "C8Q" Monday July 30, 2007 Running Fox Acquires Key Uranium Mining Claims in New Mexico, United States Steven Schurman, CEO, Professional Geologist (US) reports: Running Fox Resources is pleased to report that it has acquired 2,880 acres by staking lode mining claims covering extensive uranium mineralization in New Mexico, USA. Prior to the collapse of uranium prices in the early 1980's, exploration and development drilling by a number of major mining companies identified a series of shallow uranium and vanadium deposits covered by the area acquired by Running Fox. Based on discussions and detailed analysis with the geologist who managed several of those drill programs, and on over 150 drill holes, it is believed that the land that Running Fox has acquired may contain several million pounds of uranium and up to 8 million pounds of vanadium (this is non National Policy 43-101 compliant and is not to be relied on). Additionally, he has indicated that published chemical assays were taken from surface rock samples located within 500 feet of the existing Running Fox claims that assayed as high as 2.31% uranium and 1.64% vanadium. Chemical assays of drill cuttings in the same area varied up to 1.05% uranium and also contained vanadium. Some of the uranium mineralization encountered in these drill holes is near the surface. Running Fox will compile all available geological and drill data and be commissioning a 43-101 report from the qualified geologist, and will continue to study the area surrounding this acquisition, acquireing additional property as warranted. This is one of four uranium mineralized projects situated in the United States that Running Fox has been working to acquire. Running Fox is a Canadian growth-oriented small cap company developing four key divisions: 1. Energy Sector Oilfield Services and Technology; 2. Oil and Natural Gas Exploration and Production; 3. Uranium and Gold Exploration Mineral Projects; and 4. Environmental Services: Encapsulation and Remediation. On behalf of the Board of Directors: Steven Schurman, Running Fox Resource Corp. Contact: Steve Schurman 1 403 742 0500 www.foxgold.ca The Company relies on legislation applicable to forward looking statements, and seeks safe harbour. The TSX-V has neither approved nor disapproved of this news release.


 

OTTAWA, CANADA -- (MARKET WIRE) -- 07/30/07 -- Paramount Gold Mining Corp. (OTCBB: PGDP)(FRANKFURT: P6G)(WKN: A0HGKQ)(AMEX: PZG) is pleased to announce that the American Stock Exchange ("AMEX") has approved the listing of the Company's common stock for trading on the AMEX. Trading is anticipated to commence August 1, 2007 under the new symbol PZG. "Our listing on the AMEX is an important step in our continuing efforts to ensure a liquid trading market for all of our shareholders and to lay the foundation to increase our shareholder base. Our AMEX listing will allow better access for Canadian and U.S. investors to participate in our current exploration program at our San Miguel silver and gold project in the Sierra Madre gold/silver belt in Mexico" commented Christopher Crupi, CEO of Paramount Gold. Paramount Gold is a precious metals mining exploration company, presently in the early stages of an extensive exploration program at their San Miguel project in the Sierra Madre, Temoris mining district of Mexico. Paramount has completed 15,000 meters of drilling, totaling 98 drill holes on the project with results pending on the last 25 of these holes. Paramount began a 50,000 meter drill program in early 2007 and to date 8,000 meters have been completed. Paramount is well funded to exploit the opportunities of their property portfolio, with the completion of a $21.8 million financing in March of this year. "Safe-Harbor" Statement: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company may not be realized. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially. Contacts: Paramount Gold Mining Corp. Christopher Crupi, CEO Chris Halkai, Corporate Communications Toll-free: 1-866-481-2233 613-226-9881 --- End of Message --- Paramount Gold Mining Corp. 346 Waverley Street, Suite 110 Ottawa, Ontario Canada WKN: A0HGKQ; ISIN: US69924P1021; Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Freiverkehr in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen;


 

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | AXA Investment Managers UK | | | Limited/AXA Framlington | | | Investment Management Limited | |----------------------------------+--------------------------------| | Company dealt in | Quintain Estates & Development | |----------------------------------+--------------------------------| | Class of relevant security to | Ordinary shares | | which the dealings being | | | disclosed relate (Note 2) | | |----------------------------------+--------------------------------| | Date of dealing | 27/07/07 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------------------------------+ | | Long | Short | | | | | |---------------+--------------------------+------------------------------------------------| | |Number |Number | | | (%) | (%) | |---------------+--------------------------+------------------------------------------------| |(1) Relevant |1,572,929 (1.21%) | | |securities | | | | | | | |---------------+--------------------------+------------------------------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+--------------------------+------------------------------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+--------------------------+------------------------------------------------| |Total |1,572,929 (1.21%) | | | | | | +-------------------------------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +--------------------------------------------------------------------------+ |Class of | Long | Short | |relevant | | | |security: | | | | | | | |---------------+----------------------------+-----------------------------| | |Number |Number | | | (%) | (%) | |---------------+----------------------------+-----------------------------| |(1) Relevant | | | |securities | | | | | | | |---------------+----------------------------+-----------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+----------------------------+-----------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+----------------------------+-----------------------------| |Total | | | | | | | +--------------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | Sell | 5,664 | 9.13p | | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short (Note | Number of securities | Price per | | name, | 6) | (Note 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------------+------------------------+------------| | | | | | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 30/07/2007 | |---------------------------------------------------+---------------| | Contact name | Maria Mauro | |---------------------------------------------------+---------------| | Telephone number | 0207 003 2812 | |---------------------------------------------------+---------------| | If a connected EFM, name of offeree/offeror with | N/A | | which connected | | |---------------------------------------------------+---------------| | If a connected EFM, state nature of connection | N/A | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

AIM RELEASE 30 JULY 2007 DISCOVERY METALS LIMITED ("DME") NOTICE OF GENERAL MEETING Please find attached the following documentation:- 1. Chairman's letter 2. Notice of Meeting, Explanatory Statement & Attachment A 3. Proxy Form NOTE: For further information contact Jeremy Read Managing Director Tel: +617 3218 0202 Mobile: 0409 484322 Email: jeremy@discoverymetals.com.au Glen Parsons Richard Hail RFC Corporate Finance Ltd Fox-Davies Capital Ltd (AIM (Nomad) Broker) Tel: +612 9250 0036 Telephone: +44(0) 20 7936 5200 Email: glen.parsons@rfc.com.au Email: Richard.Hail@fdcap.com ---END OF MESSAGE---


 

Arnhem, the Netherlands, July 30, 2007 - Akzo Nobel (Euronext Amsterdam: AKZ; Nasdaq: AKZOY) has announced that, in line with the launch of its EUR 1.6 billion share buyback program on May 3, 2007, the company has repurchased 1,618,000 common shares in the period July 23 until July 27, 2007. Shares were repurchased at an average price of EUR 62.30 for a total amount of EUR 100.1 million. For detailed information on the daily repurchased shares, see the Akzo Nobel website at www.akzonobel.com/com/Investor+Relations/Financial+FAQ. The total number of shares repurchased under this program to date is 16,581,033 common shares for a total consideration of EUR 1.0 billion. The completion of the share buyback program is expected by the end of 2007. - - - Note to editors Akzo Nobel is a Fortune Global 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with coatings, chemicals and human and animal healthcare products. We employ around 62,000 people and conduct our activities in these four segments, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2006 totaled EUR 13.7 billion. The financial results for the third quarter will be published on October, 23, 2007. Internet: www.akzonobel.com Not for publication - for more information Akzo Nobel nv Corporate Media Relations, tel. +31 26 366 43 43 Contact: Tim van der Zanden


 
Hitt og þetta
30. júlí 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION AMENDMENT +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |-------------------------------------------------+-----------------| | Company dealt in | Homeserve Plc | |-------------------------------------------------+-----------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |-------------------------------------------------+-----------------| | Date of dealing | 27th July 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price paid | | securities | (Note 3) | (Note 3) | | purchased | | | |--------------------------+--------------------+-------------------| | 629 | 1,700.10p | 1,681.30p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |------------------------+---------------------+--------------------| | 2,480 | 1,671.80p | 1,697p | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +-------------------------------------------------------------------+ | Date of disclosure | 30th July 2007 | |---------------------------------------+---------------------------| | Contact name | Seema Soni | |---------------------------------------+---------------------------| | Telephone number | 0207 992 1565 | |---------------------------------------+---------------------------| | Name of offeree/offeror with which | Domestic & General Group | | connected | Plc | |---------------------------------------+---------------------------| | Nature of connection (Note 6) | Connected Advisor | +-------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 
Hitt og þetta
30. júlí 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |-------------------------------------------------+-----------------| | Company dealt in | Freeport Plc | |-------------------------------------------------+-----------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |-------------------------------------------------+-----------------| | Date of dealing | 27th July 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 219 | 341p | 341p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 5,543 | 346.75p | 350.25p | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +------------------------------------------------------------------+ | Date of disclosure | 30th July 2007 | |----------------------------------------------+-------------------| | Contact name | Seema Soni | |----------------------------------------------+-------------------| | Telephone number | 0207 992 1565 | |----------------------------------------------+-------------------| | Name of offeree/offeror with which connected | Freeport Plc | |----------------------------------------------+-------------------| | Nature of connection (Note 6) | Connected Advisor | +------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Incumbent Portuguese carrier uses the ADVA FSP 3000 in metro connectivity between major cities for business and residential services Mahwah, New Jersey, USA, and Martinsried/Munich, Germany. July 30, 2007. ADVA Optical Networking and Nokia Siemens Networks today announced that PT Comunicações, the fixed communications division of Portugal Telecom, has deployed the ADVA Fiber Service Platform (FSP) 3000 and FSP Network Manager in new metro deployments throughout Portugal's major cities. The new deployments enable PT Comunicações to ease traffic congestion and relieve fiber exhaust in the metro core as it continues to roll out new bandwidth intensive business and residential services to a wider market. PT Comunicações is the leading service provider of telecommunications in Portugal, offering a broad range of multimedia packages, data business solutions and wireline telephone services for residential, retail and wholesale customers. These services include Ethernet connectivity, Voice over Internet Protocol (VoIP) and triple play applications, including data, voice and video services. With traffic rapidly increasing from the metro access to the metro core, PT Comunicações needs to alleviate congestion within Portugal's main cities and simplify network operations. The ADVA FSP 3000 provides the flexible bandwidth PT Comunicações requires to respond to its growing traffic demands and provision for future network growth. The product transports data streams of up to 10Gbit/s Ethernet in metro rings that reach in excess of 80km. This extra bandwidth enables PT Comunicações to accommodate increased Digital Subscriber Line (DSL) backhaul traffic from the metro access to the metro core, implement fiber relief and extend local area network (LAN) and storage area networking (SAN) interconnections. Deployed along with the FSP Network Manager, the ADVA FSP 3000 provides PT Comunicações with detailed service intelligence that provides end-to-end network monitoring and advanced remote operations. PT Comunicações commented, "ADVA Optical Networking's commitment to optical transport innovation provides the performance PT Comunicações needs to meet an increasingly competitive marketplace. The FSP 3000 enables us to respond to our customers' demands, providing the scalable bandwidth needed for current and future data-intensive applications. Throughout Portugal's major cities, customers will now benefit from increased broadband performance and improved data connection speeds." The selection of the ADVA FSP 3000 was dependent on several critical factors: its ability to run applications at their native speeds; to transport Time Division Multiplexing (TDM) traffic; and to support a hybrid architecture with multiple interfaces, including Synchronous Digital Hierarchy (SDH). "Portugal Telecom is a European carrier with an international presence, offering services in countries as diverse as Brazil, China and Kenya," stated Brian P. McCann, ADVA Optical Networking's chief marketing and strategy officer. "In its domestic market, Portugal Telecom is rapidly rolling out new bandwidth intensive services, offering business and residential customers the latest broadband applications. ADVA Optical Networking's FSP 3000 and Network Manager ensure PT Comunicações is able to integrate these services smoothly, delivering bandwidth when and where it is needed." Ricardo Azevedo of Nokia Siemens Networks added, "ADVA Optical Networking and Nokia Siemens Networks have provided PT Comunicações with a flexible network solution that ensures its customers continue to receive a leading-edge service." # # # ABOUT ADVA OPTICAL NETWORKING ADVA Optical Networking (FSE: ADV) is at the forefront of providing Optical+Ethernet solutions that advance next-generation networks for data, storage, voice and video services. Our company's strength comes from passionate and dedicated employees, all sharing a common vision: a fast, customized response to customers' ever-changing needs. Our innovative Fiber Service Platform (FSP) and strong customer focus provide carriers and enterprises the ability to scale their networks and deliver intelligent, competitive new services. ADVA Optical Networking's solutions have been deployed at more than 200 carriers and 10,000 enterprises around the world. For further information about ADVA Optical Networking: www.advaoptical.com. ABOUT PORTUGAL TELECOM The Portugal Telecom Group is a global telecommunications operator that is a national leader in all of the sectors in which it participates. It is seen as the Portuguese company that has the biggest national and international projection and has a diversified business portfolio where quality and innovation are decisive aspects, alongside the most advanced international companies in this sector. For further information about Portugal Telecom: www.telecom.pt. ABOUT NOKIA SIEMENS NETWORKS Nokia Siemens Networks is a leading global enabler of communications services. The company provides a complete, well-balanced product portfolio of mobile and fixed network infrastructure solutions and addresses the growing demand for services with 20,000 service professionals worldwide. The combined pro-forma revenues of ¤17.1bn in fiscal year 2006 make Nokia Siemens Networks one of the largest telecommunications infrastructure companies. Nokia Siemens Networks has operations in some 150 countries and is headquartered in Espoo, Finland. It combines Nokia's Networks Business Group and the carrier related businesses of Siemens Communications. www.nokiasiemensnetworks.com. PUBLISHED BY: ADVA AG Optical Networking, Martinsried/Munich and Meiningen, Germany ADVA Optical Networking Inc., Mahwah, New Jersey, USA ADVA Optical Networking Corp., Tokyo, Japan www.advaoptical.com FOR PRESS: Gareth Spence t +1 201 258 8293 (U.S.) t +44 1904 699 358 (Europe) t +81 3 6667 5830 (Asia) public-relations@advaoptical.com FOR INVESTORS: Wolfgang Guessgen t +1 201 258 8300 (U.S.) t +49 89 89 0665 940 (Europe) t +81 3 6667 5830 (Asia) investor-relations@advaoptical.com


 

orizon AG ("orizon" or "orizon group"), a portfolio company of PPM Capital ("PPMC"), has signed a definitive agreement to acquire jobs in time Holding GmbH ("JiT"). The transaction is the second strategic add-on for orizon in the last two months, following the acquisition of SIR Industrieservice GmbH ("SIR"). The initial investment in orizon by PPMC was completed in March 2007. JiT, based in Hamburg, is a national provider of human resource solutions with 18 offices throughout Germany, some 2400 external employees and a focus on the North Rhine-Westphalia region. The company has specialised sector expertise in the areas of IT, banking and telecommunications as well as an overall focus on highly skilled commercial employees. For the financial year 2007 the management of JiT expects sales to the amount of more than ¤60 million. orizon AG, headquartered in Augsburg, is one of Germany's ten largest temporary work agencies (TWA). With 10,000 external employees, more than 120 offices and projected sales of over ¤300 million for the 2007 financial year, orizon primarily serves the aerospace, automotive, engineering, IT, telecommunication and finance industries. The orizon group is now pooling the strengths of seven TWAs specialising in various sectors and regions: JiT, SIR, Rolf Plümer GmbH, Plümer Konstruktionen GmbH, Andreas Wust GmbH, PersonnelConsultants HR GmbH and RKM GmbH. Dr. Dieter Traub, CEO of orizon AG: "JiT is an ideal extension of the orizon group with its complementing, high quality services, while also increasing customer and geographic diversity, especially in the IT, banking and telecommunication sector. The orizon group will support JiT to continue its organic growth, which it has already demonstrated by the formation of six new independent and successful offices over the past two years. Both parties will benefit from this new nationwide presence." PPMC and orizon believe in management continuity: The JiT business will be led by the existing management team headed by Mr. Frank Lambert, a co-founder of JiT. Guido May, Managing Director of PPM Capital GmbH comments: "Together with the company's management, we are convinced that our expectations for the continued growth of orizon will be met with this add-on acquisition. With our Buy & Build strategy, we invest in companies with growth potential and arrange additional funding for strategic acquisitions." PPMC has already demonstrated the success of its Buy & Build strategy with companies such as the Barracuda Group, European Dental Partners and The Astron Group, which grew substantially through acquisitions under PPMC's ownership. The transaction is subject to the approval by the Federal Cartel Office (Bundeskartellamt), which is expected for August. PPMC was advised by RWBaird (M&A), PwC (Financial/Tax) and Latham & Watkins (Legal). The funding of the acquisition and orizon group was provided by UniCredit / Bayerische Hypo- und Vereinsbank as Mandated Lead Arranger (MLA). -End- Approved by PPM Capital Limited; PPMC is authorised & regulated in the UK by the Financial Services Authority. For further information please contact: Guido May Managing Director PPM Capital Andreas Holtschneider Associate PPM Capital Tel.: +49 (0)89 2388 96 0 For German media enquiries: Ulf Ziegler fischerAppelt, ziegler Tel.: + 49 (0)40 899 699 810 Notes to PPMC PPM Capital is a leading source of private equity finance for mid-market transactions and has more than ¤2 billion of allocated funds available for investment. An established office network operates in London, Munich, Paris and Chicago with 25 local investment professionals. Although PPMC's investment portfolio is broadly based, the firm has established a reputation for its expertise in the healthcare, retail, leisure, business and financial services sectors and a number of successful investments have recently been completed. Recent Investments * Acquisition of Prodent International d.o.o. in 2007 * Acquisition of SIR Industrieservice GmbH in 2007 * ¤176.5 million acquisition of orizon AG from GL AG in 2007 * Acquisition of Interadent Zahntechnik AG in 2006 * GBP 107.5 million acquisition of Paramount Restaurants from Starlight in 2006 * GBP 183 million acquisition of Azzurri Communications from 3i in 2006 * ¤230 million acquisition of Histoire d'Or from Apax-Partners in 2006 Recent Divestments * ¤1.3 billion sale (together with Triton) of Phadia to Cinven in 2006 * Sale of BST Safety Textiles to the WLRoss Group in 2006 * Sale of OREFI Participation to Investcorp in 2006 PPM Capital Limited is the private equity arm of Prudential plc. www.ppmcapital.com


 

Video interviews available now on www.cantos.com and www.hsbc.com with Michael Geoghegan, Group CEO and Douglas Flint, Group FD (LSE:HSBA) * Results overview * Emerging markets * US - Mortgage Services * Europe/UK - Personal Financial Services * Capital efficiency and credit * Strategic priorities and outlook This programming is available in video, audio and transcript. It's free to view. All you need to do is register at www.cantos.com. Cantos.com is an online financial website where top management of companies address the critical issues facing their businesses. If you would like to contact us, please email enquiries@cantos.com.


 

Update July 23-27 Amsterdam (July 30, 2007) - Wolters Kluwer, a leading global information services and publishing company, today announces that in line with the launch of its ¤475 million share buy-back program on June 15, 2007, the company has repurchased 1,517,000 ordinary shares in the period July 23 until July 27, 2007. Shares were repurchased at an average price of ¤22.32 for a total amount of ¤33.9 million. For detailed information on the daily repurchased shares, see the Wolters Kluwer website at http://www.wolterskluwer.com/WK/Investors/Share+Information/Share+Buy-back+Program/ The total number of shares repurchased under this program to date is 7,053,619 ordinary shares for a total consideration of ¤159.9 million. About Wolters Kluwer Wolters Kluwer is a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal and regulatory sectors. Wolters Kluwer has annual revenues (2006) of ¤3.4 billion, employs approximately 18,450 people worldwide, and maintains operations across Europe, North America, and Asia Pacific. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its shares are quoted on the Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. For more information, visit www.wolterskluwer.com. Contact: Caroline Wouters Kevin Entricken Vice President, Vice President, Corporate Communications Investor Relations Wolters Kluwer nv Wolters Kluwer nv + 31 (0)20 6070 459 + 31 (0)20 6070 407 press@wolterskluwer.com ir@wolterskluwer.com Forward-looking Statements This press release contains forward-looking statements. These statements may be identified by words such as "expect," "should," "could," "shall," and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


 

Bakkvör Group released its report for the second quarter 2007 on Thursday, July 26. On Monday, July 30 CEO Ágúst Gudmundsson will present and comment on the report at a meeting held for analysts and market participants at Bakkavör head office in Reykjavik, Iceland. The presentation will be available on the Internet live at 11.15 a.m CET, see link below. http://webcast.zoomvision.se/clients/bakkavor/070730/ Participants can also dial in to listen to the presentation, numbers are found in the invitation attached.


 

Glitnir will host the following presentations and webcasts in relation to the publication of its second quarter results for 2007. An English version of the presentation will be available on www.glitnirbank.com as of its publishing midday on 31 July. Lárus Welding, CEO, and Alexander Guðmundsson, CFO, will present Glitnir's second quarter results for 2007 to shareholders and market participants on Wednesday, 1 August, at 11 a.m. at The Great Eastern Hotel, Liverpool Street, EC2M 7QN, London. Lunch will be offered after the presentation. A live broadcast of the meeting can be accessed on Glitnir's web: www.glitnirbank.com, where questions can be sent to the meeting via the web cast. You can also participate with questions by telephone by dialling +44 (0) 208 817 9301. Attendance should register with Vala Pálsdóttir, Head of Investor Relations, by e-mail at ir@glitnir.is or by calling +354 440 4989.


 

ING announced today that, in line with the launch of its EUR 5.0 billion share buy back programme on 4 June 2007, the company has repurchased 1,767,988 (depositary receipts for) shares during the week of 23 July until 30 July. The (depositary receipts for) shares were repurchased at an average price of EUR 31.74 for a total amount of EUR 56,120,148.79. For detailed information on the daily repurchased shares, see the ING website at www.ing.com/investorrelations. The total number of (depositary receipts for) shares repurchased under this programme to date is 31,854,009 ordinary shares for a total consideration of EUR 1,043,133,800.93. To date approximately 20.9% of the repurchase programme has been completed. The repurchase programme is expected to run until June 2008. +-----------------------------------------------------+ | Press enquiries: | | Debbie Brand, +31 20 541 6526, debbie.brand@ing.com | +-----------------------------------------------------+ ING is a global financial institution of Dutch origin offering banking, insurance and asset management to over 60 million private, corporate and institutional clients in more than 50 countries. With a diverse workforce in excess of 120,000 people, ING comprises a broad spectrum of prominent companies that increasingly serve their clients under the ING brand.


 

Getronics Analyst Conference Call: Pre-release H1 2007 We are pleased to invite you to a Getronics Analyst Conference Call, which will take place from 9.30am to 10.00am (CET). The Q&A conference call will focus on the pre-release only. Both the CFO Maarten Henderson and Head of Investor Relations Simon Theeuwes will be available to answer your questions during the conference call. As this will only be a 30 minutes session we are not providing you with a presentation or any presentation materials. Dial-in numbers are: Country Toll Numbers Freephone/Toll Free Number FRANCE LYON: 33-4-26-69-12-75 080-511-1431 FRANCE MARSEILLE: 33-4-86-06-00-75 080-511-1431 FRANCE PARIS: 33-1-70-75-00-04 080-511-1431 GERMANY 49-69-2222-52104 0800-216-1601 NETHERLANDS 31-20-710-9321 0800-023-4655 UNITED KINGDOM BIRMINGHAM: 44-121-210-9015 0800-018-0795 UNITED KINGDOM GLASGOW: 44-141-202-3215 0800-018-0795 UNITED KINGDOM LEEDS: 44-113-301-2115 0800-018-0795 UNITED KINGDOM LONDON: 44-20-7019-0812 0800-018-0795 UNITED KINGDOM MANCHESTER: 44-161-601-1415 0800-018-0795 USA 1-210-795-0472 877-818-6787 PASSCODE: INTERIM RESU Replay A replay will be available until 8 August 2007: Replay numbers are: UK TOLL NUMBER: +44-20-7192-0863 UK TOLL FREE NUMBER: 0800-279-5548 US TOLL NUMBER: 001-203-369-4995 US TOLL FREE NUMBER: 001-866-856-0220


 

ING Group announces that it has signed a Memorandum of Understanding with Piraeus Bank for a 10-year exclusive distribution partnership in Greece covering life, employee benefits and pension insurances. In addition, ING will acquire full ownership of ING Piraeus Life, the joint venture between ING and Piraeus Bank. Financial details were not disclosed. The new partnership follows on the current agreement, which was signed in 2002. The new distribution partnership fits into ING's growth strategy in Central Europe of which extending and broadening of distribution is one of the spearheads. The distribution partnership will give ING exclusive access to Piraeus Bank's network of 305 branch offices in Greece for the distribution of life insurance and pension products. Piraeus Bank is the 4th largest bank in Greece. Jacques de Vaucleroy, Executive Board member ING Group responsible for Insurance Europe, said: "We are pleased that we will be able to continue the fruitful co-operation with Piraeus Bank. The 10-year term of this distribution agreement confirms ING's firm commitment to the Greek insurance market." ING Piraeus Life has grown rapidly mainly through sales of unit-linked products. It is currently the 8th largest life insurer in the Greek market with a market share of 3.7%. ING also sells insurance products via tied agents through ING Greece. ING Greece ranks 5th in the Greek life market with a market share of 8.4%. Combined, ING Greece and ING Piraeus Life occupy the 3rd position in the Greek life insurance market. ING and Piraeus Bank expect to sign the final agreement in September 2007. +---------------------------------------------------------+ | Press enquiries: | | Nanne Bos, ING Group +31 20 541 6516, nanne.bos@ing.com | +---------------------------------------------------------+ ING is a global financial institution of Dutch origin offering banking, insurance and asset management to over 60 million private, corporate and institutional clients in more than 50 countries. With a diverse workforce of about 120,000 people, ING comprises a broad spectrum of prominent companies that increasingly serve their clients under the ING brand.


 

OctoPlus N.V. (Euronext: OCTO), the drug delivery and development company, announces today that it will release its 2007 first half-year results on Friday 3 August 2007, at 7:45 Central European Time (CET). OctoPlus will conduct a conference call on Friday 3 August at 10:00 AM CET, which will also be webcast. To participate in the conference call, please dial the following telephone number: +31 45 631 6901. After the presentation of the results, Joost Holthuis, CEO of OctoPlus and Hans Pauli, CFO, will be available to answer questions. The live audio webcast can be accessed via OctoPlus' website at www.octoplus.nl, and will be available for replay following the event. For further information, please contact: Rianne Roukema, Corporate Communications, +31 71 524 1071 About OctoPlus OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines. Our pipeline consists of 5 products in preclinical and clinical development. Our lead product is Locteron(TM), a sustained-release formulation of interferon alfa for the treatment of chronic hepatitis C, which we are co-developing with Biolex Therapeutics. Locteron is in Phase IIa clinical development. Furthermore, our pipeline comprises a product for the treatment of chronic middle ear infection also in Phase II development, a sustained-release formulation of growth hormone in Phase I and two preclinical single-shot vaccines. In addition, OctoPlus is a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. The earnings and expertise that we derive from rendering formulation and manufacturing services help to support our own drug development programs. OctoPlus is listed on Euronext Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl. This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.


 

MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX) today reported financial results according to IFRS for its first six months ended June 30, 2007. During the first half of 2007, the operating profit amounted to EUR 3.5 million (H1 2006: EUR 5.6 million). Total Group revenues increased by 8% to EUR 28.6 million (H1 2006: EUR 26.5 million). MorphoSys's cash position amounted to EUR 102.1 million at the end of the second quarter of 2007, compared to EUR 66.0 million at year-end 2006. Events of the Second Quarter 2007: * During the ASCO (American Society of Oncology) meeting in Chicago in June 2007, MorphoSys presented preliminary preclinical data for MOR202, its proprietary therapeutic antibody of MorphoSys, designed to treat Multiple Myeloma. At the conference, MorphoSys showed that in an in vivo animal model, MOR202 demonstrated superior efficacy in comparison to Velcade, one of the better therapeutic options for Multiple Myeloma patients currently on the market. * Clinical milestone in partnered therapeutic antibody program achieved - the third HuCAL-based antibody to begin human clinical trials * Existing partnered therapeutic antibody pipeline increased to 45 programs in total, of which currently three are in phase 1 clinical development, 17 in pre-clinical development, and 25 in research. * MorphoSys successfully completed EUR 32.6 million equity issue in private placement to investors in Europe and North America * During the second quarter of 2007, the collaborations with Bristol-Myers Squibb and Chemicon were successfully concluded "During the first six months of 2007, our overall business performed positively" commented Dave Lemus, Chief Financial Officer of MorphoSys AG. "While the AbD segment's performance for the year's first six months came in somewhat beneath our expectations, several measures have been undertaken with the aim of achieving the units profitability goal for the year." Financial Review of the First Half Year 2007 (IFRS): Group revenues increased by 8% in the first six months of 2007 to EUR 28.6 million (H1 2006: EUR 26.5 million). The increase is due mainly to higher levels of funded research and licensing fees in the therapeutic antibody segment and increased sales levels in the AbD segment. Revenues arising from the Therapeutic Antibodies segment amounted to EUR 18.7 million or 65% of total Group revenues, which included success-based payments in the amount of EUR 4.0 million. The AbD segment contributed EUR 9.9 million or 35% to total revenues. Total operating expenses for the first six months of 2007 amounted to EUR 25.1 million, compared to EUR 21.0 million in the same period of 2006. Cost of goods sold (COGS) amounted to EUR 4.2 million (H1 2006: EUR 4.0 million), representing cost of sales for goods sold by the AbD segment. Research and development costs increased to EUR 10.5 million from EUR 7.9 million; sales, general & administrative expenses amounted to EUR 10.5 million compared to EUR 9.1 million in the previous year. Stock-based compensation, reported as components within COGS, R&D and S,G&A expenses, increased to EUR 0.7 million (H1 2006: EUR 0.6 million). Operating profit for the first six months of 2007 reached EUR 3.5 million (H1 2006: EUR 5.6 million). Non-operating expenses, including tax expenses, in the first six months of 2007 rose from EUR 1.0 million in H1 2006 to EUR 1.4 million in 2007. In the first half of 2007, MorphoSys achieved a net income of EUR 2.0 million, compared to a net income of EUR 4.5 million in the same period of the previous year. Diluted net income per share for the first six months of 2007 amounted to EUR 0.29 (H1 2006: EUR 0.70). On June 30, 2007, MorphoSys held cash, cash equivalents and available-for-sale financial assets of EUR 102.1 million, compared to EUR 66.0 million on December 31, 2006. The number of shares issued at June 30, 2007 was 7,376,890, compared to 6,715,322 at December 31, 2006, reflecting the Company's private placement successfully concluded in May 2007. Second Quarter - 2007: In the second quarter of 2007, the Company generated revenues of EUR 14.5 million, compared to EUR 11.7 million in the same quarter of 2006. Total operating expenses amounted to EUR 12.4 million, compared to EUR 10.8 million in the same period of 2006. The resulting profit from operations for the second quarter of 2007 amounted to EUR 2.1 million, compared to EUR 0.9 million in the second quarter of 2006. A net profit of EUR 1.4 million resulted for the second quarter of 2007, compared to net loss of EUR 0.4 million during the same period of 2006. Financial Outlook MorphoSys left its financial guidance for 2007 unchanged at the Group level for revenues. However, the Company reduced its AbD segment profit goal from up to 10% of segment operating profit to up to 5% of segment operating profit. Company projects total revenues of EUR 60 to 65 million, and profit from operations of EUR 7 to 10 million for fiscal year 2007. MorphoSys will hold a public conference call today at 10:00 am CEST to present the financial results of the first six months 2007. Dial-in number for the Conference Call: +49 (0)69 9897 2623 (listen-only) U.K. residents: +44 (0)20 7138 0843 (listen-only) Please dial in 10 minutes before the beginning of the conference. A replay and the manuscript of the conference call will be available on http://www.morphosys.com/conferencecalls For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications, Tel: +49 (0) 89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Manager Public Relations, Tel: +49 (0) 89 / 899 27-454, brkulj@morphosys.com About MorphoSys: MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing agreements and/or research collaborations with Astellas (Japan), Bayer-Schering (USA/Germany), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (USA), Centocor Inc. (USA), Daiichi Sankyo & Co., Ltd. (Japan), GPC Biotech AG (Germany), Hoffmann-La Roche AG (Switzerland), ImmunoGen Inc. (USA), Merck & Co., Inc. (USA), Novartis AG (Switzerland), Novoplant GmbH (Germany), OncoMed Pharmaceuticals, Inc. (USA), Pfizer Inc. (USA), ProChon Biotech Ltd. (Israel), Schering-Plough (USA), Shionogi & Co., Ltd. (Japan), Xoma Ltd. (USA) and others. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit was founded in 2003 for the purpose of exploiting the MorphoSys non-therapeutic antibody markets. MorphoSys' activities in the research antibody segment were significantly strengthened through the acquisition of the U.K. and U.S.-based Biogenesis Group in January 2005 and Serotec Group in 2006. For further information please visit the corporate website at: http://www.morphosys.com/ HuCAL® and HuCAL GOLD® are registered trademarks of MorphoSys AG Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the prospectus relating to the company's recent public offering.


 

Martinsried/Munich (Germany) and Princeton, N.J., July 27, 2007 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) today announced that it has been sued in the United States District Court for the Southern District of New York, purportedly in a class action lawsuit on behalf of all persons who purchased or acquired securities of GPC Biotech between December 5, 2005 and July 24, 2007 inclusive. Bernd R. Seizinger (CEO), Martine George and Marcel Rozencweig were also named as defendants. The complaint alleges that GPC Biotech violated U.S. federal securities laws by making false public statements relating to the prospects of its most advanced product candidate, satraplatin, and thereby artificially inflating the price of GPC Biotech securities. GPC Biotech believes the allegations in the complaint to be without merit and intends to vigorously defend itself against them. END OF AD HOC ANNOUNCEMENT This ad hoc release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech AG, including those relating to the possible outcome of the proceedings and legal actions referenced herein. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this ad hoc release. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2006 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Satraplatin has not yet been approved by the FDA in the U.S., the EMEA in Europe or any other regulatory authority and no conclusions can or should be drawn regarding its safety or effectiveness. Only the relevant regulatory authorities can determine whether satraplatin is safe and effective for the use(s) being investigated. For further information, please contact: GPC Biotech AG Martin Braendle Director, Investor Relations & Corporate Communications Phone: +49 (0)89 8565-2693 ir@gpc-biotech.com In the U.S.: Laurie Doyle Director, Investor Relations & Corporate Communications Phone: +1 609 524 5884 usinvestors@gpc-biotech.com --- End of Message --- GPC Biotech AG Fraunhoferstr. 20 Martinsried WKN: 585150; ISIN: DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX, HDAX, TECH All Share; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Geregelter Markt in Frankfurter Wertpapierbörse;


 

TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hat Pin plc 2. Reason for the notification (please state Yes/No): An acquisition or disposal of voting rights: Yes An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: No An event changing the breakdown of voting rights: No Other (please specify): No 3. Full name of person(s) subject to the notification obligation: Standard Life Investments Ltd 4. Full name of shareholder(s) (if different from 3): Vidacos Nominees 5. Date of the transaction (and date on which the threshold is crossed or reached if different) : 25 July 2007 6. Date on which issuer notified: 26 July 2007 7. Threshold(s) that is/are crossed or reached: 3%, 4%, 5% and 6% 8. Notified details: Standard Life Investments Ltd acquired voting rights resulting in their voting rights exceeding the 3% minimum disclosable threshold. A: Voting rights attached to shares +-------------------------------------------------------------------+ | Class/type of shares if possible | Situation previous to the | | using the ISIN CODE | Triggering transaction | |------------------------------------+------------------------------| | Ordinary Shares | Number of | Number of voting | | | shares | Rights | |------------------------------------+-----------+------------------| | GB0030348576 | Below 3% | Below 3% | +-------------------------------------------------------------------+ Resulting situation after the triggering transaction +---------------------------------------------------------------------+ |Class/type of shares|Number of|Number of voting |% of voting rights| |if possible using |shares |rights | | |the ISIN CODE | | | | |--------------------+---------+-------------------+------------------| |Ordinary Shares |Direct |Direct |Indirect |Direct |Indirect | |--------------------+---------+---------+---------+--------+---------| |GB0030348576 |1,500,000|1,500,000| |6.259% | | +---------------------------------------------------------------------+ B: Financial Instruments Resulting situation after the triggering transaction +---------------------------------------------------------------------+ |Type of |Expiration|Exercise/Conversion|Number of voting |% of | |financial |Date |Period/ Date |rights that may be |voting| |instrument| | |acquired if the |rights| | | | |instrument is | | | | | |exercised/ | | | | | |converted. | | |----------+----------+-------------------+--------------------+------| |N/A |N/A |N/A |N/A |N/A | +---------------------------------------------------------------------+ Total (A+B) +----------------------------------------------+ | Number of voting rights | % of voting rights | |-------------------------+--------------------| | 1,500,000 | 6.259% | +----------------------------------------------+ 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable Standard Life Investments Ltd Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting rights: N/A 13. Additional information: 14. Contact name: Paul Billett Finance Director Hat Pin plc 15. Contact telephone number: +44 (0) 20 7438 8602 ---END OF MESSAGE---


 

Pursuant to article 26 sec 1 WpHG BB BIOTECH AG, Vordergasse 3, 8200 Schaffhausen, Switzerland hereby reports that it decreased its holding in own shares as per July 25, 2007 to below the thresholds of 5% and 3% of the proportion of voting rights. 1 400 000 bearer shares, which were bought during the repurchase program and approved for cancellation at the Annual General Meeting of March 26, 2007, were cancelled in the commercial register as at July 25, 2007. The share capital of BB BIOTECH AG now consists of 22.5 mn fully paid bearer shares with a pair value of CHF 1.00 each. Pursuant to article 22 sec 1 clause 1 no 1 WpHG 6.03% of the proportion of voting rights (a total of 1 356 148 bearer shares), which are held through the wholly-owned subsidiary Biotech Target N.V., Snipweg 26, Curaçao, Netherlands Antilles, need to be added to the voting rights of BB BIOTECH AG. BB BIOTECH AG does not hold any own shares as at July 25, 2007. For further information please contact: Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland Adrian Bruengger or Dr. Christian Lach, Tel. +41 44 267 67 00 --- End of Message --- BB BIOTECH AG Vordergasse 3 Schaffhausen Switzerland WKN: 888509; ISIN: CH0001441580; Index: SBIOM, IGSP, SLIFE; Listed: Investment Companies in SWX Swiss Exchange;


 

P/R International Offshore Services ANS, a wholly owned company of Farstad Shipping ASA, has reached an agreement to sell the "Lady Elizabeth" to European Venture II AS. Delivery of the vessels to the new owner will take place the first week in August 2007. The vessel is a platform supply vessel (PSV) of design ME 202 built in 1983. The price for the vessel is USD 10.6 million. This will give a booked profit of approx. NOK 42.5 million in the 3rd quarter 2007. Contacts: Karl-Johan Bakken tlf. +47 901 05 697 Torstein L. Stavseng tlf. +47 911 07 001


 

27 July 2007 For immediate release Novae Group plc Syndicate Business Forecasts Novae Syndicates Limited ("NSL") the Lloyd's managing agency owned by Novae Group plc, has submitted a business forecast for Syndicate 2007 to Lloyd's. A summary version of certain aspects of this syndicate business forecast is now available on the Company's website www.novae.com. This syndicate business forecast will be reviewed again by NSL prior to final submission in September according to the Lloyd's timetable and is subject to Lloyd's approval. For further information: Matthew Fosh - Novae Group plc 020 7903 7300 Nick Miles - M:Communications 020 7153 1535 ---END OF MESSAGE---


 

Bayer AG will be publishing its Second Quarter 2007 results on August 7, 2007 at 7:30 a.m. CEST (5:30 a.m. GMT). Starting at around 2:00 p.m. CEST (12:00 noon GMT) live on the Internet, Bayer AG will be broadcasting the speech and discussion of the Investor Conference Call. With Werner Wenning, CEO of Bayer AG, and Klaus Kühn, CFO of Bayer AG. A recording of the conference call will be available as from approx 7:00 p.m. CEST (5:00 p.m. GMT). The audio transmission and recording can be accessed on these sites: English: http://www.investor.bayer.com German: http://www.investor.bayer.de Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com If you have any questions, please contact: Dr. Alexander Rosar (+49-214-30-81013) Dr. Juergen Beunink (+49-214-30-65742) Peter Dahlhoff (+49-214-30-33022) Ilia Kürten (+49-214-30-35426) Ute Menke (+49-214-30-33021) Judith Nestmann (+49-214-30-66836) Dr. Olaf Weber (+49-214-30-33567) --- End of Message --- Bayer AG Gebäude W 11 Leverkusen WKN: 575200; ISIN: DE0005752000; Index: CDAX, DAX, HDAX, Prime All Share; Listed: Amtlicher Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Amtlicher Markt in Börse Berlin Bremen, Amtlicher Markt in Börse Düsseldorf, Amtlicher Markt in Hanseatische Wertpapierbörse zu Hamburg, Amtlicher Markt in Niedersächsische Börse zu Hannover, Amtlicher Markt in Bayerische Börse München, Amtlicher Markt in Börse Stuttgart;


 

Fitch Ratings has affirmed Kaupthing Bank's ("Kaupthing") ratings at Long-term Issuer Default 'A', Short-term 'F1', Individual 'B/C' and Support '2'. The Outlook on the Long-term Rating ("IDR") is Stable. The Support Rating Floor was affirmed at 'BBB'. Fitch states: "The ratings of Kaupthing reflect its strong position in the Icelandic market, the improved diversification of its profits and assets, its good asset quality, its satisfactory capitalisation and underlying profitability."


 

OUTOTEC OYJ PRESS RELEASE, JULY 27, 2007 AT 11.30 AM Outotec to deliver chromite pelletising and sinter plant for Samancor Chrome in South Africa Outotec has been awarded the third pelletising and sinter plant order from Samancor Chrome of South Africa. The new plant will produce 600,000 tonnes of sintered pellets annually from chromite ore and it will be built in Middelburg. In 1998, Outotec delivered a similar plant to Samancor Chrome's Ferrometals operations in Witbank and in 2002, to Tubatse in Steelpoort. The delivery includes Outotec's SBSTM Steel Belt Sinter technology, license, basic engineering, supply of key equipment as well as installation supervision and commissioning services. A local contractor will provide process equipment outside Outotec's scope, installation and construction. Outotec's share of the project is approximately EUR 15 million. The plant is expected to be commissioned towards the end of 2008. For further information please contact: OUTOTEC OYJ Jorma Daavittila, Vice President - Base Metals, Ferroalloys tel. +358 20 529 2107 e-mail: jorma.daavittila(at)outotec.com Eila Paatela Vice President - Corporate Communications tel. +358 20 529 2004, mobile +358 400 817198 e-mail: eila.paatela(at)outotec.com DISTRIBUTION Main media www.outotec.com


 

Reference is made to earlier notices regarding the acquisition of Provimar dated 2 July 2007 and acquisition of Indian operations dated 5 July 2007 by Eitzen Maritime Services ASA. The Information Memorandum regarding the transactions is attached to this stock exchange notice at http://www.newsweb.no. The Information Memorandum does not constitute an offer to sell or solicitation to buy any securities. With reference to previous announcement dated 5 July 2007, the acquisition of two Bermuda based maritime services companies are expected to be completed in near future. For further information: Annette Malm Justad Chief Executive Officer Tel: +47 95 20 93 96 Knut Abrahamsen Chief Financial Officer Tel: +47 92 40 10 38


 

Royal DSM N.V. has repurchased 598,725 of its own shares in the period from 19 July 2007 up to and including 25 July 2007 at an average price of EUR 37.23. This is in accordance with the second phase of the share buyback program, announced on 27 April 2007. The consideration of this repurchase was EUR 22.3 million. The total number of shares repurchased under the second phase of this program to date is 8,723,379 shares for a total consideration of EUR 319.3 million. DSM DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named Vision 2010 - Building on Strengths, focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over ¤8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com. For more information: DSM Corporate Communications DSM Investor Relations Elvira Luykx Dries Ausems tel. +31 (0) 45 tel. +31 (0) 45 5782864 5782035 fax +31 (0) 45 5782595 fax +31 (0) 45 e-mail 5740680 investor.relations@dsm.com e-mail media.relations@dsm.com


 

The Company is pleased to announce that it proposes to raise approximately £6.1 million (before expenses) by means of a placing ("the Placing") of 5,789,137 new ordinary shares (the "Placing Shares") of 30 pence each ("New Ordinary Shares") at 105 pence per share. The placing price of 105 pence per share, reflects the proposed 30 for one consolidation of the ordinary share capital of the Company. The Directors intend to use the net proceeds of the Placing to prepare for Phase III studies of its lead drug M6G (morphine-6-glucuronide) in the United States and to carry out clinical trials of its other products, further details of which are set out below. The Placing is conditional, inter alia, on the passing of the necessary resolutions at an Extraordinary General Meeting of the Company ("the EGM") to be held on 22 August 2007. The Company will also hold its Annual General Meeting on the same date. Background to the Placing CeNeS recently announced positive results from the largest ever European Phase III trial of M6G, its lead drug candidate for the treatment of post-operative pain. The trial demonstrated that M6G gives equivalent pain relief to the "gold standard" treatment regimen of morphine and also that M6G gives a clinically relevant reduction in side effects such as nausea, dry retching, vomiting and sedation. CeNeS now intends to find partners to complete the clinical package that is required for US and European product filings. CeNeS is actively pursuing partners for M6G and maintaining momentum in the planning of the US trials will assist greatly in this process. CeNeS has other clinical programmes that are currently not being prioritised. CNS 5161, a novel drug for the treatment of intractable chronic pain, has already been successfully tested in Phase IIa trials in neuropathic pain and is partnered for clinical development purposes with Ergomed. CeNeS and Ergomed have developed a clinical development plan to test CNS 5161 in two Phase II studies in cancer pain and neuropathic pain respectively. CeNeS is also currently completing the pre-clinical package for its novel short-acting sedative CNS 7056 and plans to file an IND application and carry out proof of concept Phase I trials. The Directors believe that the progress of the Company's products is promising and that they are well positioned in its chosen markets. CeNeS intends to use the funds raised from the Placing as follows: * Complete preparation for two US Phase III trials for M6G. * Complete the IND - opening Phase I pharmacokinetic study for M6G. * Complete two Phase II studies with CNS 5161. * Carry out transdermal patch formulation development for CNS 5161. * Complete a Phase I proof of concept study with CNS 7056. * Progress the early stage discovery programme in COMT inhibitors. * General working capital. The Company's strategy remains primarily focused on further clinical development of its later-stage product portfolio candidates, being M6G and CNS 5161. The Directors believe that the further successful development of M6G and CNS 5161 will significantly add to the value of the Group's product pipeline. Further programme development will also enable partnership of these products at a later stage in the product development cycle, thereby potentially enabling CeNeS to secure improved milestone and royalty rates in any future partnership agreements with pharmaceutical companies. The Directors further believe that development of the Group's pre-clinical products will provide CeNeS with a broader platform from which to build a focused, sustainable and profitable business. In addition, a stronger balance sheet will enable the Directors to negotiate from a better position should merger and acquisition opportunities arise and will also greatly assist in negotiations with potential licensing partners. Indeed, the Company anticipates that it will shortly be completing a licensing deal for one of its products. The terms of the deal are in a standard format and include milestones and royalties. Neil Clark, CEO of CeNeS, commented: "We are delighted with the support from existing and new investors for the Placing, and the Company is now well funded as we continue our partnering discussions. These funds allow the Company to prepare for Phase III studies of its lead drug M6G in the United States and to carry out clinical trials for the remainder of the portfolio." Consolidation of Share Capital The Company's share register currently records over 5,000 shareholders. The cost in maintaining the register and posting documentation to this large shareholder base is both unduly expensive and time consuming. Accordingly, at the forthcoming EGM, the Company proposes to consolidate every 30 existing ordinary share of 1 pence ("Existing Ordinary Share") each into one new ordinary share of 30 pence each. Management Participation in the Placing Of the Placing Shares issued, the following have been placed with Directors and senior management. Director New Ordinary Total Percentage of Shares Shareholding enlarged subscribed for on Admission ordinary share capital held Alan Goodman 9,523 542,365* 2.60* Neil Clark 9,523 28,673 0.12 Ronald Irwin 4,762 20,648 0.10 Alan Smith 4,762 4,762 0.02 Gavin Kilpatrick 2,857 15,079 0.07 Total 31,427 611,527 2.91 Note:* 4,638,176 Existing Ordinary Shares (representing 154,605 New Ordinary Shares) are held by ATM Investments Limited, a company of which Mr Goodman is a director. In addition, Mr Goodman is a director and limited partner of Avlar Bioventures Limited ("Avlar"). Avlar has an interest in 26,807,760 Existing Ordinary Shares (representing 893,592 New Ordinary Shares). Application will be made for the Placing Shares to be admitted to trading on AIM and it is anticipated that dealings will commence in these shares on 23 August 2007. The Placing Shares and the New Ordinary Shares will, when issued, be credited as fully paid and rank pari passu in all respects with the existing issued ordinary shares in the capital of the Company. EXPECTED TIMETABLE OF PRINCIPAL EVENTS Latest time and date for receipt of Forms of 10.00 am on 20 August Proxy for the EGM 2007 Latest time and date for receipt of Forms of 10.30 am on 20 August Proxy for the AGM 2007 Extraordinary General Meeting 10.00 am on 22 August 2007 Annual General Meeting 10.30 am on 22 August 2007* Record Date for the Consolidation 22 August 2007 Admission and commencement of dealings in the 23 August 2007 Placing Shares on AIM Commencement of dealings in the New Ordinary Shares on AIM 23 August 2007 Delivery in CREST of Placing Shares to be held 23 August 2007 in uncertificated form Despatch of share certificates for Placing By 31 August 2007 Shares to be held in certificated form *Or as soon therafter as the EGM has been concluded or adjourned. Enquiries CeNeS Pharmaceuticals plc Neil Clark 01223 266 466 JM Finn Geoff Nash/Sam Smith 020 7638 9688 Financial Dynamics Ben Brewerton/Emma Thompson 020 7831 3113 J.M. Finn & Co Ltd is nominated adviser and broker to the Company for the purpose of the AIM Rules. J.M. Finn & Co Ltd, which is authorised and regulated in the United Kingdom by the Financial Services Authority and is a member of the London Stock Exchange, is acting exclusively for the Company in relation to the Placing. J.M. Finn & Co Ltd is not acting for any other person in connection with the matters referred to in this announcement and will not be responsible to anyone other than the Company for providing the protections afforded to clients of J.M. Finn & Co Ltd or for giving advice in relation to the matters referred to in this announcement. This announcement has been issued by the Company and is the sole responsibility of the Company. This announcement has not been approved by J.M. Finn & Co Ltd for the purposes of section 21 of the Financial Services and Markets Act 2000 (as amended). This announcement does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities or any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, such securities by any person in any circumstances, and in any jurisdiction, in which such offer or solicitation is unlawful. Accordingly, copies of this announcement are not being and must not be mailed or otherwise distributed or sent in or into or from the United States, Canada, Australia or Japan or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration thereof in, such jurisdiction or to, or for the account or benefit of, any United States, Canadian, Australian or Japanese person and any person receiving this announcement (including, without limitation, custodians, nominees and trustees) must not distribute or send it in or into or from the United States, Canada, Australia or Japan. The press release can be downloaded from the following link: --- End of Message --- CeNeS Pharmaceuticals Plc WKN: 913665; ISIN: GB0002070505; Listed: Freiverkehr in Börse Berlin Bremen, Freiverkehr in Frankfurter Wertpapierbörse;


 

Norwegian Property expects a profit before tax of mnok 1 142 in the second quarter (compared to mnok 345 in the first quarter). The positive result is due to a positive result from operations, a strong rental growth in the property market and the resulting revaluation of the group's portfolio of commercial properties. Positive value development for the group's financial hedging contracts also contributes positively. The full earnings report for the 2rd Quarter will, as previously announced, be released on 10th August. --------------------------------------------------- Gain for fair value adjustements in the second quarter for the group's portfolio of investments properties totals mnok 830. DTZ Realkapital has, as in previous quarters, carried out a valuation of the group's properties. Total value of the group's properties (prior to the acquisition of the DnB portfolio at Aker Brygge and assumed completion of Aker Hus) is mnok 19 088. The main contributors to the positive revaluation are the continued strong development in market rents and reduction in the market's required yield gap. The long term interest rates have increased during the second quarter, and increased discount rates have contributed negatively to the property values. Net financial items includes a positive effect of mnok 246 relating to a positive development in the market value of financial hedging contracts not qualifying for hedge accounting (mnok 362) and expensing of previously accrued arrangement fees and refinancing expenses (mnok - 116). Total value of the financial hedging contracts were mnok 580 at the end of second quarter. At the end of second quarter the group had cash and cash equivalents of mnok 1 100. 80% of the group's interest bearing debt has been hedged with an average remaining duration of 5.8 years. Average interest for the group's interest bearing debt was 5.0% including margins and fees. "The rental growth is still strong, in particular in central areas of Oslo and Stavanger, where Norwegian Property has most of our properties. We recently signed a contract of nok 4 300 per square meter at Aker Brygge, but we believe it is just a matter of time before this record is beaten," says CEO Petter Jansen. For further information, contact: CEO and President, Petter Jansen, mobile +47 900 98 728 CFO Svein Hov Skjelle, mobile +47 930 55 566


 

For further information Viktor Svensson, Informationschef 08-657 12 01/ 070-657 20 26 Shareholders in AB Ångpanneföreningen (publ) are invited to an Extraordinary General Meeting (EGM) of the company that will take place at 10.00 a.m. on Tuesday 14 August 2007 at AB Ångpanneföreningen's head office at number 7 Fleminggatan in Stockholm, Sweden. Entitlement to attend Shareholders who wish to participate in the EGM must * have their names entered in the shareholders' register maintained by VPC AB, (the Swedish Securities Register Centre) by Wednesday 8 August 2007 at the latest, and * confirm their intention to participate by 16.00 (4.00 p.m.) on Friday 10 August 2007 at the latest. Shareholders who have elected to use a nominee for their shareholding must temporarily re-register their shares in their own name if they wish to exercise the right to participate in the meeting. Shareholders who wish to re-register their shareholding in this way must inform their nominee of this in good time prior to 8 August 2007. Registration Notice of an intention to participate in the EGM may be made by post to AB Ångpanne-föreningen, Corporate Information, Box 8133, SE-104 20 Stockholm, Sweden, or by telephone on +46 (0)10-505 00 00, by fax on +46 (0)8-653 56 13, or by e-mail via www.afconsult.com. Please specify your name, personal or corporate identity number, address, telephone number, registered shareholding and number of assistants/advisors (maximum of two). You are also kindly requested to provide documentary proof of entitlement to attend the meeting (power of attorney, registration certificate, etc.) together with your notification of attendance. Proposed agenda for the EGM 1 Election of a chairman for the meeting 2 Preparation and approval of the list of those eligible to vote 3 Approval of agenda 4 Election of one or two persons to check the minutes 5 Confirmation of the legality of the call to meet 6 Approval of the resolution to sell subsidiary companies Approval of the resolution to sell subsidiary companies (item 6 on the agenda) (a) The Board of Directors of the company has approved the sale of all of the shares in the Finnish subsidiary ÅF-CTS Oy for a consideration of ¤4,000,000 (four million euros), which is in line with the book value of the subsidiary. The purchaser is the management of ÅF-CTS Oy which in turn will subsequently sell parts of the company to the venture capital company Nordic Mezzanine Ltd and the venture capital company Nordic Mezzanine Ltd. ÅF-CTS Oy has 130 employees and reports sales of approximately ¤9,000,000 (nine million euros) a year. (b) The Board of Directors of the company has approved the sale of all the shares in the French subsidiary AF-Chleq Froté S.A. for a consideration of ¤3 (three euros). The purchaser is the management of AF-Chleq Froté S.A. AF-Chleq Froté S.A. has 50 employees and reports sales of approximately ¤6,000,000 (six million euros) a year. These divestments are part of the process of re-alignment currently being undertaken within the ÅF Process Division. In view of the fact that the purchasers in both the above instances, (a) and (b), hold a position such as that described in Chapter 16, Section 2, paragraph 1, clause 2 of the Swedish Companies Act, it is necessary for the resolutions to acquire legal force that the sale in each instance is approved by a general meeting of shareholders in AB Ångpanneföreningen. For the resolution under item 6 of the agenda to be valid, it is required that the proposal is adopted by shareholders representing at least nine-tenths both of the votes cast and of the shares represented at the general meeting. --------------------- A proxy form for shareholders who wish to take part in the meeting via proxy will be available from the company at Fleminggatan 7 in Stockholm from 31 July 2007 and on the company's website: www.afconsult.com. As per 26 July 2007 there was a total of 16,368,926 shares issued and outstanding in the company: these represent 23,608,868 votes, divided into 804,438 "A" shares representing 8,044,380 votes and 15,564,488 "B" shares representing 15,564,488 votes. After full conversion the number of shares will rise to 16,993,926. Stockholm, Sweden - July 2007 AB Ångpanneföreningen (publ) The Board of Directors


 

This document (and the information contained herein) is not for publication or distribution in or into the United States, Australia, Canada and Japan. Hamilton, Bermuda, 27 July 2007- Sealift Ltd ( the Company), the parent company of the Dockwise group of companies, intends to apply for a listing on the Oslo Stock Exchange. In connection with the intended listing, an offering of shares, consisting of both primary and secondary shares, is currently envisaged. The listing and share offering is expected to take place before the end of September 2007. The Company will be renamed Dockwise Ltd pending shareholder approval on 30 July 2007. The Company's shares are currently traded on the Norwegian OTC market with a market capitalization of NOK 5.3 billion. On Monday, 30 July 2007, the Company will publish its Q1 2007 results at 08:00 CET; 07:00 BST; 02:00 EST. Other dates: AGM 30 July 2007 Q2 Results Release 22 August 2007 About Sealift/the Dockwise Group The Dockwise group of companies is one of the world's leading integrated heavy lift services providers. Following its recent combination with its parent company Sealift Ltd, the Dockwise Group currently owns a fleet of 22 vessels, of which 17 are semi-submersible heavy transport vessels and the remaining 5 are due to be converted into semi-submersible heavy transport vessels. The Dockwise group of companies is able to transport the heaviest cargos over vast distances. In addition, the Dockwise group of companies provides its customers with high value added services such as engineering, project management and front-end engineering design, particularly in the transportation and installation of offshore structures business. This capability will be further enhanced after completion of the recent acquisitions of Offshore Kinematics Inc and Ocean Dynamics LLC. Such completion is expected to take place before the end of July 2007. The Dockwise Group of companies employs about 800 people worldwide and has a global network of offices in Bermuda (the Company's headquarters), Breda (The Netherlands, where the operational headquarters of the Dockwise Group of companies are located), Houston (Texas, USA), Shanghai (China), Shenzen (China), Busan (South Korea), Lagos (Nigeria), Fort Lauderdale (USA), Golfe Juan (France) and Genua (Italy), as well as 8 representing agents, the Dockwise Group of companies provides an extensive service network to its clients. For further information: www.dockwise.com -------------------------------------------------------------------------------------------------------------- Note, not for publication For further information: Stefan Malfliet, Chief Financial Officer Jacqueline Lenterman, Investor Relations Tel : +31 (0)6 29 39 39 69 This announcement is not an offer to sell or a solicitation of any offer to buy the securities of Sealift Ltd, to be renamed Dockwise Ltd following shareholder approval, (the "Company", and any such securities, the "Securities") in the United States or in any other jurisdiction. The Securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States unless registered under the Securities Act or an exemption from such registration is available. No public offering of Securities in the Company is being made in the United States. The offer to acquire securities pursuant to the proposed offering will be made, and any investor should make his investment, solely on the basis of information that will be contained in the prospectus to be made generally available in Norway in connection with such offering. This communication is directed only at (i) persons outside the United Kingdom, or (ii) persons having professional experience in matters relating to investments who fall within the definition of investment professionals in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or (iii) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. Any investment or investment activity to which this communication relates is available only to and will be engaged in only with such persons. Persons within the United Kingdom who receive this communication (other than persons falling within (ii) and (iii) above) should not rely on or act upon this communication.


 

- All segments contribute to sales growth - Wholesale and mail order show particularly strong growth - Fiscal year targets for 2007 reaffirmed Hamburg, 27 July 2007. Today the wine trading group Hawesko Holding AG (HAW GR, HAWG.DE, DE0006042708) released its interim report for the first six months of fiscal year 2007 as well as the figures for the second quarter. During the quarterly period from 1 April to 30 June 2007 the Group increased its net sales compared to the same quarter of the previous year (¤ 63.9 million) by 14% to ¤ 73.1 million (not including value-added tax, VAT). All segments contributed to this increase in sales. In particular, the wholesale and mail order segments each showed solid growth of 21% compared to the same period of the previous year; mail order benefited especially from sales to new customers. In the quarter under review, the consolidated operating result (EBIT) totalled ¤ 1.5 million (previous year: ¤ 1.9 million) and was affected primarily by the realisation of planned measures to acquire new customers. Consolidated earnings (after taxes and minority interests) were ¤ 0.6 million (same quarter in the previous year: ¤ 0.9 million). In the first six months of the current fiscal year (1 January to 30 June 2007), the Group posted sales of ¤ 146.3 million, an increase of 10% compared to first six months of the previous year (¤ 132.9 million). In the same period, the market for wine as a whole in Germany grew by 1.2% (in gross terms, including the increase in VAT from the beginning of the year), according to a survey of the Gesellschaft für Konsumforschung, GfK. Particularly noteworthy here is the clear improvement in the second quarter, after the wine market suffered a decline of 2.3% in the first three months of the year directly following the increase of VAT in Germany. The Hawesko Group once again performed better than the wine market overall and gained market share. The operating result of the Hawesko Group in the first six months was ¤ 3.4 million (first six months of the previous year: ¤ 4.9 million). Consolidated earnings after taxes and minority interests amounted to ¤ 1.5 million (¤ 2.8 million). In the view of the Hawesko management board, the operational targets for fiscal year 2007 as a whole remain valid: an increase in sales (previous year sales: ¤ 303 million) and an EBIT at the previous year's level (¤ 18.6 million). In the management board's estimation, economic and business conditions remain good, and these have given a noticeable boost to efforts aimed at the acquisition of new customers. CEO Alexander Margaritoff stated: "With the current push, we are improving our potential for organic sales and earnings growth, and are looking forward to the advancements on the German wine market with great confidence. Current trends are clearly in our favour, especially the renewed consumer interest in real quality and in the things that make life enjoyable. Thus our position in the market is excellent and we will resolutely make use of these trends." Hawesko Holding AG is the leading supplier of premium wines and champagnes. Its sales channels include specialist wine retail (Jacques' Wein-Depot), wholesale (Wein Wolf and CWD Champagner- und Wein-Distributionsgesellschaft) and mail order (particularly Hanseatisches Wein- und Sekt-Kontor). The Group employed an average of 551 staff members during the past fiscal year. The shares of Hawesko Holding AG are listed on the Hanseatic Stock Exchange in Hamburg as well as in the GEX of the Frankfurt Stock Exchange. # # # The complete six-months report for 2007 can be found at http://www.hawesko.com, "Investor Relations" --> "Financial Infos" --> "Financial Reports". Published by: Hawesko Holding AG Postfach 20 15 52 20205 Hamburg, Germany Internet: http://www.hawesko.com (company information) http://www.hawesko.de (online shop) http://www.jacques.de (Information Jacques' Wein-Depot) Press/Media: Vera Maria Bau VMB Consulting Phone +49 (0)228 4496 240 Fax +49 (0)228 4496 298 E-mail: vmb.pr@t-online.de Investor Relations: Thomas Hutchinson Hawesko Holding AG Phone +49 (0)40 30 39 21 00 Fax +49 (0)40 30 39 21 05 E-mail: ir@hawesko.com --- End of Message --- HAWESKO Holding AG Postfach 201552 Hamburg WKN: 604270; ISIN: DE0006042708; Index: CDAX, Prime All Share, SDAX, CLASSIC All Share, GEX; Listed: Amtlicher Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Amtlicher Markt in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover;


 

Oslo, July 27, 2007: Renewable Energy Corporation ASA (REC) reported revenues of NOK 1,673 million in the second quarter 2007, an increase of 67 percent from the NOK 1,003 million reported in the second quarter of 2006. Revenues for the first half of 2007 were NOK 3,288 million compared with the NOK 1,875 million reported for the first half of 2006, representing an increase of 75 percent. Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to NOK 812 million in the second quarter 2007, compared with NOK 387 million in the second quarter 2006. The EBITDA margin of 49 percent in the second quarter 2007 compares with 39 percent in the same quarter last year. First half over first half, the EBITDA increased 119 percent from NOK 766 million in 2006 to NOK 1,681 million in 2007. The operating profit (EBIT) was NOK 679 million in the second quarter, compared with NOK 303 million in the same quarter in 2006. The EBIT margin increased to 41 percent from 30 percent. For the first six months of 2007 the EBIT was NOK 1,416 million compared with NOK 601 million for the same period of 2006, representing an increase of 135%. Profit before tax was NOK 716 million in the second quarter 2007, compared with NOK 274 million, excluding and effect of convertible loans, in the second quarter 2006. For the first two quarters of 2007 the adjusted profit before tax was NOK 1,498 million in 2007 and NOK 518 million in 2006. Earnings per share were NOK 1.01 in the second quarter 2007 and 2.09 year to date, compared with NOK 0.40 in the second quarter 2006 and -0.56 for the first six months of 2006, on both a basic and diluted basis. Please see the attachments on www.newsweb.no or www.recgroup.com For more information, please contact; Jon Andre Løkke, SVP & Investor Relation Officer, +47 67 81 52 65 About REC REC is uniquely positioned in the solar energy industry as the only company with a presence across the entire value chain. REC Silicon and REC Wafer are the world's largest producers of polysilicon and wafers for solar applications. REC Solar produces solar cells and solar modules. REC Group had revenues in 2006 of NOK 4,334 million and an operating profit of NOK 1,574 million. Please also see www.recgroup.com


 

NEWS RELEASE DATE: July 27, 2007 FOR IMMEDIATE RELEASE TRADING SYMBOLS: TSX-V (Canada): WGP.V FRANKFURT: WE6.F WESTERN GEOPOWER RAISES $18.4 MILLION VANCOUVER, Canada, July 27, 2007, TSX Venture Exchange Trading Symbol: WGP - Western GeoPower Corp., a renewable energy development company, today announced commitments for $18.4 million in financing through a combination of private placement and exercise of warrants and options. The private placement comprises 25,000,000 shares of Western GeoPower at $0.25 per share for proceeds of $6,250,000 from two strategic investors - Iceland-based geothermal developer, Geysir Green Energy will acquire 20,000,000 common shares and Glitnir Bank, the second-largest Icelandic bank, will acquire 5,000,000 common shares. On closing of the private placement, a representative of Geysir will be appointed to the Western GeoPower Board. The private placement is subject to regulatory approval and the shares will be subject to a four-month hold. A total of 46,026,668 warrants are currently being exercised at a price of $0.25 per share for proceeds of $11,506,667. Of this amount, 15,333,334 free-trading shares will be issued to some subscribers and 30,693,334 units (the "Units") will be issued to other subscribers pursuant to the warrant exercise incentive program announced June 29, 2007. The Units comprise one common share at $0.25 and one new warrant which will allow the holder to acquire one common share of Western GeoPower at $0.35 per share until December 30, 2008. The warrants are subject to an acceleration provision, which provides that, if the Company's shares trade at $0.50 or more for ten consecutive trading days, it will trigger a 30 day timeframe within which to exercise the warrants or they will expire. The Units are subject to a four-month hold. A Canadian financial institution has exercised 4,170,416 Agents Options at $0.15 for proceeds of $625,562. "We are pleased to report that the $18.38 million of funding represents most of the equity component of the project finance for drilling the wells and constructing our proposed 25.5 megawatt (net) power plant at The Geysers Geothermal Field in California," said Kenneth MacLeod, President and CEO of Western GeoPower. "As an added benefit, having Geysir Green Energy and Glitnir Bank as strategic investors reinforces our ability to secure the remainder of the project finance on favourable terms." Geysir Green Energy was formed in early 2007 with a mission to become a leading investor in geothermal power projects. Geysir is pursuing expansion through mergers and acquisitions and the development of new projects. Well capitalized to realize on its goals, Geysir has a suite of directors, management and technical staff with considerable experience in geothermal funding, development and operations. Under the leadership of CEO Asgeir Margeirsson, Geysir is investing in the development and construction of geothermal plants, acquiring interests in geothermal plants currently owned by power utilities and participating in the privatization of energy companies in various parts of the world. "Our purchase of an equity interest in Western GeoPower fits perfectly with our plan to be a participant in the largest energy market in the world - the United States," said Mr. Margeirsson. "We look forward to assisting Western GeoPower in expanding its capacity to acquire and develop additional projects." The financial group Glitnir offers universal banking and financial services. Glitnir is a leading niche player in three global industry segments; seafood/food, sustainable energy, and offshore services vessels. The Glitnir group has operations in Iceland, Norway, Sweden, Denmark, Finland, the UK, Luxembourg, Russia, Canada and China and plans to open a US office in New York in the fall of 2007. Glitnir is listed on the Icelandic Stock Exchange. . Corporate Overview Western GeoPower Corp. is a renewable energy company dedicated to the development of geothermal energy projects for the delivery of clean, baseload electricity generation. The Company is developing a 25.5 Megawatt (net) geothermal power plant at The Geysers Geothermal Field in Sonoma County, California, United States. Western GeoPower is also developing the South Meager Geothermal Project in British Columbia, Canada. On behalf of Western GeoPower Corp. "Kenneth MacLeod" Kenneth MacLeod, President & CEO Cautionary Note Regarding Forward-Looking Statements Statements in this release that are forward-looking are subject to various risks and uncertainties concerning the specific factors identified above that reflect the Company's expectations and projections about its future results. The Company has tried whenever possible to identify these forward-looking statements which include but are not limited to, words such as "anticipates," believes," "estimates," "expects," "plans," "intends," "potential," and similar expressions. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in the forward-looking statements. The Company disclaims any obligation or intention to update or to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Such information contained herein represents management's best judgment as of the date hereof based on information currently available. This news release is not for dissemination in the United States of America or to United States of America news services. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. For more information or to be put on our email list, please contact our office: (604) 662-3338 or US/Canada Toll Free: 1-866-662-3322, email: info@geopower.ca Investor Relations: IR@geopower.ca --- End of Message --- Western GeoPower Corp. 837 West Hastings Street Suite 411 Vancouver, BC<br>V6C 3N6 Canada WKN: 254049; ISIN: CA95827Q1037; ;


 

Gross margin rose from 24.0% to 25.0%; operating income rose by 28.0%; operating margin increased to 6.8% Almere, 27 July 2007, 07.00 hrs Highlights second quarter 2007 * Revenue rose by 11.2%; double-digit growth was realised for the seventh consecutive quarter. Corrected for working days revenue grew by 12.1% * The gross margin rose by 100 basis points to 25.0% (2nd quarter 2006 24.0%) * Operating income rose by 28.0% to ¤ 65.3 million (2nd quarter 2006: ¤ 51.0 million) * The recurring EBITA (not including ¤ 4 million rebranding expenses and ¤ 5.7 million French subsidies from preceding periods) amounted to ¤ 63.6 million * The operating margin came to 6.8% and rose by 90 basis points on the second quarter of 2006 * Net income totalled ¤ 39.2 million and rose 40.0% on last year (2nd quarter 2006: ¤ 28.0 million not including income from sale Luzac College). Earnings per share came to ¤ 0.62 compared with ¤ 0.44 (not including non-recurring income of ¤ 19.3 million from the sale of Luzac) in 2006 "Our focus on profitability brought our strategic objectives another step nearer in the second quarter", says Ron Icke, CEO of USG People. "The gross margin rose strongly to 25.0% and this improvement combined with revenue growth increased the operating margin to 6.8%.Operating profit from our activities outside the Benelux area more than doubled on last year. This substantially improved the geographic spread of our result. Meanwhile, our specialised labels also showed a clear revenue and profit growth in the second quarter." Consolidated Q2 Q2 growth HY1 HY1 growth results (¤ million) 2007 2006 2007 2006 Revenue 953.7 857.8 11.2% 1,859.9 1,649.2 12.8% Gross profit 238.9 206.2 15.9% 460.6 395.3 16.5% Operating 167.2 148.4 12.7% 332.9 294.0 13.2% expenses Income from sale of Luzac 19.3 19.3 College EBITDA 71.7 77.1 -7.0% 127.7 120.6 5.9% Depreciation 6.4 6.8 -5.9% 12.7 13.5 -5.9% Operating 65.3 51.0 28.0% 115.0 87.8 31.0% income EBITA 65.3 70.3 -7.1% 115.0 107.1 7.4% Amortisation 3.8 3.9 -2.6% 10.1 7.8 29.5% goodwill EBIT 61.5 66.4 -7.4% 104.9 99.4 5.5% Interest -5.2 -5.9 -11.9% -12.8 -12.3 4.1% Income tax -16.8 -13.0 29.2% -28.0 -21.5 30.2% Minority -0.2 -0.3 -0.3 -0.5 interest Net income 39.2 47.3 -17.1% 63.7 65.2 -2.3% Gross margin 25.0% 24.0% 100 bp 24.8% 24.0% 80 bp Cost ratio 18.2% 18.1% 10 bp 18.6% 18.6% EBITA margin 6.8% 8.2% -140bp 6.2% 6.5% - 30 bp Operating 6.8% 5.9% 90 bp 6.2% 5.3% 90 bp margin Earnings per 0.62 0.75 1.00 1.03 share Recurring earnings per 0.60 0.44 1.07 0.73 share * Operating income is EBITA excluding profit from sale of Luzac College ** Operating margin is operating income as a percentage of revenue Notes to the second quarter results 2007 Revenue In the second quarter the group realised 11.2% revenue growth compared with the same period in 2006. Based on the same number of working days the second quarter of 2007 had 0.5 less working days than in 2006, growth stood at 12.1%. At 10.1% organic growth was somewhat lower due to a net positive contribution to revenues from acquisitions and operating companies which had been sold. The strong growth trend of previous quarters declined somewhat during the second quarter. The Netherlands posted 9.3% growth which was slightly below the market level. This was partly due to USG People's large market share in the administrative market segment, which was less fast growing in the second quarter of 2007. In the Dutch market the industrial segment grew by 14.3% in the second quarter while the administrative segment reported 7.4% growth. Second quarter growth in Belgium stood at 7.6% which was more or less in line with first quarter growth. The General and Specialist segments performed somewhat better than in the previous quarter while the exuberant growth at Professionals flattened out slightly. In the Dutch and Belgian home markets the greater focus on profitability meant that revenue growth lagged somewhat on the market. Growth in France and Germany continued strong with revenue up 18.8% and 20.0% respectively compared with the second quarter of 2006. This meant that the group considerably outperformed the market in France. Spain and Italy posted around 9% growth and other countries posted joint growth of 32.7%. Gross margin The second quarter gross margin totalled 25.0% compared with 24.0% in the same period of 2006. Extraordinary income in France had a positive effect on the group's gross margin in the second quarter. In France a social security premiums grant arrangement was adjusted and was calculated in arrears as from 2006. Without this non-recurring income the margin stood at 24.5% and hence 0.5 percentage points higher than the second quarter of the previous year. For the third consecutive quarter the gross margin in the Benelux region showed a significant improvement hence reflecting our focus on profitability. Operating expenses In the second quarter operating expenses including depreciation increased by 11.9% on the same period of 2006 whereby expenses, including rebranding expenses, were ¤ 18.4 million higher than the previous year. As in the previous quarter, the second quarter brought incidental marketing and promotion expenses for the ongoing rebranding operations. These expenses amounted to ¤ 4 million in the second quarter. Not counting these expenses the increase in expenses totals 9.3% which is in line with the increase in the first quarter. Hence the adjusted cost ratio stands at 17.8% for the second quarter (2nd quarter 2006: 18.1%). Up to and including June rebranding expenses totalled ¤ 10 million. Alongside expense increases due to volume growth and additional rebranding expenses, in the first half of 2007 a reserve was also formed for a share based bonus plan. In 2006 the reserve was only formed in the fourth quarter. Expenses for this share plan totalled ¤ 1.5 million in the second quarter and ¤ 2.8 million for the first half year. Not including the expenses for rebranding and for the share plan the cost increase in the second quarter was 8.3% compared with the second quarter of 2006. EBITA Volume growth with higher gross margins resulted in an EBITA of ¤ 65.3 million for the second quarter (2nd quarter 2006 not including income from the sale of Luzac: ¤ 51.0 million). The recurring EBITA, adjusted for the effect of the French subsidies from preceding periods, and rebranding expenses in 2007, and not including income from the sale of Luzac in 2006, totalled ¤ 63.6 million compared to ¤ 51.0 million in 2006. Operating income rose by 28.0% compared with the same period of 2006. As a percentage of revenue the EBITA margin stood at 6.8%. Profitability rose in all regions and, not including the effect of the French subsidies in preceding periods; during the second quarter just over 14% of the EBITA was realised outside the Benelux area (2nd quarter 2006: 11.8%). In line with our objectives this significantly improved the geographic spread. Amortisation Second quarter amortisation amounted to ¤ 3.8 million. This amortisation relates to full regular amortisation of financial stated client relations and brand rights. Financial expenses Financial expenses totalled ¤ 5.2 million compared with ¤ 5.9 million in the second quarter of the previous year. Second quarter financial expenses in both 2007 and in 2006 include a fair value increase for interest derivatives. This value increase amounted to ¤ 3.3 million in 2007 and ¤ 3.0 million in 2006. The decline in financial expenses results from a lower debt position in 2007. Tax At 29.9% the tax rate was exactly at the average nominal rate. The structural tax-exempted income from the Belgian coordination centre compensated for the negative effect of the one-off decrease in German tax rate and non-deductible expenses, mainly in Belgium. Tax paid in the second quarter totalled ¤ 3.3 million whereby the cash out tax rate stood at 5.9%. The cash out tax rate for the first half year totalled 21.5%. Net income Net income in the second quarter stood at ¤ 39.2 million which is ¤ 11.2 million higher than profit not including the income from the sale of Luzac in the second quarter of 2006 (2006 net income 2nd quarter not including income from the sale of Luzac: ¤ 28.0 million). Earnings per share in the second quarter of 2007 based on the number of issued shares on 30 June came to ¤ 0.62. Working on the basis of a recurring net income, not including the net incidental subsidies and rebranding expenses (net effect ¤ 1 million) of ¤ 38.3 million, earnings per share amount to ¤ 0.60. In the second quarter the number of issued shares increased by 516,370 due to stock dividends payout and the exercise of rights on personnel options. Balance sheet and cash flow In the second quarter the balance total increased by ¤ 60 million due to factors including the seasonal increase of operating capital. There was also a net increase in equity due to the addition of the net result for the second quarter, contrasting with a cash dividend of ¤ 29 million. The increase in equity in the second quarter totalled a net ¤ 11 million whereby equity on 30 June stood at ¤ 612 million. On 30 June the net debt position stood at ¤ 663 million and increased during the second quarter due to factors including increased operating capital and the dividend, as well as the acquisition paid in cash. Capital adequacy on 30 June stood at 31.3%. During the first half of 2007 operating cash flow totalled just over ¤ 40 million and was hence double the level of the first half of 2006. Due to the cash dividend payout and an acquisition paid in cash in May, together with capital expenditure in software, net cash flow in the second quarter totalled - ¤ 3 million. Results by segment a. General Staffing Results Q2 Q2 Growth Inc. June Inc. June Growth ( in m euro) 2007 2006 2007 2006 Revenue 577.2 520.5 10.9% 1,112.9 983.2 13.2% EBITA 31.7 22.9 38.4% 49.5 33.1 49.5% General Staffing posted 10.9% higher revenue in the second quarter with income strongly improved by 38.4% compared with last year. The EBITA stood at ¤ 31.7 million compared with ¤ 22.9 million in the second quarter of 2006. Due to a sharper focus on performance profitability improved in all regions. The rebranding operations were continued apace and the second quarter saw completion of the first campaigns in Belgium for the name change from Creyf's to Start People. In the Netherlands revenue at Start People rose by 7.9% and a strong year-on-year improvement was realised in the EBITA, mainly due to a higher gross margin. A combination of factors meant that this was below the market level. USG People has a relatively large share of the administrative segment and of the central government sector - where growth in 2007 was below the industrial market. Furthermore, sharper pricing policy in the faster-growing industrial segment meant that a large number of volume contracts were discontinued. Growth in Belgium improved somewhat compared with the preceding first quarter. Revenue increased by 5.2% in the second quarter compared to the previous year. First quarter growth stood at 4.4%. As in the Netherlands growth was lower due to discontinuation of a number of low-profit volume contracts, due to a focus on better profitability. Growth in France remained strong with revenue up 17.0% on the second quarter of the previous year. Meanwhile, profitability rose strongly without the impact of higher subsidies on social security expenses. In Spain growth in the General segment was lower due to the transfers of a number of specialist-oriented branches from the old Creyf's label to Unique (Specialist Staffing). At 9.3% growth in Italy was slightly up on the 8.3% of the first quarter. A large-scale operation to integrate and renovate the office network is now in its final phase. During the first half year the restructuring programme meant a lower level of growth with improved profitability due to lower cost levels. Germany and the other countries posted 20.0% and 32.7% growth consecutively. Both regions posted a positive result. b. Specialist Staffing* Results Q2 Q2 Growth Inc. June Inc. June Growth ( in m euro) 2007 2006 2007 2006 Revenue 279.4 251.0 11.3% 549.9 491.7 11.8% EBITA 32.9 26.3 25.1% 63.7 49.7 28.2% The Specialist Staffing labels, including Content and Unique posted 11.3% higher revenue in the second quarter. Specialist staffing also realises most revenue in the administrative segment. At 10.9% growth in the Netherlands was higher than total market growth of 10.5%. In Belgium growth in Specialist Staffing stood at 6.3% which was higher than at general staffing. As with General Staffing the pricing policy at Specialists was also sharpened, with a focus on increasing profitability. c. Professionals* Results Q2 Q2 Growth Inc. June Inc. June Growth ( in m euro) 2007 2006 2007 2006 Revenue 92.5 80.4 15.0% 185.0 157.0 17.8% EBITA 8.3 8.1 2.5% 15.4 16.5 -6.7% The Professionals segment showed the strongest growth due to the addition of the Utrechtse Juristen Groep as from June 2006. Organic growth stood at 9.0%. The labels for highly trained technical personnel (ICT specialists and engineers) including the activities of Innotiv, Beaver, United Technical Solutions and United ICT Solutions were combined under the USG Innotiv label earlier in the year. The EBITA, which had declined year-on-year in the first quarter, rose again in the second quarter. Prospects 2007 The continuing growth confirms our previous expectations of increases in revenue in all regions where we provide our services. Looking to the rest of the year we also expect continuing revenue growth at around 10% for USG People. In this context the gross margin in the home markets may improve lightly apace with the further development of the economic cycle. In view of the positive revenue and result developments in the first half year, and expectations for the remainder of the year, we confirm our operating margin target for 2007, which we raised in the first quarter, at around 7%. * Compared with previous presentations the segments have been adjusted whereby 2006 figures have been made comparable. For more information please contact: Ron Icke CEO +31 (0)36 529 95 05 ricke@usgpeople.com Financial calendar 29 October 2007 Publication third quarter results 2007 (before start of trading) Analysts' meeting and press conference third quarter results 7 March 2008 Publication fourth quarter and annual results 2007 (before start of trading) Analysts' meeting and press conference fourth quarter and annual results 29 April 2008 Publication first quarter results 2008 (before start of trading) Conference call analysts first quarter results General Meeting of Shareholders The predictions and expectations given in this press release are provided without any form of guarantee as to their future realisation. This press release comprises or refers to statements related to the future as regards the intentions, opinions or current expectations of USG People and its board/management or other management in regard to USG People and its operations. In general such terms as "may", "shall", "expect", "intention", "estimate", "foresee", "believe", "intend to", "attempt", "continue" refer to statements regarding the future. Such future-related statements do not guarantee future performances. They are based on current views and assumptions and are subject to known and unknown risks, uncertainties and other factors which are largely outside the sphere of influence of USG People, whereby the actual results or developments may in fact diverge from future results or developments as set out implicitly or explicitly in the statements regarding the future. USG People does not accept any obligation whatsoever in regard to the updating or alteration of the statements regarding the future on the basis of new information, future events or for whatsoever reason, except where so required as per legislation and regulation or a duly authorised body. Profile USG People USG People provides all forms of flexible staffing/employment and a service offering covering human resources and customer care. The group, with headquarters in Almere in the Netherlands is active in a substantial number of European countries - the Netherlands, Belgium, Luxembourg, Germany, Austria, Switzerland, the Czech Republic, Slovakia, Poland, France, Italy, Spain and Portugal. The brand portfolio of USG People comprises Start People, Creyf's, Proflex (General Staffing), Unique, Content, Technicum, Secretary Plus, StarJob, Express Medical, Ad Rem Young Professionals, SYS, Financial Forces (Specialist Staffing), USG Innotiv, USG Energy, USG Capacity, HR Forces, Legal Forces, Utrechtse Juristen Groep, Accea, Carela, USG Restart and Multicompta (Professionals), and Call-IT (Customer Care Services). The shares of USG People are listed on the Euronext Amsterdam N.V. stock exchange (ticker: USG) and are included in the Midkap-index (AMX). For more information on USG People or one of its operating companies visit our website: www.usgpeople.com. Appendix 1: Information per segment Appendix 2: Segmentation by geography Appendix 3: Income statement Appendix 4: Consolidated balance sheet Appendix 5: Consolidated statement of changes in shareholders equity Appendix 6: Cash flow statement Appendix 7: Key figures THE PRESS RELEASE INCLUDING APPENDICES IS ENCLOSED AS A PDF FILE


 

CAMBRIDGE, U.K. and LILLE, FRANCE -- (MARKET WIRE) -- 07/26/07 -- Pathogen Removal and Diagnostic Technologies Inc. ("PRDT"), a joint-venture between ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") and The American Red Cross ("ARC"), along with MacoPharma, PRDT's co-development, commercial and manufacturing partner, announces that MacoPharma contributed to an Independent Public Inquiry on Contaminated Blood and Blood Products that was held in London, U.K., on July 25, 2007. The purpose of the Independent Public Inquiry on Contaminated Blood and Blood Products as cited in The Rt Hon The Lord Archer of Sandwell QC's opening statement is, "To unravel the facts, so far as we are able, and to point to lessons that may be learnt. As in the case of any Public Inquiry the consequences of its report cannot be foreseen. Hopefully our findings may help to restore public confidence in the future treatment of patients. We trust it will also help those afflicted and bereaved to come to terms with the tragedy; knowing much more of how it came about." For more information refer to the Independent Public Inquiry on Contaminated Blood and Blood Products site www.archercbbp.com. Copy of the transcript is available at http://www.archercbbp.com/hearing.php. MacoPharma, as an authority in the blood product and medical device field, has voluntarily come forward to offer its expertise on these matters to the panel of the Independent Public Inquiry on Contaminated blood and blood products. This is pursuant to PRDT and MacoPharma's efforts with the National Blood Transfusion Services of the U.K. and Ireland. In 2004 PRDT formed a strategic alliance with MacoPharma. In May 2006 a licensing agreement was signed for the P-CAPT(R) filter, which is targeted initially at reduction of TSE pathogens from red blood cell concentrate, with a further co-development agreement signed between the parties in June 2006. It was further announced at the British Blood Transfusion Society Meeting in September 2006, that the P-Capt(R), had received European Regulatory Approval (CE mark). About ProMetic Life Sciences Inc. ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle-East. About Pathogen Removal and Diagnostic Technologies Inc. (PRDT) PRDT is a joint-venture company set up in April 2002 by The American Red Cross and ProMetic Life Sciences Inc. PRDT allows for a reciprocal exchange of technology and knowledge developed between the American Red Cross and ProMetic. PRDT's main goal is to develop products and devices to remove and detect different pathogens from biological sources. This research augments work that ProMetic, the American Red Cross and PRDT's scientific founders have been conducting independently for many years. About MacoPharma MacoPharma (www.macopharma.com) is an innovator in global healthcare with expertise in the fields of transfusion and infusion. The Company has become the largest supplier of in-line leucodepletion filtration sets in Europe and is expanding its efforts into the biotherapy field by developing products for cell expansion, in addition to cell/organ processing and freezing. Headquartered in the Lille metropolitan area (France), MacoPharma has three manufacturing facilities in Europe and its products are now sold into more than 55 countries worldwide. One of MacoPharma's aims is to provide a comprehensive range for the reduction of infectious agents in plasma, platelets and red cells. This is conducive with the MacoPharma product development strategy of the continuous quest, through partnerships, for improved safety, efficacy, and quality of transfusion, infusion and biotherapy. Forward Looking Statements This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, the Company's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of the Company's Annual Information Form for the year ended December 31, 2006, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason. Contacts: ProMetic Life Sciences Inc. Pierre Laurin President and CEO +1-514-341-2115 p.laurin@prometic.com ProMetic Life Sciences Inc. Anne Leduc Manager, Communications +1-514-341-2115 ext 234 a.leduc@prometic.com Iwona Walicka Marketing Director +33-67-683-5621 iwona.walicka@macopharma.com www.prometic.com


 

Venlo, The Netherlands -- July 26, 2007 - QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced that it has successfully completed its exchange offer for all outstanding shares of common stock of Digene Corporation (NASDAQ: DIGE). The exchange offer expired at 11:59 p.m. Eastern Time on Friday, July 20, 2007. At the time the exchange offer closed, 23,270,298 shares, representing approximately 94.6%, of Digene's outstanding common stock, had been tendered. Digene stockholders elected to receive QIAGEN ordinary shares in exchange for approximately 90% of the Digene shares tendered, and therefore proration of Digene common stock elections will be required. QIAGEN will announce the proration calculations when completed and, in any event, on or before Thursday, August 2, 2007. QIAGEN expects to complete its acquisition of Digene on Monday July 30, 2007 through a short-form merger under Delaware law. In the short form merger, QIAGEN will acquire all other Digene shares at the same price and with the same election procedure (other than for those shares as to which holders properly exercise appraisal rights) offered in the exchange offer. QIAGEN will be able to effect this merger without a meeting of Digene stockholders. Stockholders who continue to hold Digene shares at the time of the merger and who fulfill certain other requirements of Delaware law will have appraisal rights in connection with the merger. At the completion of the merger, Digene will become a wholly owned subsidiary of QIAGEN's affiliate QIAGEN North American Holdings, Inc. "We are rapidly advancing towards closing this transaction and are very pleased with the speed and results of this process", said Peer M. Schatz, QIAGEN's Chief Executive Officer. About QIAGEN QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such as pre-analytical sample preparation and assay solutions in research for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and target specific assays. The company's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 2,000 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. In this press release QIAGEN is using the term molecular diagnostics. The use of this term is in reference to certain countries, such as the United States, limited to products subject to regulatory requirements. Current QIAGEN molecular diagnostics products are 34 EU CE IVD assays, six EU CE IVD sample preparation products, one 510k PAX RNA product, nine China SFDA IVD assays and 98 general purpose reagents. Further information about QIAGEN can be found at www.qiagen.com. Forward-Looking Statements This communication contains certain forward-looking statements. These forward-looking statements are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, the risk of unanticipated administrative delays, risks relating to the integration of the technologies and businesses of QIAGEN and Digene, unanticipated expenditures, changing relationships with customers, suppliers and strategic partners, conditions of the economy and other factors described in the most recent reports on Form 20-F, Form 6-K and other periodic reports filed with or furnished to the Securities and Exchange Commission by QIAGEN and the most recent reports on Form 10-K, Form 10-Q, Form 8-K and other periodic reports filed by Digene with the Securities and Exchange Commission. Additional Information This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Digene. QIAGEN has filed a Registration Statement on Form F-4, as amended, with the Securities and Exchange Commission in connection with the exchange offer and subsequent merger. Digene stockholders should read those filings, and any other filings made by QIAGEN with the SEC in connection with the proposed Digene acquisition, as they contain important information. These SEC filings, as well as QIAGEN's other public SEC filings, can be obtained without charge at the SEC website at www.sec.gov. and at QIAGEN's website at www.qiagen.com. Additional copies of the prospectus, which is a part of QIAGEN's Registration Statement on Form F-4, can be obtained by contacting QIAGEN's IR department at QIAGEN Strasse 1, 40724 Hilden, Germany, or from Digene, by directing a request to Digene at 1201 Clopper Road, Gaithersburg, MD, 20878. # # # --- End of Message --- Qiagen N.V. Spoorstraat 50 KJ Venlo Netherlands WKN: 901626; ISIN: NL0000240000; Index: HDAX, MIDCAP, Prime All Share, TECH All Share, TecDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;


 

- Finance will support development of US geothermal industry Reykjavík, 25th July 2007 Link to photos of Jonathan Logan, Timothy Spanos, Jóhannes Hauksson and Árni Magnússon from Glitnir, Louis Capiano from ThermaSource, Thomas King from US renewables, Hjörtur Steindórsson and Michael Richard from Glitnir: Photo 1, Photo 2, Photo 3 Glitnir bank has agreed to provide ThermaSource LLC (TSL) with up to USD 22.5 million to finance the acquisitions of drilling rigs (and related equipment) and working capital needs. TSL will provide project management, engineering services and supervise effective drilling programs as well as provide the geothermal industry with a fleet of drilling rigs and experienced geothermal crews. Louis Capuano Jr. CEO of ThermaSource LLC: "With the completion of Glitnir's financing ThermaSource will have the financial resources to fund our rapid growth. Glitnir's focus on the geothermal energy projects will provide a strong partner in ThermaSource's continuing growth." ThermaSource's majority owners, US Renewables Group and Carlyle/Riverstone Group, are leading Private Equity Funds with focus on the energy sector. Thomas King, CEO of US Renewables: "This financing is an important milestone in the growth of ThermaSource as the premier supplier of drilling and consulting services to the geothermal sector. We have been very impressed by Glitnir's knowledge of the geothermal market, its ability to anticipate structural requirements, and its approach to deal making in a spirit of partnership. We look forward to a long and profitable relationship with Glitnir through ThermaSource and in other renewable energy investments." Lárus Welding, CEO of Glitnir: "This agreement is an important milestone in establishing Glitnir as the leading geothermal bank in the world. The renewable energy team, led by Árni Magnússon, is both dedicated and focused and I am certain that the teamwork between Glitnir and ThermaSource will be very successful." Árni Magnússon, Managing director of global sustainable energy at Glitnir: "Glitnir aims to be the leading bank in financial services to the geothermal sector. ThermaSource is a very professional, fast growing drilling company in the US, which specialises in servicing the geothermal industry. It is therefore a great pleasure to ensure ThermaSource with the financing of machines and equipment which will support the important development of the US geothermal industry." About ThermaSource ThermaSource LLC provides the geothermal industry with engineering project management, consultation services and drilling rigs with crews. With over 420 years of geothermal experience on the ThermaSource, LLC management team, the educated and experienced drill crews and a consultation service that has been our business mainstay since 1980,ThermaSource, LLC is a well-respected contributor to the geothermal industry. For more information: www.thermasource.com About Glitnir The financial group Glitnir offers universal banking and financial services. Glitnir is a leading niche player in three global industry segments; seafood/food, sustainable energy, and offshore services vessels. Services include retail, corporate and investment banking, stock trade/brokerage and capital management. Glitnir considers Iceland and Norway its home markets. The Glitnir group has operations in Iceland, Norway, Sweden, Denmark, Finland, the UK, Luxembourg, Russia, Canada and China and plans to open a US office in New York in the fall of 2007. Glitnir is listed on the Icelandic Stock Exchange. For more information: www.glitnirbank.com Further information: Árni Magnússon, Managing director of sustainable energy, tel: +354 440 4688 Pétur Þ. Óskarsson, Executive director Communications, tel: +354 844 4990. Photo Caption: Representatives of Glitnir and ThermaSource celebrate the agreement at Glitnir headquarters in Reykjavík, Iceland.


 

Today the financial services company Exista hf. published its interim financial statements for the first six months of the year 2007. Performance in the second quarter: * After-tax profit EUR 221 million * Earnings per share during the period 1.96 cents * Annualised return on equity 32% Main results from the interim financial statements for the period January through June 2007: * After-tax profit EUR 862 million * Earnings per share during the period 7.65 cents * Annualised return on equity 70% * Operating Businesses yielded a profit of EUR 210 million after taxes * Investment Businesses yielded a profit of EUR 652 million after taxes * Total assets EUR 7.7 billion at the end of June, an increase of 75% during the first half of the year * Total equity EUR 2.8 billion, an increase of 49% during the first half of the year * Equity ratio 36.7% at the end of the period Lýdur Gudmundsson, Executive Chairman of the Board: "Operations in the second quarter were sound, and Exista turned in a strong performance for the first six months of the year. Market conditions have been favourable, which has facilitated the Group's development. We are working steadily toward our objective of creating an even broader revenue base for Exista." For further information on the Group's interim accounts, please contact: Sigurdur Nordal Managing Director Group Communications tel: +354 550 8620 (ir@exista.com) About Exista Exista hf. is a financial services group with particular focus on insurance and asset finance. As an international investor, Exista also has strategic holdings in several companies, including Sampo Group, Kaupthing Bank, Bakkavör Group, and Iceland Telecom. Exista's goal is to use its financial strength for the further development of its business in Northern Europe. Information on Exista hf. and its financial statements can be found on the Group's website: www.exista.com.


 

Business highlights for the half year and Q2 2007 * Turnover £723.0 million in H1, up 30% and £373.6 million in Q2, up 25% * Growth in like-for-like sales in underlying business 10.0% in H1 and 6.4% in Q2 * EBITDA £75.9 million in H1, up 12%, and £40.8 million in Q2, flat year-on-year * EBITDA ratio, net of agency sales change 11.2% in H1 and 11.7% in Q2 * Operating profit (EBIT) £56.8 million in H1, up 11%, and £31.4 million in Q2, down 4% * Profit after tax £25.6 million in H1, up 27%, and £15.7 million in Q2, up 11% * Shareholders' earnings £25.1 million in H1, up 27%, and £15.5 million in Q2, up 10% * Cash generated from operations £80.3 million in H1, up 29%, £42.1 million in Q2, up 24% * Free cash generated by operating activities £37.2 million in H1, up 28%, £20.3 million in Q2, up 23% * Equity ratio 19.1%, up from 18.2% at year end 2006 * Earnings per share 1.2 pence in H1, up 3% * Return on equity 20.3% compared with 25.2% in H1 2006 * Three acquisitions strengthened Bakkavör Group's operations in Continental Europe and China - 4G in France, Heli Food Fresh in the Czech Republic and Creative Food in China * Re-financing completed providing new £700 million banking facility on favourable terms Ágúst Gudmundsson, Chief Executive Officer, said: "A challenging trading environment, extreme weather conditions in the UK and the impact of a major product-recall affected Bakkavör Group's performance in the first six months of the year. However, our fresh prepared foods sales continued to outperform the total UK food market which is reflected in strong growth in the underlying business. In the first half of the year, we also strengthened our position through acquisitions in Continental Europe and China. Looking ahead, the trading conditions are expected to remain difficult with commodity price pressures coupled with rising inflation and interest rates. Furthermore, the unusually poor weather in the UK, will have an impact on the Group's performance for the remainder of the year. However, consumer demand for healthy and convenient quality foods remains strong and we believe that our products are well suited to continue to meet these consumer needs across our markets." Further Information: Ásdís Pétursdóttir Investor Relations, Bakkavör Group investor.relations@bakkavor.com Tel: +354 858-9715 To subscribe to Bakkavör Group's mailing list, please log onto: www.bakkavor.com/subscribe


 

LOS ANGELES, CA--(Marketwire - July 26, 2007) - The Chief Marketing Officer (CMO) Council and its founder, GlobalFluency, Inc., today announced that they have selected Marketwire as their official newswire service. Marketwire will distribute all news releases associated with the two organizations and their services. GlobalFluency, a worldwide marketing and communication services firm, operates the CMO Council, a non-profit organization dedicated to high-level knowledge exchange, thought leadership and personal relationship building among senior marketing and brand decision-makers. The partnership underscores the value of Marketwire's industry-leading tools for news distribution and communications workflow. With Marketwire as their newswire partner, the CMO Council, the BPM Forum, an organization focused on the understanding of business performance management techniques, technologies, and processes in global enterprises, as well as GlobalFluency and its global clients, will benefit from: -- Marketwire's news optimization services and new media tools, including Search Engine Optimization (SEO) and Social Media tagging; -- Multimedia enhancements such as embedded videos and images; -- Customized news distribution circuits tailored specifically to the industry sector and region; and -- News monitoring and reporting services through Marketwire's News Dashboard. "We chose to partner with Marketwire to enhance our news distribution needs, while meeting the needs of today's marketers," said Liz Miller, vice president, programs & operations, CMO Council. "As an organization of marketing executives, our mission is to stay ahead of industry trends. By partnering with Marketwire, we have a significant opportunity to leverage the latest new media tools and align with the interactive and user-centric nature of communications." Additionally, through Marketwire's Easy PR hosted press room solution, journalists covering CMO Council news and programs will have access to information in a single, easy-to-use, custom online press room. CMO Council member companies and GlobalFluency clients also will have access to exclusive offers when distributing their news through Marketwire. "It is a mark of distinction to partner with a respected organization like the CMO Council -- one with such influence in our own industry and on such a global scale," said Paolina Milana, vice president, marketing, Marketwire. "We look forward to providing the CMO Council with distribution and new media tools to enhance the reach of their news and marketing studies." For more information on all of Marketwire's communication and news distribution solutions, please call 800-774-9473. About the CMO Council The Chief Marketing Officer (CMO) Council is dedicated to high-level knowledge exchange, thought leadership and personal relationship building among senior marketing and brand decision-makers across a wide-range of global industries. The CMO Council's 3,000 members control more than $70 billion in aggregated annual marketing expenditures. Companies represented on the CMO Council have combined annual revenue of over $600 billion. Visit the CMO Council web site to find out about the initiatives geared to address executive marketers' challenges at www.cmocouncil.org. About Marketwire The only fully integrated North America-based global newswire, Marketwire, Inc. is a full-service partner to IR, PR, and MarCom professionals seeking premier distribution, media management, multimedia and monitoring solutions. Marketwire's customer-centric corporate philosophy focuses on being the best by infusing every aspect of its business with the following core attributes: precision, adaptability, innovation, and simplicity. Marketwire delivers its clients' news to the world's media and financial communities. With a reputation for technological leadership, Marketwire offers innovative products and services -- including Social Media, Search Engine Optimization, Dashboard Mobile Financial, News Dashboard coverage reports, exclusive access to networks such as the Canadian Press Wire Network, Easy IR and Easy PR workflow solutions, and more -- that help communication professionals maximize their effectiveness while ensuring accuracy and best practices. Having merged companies (Market Wire and CCNMatthews) in April 2006, and enjoying a combined history of 25 years of service, Marketwire is now majority-owned by OMERS Capital Partners, the private equity arm of one of Canada's largest pension funds. Operating 12 offices worldwide, Marketwire distributes the majority of press releases issued by publicly traded companies in Canada. For more information, visit us at www.marketwire.com. For additional information: Paolina Milana Marketwire (310) 765-3250 pmilana@marketwire.com Jamie Ernst Brodeur (210) 495-5757 jernst@brodeur.com


 

Schiphol, 26 July 2007 - Royal Numico N.V. announces that its Indonesian Baby Food subsidiary PT Sari Husada Tbk. has now been successfully privatised. Following the successful delisting of Sari Husada in December 2006, the Indonesian Minister of Justice and Human Rights has now officially approved the privatisation of Sari Husada. Mr Gerrit Keyaerts, President Commissioner of Sari Husada, commented: "We are very happy with the speed at which we have been able to privatise Sari Husada. We are grateful for the support and understanding of our shareholders during the last years and we would like to thank the relevant regulatory bodies for their cooperation during the entire privatisation process. I would also like to express my gratitude to Sari Husada's Board of Directors who has played an instrumental role in this process and in fortifying the foundations of this great business over the last years." Royal Numico is a high-growth, high-margin specialised nutrition company with leading positions in Baby Food and Clinical Nutrition and brings products to the market under the brand names Nutricia, Milupa, Cow & Gate, Mellin and Dumex, among others. The company serves customers in over 100 countries and employs approx. 13,000 people (see also: www.numico.com). For any questions you might have, please contact: Royal Numico N.V. Corporate Communications tel. +31 20 456 9077 Royal Numico N.V. Investor Relations tel. +31 20 456 9003


 
Hitt og þetta
26. júlí 2007

AGM Statement

ProVen VCT plc 26 July 2007 At the Annual General Meeting of ProVen VCT plc, held today, all resolutions were passed. Details of the proxy votes in respect of the resolutions passed at the Annual General Meeting received as at 2.15 pm. on 24 July 2007, 48 hours before the time of the meeting, at Downing Management Services are set out below: For Discretionary Against Withheld Resolution No. of No. of Votes No. of No. of Total No. Votes Votes Votes Votes % of votes % of votes % of % of votes votes 1 1,641,727 35,675 - - 1,677,402 97.87% 2.13% - 100% 2 1,569,268 64,589 20,555 22,990 1,677,402 94.85% 3.90% 1.24% 100% 3 1,636,727 35,675 - 5,000 1,677,402 97.87% 2.13% 0.00% 100% 4 1,631,502 40,675 5,225 - 1,677,402 97.26% 2.42% 0.31% 100% 5 1,614,502 40,675 22,225 - 1,677,402 96.25% 2.42% 1.32% 100% 6 1,610,037 45,825 9,000 12,540 1,677,402 96.71% 2.75% 0.54% 100% 7 1,576,312 45,825 42,725 12,540 1,677,402 94.68% 2.75% 2.57% 100.00% 8 1,609,352 45,825 22,225 - 1,677,402 95.94% 2.73% 1.32% 100% A copy of the resolutions passed have been submitted to the UK Listing Authority and will shortly be available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at: Financial Services Authority 25 The North Colonnade Canary Wharf London E14 5HS Telephone: 020 7066 1000 ---END OF MESSAGE---


 

Høvik, July 26, 2007 REC has entered into a significant long-term agreement for the supply of multi-crystalline silicon wafers to Moser Baer. Under the agreement, REC will deliver wafers worth approximately NOK 5.1 billion over the next 8 years. REC, the world's largest manufacturer of multicrystalline silicon wafers for solar cells, has signed a long-term agreement with Moser Baer Photo Voltaic Ltd. (MBPV) for the supply of wafers. The 8-year agreement is structured as a take-and-pay contract with pre-determined prices and volumes for the entire contract period. The contract has a value of approximately USD 880 million (approximately NOK 5.1 billion). "The significant level of planned and ongoing capacity expansions has given us the flexibility to secure additional sales contracts; this will provide further visibility on future revenues and earnings. The agreement will also enable us to broaden our customer and market base even more", says Erik Thorsen, President & CEO. Delivery of wafers under the agreement will start in 2008 and increase over time in relation to future planned wafer production capacity increases. Prices and commercial terms are in line with contracts signed in the second half of 2006. Moser Baer India Ltd., the parent of MBPV, is a world leader in the development and manufacturing of CD's and DVD's. The company has a strong future strategic focus on solar and is currently involved in both solar cell and solar module production. Moser Bear is listed in India. "We are very happy to add Moser Baer as one of our strategic customers, a company that has a clearly proven track record of mass production of quality products", says Ingelise Arntsen, Executive Vice President Wafers. About REC REC is uniquely positioned in the solar energy industry with a broad presence across the solar value chain. REC Silicon and REC Wafer are the world's largest producers of polysilicon and wafers for solar applications. REC Solar produces solar cells and solar modules. REC Group had revenues in 2006 of NOK 4,334 million and an operating profit of NOK 1,574 million. Please also see www.recgroup.com About Moser Bear Photovoltaic Moser Baer India Ltd. (MBI) is the second largest manufacturer of optical storage media in the world and reported revenues of more than Rs 20 Billion in FY07. Moser Baer Photo Voltaic Ltd. (MBPV), a wholly owned subsidiary of MBI, is in the business of photovoltaic cells and modules. MBPV plans to manufacture solar modules using different technologies including crystalline silicon, concentrators, thin films and other. Please also see www.moserbaer.in For further information please contact: Erik Thorsen, President & CEO; +47 907 56 685 Jon Andre Løkke, SVP & Investor Relations Officer; +47 67 81 52 65


 

VICTORIA, British Columbia, July 26, 2007 - Maple Seal Homes Ltd. "MSH" http://www.maplesealhomes.com the wholly owned Canadian subsidiary of Maisonette International Enterprises Ltd. "the Company" (PINKSHEETS:MAEN) is pleased to announce that it has been meeting with its buyer's representative Architect for the last few days and that everything went exceptionally well. The visit was instrumental to the final development of MSH's sales effort in France and it included a tour of projects built by MSH's Eco-Friendly partner manufacturer and a tour of the Factory. MSH and the buyer have finalized several technical details for the first residential home project to be exported to France as soon as September 2007 and for the large commercial Eco- Friendly project to be exported in the beginning of 2008. The large commercial project is to be the headquarters for a Nationally knows French company and the name is being kept confidentially for now to the general public. MSH has done its due diligence and is very pleased by this news, as this project, if MSH gets to build it, will propel MSH into the front page limelight of the entire lumber frame construction in France. The Company expects to generate a tremendous amount of leads if this project gets built. The order magnitude of these two projects alone represents over 27,000 square feet in addition to a very probable 20,000 sq.ft. of housing following after that. MSH is working on the final numbers for the large commercial project and will have an update on the approval by the client as soon as possible. Furthermore, MSH is in advanced stage partnership talks with another company in France which could purchase up to 100,000 sq.ft. of housing per year for the next few years. In light of these new developments, the Company is planning to increase its marketing efforts in Europe in order to achieve a first mover advantage position. The potential in France alone can grow another 3200% from today's market segment of the general construction market. The Company will keep its shareholders informed as more development arises. About Maisonette International Enterprises Ltd. Maisonette International Enterprises Ltd. is a publicly held holding company incorporated in Nevada, USA. Its primary asset is a 100% wholly owned Canadian company called Maple Seal Homes Ltd. (www.maplesealhomes.com) with its primary activity being the sale and distribution of panelized prefabricated housing and building materials for the general public and professionals. Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors affecting the Company's operations, markets, products and prices and other factors discussed in the Company's various filings with the Securities and Exchange Commission. There may be other factors not mentioned above that may cause actual results to differ materially from any forward-looking information. Inquiry Contact: Maple Seal Homes Ltd. sales@maplesealhomes.com www.maplesealhomes.com


 

Espoo, Finland - Nokia will publish its second quarter financial results on Thursday August 2, 2007, at approximately 1 pm Helsinki time (CET +1). The press release will be available on the Nokia website immediately after publication. Nokia's investor conference call will begin at 3 pm Helsinki time (CET +1.) Media representatives wishing to listen may call +1 706 634 5012 or follow it from the Nokia website at www.nokia.com/investor. Media Enquiries: Nokia Communications Tel: +358 7180 34900 E-mail: press.office@nokia.com www.nokia.com --- End of Message --- NOKIA P.O. Box 226<br>FIN-00045 NOKIA GROUP Espoo WKN: 870737; ISIN: FI0009000681; Index: DJ STOXX Large 200, DJ STOXX 50; Listed: Nordic list (Large Cap) in THE HELSINKI STOCK EXCHANGE;


 

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | AXA Investment Managers UK | | | Limited/AXA Framlington | | | Investment Management Limited | |-----------------------------------+-------------------------------| | Company dealt in | Civica Plc | |-----------------------------------+-------------------------------| | Class of relevant security to | Ordinary shares | | which the dealings being | | | disclosed relate (Note 2) | | |-----------------------------------+-------------------------------| | Date of dealing | 25/07/07 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------------------------------+ | | Long | Short | | | | | |---------------+--------------------------+------------------------------------------------| | |Number |Number | | | (%) | (%) | |---------------+--------------------------+------------------------------------------------| |(1) Relevant |11,524,770 (18.32%) | | |securities | | | | | | | |---------------+--------------------------+------------------------------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+--------------------------+------------------------------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+--------------------------+------------------------------------------------| |Total |11,524,770 (18.32%) | | | | | | +-------------------------------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +--------------------------------------------------------------------------+ |Class of | Long | Short | |relevant | | | |security: | | | | | | | |---------------+----------------------------+-----------------------------| | |Number |Number | | | (%) | (%) | |---------------+----------------------------+-----------------------------| |(1) Relevant | | | |securities | | | | | | | |---------------+----------------------------+-----------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+----------------------------+-----------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+----------------------------+-----------------------------| |Total | | | | | | | +--------------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | Buy | 100,000 | 2.60p | | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short (Note | Number of securities | Price per | | name, | 6) | (Note 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------------+------------------------+------------| | | | | | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 26/07/2007 | |---------------------------------------------------+---------------| | Contact name | Maria Mauro | |---------------------------------------------------+---------------| | Telephone number | 0207 003 2812 | |---------------------------------------------------+---------------| | If a connected EFM, name of offeree/offeror with | N/A | | which connected | | |---------------------------------------------------+---------------| | If a connected EFM, state nature of connection | N/A | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Order intake increased 28 percent year-on-year - management expects 2007 sales at EUR 190-200m (previously: EUR 180-190m) Waldenburg, 26 July 2007 - R. STAHL Group is now fully focussed on explosion protection. In the first six months of 2007, consolidated sales improved 24.3% to EUR 97.2m (previous year: EUR 78.2m) indicating that the group is staying its growth course. Pre-tax earnings reached EUR 11.5m (previous year: EUR 8.6m). This includes EUR 1.6m in extraordinary earnings from divesting the IT division at the beginning of this year. 6M-earnings stand at EUR 5.5m after a one-off tax provision of EUR 2.5m. In the period under review, order intake came to EUR 111.1m (previous year: EUR 86.5m) representing a 28.4% increase year-on-year. Orders on hand rose to EUR 45.4m (previous year: EUR 26.8m). The robust business growth in our customer sectors and all sales regions contributed to our healthy operating development in the first half of fiscal 2007. While our German sales remained at the high level of the preceding year, our revenues in the Americas (+46%) and in the Asian/Pacific region (+51%) advanced considerably. The implementation of our growth strategy for these regions is bearing first fruit there. We moreover managed to grow our sales in Europe (excluding Germany) by 35.4%. This brings R. STAHL's foreign sales share to 70% after 63% in 2006. In light of our business development so far this year, R. STAHL Technologies' management increased the sales guidance for fiscal 2007 to EUR 190-200m (from EUR 180-190m). Pre-tax operating earnings will probably turn out near the upper edge of the target range of 8-10% of sales. All of the above figures are still preliminary and subject to revision as the audit progresses. R. STAHL will publish its detailed report on the first half of this fiscal year on 14 August 2007. Contact: R. STAHL AG Communication / Investor Relations Judith Schäuble Am Bahnhof 30, D-74638 Waldenburg, Germany Phone: +49 (7942) 943-1217, Fax: +49 (7942) 943-1364 E-mail: judith.schaeuble@stahl.de --- End of Message --- R. STAHL AG Am Bahnhof 30 Waldenburg WKN: 725772; ISIN: DE0007257727 ; Index: CDAX, CLASSIC All Share, Prime All Share, GEX; Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in Börse Stuttgart, Geregelter Markt in Börse Stuttgart, Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Düsseldorf;


 

Waldenburg, 26 July 2007 - R. STAHL Group is now fully focussed on explosion protection. In the first six months of 2007, consolidated sales improved 24.3% to EUR 97.2m (previous year: EUR 78.2m) indicating that the group is staying its growth course. Pre-tax earnings reached EUR 11.5m (previous year: EUR 8.6m). This includes EUR 1.6m in extraordinary earnings from divesting the IT division at the beginning of this year. 6M-earnings stand at EUR 5.5m after a one-off tax provision of EUR 2.5m. In the period under review, order intake came to EUR 111.1m (previous year: EUR 86.5m) representing a 28.4% increase year-on-year. Orders on hand rose to EUR 45.4m (previous year: EUR 26.8m). In light of our business development so far this year, R. STAHL Technologies' management increased the sales guidance for fiscal 2007 to EUR 190-200m (from EUR 180-190m). Pre-tax operating earnings will probably turn out near the upper edge of the target range of 8-10% of sales. All of the above figures are still preliminary and subject to revision as the audit progresses. R. STAHL will publish its detailed report on the first half of this fiscal year on 14 August 2007. Contact: R. STAHL AG Communication / Investor Relations Judith Schäuble Am Bahnhof 30, D-74638 Waldenburg, Germany Phone: +49 (7942) 943-1217, Fax: +49 (7942) 943-1364 E-mail: judith.schaeuble@stahl.de --- End of Message --- R. STAHL AG Am Bahnhof 30 Waldenburg WKN: 725772; ISIN: DE0007257727 ; Index: CDAX, CLASSIC All Share, Prime All Share, GEX; Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in Börse Stuttgart, Geregelter Markt in Börse Stuttgart, Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Düsseldorf;


 

On the 2nd annual general meeting of the WINDSOR AG (Berlin, Germany) in Ludwig-Erhard-Haus in the Fasanenstraße in Berlin on 25 July 2007 all agenda items were decided with the vast majority by the voting capital. Against the agenda item no. 2 "Taking of a decision about the appropriation of the profit" there was entered an objection given to the minute. The dividend payment of 0,30 ¤ per share proposed by the management board and supervisory board is kept back till the end of the appeal period. The Windsor AG will inform you about the further procedure immediately. WINDSOR AG Kochstraße 28, 10969 Berlin Investor Relations Thorsten Schrader Telefon: 030-88672262 Fax: 030-88672299 schrader@windsor-ag.com --- End of Message --- Windsor AG Kochstr. 28 Berlin Germany WKN: 619070; ISIN: DE0006190705; Listed: Freiverkehr in Frankfurter Wertpapierbörse, Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin Bremen;


 
Hitt og þetta
26. júlí 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |--------------------------------------------+----------------------| | Company dealt in | C.I. Traders Limited | |--------------------------------------------+----------------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |--------------------------------------------+----------------------| | Date of dealing | 25th July 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 0 | | | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 322 | 98p | 98p | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +-------------------------------------------------------------------+ | Date of disclosure | 26th July 2007 | |--------------------------------------------+----------------------| | Contact name | Edward Hodge | |--------------------------------------------+----------------------| | Telephone number | 0207 991 6661 | |--------------------------------------------+----------------------| | Name of offeree/offeror with which | C.I. Traders Limited | | connected | | |--------------------------------------------+----------------------| | Nature of connection (Note 6) | Connected Advisor | +-------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

The board of Metro International S.A. ("Metro International"), the world's largest global newspaper, has appointed Per Mikael Jensen as the new CEO and President of Metro International. Per Mikael will join the company on 1st of November 2007. Mr Jensen is currently Chief Executive Officer of TV2 Denmark, Denmark's largest free-to-air TV channel. Prior to joining TV 2 Denmark he was the Global Editor-in-Chief of Metro International. "The Board of Directors is delighted that Per Mikael Jensen will be joining Metro International as CEO. He brings a long and broad experience from the media industry, a strong commitment to creating unique and successful content and a recent track record of improving profitability in TV2 Denmark," comments Dennis Malamatinas, Chairman of Metro International. Mr Jensen, born in 1962, holds a degree in journalism from the Denmark School of Journalism. He has had a 21-year career in the media industry including management positions with the Danish newspapers Politiken, Jyllandsposten and MetroXpress (subsidiary of Metro International), as well as Global Editor-in-Chief of Metro International and CEO of TV2 Denmark. TV 2 Denmark is a state owned public service channel. It is the leading free-to-air TV channel in Denmark comprising 6 TV-channels, a national radio station and extensive on-line businesses. TV 2 Denmark has approximately 950 employees and an annual turnover of USD 355 million. "I am thrilled to re-join Metro International, which I believe is one of the most interesting media companies there is. Metro is a young company, with many young and talented employees and strong positions in a number of large advertising markets. It has significant potential to further develop its position," comments Per Mikael Jensen. Pelle Törnberg will leave his position as CEO and President on the 31st of July, 2007. Metro International's Chief Operating Officer Chris Spalding will act as interim CEO and Dennis Malamatinas will assume the role of Executive Chairman until 1st of November 2007. For further information, please visit www.metro.lu or contact: Dennis Malamatinas, Chairman of the Board tel: +44 (0)20 7016 1300 Birgitta Henriksson, Brunswick Group, IR Contact tel: +46 (0) 708 12 86 39 *** ABOUT METRO INTERNATIONAL AND METRO Metro is the largest and fastest growing international newspaper in the world. Metro is published in over 100 major cities in 21 countries across Europe, North & South America and Asia. Metro has a unique global reach - attracting a young, active, well-educated Metropolitan audience of over 20 million daily readers. Metro International's advertising sales have grown at a compound annual rate of 41% since the launch of the first edition in 1995. Metro International 'A' and 'B' shares are listed on the OMX Nordic Exchange's Nordic List under the symbols MTRO SBD A and MTRO SBD B.


 

William Fall, CEO: "We are very pleased to confirm to our stakeholders and to the market that Straumur has made considerable advances towards its goal of becoming the leading Nordic investment bank. Our emphasis on the growth of the platform and the diversification in the services we offer exemplifies Straumur's drive to assure the stability of its income sources. The acquisitions of eQ and Wood & Company have enabled the Bank to reach its goals much earlier than the anticipated 2009 target: the Bank's customer base has increased threefold, it derives 20% of its revenue from new products and services, and it has achieved an ROE of 15% over risk-free rates. Straumur offers a complete and diversified range of integrated investment banking services, including capital markets, corporate finance, debt finance, and asset management services. We now operate in eight countries and employ the equivalent of 442 full-time members of staff, which is a fivefold increase from the same time last year." After-tax profit soars year-on-year * After-tax profit for the second quarter of 2007 was EUR 94.19 million, as compared with EUR 3.51 million during the same period last year. After-tax profit for the first half of 2007 dropped by 35% to EUR 163.35 million from its prior-year level of EUR 221.01 million. Included in the financial statements are one month's results from Finnish bank eQ, the acquisition which was announced at the end of May 2007. * Net income from operations during the quarter was EUR 148.20 million, as compared with EUR 13.72 million for the same period in 2006. For the first six months of 2007, net income from operations decreased to EUR 240.71 million, a 20% year-on-year drop. Excluding the profit from the sale in Islandsbanki, net income from operations increased by 15% for the first half of 2007, compared to EUR 209,74 million in the first half of 2006. * Annualised return on equity (ROE) was 23.80%, which is in line with the Bank's targets. * The cost-income ratio was 17.6% in the first half of the year, as compared with 5.9% for the same period in 2006. The Bank will continue to invest in further growth in core markets. 84% increase in fees and commissions * Net commission income in the second quarter amounted to EUR 42.88 million, as opposed to EUR 12.57 million in the same quarter last year. Net commission income for the first half of the year, at EUR 73.16 million, was 84% higher than the EUR 39.55 million earned during the same period in 2006. * Net interest income in the first half of the year was EUR 19.53 million, as compared with EUR 21.41 million for the same period in 2006. Total assets up 57% since year-end 2006 * The Bank's total assets at the end of the second quarter amounted to EUR 6,828.66 million, where as they totalled EUR 4,357.76 million at the end of 2006. This represents an increase of 57%. * The Bank's CAD ratio was 28,4%, with a Tier 1 capital ratio of 25.9%. In comparison, at year-end 2006 the CAD ratio was 37.59% and the Tier 1 capital ratio 35.20%. * Shareholders' equity amounted to EUR 1,585.07 million at the end of the second quarter, after the deduction of the Bank's own shares. Steady increase in loan portfolio * Straumur's loan portfolio grew from EUR 1,322.54 million at the end of 2006 to EUR 2,113.36 million at the end of the second quarter 2007, a 60% increase.


 

CONSIDERABLE PLATFORM AND SERVICE GROWTH ENLARGED MARKET AREA WITH INCREASED GEOGRAPHICAL DIVERSIFICATION FEES AND COMMISSIONS CONTINUE TO GROW William Fall, CEO: "We are very pleased to confirm to our stakeholders and to the market that Straumur has made considerable advances towards its goal of becoming the leading Nordic investment bank. Our emphasis on the growth of the platform and the diversification in the services we offer exemplifies Straumur's drive to assure the stability of its income sources. The acquisitions of eQ and Wood & Company have enabled the Bank to reach its goals much earlier than the anticipated 2009 target: the Bank's customer base has increased threefold, it derives 20% of its revenue from new products and services, and it has achieved an ROE of 15% over risk-free rates. Straumur offers a complete and diversified range of integrated investment banking services, including capital markets, corporate finance, debt finance, and asset management services. We now operate in eight countries and employ the equivalent of 442 full-time members of staff, which is a fivefold increase from the same time last year." After-tax profit soars year-on-year * After-tax profit for the second quarter of 2007 was EUR 94.19 million, as compared with EUR 3.51 million during the same period last year. After-tax profit for the first half of 2007 dropped by 35% to EUR 163.35 million from its prior-year level of EUR 221.01 million. Included in the financial statements are one month's results from Finnish bank eQ, the acquisition which was announced at the end of May 2007. * Net income from operations during the quarter was EUR 148.20 million, as compared with EUR 13.72 million for the same period in 2006. For the first six months of 2007, net income from operations decreased to EUR 240.71 million, a 20% year-on-year drop. Excluding the profit from the sale in Islandsbanki, net income from operations increased by 15% for the first half of 2007, compared to EUR 209,74 million in the first half of 2006. * Annualised return on equity (ROE) was 23.80%, which is in line with the Bank's targets. * The cost-income ratio was 17.6% in the first half of the year, as compared with 5.9% for the same period in 2006. The Bank will continue to invest in further growth in core markets. 84% increase in fees and commissions * Net commission income in the second quarter amounted to EUR 42.88 million, as opposed to EUR 12.57 million in the same quarter last year. Net commission income for the first half of the year, at EUR 73.16 million, was 84% higher than the EUR 39.55 million earned during the same period in 2006. * Net interest income in the first half of the year was EUR 19.53 million, as compared with EUR 21.41 million for the same period in 2006. Total assets up 57% since year-end 2006 * The Bank's total assets at the end of the second quarter amounted to EUR 6,828.66 million, where as they totalled EUR 4,357.76 million at the end of 2006. This represents an increase of 57%. * The Bank's CAD ratio was 28,4%, with a Tier 1 capital ratio of 25.9%. In comparison, at year-end 2006 the CAD ratio was 37.59% and the Tier 1 capital ratio 35.20%. * Shareholders' equity amounted to EUR 1,585.07 million at the end of the second quarter, after the deduction of the Bank's own shares. Steady increase in loan portfolio * Straumur's loan portfolio grew from EUR 1,322.54 million at the end of 2006 to EUR 2,113.36 million at the end of the second quarter 2007, a 60% increase. The interim financial statements and further information For further information, please contact Jóhanna Vigdís Gudmundsdóttir (johanna@straumur.net, mobile: +354 8409133). The interim financial statements for the first six months of 2007 will be available at the Bank's offices in Borgartún 25, Reykjavík and will be accessible, together with other information on the Bank, on its website: www.straumur.net. Borgartún 25 105 Reykjavík Tel: +354 580-9100 E-mail: straumur@straumur.net The full report including tables can be downloaded from the following link:


 

"Mr. Poggenpohl" was a driving force behind the entire industry Herford, 25. July 2007 - Walter Ludewig, the great man and mastermind of the German kitchen industry, passed away on Monday, 23.07.2007 in Herford at the age of 97. As Poggenpohl's chief executive and a personally liable partner, he was at the helm of the company, now in its 115th year, for 52 years, making a name for himself as a pioneer of the German kitchen furniture industry. Born at Herford in 1910, he shaped the oldest German kitchen brand into what it continues to be today: a synonym for technical and aesthetic quality as well as practical functionality. Having trained as a bank clerk, Walter Ludewig came to Poggenpohl as a young man in 1935. He became a personally liable partner within just five years of entering the company. At that time, Poggenpohl was concentrating on selling the "Reform Kitchen" that had been inspired by Werkbund and Bauhaus in 1928. This was the first kitchen to unite dresser, crockery cabinet and food cupboard, and included separately standing sink, table, chairs and electrical appliances. After the war, Walter Ludewig became actively involved as mastermind and trendsetter in developing the unit kitchen into an industrially manufactured fitted kitchen that integrates all functions and pre-plans all work flow to save time. Ludewig earned the title of being one of the "fathers of the modern fitted kitchen". To prove it: in 1950 Poggenpohl presented "form 1000", the first mass-produced German unit kitchen with the function handle as its external distinguishing feature. "Mr. Poggenpohl", however, did not restrict himself to the company's own four walls. In the furniture industry and in business associations he took on numerous honorary appointments at regional level and beyond, e.g. as founding member and, for many decades, member of the executive board of the German association "The Modern Kitchen" (AMK), and as President of the European Association of Kitchen Furniture Manufacturers (Paris, Brussels). The East Westphalia-Lippe region and Herford in particular, which is home to over half of Germany's kitchen manufacturers, have Ludewig to thank for much of their strength as a business hub. In 1980, the North Rhine-Westphalian Minister for Economic Affairs awarded him the Federal Republic of Germany's Great Cross of Merit for his achievements. Text & Photo: www.poggenpohl.de Further information: Elmar Duffner, Geschäftsführung Poggenpohl Möbelwerke GmbH, Herford, Tel. 05221/381-213 oder 0171/7658360 elmar.duffner@poggenpohl.de, www.poggenpohl.de


 

Flourishing international project business / German consumers cautious about spending Herford, 23 July 2007 - Turning over ¤ 59.1 million in the first six months of 2007, East-Westphalian kitchen manufacturer Poggenpohl Möbelwerke GmbH is exactly on a par with the level reached at the same time last year. So far, business on the German market has been rather slow. As expected, the rise in value-added tax has put the brakes on kitchen sales and reflects the general trend in the furniture industry after the last few months of 2006 were pushed by the effects of consumers trying to avoid the tax hike. The international project business with luxury Poggenpohl kitchens for large construction projects, in contrast, is going extremely well, particularly at the moment in the Gulf states and the United Kingdom. The company has had some very positive experience with its own sales studios of which there are now 27. "Within four years, we have more than doubled the number of shops we run ourselves", Poggenpohl's Managing Director Elmar Duffner reports and explains the company's strategy: "All of our studios are located in the main cities of major international markets. They perform a kind of lighthouse function, strengthening the brand and radiating positively on the distribution network. They provide dealers in each region with a model for their own brand-focused presentations. And it's working very well!" The most recent shops to be integrated and opened are in city centres of San Francisco, Birmingham, Frankfurt and Hanover. In Germany, Poggenpohl operates further outlets of its own in Hamburg, Düsseldorf and Stuttgart. Here, the Poggenpohl brand is represented by 140 independent dealers. The next showrooms are planned for the US (9 to date) and the UK (8). To download text, go to www.poggenpohl.de Further information: Elmar Duffner, Managing Director, Poggenpohl Möbelwerke GmbH, Herford, Tel. ++49 (0)5221 381 213 or ++49 (0)171 7658 360 elmar.duffner@poggenpohl.de, www.poggenpohl.de


 

TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying Dwyka Resources Limited issuer of existing shares to which voting rights are attached: 2. Reason for the notification: An acquisition or disposal of voting rights 3. Full name of person(s) subject to the Bluehone Investors LLP notification obligation: 4. Full name of shareholder(s) (if different Active Capital Trust from 3): plc 5. Date of the transaction (and date on which 24th July 2007 the threshold is crossed or reached if different): 6. Date on which issuer notified: 25th July 2007 7. Threshold(s) that is/are crossed or 3% reached: 8. Notified details: A: Voting rights attached to shares Class/type Situation previous Resulting situation after the triggering of shares to the Triggering transaction if possible transaction using the Number of Number of Number of Number of voting % of voting ISIN CODE Shares Voting shares rights rights Rights Direct Direct Indirect Direct Indirect AU000000DWY1 3,858,580 3,858,580 3,500,000 - 3,500,000 - 2.93 B: Financial Instruments Resulting situation after the triggering transaction Type of Expiration Exercise/ Number of voting rights % of financial date Conversion that may be acquired if the voting instrument Period/ Date instrument is exercised/ rights converted. +----------------------------------------------+ | Total (A+B) | |----------------------------------------------| | Number of voting rights | % of voting rights | |-------------------------+--------------------| | 3,500,00 | 2.93% | +----------------------------------------------+ +-------------------------------------------------------------------+ | 9. Chain of controlled undertakings through which the voting | | rights and/or the financial instruments are effectively held, if | | applicable: | |-------------------------------------------------------------------| | Bluehone Investors LLP | | Client holding less than 3% | | | |-------------------------------------------------------------------| | | |-------------------------------------------------------------------| | PROXY VOTING: | |-------------------------------------------------------------------| | | |-------------------------------------------------------------------| | 10. Name of the proxy holder: | Bluehone Investors LLP | |-------------------------------------------------------------------| | | |-------------------------------------------------------------------| | 11. Number of voting rights | N/A | | proxy holder will cease to | | | hold: | | |-------------------------------------------------------------------| | | |-------------------------------------------------------------------| | 12. Date on which proxy holder | N/A | | will cease to hold voting | | | rights: | | |-------------------------------------------------------------------| | | |-------------------------------------------------------------------| | 13. Additional information: | | |-------------------------------------------------------------------| | | |-------------------------------------------------------------------| | 14. Contact name: | Peter Fraser, F&C Asset | | | Management plc, Administrator | | | for Bluehone Investors LLP | |-------------------------------------------------------------------| | | |-------------------------------------------------------------------| | 15. Contact telephone number: | +44 131 718 1051 | +-------------------------------------------------------------------+ Annex Notification Of Major Interests In Shares A: Identity of the person or legal entity subject to the notification obligation Full name (including legal form for legal entities) N/A Contact address (registered office for legal entities) N/A Phone number N/A Other useful information (at least legal representative for N/A legal persons) B: Identity of the notifier, if applicable Full name: N/A Contact address: N/A Phone number: N/A Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation): C: Additional information ---END OF MESSAGE---


 

Funcom`s 2nd quarter financial report for 2007 can be downloaded from the company`s website, under the page `Investor Relations`. For more information, please contact: company CFO Olav Sandnes on e-mail olav.sandnes@funcom.com or by telephone +47 92 22 55 40. The report is also avaible at www.newsweb.no Funcom N.V. July 26, 2007


 

Aker Yards has entered into a contract with Portosalvo Ltd.for building of one Platform Supply Vessel based of the design Aker PSV 09 CD. The value of the contract is approximately NOK 310 million. Delivery is scheduled in 4Q 2010. Portosalvo Ltd. also have an option for one more identical vessel. Portosalvo Ltd is a UK based subsidiary of the Rimorchiatori Napoletani Group. See web site: www.rimnap.it. The vessel will be equipped with dynamic positioning, diesel electric propulsion and will have the class notation Clean Design. The vessels are designed for good sea keeping performance, low fuel consumption and environmental friendly operations. The hull for the vessel will be built at Aker Yards in Romania and outfitted at Aker Yards in Norway. Roy Reite in charge of Aker Yards' Offshore & Specialized Vessels business area, says: "I am very pleased that Portosalvo again has placed a newbuilding contract with Aker Yards. In the past Aker Yards have built two vessels for Portosalvo Ltd. whereas the last vessel was delivered in 2002". Fast facts Vessel type. Platform Supply Vessel Length 86,6 m Beam. 19 m Dwt. capacity. 4800 ton Design. Aker PSV 09 CD For further information please contact: Aker Yards ASA Tore Langballe, SVP Communications & IR, phone +47 24 13 01 30 Aker Yards, Offshore & Specialized Vessels Hege Anita Akselvoll, Communications Manager, phone +47 71 18 35 34 Portosalvo Ltd. Dott. Ing. Gianni Andrea de Domenico, Chairman. Mobile phone: +39 33 562 201 27 Aker Yards ASA is an international shipbuilding group focusing on sophisticated vessels. The group has a strong position both in terms of innovation, product range, technology, experience and capacity. The product range includes cruise vessels & ferries, merchant vessels and offshore & specialized vessels. Aker Yards comprises 18 yards in Brazil, Finland, France, Germany, Norway, Romania, Ukraine and Vietnam. Aker Yards has approximately 20,000 employees. www.akeryards.com


 

Active Biotech AB (OMX Nordic:ACTI) today announced that ANYARA has been granted Orphan Drug Status by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA). Orphan Drug designation provides a variety of incentives, including market exclusivity for up to 10 years following approval. ANYARA, one of Active Biotech's lead oncology candidate drugs, is currently in clinical Phase II/III trials for the indication Renal Cancer. "EMEA's decision to grant orphan drug status for the treatment of patients with Renal Cancer is an important step in the development of ANYARA," said Sven Andréasson, CEO of Active Biotech. "It provides us with important benefits, both in preparation for a marketing application and also commercially in the form of potential market exclusivity for our technology". Lund, July 26, 2007 Active Biotech AB (publ) Sven Andréasson President and CEO About EMEA's Orphan Medicinal Product Designation The EMEA's "Orphan Medicinal Product Designation" is designed to promote the development of drugs which may provide significant benefit to patients suffering from rare diseases identified as "life-threatening or very serious." Under EMEA guidelines, Orphan Medicinal Product Designation provides 10 years of potential market exclusivity if the product candidate is approved for marketing in the European Union. Orphan status also permits EMEA assistance in optimizing the candidate's clinical development through participation in designing the clinical protocol and preparing the marketing application. Additionally, a drug candidate designated by the EMEA as an Orphan Medicinal Product may qualify for a reduction in regulatory fees as well as a European Union-funded research grant. About ANYARA Active Biotech's ANYARA* project develops a drug for use in cancer targeted therapy, primarily for the treatment of renal cancer. A Phase II/III study is ongoing since the end of 2006. It is a randomized study of ANYARA in combination with interferon-alpha, compared with only interferon-alpha, in patients with advanced renal cancer. The primary clinical effect parameter for this study is survival and it will include approximately 500 patients at 45 clinics in Europe. Expected survival with conventional treatment for these patients is 10-15 months and the length of the study will depend on the patients' disease progression. An interim analysis based on approximately 200 patients is scheduled for mid-2008. *naptumomab estafenatox (rINN, Recommended International Non-proprietary Name) About Renal cell carcinoma Renal cancer affects approximately 40,000 people annually in the US and 200,000 people worldwide. The usual age of onset of the disease is between 50 and 70, and it affects more men than women. Five-year survival for non-metastatic forms of the disease is approximately 64%. If the disease has metastasized to the lymphatic glands, five-year survival declines to 5-15%. The market for treatment of renal cancer is estimated at about USD 1 billion a year (Cowen & Co.). About Active Biotech Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is conducted in cooperation with Chelsea Therapeutics. Active Biotech AB P.O. Box 724, SE-220 07 Lund, Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 20 50


 

* Organic growth of 5% in Q2 2007 due to higher volumes (2%) and prices (3%). * Operating profit from continuing operations 3% lower than in Q2 2006, substantially impacted by currency exchange rates. * Earnings per share before exceptional items increased by 8%. * Conclusions of Vision 2010 mid-term evaluation to be presented at the September Analysts' Conference. * Outlook: full-year 2007 operating profit now expected to be EUR 790 million +/-3% (versus EUR 760 million +/- 5% indicated in Q1 report). Feike Sijbesma, Chairman of the DSM Managing Board, gave the following comment on the results: 'This has been a good second quarter for DSM, benefiting from higher volumes and increased prices. Looking ahead to the remainder of the year, our expectations are that these trading conditions will continue, enabling us to raise our full-year guidance for 2007 today.' second quarter in EUR million first half 2007 2006 +/- 2007 2006 +/- Continuing operations: 2,198 2,126 3% Net sales 4,344 4,187 4% 331 342 -3% Operating profit plus depreciation 626 656 -5% & amortization (EBITDA) 227 234 -3% Operating profit (EBIT) 419 440 -5% 65 87 -25% - Nutrition 126 169 -25% 30 14 114% - Pharma 40 29 38% 84 88 -5% - Performance Materials 168 172 -2% 66 53 25% - Industrial Chemicals 116 93 25% -18 -8 - Other activities -31 -23 Total DSM: 2,198 2,132 3% Net sales 4,344 4,200 3% 227 234 -3% Operating profit (EBIT) 419 439 -5% 158 152 4% Net profit before exceptional items 286 292 -2% -111 5 Net result from exceptional items -111 26 47 157 -70% Net profit 175 318 -45% Net earnings per share in EUR: 0.85 0.79 - before exceptional items 1.52 1.50 0.24 0.81 - including exceptional items 0.92 1.64 In this report: * 'operating profit' (plus depreciation and amortization) is understood to be operating profit (plus depreciation and amortization) before exceptional items. * 'net profit' is the net profit attributable to equity holders of Royal DSM N.V. Net sales in EUR million second quarter 2007 2006 differ-ence vol-umes prices exch. other rates Nutrition 630 612 3% 8% -2% -3% 0% Pharma 250 233 7% 1% 9% -2% -1% Performance 738 698 6% 3% 4% -1% 0% Materials Industrial 484 480 1% -3% 8% -4% 0% Chemicals Other activities 96 103 Total, continuing 2,198 2,126 3% 2% 3% -2% 0% operations Net sales from continuing operations in Q2 2007 were up 3% from Q2 2006 due to organic volume growth and higher selling prices. The effect of exchange-rate developments on DSM's net sales was 2% negative. The US dollar was on average 7% lower against the euro and the Japanese yen 13%. Sales volumes in Performance Materials and Industrial Chemicals were negatively affected by an unplanned outage of the European caprolactam plant. Operating profit Q2 operating profit from continuing operations amounted to EUR 227 million, 3% less than in Q2 2006. The change in operating profit was the result of a number of developments, which in total almost offset one another. On the one hand there were the unfavorable general issues mentioned earlier this year: the development of currency exchange rates had an adverse effect of EUR 20 million (after hedging); fixed costs increased, mainly because of the intensified innovation effort; and the phasing-out of contracts related to the Roche Vitamins acquisition had an effect of almost EUR 10 million. In addition to this there was an unplanned outage of the European caprolactam plant, which caused production and sales losses not only at DSM Fibre Intermediates, but also in DSM Engineering Plastics' nylon business. In total this had an effect of some EUR 10 million. On the other hand these unfavorable developments were almost compensated for by strong underlying trading conditions. Nutrition showed a strong increase in volumes and market share, while price pressure eased somewhat. In Pharma, DSM Anti-Infectives profited from a sudden and strong increase in prices of penicillin and penicillin-related products. Performance Materials was able to increase volumes and prices. In Industrial Chemicals the selling price increase was clearly higher than the increase in feedstock and energy prices. Business review Nutrition +-------------------------------------------------------------------+ | second quarter | | in EUR million | first half | |----------------+---+--------------------------+-------------------| | 2007 | 2006 | | | | 2007 | 2006 | |--------+-------+---+--------------------------+---+-------+-------| | | | | | | | | |--------+-------+---+--------------------------+---+-------+-------| | 630 | 612 | | Net sales | | 1,243 | 1,225 | |--------+-------+---+--------------------------+---+-------+-------| | 100 | 124 | | Operating profit plus | | 196 | 243 | | | | | depreciation and | | | | |--------+-------+---+--------------------------+---+-------+-------| | | | | amortization | | | | |--------+-------+---+--------------------------+---+-------+-------| | 65 | 87 | | Operating profit | | 126 | 169 | +-------------------------------------------------------------------+ Sales in this cluster increased by 3%. This was the balance of higher sales volumes, lower selling prices and negative exchange-rate effects (mainly US dollar). Compared to Q2 2006, DSM Nutritional Products achieved solid volume growth at slightly lower prices, with Animal Nutrition & Health performing slightly better than Human Nutrition & Health. DSM Nutritional Products' operating profit decreased, mainly because of the strongly negative impact of the US dollar and higher innovation costs. The price pressure in the more mature parts of the portfolio eased somewhat. DSM Food Specialties' sales and operating profit decreased due to lower sales volumes (phasing out of phytase tolling) and higher innovation costs. DSM Special Products (benzoic acid and benzaldehyde) showed a small loss, as in Q2 2006. In June DSM announced a comprehensive profit improvement program for DSM Nutritional Products which, through a mix of cost savings and higher revenues, is expected to deliver at least EUR 100 million per annum of improved profitability by 2010. Pharma +-------------------------------------------------------------------+ | second quarter | | in EUR million | first half | |----------------+---+----------------------------+-----------------| | 2007 | 2006 | | | | 2007 | 2006 | |--------+-------+---+----------------------------+---+------+------| | | | | | | | | |--------+-------+---+----------------------------+---+------+------| | 250 | 233 | | Net sales | | 467 | 470 | |--------+-------+---+----------------------------+---+------+------| | 50 | 34 | | Operating profit plus | | 80 | 70 | | | | | depreciation and | | | | |--------+-------+---+----------------------------+---+------+------| | | | | amortization | | | | |--------+-------+---+----------------------------+---+------+------| | 30 | 14 | | Operating profit | | 40 | 29 | +-------------------------------------------------------------------+ Sales were up 7% due to higher selling prices (mainly at DSM Anti-Infectives) and despite the weaker US dollar. DSM Pharmaceutical Products' operating profit was slightly higher than in Q2 2006, owing to higher margins and a good production level, which was partly due to overflow from Q1. The operating result of DSM Anti-Infectives was positive and much higher than in Q2 2006. The main driver for the better performance of DSM Anti-Infectives was the increase in prices for penicillin and related products. This increase was due to shortages on the market caused by temporary curtailments of domestic production in China. In the light of these shortages DSM Anti-Infectives was able to significantly raise its prices for penicillin derivatives as well. In mid-June DSM published the outcome of the strategic review of its Anti-Infectives business. DSM has studied all options and has concluded that the greatest value will be generated through a partnering strategy (possibly with - partial - divestments) for the business combined with innovation initiatives and further restructuring measures to improve profitability. As a result, DSM Anti-Infectives aims to report a sustainable profit as from 2008. One of the implications of the strategic review is the impairment (as an exceptional item) of the cash-generating unit DSM Anti-Infectives to net realizable value as at June 30. Performance Materials +-------------------------------------------------------------------+ | second quarter | | in EUR million | first half | |----------------+---+--------------------------+-------------------| | 2007 | 2006 | | | | 2007 | 2006 | |--------+-------+---+--------------------------+---+-------+-------| | | | | | | | | |--------+-------+---+--------------------------+---+-------+-------| | 738 | 698 | | Net sales | | 1,458 | 1,378 | |--------+-------+---+--------------------------+---+-------+-------| | 108 | 113 | | Operating profit plus | | 215 | 221 | | | | | depreciation and | | | | |--------+-------+---+--------------------------+---+-------+-------| | | | | amortization | | | | |--------+-------+---+--------------------------+---+-------+-------| | 84 | 88 | | Operating profit | | 168 | 172 | +-------------------------------------------------------------------+ Sales were up almost 6% due to higher sales volumes and selling prices and despite the lower exchange rate for the US dollar and the caprolactam plant outage. The operating profit for the cluster decreased slightly, mainly due to the production outage of DSM Fibre Intermediates' European caprolactam plant, which had an adverse effect on DSM Engineering Plastics' nylon business. DSM Engineering Plastics' operating profit also suffered from lower margins and from the weaker US dollar and Japanese yen. DSM Dyneema showed the same operating profit as in Q2 2006, with volume growth being offset by a less favorable product mix and increased fixed costs. The operating profit of DSM Resins was slightly lower, as higher margins could not completely compensate for increased costs for innovation and expansion. DSM Elastomers' operating profit was higher than in Q2 2006 because of higher sales volumes. Industrial Chemicals +-------------------------------------------------------------------+ | second quarter | | in EUR million | first half | |----------------+---+----------------------------+-----------------| | 2007 | 2006 | | | | 2007 | 2006 | |--------+-------+---+----------------------------+---+------+------| | | | | | | | | |--------+-------+---+----------------------------+---+------+------| | 484 | 480 | | Net sales | | 964 | 907 | |--------+-------+---+----------------------------+---+------+------| | 82 | 70 | | Operating profit plus | | 148 | 127 | | | | | depreciation and | | | | |--------+-------+---+----------------------------+---+------+------| | | | | amortization | | | | |--------+-------+---+----------------------------+---+------+------| | 66 | 53 | | Operating profit | | 116 | 93 | +-------------------------------------------------------------------+ Sales in this cluster were up 1% from Q2 2006 due to clearly increased selling prices and despite lower sales volumes (caused in part by the production outage) and a weaker US dollar. All business groups in this cluster except DSM Energy posted a higher operating profit. Selling prices increased more than raw-material costs. The operating profits recorded by DSM Fibre Intermediates and DSM Agro were higher due to higher margins. The results of DSM Melamine improved strongly due to higher sales volumes and margins. DSM Energy showed a slightly lower profit, reflecting the natural decline of the business. Other activities +-------------------------------------------------------------------+ | second quarter | | in EUR million | first half | |----------------+---+----------------------------+-----------------| | 2007 | 2006 | | | | 2007 | 2006 | |--------+-------+---+----------------------------+---+------+------| | | | | | | | | |--------+-------+---+----------------------------+---+------+------| | 96 | 103 | | Net sales | | 212 | 207 | |--------+-------+---+----------------------------+---+------+------| | -9 | 1 | | Operating profit plus | | -13 | -5 | | | | | depreciation and | | | | |--------+-------+---+----------------------------+---+------+------| | | | | amortization | | | | |--------+-------+---+----------------------------+---+------+------| | -18 | -8 | | Operating profit | | -31 | -23 | +-------------------------------------------------------------------+ The operating result for Other activities was substantially lower than in Q2 2006. Innovation expenditure and costs relating to share-based payments were considerably higher, the latter being due to the increase in the DSM share price. On the other hand, DSM's captive insurance company posted a higher result due to lower damage amounts. Exceptional items As already indicated, in order to align the book value of the cash-generating unit DSM Anti-Infectives with the net realizable value, DSM has recognized an impairment charge of EUR 150 million before tax (EUR 110 million after tax). Net profit Net profit decreased compared to the second quarter of 2006, from EUR 157 million to EUR 47 million, strongly influenced by the exceptional item for DSM Anti-Infectives. Net finance costs in Q2 2007 amounted to EUR 15 million. This represents a decrease of EUR 8 million compared to Q2 2006, which was due to interest results on derivatives, higher capitalized interest during construction and interest income on a tax refund. The effective tax rate in Q2 2007 was 25%. This is 2% below Q2 2006, due mainly to the lower tax rate in the Netherlands. Net profit before exceptional items was EUR 158 million, up EUR 6 million (4%) from the second quarter of 2006. Net earnings before exceptional items per share increased by 8%, 4% arising from the higher net profit and 4% from the lower number of shares outstanding as a result of the share buy-back program. Cash flow, capital expenditure and financing Cash flow from operating activities in the first half of the year increased substantially to EUR 292 million. This was mainly due to a lower seasonal increase in working capital. At EUR 99 million, capital expenditure (excluding acquisitions) in Q2 was slightly below the level of depreciation (EUR 104 million), but above the Q2 2006 level (EUR 87 million). Compared to year-end 2006, the operating working capital increased by EUR 150 million in the first half of 2007 (of which EUR 68 million in the second quarter). This was due to the increase in sales and the usual seasonal pattern. Net debt increased by EUR 221 million in Q2 2007 and stood at EUR 1,089 million. Gearing increased to 16%. The increase was due mainly to the payment of the final dividend for 2006 and the repurchase of ordinary shares. Share buy-back program After the publication of the Q1 2007 results DSM resumed the execution of the share buy-back program of EUR 750 million that the company initiated in September 2006. The total number of shares repurchased under the second phase of this program up till 24 July amounted to 8,569,879 shares for a total consideration of EUR 313.6 million. Interim dividend It has been decided to pay out an interim dividend of EUR 0.33 per ordinary share for the year 2007 (2006: EUR 0.33). This represents one third of the dividend paid out for 2006. The interim dividend is no indication of the total dividend for 2007. The interim dividend for 2007 will be paid out in cash on 22 August 2007. Workforce The workforce increased by 209 in Q2 2007 to 22,723. Progress update on DSM strategy Vision 2010 DSM's strategy program Vision 2010 - Building on Strengths focuses on accelerating the profitable and innovative growth of the company's specialties portfolio. The overall objective is strong value creation, to be accomplished via three main levers. 1. Market-driven growth and innovation In Q2 DSM's innovation initiatives resulted in the introduction of new products, new applications of existing products, and significant expansion in recently introduced products. Examples of products launched by DSM in Q2 are given in the appendix. Recently DSM has acquired Pentapharm, a company that holds a global leading position in the development and production of active ingredients and system solutions for the cosmetics industry, thereby increasing DSM's innovation potential in Personal Care. 2. Increased presence in emerging markets In Q2 sales in China grew by USD 41 million (21%) to USD 234 million. In June DSM announced the opening of Wuxi NutriRice® Co. Ltd., a production facility in China operated in a joint venture between Bühler and DSM. This facility - the first commercial scale production of its kind in the world - produces NutriRice®, nutritionally enriched rice kernels to be mixed with natural rice. Last month the Chinese Premier visited the DSM Citric Acid manufacturing site, also located in Wuxi, in recognition of its outstanding safety, health and environment (SHE) performance and recognized DSM as a 'Good Citizen'. 3. Operational Excellence As indicated above, in June DSM announced the outcome of the strategic review of its Anti-Infectives business. In Q2 DSM also announced a comprehensive profit improvement program for DSM Nutritional Products. Vision 2010 - evaluation The Managing Board in its new composition is evaluating the strategy program Vision 2010 - Building on Strengths and will present its conclusions at the annual conference for financial analysts on September 27 and 28. The strategic program Vision 2010 - Building on Strengths and its objectives and targets were set out at the time of the program's launch in September 2005. The mid-term evaluation was originally planned for 2008. Outlook Trading conditions in the majority of DSM's business portfolio have improved further and are favorable. Based on this, DSM is able to raise its guidance as published in the Q1 report (EUR 760 million with an uncertainty of plus or minus 5%) for the 2007 operating profit (before exceptional items). Barring unforeseeable developments and based on current trading conditions and exchange rates, DSM now expects the operating profit (before exceptional items) for the year 2007 to be EUR 790 million with an uncertainty of plus or minus 3%. Heerlen, 26 July 2007 The Managing Board of Directors Important dates Ex-dividend date (interim dividend 2007): 27-Jul-07 Record date (interim dividend 2007): 31-Jul-07 Interim dividend 2007 made payable: 22-Aug-07 Annual Analysts' Conference: 27-28 September 2007 Publication of third-quarter report: 25-Oct-07 Annual Report 2007: 13-Feb-08 Annual General Meeting: 26-Mar-08 For more information DSM, Corporate Communications tel.: +31 (45) 5782421 e-mail: media.relations@dsm.com Investors DSM, Investor Relations tel.: +31 (45) 5782864 e-mail: investor.relations@dsm.com internet: www.dsm.com Condensed consolidated statement of income second quarter 2007 in EUR million second quarter 2006 before excep- total before excep- total excep- tional excep- tional tional items tional items items items 2,198 - 2,198 net sales 2,132 - 2,132 operating profit plus depreciation and 331 -1 330 amortization (EBITDA) 342 17 359 227 -151 76 operating profit (EBIT) 234 17 251 0 - 0 operating profit from 0 - 0 discontinued operations 227 -151 76 operating profit from 234 17 251 continuing operations -15 - -15 net finance costs -23 - -23 0 - 0 share of the profit of 1 -8 -7 associates 212 -151 61 profit before income tax 212 9 221 expense -52 40 -12 income tax expense -58 -4 -62 160 -111 49 net profit from 154 5 159 continuing operations net profit from discontinued / discontinuing - - - operations 0 - 0 160 -111 49 profit for the period 154 5 159 -2 - -2 minority interests -2 - -2 158 -111 47 net profit 152 5 157 158 -111 47 net profit 152 5 157 -2 - -2 dividend on cumulative -2 - -2 preference shares 156 -111 45 net profit used for 150 5 155 calculating earnings per share 104 150 254 depreciation and 108 - 108 amortization 260 39 299 cash flow 258 5 263 99 capital expenditure 87 - acquisitions 8 per ordinary share in EUR*: 0.85 0.24 - net earnings 0.79 0.81 1.41 1.62 - cash flow 1.36 1.38 183.9 average number of 190.3 ordinary shares (x million) 179.9 number of ordinary 190.4 shares, end of period (x million) 22,723 workforce at end of **22,156 period 7,161 of which in the **7,061 Netherlands * After deduction of dividend on cumulative preference shares. ** Year-end 2006. This quarterly report has not been audited. Condensed consolidated statement of income for the first half first half 2007 in EUR million first half 2006 before excep- total before excep- total excep- tional excep- tional tional items tional items items items 4,344 - 4,344 net sales 4,200 - 4,200 operating profit plus depreciation and 626 -1 625 amortization (EBITDA) 656 37 693 419 -151 268 operating profit (EBIT) 439 35 474 0 - 0 operating profit from 1 - 1 discontinued operations 419 -151 268 operating profit from 440 35 475 continuing operations -32 - -32 net finance costs -42 - -42 -1 - -1 share of the profit of 1 -8 -7 associates 386 -151 235 profit before income tax 399 27 426 expense -96 40 -56 income tax expense -104 -1 -105 290 -111 179 net profit from 295 26 321 continuing operations net profit from discontinued / discontinuing - - - operations 0 - 0 290 -111 179 profit for the period 295 26 321 -4 - -4 minority interests -3 - -3 286 -111 175 net profit 292 26 318 286 -111 175 net profit 292 26 318 -5 - -5 dividend on cumulative -5 - -5 preference shares 281 -111 170 net profit used for 287 26 313 calculating earnings per share 207 150 357 depreciation and 216 2 218 amortization 488 39 527 cash flow 503 28 531 179 capital expenditure 160 26 acquisitions 8 per ordinary share in EUR*: 1.52 0.92 - net earnings 1.50 1.64 2.64 2.85 - cash flow 2.64 2.78 184.6 average number of 190.7 ordinary shares (x million) 179.9 number of ordinary 190.4 shares, end of period (x million) 22,723 workforce at end of **22,156 period 7,161 of which in the **7,061 Netherlands * After deduction of dividend on cumulative preference shares. ** Year-end 2006. This quarterly report has not been audited. Consolidated balance sheet in EUR million 30 June 2007 31 December 2006 intangible assets 1,012 1,008 property, plant and equipment 3,462 3,655 deferred tax assets 457 496 pre-paid pension costs 1,016 918 associates 21 26 other financial assets 96 100 -------- -------- non-current assets 6,064 6,203 inventories 1,566 1,515 trade receivables 1,445 1,377 other receivables 272 362 financial derivatives 112 79 current investments 3 3 cash and cash equivalents 340 552 -------- -------- current assets 3,738 3,888 -------- -------- total assets 9,802 10,091 in EUR million 30 June 2007 31 December 2006 shareholders' equity 5,524 5,784 minority interests 77 71 -------- -------- equity 5,601 5,855 deferred tax liabilities 375 383 employee benefit liabilities 287 304 provisions 149 188 borrowings 890 907 other non-current liabilities 38 44 -------- -------- non-current liabilities 1,739 1,826 employee benefit liabilities 16 21 provisions 85 127 borrowings 611 607 financial derivatives 43 41 trade liabilities 1,060 1,091 other current liabilities 647 523 -------- -------- current liabilities 2,462 2,410 -------- -------- total equity and liabilities 9,802 10,091 capital employed 6,050 6,303 equity / total assets 57% 58% net debt 1,089 921 net debt / equity plus net debt 16% 14% operating working capital (OWC) 1,951 1,801 OWC / 4 x quarterly net sales 22.2% 21.8% This quarterly report has not been audited. Condensed consolidated statement of cash flows first half in EUR million 2007 2006 Cash and cash equivalents at 552 902 beginning of period Operating activities: - net profit plus 532 536 depreciation and amortization - change in working capital -213 -316 - other changes -27 -61 --------- --------- cash flow from operating 292 159 activities Investing activities: - capital expenditure -163 -162 - acquisitions -26 -8 - sale of subsidiaries - 74 - divestments 17 24 - other changes - 6 --------- --------- net cash from investing -172 -66 activities dividend -131 -146 net cash from financing -202 41 activities effects of changes in consolidation and exchange differences 1 -12 --------- --------- Cash and cash equivalents at 340 878 end of period Condensed statement of changes in shareholders' equity first half in EUR million 2007 2006 Balance at beginning of period 5,784 5,501 Changes: - net profit 175 318 - exchange differences, net of income tax -34 -68 expense - dividend -199 -216 - repurchase of ordinary shares -250 -76 - proceeds from reissue of ordinary shares 36 32 - other changes 12 57 --------- --------- Balance at end of period 5,524 5,548 This quarterly report has not been audited. Appendix Examples of DSM's innovation initiatives in Q2 2007: Nutrition * The launch of Radiance CR, a unique actives complex to beautify the skin. * The introduction of Niacinamide PC, a new exclusive grade of niacinamide with skin-lightening, anti-wrinkle, anti-acne and skin-barrier-strengthening properties. * The launch of Delvotest® Accelerator, a fully automated reliable testing system that reduces the time and costs associated with testing milk for antibiotic residues on a large scale at milk control stations and dairies. * The introduction of Bakezyme WholeGain, a unique cellulose preparation that combats the issues of reduced volume and unappealing crumb which often occur when producing high-fiber bread. * A GRAS (Generally Recognized As Safe) notification by the FDA for PreventAse(TM), the first enzyme that is able to reduce the toxic substance acrylamide in baked foods by as much as 90%. * The launch of Sensarite(TM), a revolutionary range of taste potentiators created for use in bakery and dairy applications. * The introduction of Bakezyme X-pan, a baking enzyme that offers enhanced dough development, whiteness of crumb and increased volume, guaranteeing an effective way of baking white bread. * The launch of Rapidase Maxifruit, an enzyme that ensures targeted grape component release which allows the production of supple and fruity wines and boasts a more stable and intense cherry red color after alcoholic fermentation. * The launch of Parsol Guard, an efficient shield to protect color and light-sensitive ingredients in personal care products. Pharma * A licensing agreement with Sartorius Biotech GmbH for PER.C6, the technology platform for biopharmaceutical products. Performance Materials * Beneteau, the world's leading builder of sailing yachts, and DSM Dyneema are cooperating to improve sailboat performance through the use of next-generation running rigging made with Dyneema®. * Cooperation between DSM Dyneema and the Allseas Group, an offshore pipe-laying company, to improve the safety and speed of underwater pipe-laying using stinger adjustment rope made with Dyneema®. * Machinefabriek Amersfoort, a worldwide specialist in machining, has chosen a one-size lifting sling made with Dyneema® to replace a range of polyester slings. * DSM Dyneema and Shimano are collaborating on high-tech fishing lines. * The launch of Arnitel VT for the manufacture of breathable films. Arnitel Vapor Transmission films are ideally suited for roofing applications, textile applications and plasters, as well as for medical gowns and drapes. * The introduction of Atlac E-Coat, a sprayable high-performance barrier against osmosis for the marine industry. * The launch of UVentionTM, highly specialized UV-curable custom coatings that can be optimized for just about any substrate. * The launch of HiTone polyesters for powder coating systems with improved aesthetics. * The launch of Halwedrol PU480, an environmentally friendly, waterborne poly-urethane dispersion with improved exterior durability for decorative coatings. * The launch of Uradil AZ770, an environmentally friendly, waterborne alkyd emulsion, with improved storage stability, good application properties and high gloss for decorative coatings.


 

Solid revenue and gross profit performance with stable gross profit margin. A significant strategic acquisition within search engine marketing was made on July 25th by cash payment of approximately 770 Msek. April - June * Revenues for the second quarter increased by 27,9 percent to 512,6 (400,9) Msek. * Gross Profit for the second quarter increased by 25,4 percent to 143,0 ( 114,0) Msek. * Gross profit from transactions increased by 31,0 percent to 112,3 (85,7) Msek brought on by strengthening transaction margins. * Operating profit excluding share based expenses for the second quarter increased by 14,0 percent to 47,9 (42,0) Msek. Operating profit (EBIT) including expenses relating to all existing warrant schemes for the second quarter decreased by 11,0 percent to 40,3 (45,3) Msek. * Adjusted operating margin for the second quarter was 9,3 (10,5) percent. * Profit after tax for the second quarter amounted to 30,6 (33,7) Msek. * Reported earnings per share amounted to SEK 1,07 (1,18) sek after dilution. January - June * Revenues for the period increased by 29,0 percent to 1 033,8 (801,3) Msek. * Gross Profit for the period increased by 27,9 percent to 282,7 (221,1) Msek. * Operating profit excluding share based expenses for the period increased by 17,3 percent to 96,2 (82,0) Msek. Operating profit (EBIT) including expenses relating to all existing warrant schemes for the period decreased by 1,2 percent to 81,0 (82,0) Msek. * Adjusted operating margin for the period was 9,3 (10,2) percent. * Profit after tax for the period amounted to 58,6 (54,4) Msek. * Reported earnings per share amounted to SEK 2,05 (1,91) sek after dilution. Significant events after the period * On July 25th , TradeDoubler acquired 100 percent of the shares in The IMW Group and its subsidiaries The Search Works - the UK's largest search engine marketing company - and The Technology Works thus significantly strengthening TradeDoubler's offering within the digital marketing sector. * TradeDoubler opened an office in Ireland There will be a telephone conference at 10:30 CET on 26 July, 2007 hosted by CEO William Cooper and CFO Casper Seifert who will present the results for the period. To participate in the conference call, please dial: +46-8-505 2 01 10 The report and the presentation will be published on the company website, www.tradedoubler.com prior to the start of the conference call. For local dial in numbers, please consult the TradeDoubler website. About TradeDoubler TradeDoubler is a Pan-European digital marketing company offering a range of performance-based marketing solutions. TradeDoubler's products and services provide companies with the tools and expertise to drive results online whether they are looking to generate sales or drive brand awareness. Headquartered in Sweden, the company boasts a unique European reach with local offices in 15 countries across Europe and a presence in a further three countries. With a breadth of expertise across multiple industry sectors and a network of more than 118,000 website publishers TradeDoubler helps deliver online results for over 1,200 advertisers across Europe including a mix of local and international companies such as Apple Store, Dell, Telia Sonera, eBay and Kelkoo. Please visit www.tradedoubler.com for further information.


 

OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery and development company, announces today positive initial results of the ongoing SELECT-1 Phase IIa study with its lead product Locteron(TM) , a controlled release interferon alfa for the treatment of chronic hepatitis C (HCV). In the 12-week Phase IIa study, the combination of the highest dose of Locteron evaluated until now, and the antiviral drug ribavirin, achieved an early virologic response (EVR) in 100% of the hepatitis C patients treated. The study reported an overall strong antiviral response at twelve weeks and an adverse event profile that shows substantial tolerability improvement compared to other interferons, either on the market or in development. OctoPlus is co-developing Locteron with its partner Biolex Therapeutics. These initial results are from the first three cohorts (160, 320 and 480 ug); treatment of the fourth and last cohort (640ug) is ongoing. Complete and final study results will be reported in the fourth quarter of this year. Professor Peter Jansen, head of the AMC Liver Center at the department of Gastroenterology and Hepatology of the Academic Medical Center in Amsterdam, the Netherlands, comments: "These results are very encouraging: Locteron's adverse event profile shows potential to significantly improve hepatitis C therapy. The results pave the way for the commencement of the Phase IIb study, in which I am excited to be involved." Design of the Phase IIa study The SELECT-1 (Safety and Efficacy of Locteron: European Clinical Trial 1) Phase IIa study is a European multi-center, randomized, open-label trial designed to evaluate Locteron in combination with the anti-viral drug ribavirin in previously untreated chronic hepatitis C patients. A total of 32 patients in 4 dose cohorts have been enrolled in the study. The study assesses safety and tolerability and explores viral response of a 12-week treatment with Locteron, administered once every two weeks in subcutaneous doses of 160, 320, 480 and 640 ug, and combined with oral ribavirin treatment. Dosing of the first three eight-patient cohorts commenced in January 2007. Based on a favorable safety review of the results from the first three cohorts, dosing of patients in the 640 ug cohort commenced in May 2007. Antiviral response in doses 160, 320 and 480 ug At the conclusion of the study, 12 weeks of treatment, the results for the 160, 320 and 480 ug cohorts were as follows: - A dose response was observed in the study, with patients treated with the 320 and 480 ug doses of Locteron demonstrating a greater reduction in hepatitis C virus than the patients treated with the 160 ug dose at all measurement times. Average viral reduction after 12 weeks of treatment for the 320 and 480 ug doses was 4.5 and 4.2 logs, respectively, compared to 1.8 logs in the lowest dose of 160 ug. - After 12 weeks of treatment, 63% (5/8) of the patients had undetectable levels of hepatitis C virus, measured by plasma RNA < 28 IU/ml, in both the 320 and 480 ug dose cohorts, compared to 13% (1/8) of the patients in the lowest-dose group of 160 ug. - The percentage of patients who achieved early virologic response (EVR), defined as at least a two-log reduction in hepatitis C virus after 12 weeks of treatment, was 88% (7/8) and 100% (8/8) in the 320 and 480 ug dose Locteron cohorts, respectively, compared to 38% (3/8) of the patients in the lowest-dose group of 160 ug. Achievement of EVR has been broadly established to be a pre-requisite for long-term response. Safety and tolerability in doses 160, 320 and 480 ug The following Locteron side effect and patient tolerability results were observed during the 12 weeks of treatment for the 160, 320 and 480 µg cohorts: - Locteron was safe and well tolerated. - There were no serious adverse events. - The vast majority (over 90%) of the adverse events that were experienced were rated as mild. - Dose reductions were limited to one patient each in the 320 and 480 ug cohorts with none in the 160 ug cohort. - No patients discontinued treatment. Side effects were confined to the regular flu-like symptoms and other side effects that are associated with interferon treatment. All adverse events, including flu-like symptoms, were less frequent and less severe than the side effects reported for other interferons. For example, only one patient in the SELECT-1 study receiving Locteron experienced an adverse event rated as severe, a substantial improvement over reported results for Pegasys® and Albuferon(TM) as illustrated below. <Click on the link at the bottom of the press release for the full press release including graphs.> Another objective point of comparison for evaluating the tolerability of Locteron and other interferon products across clinical studies is fever, a marker for the family of adverse events characterized as flu-like symptoms. Fever occurred in only one (4%) of the Locteron patients in SELECT-1, notably lower than other interferon products, as illustrated below. <Click on the link at the bottom of the press release for the full press release including graphs.> Furthermore, the rates of other side effects reported for pegylated interferons and Albuferon, such as chills, nausea, diarrhea and dizziness, were also markedly lower in patients treated with Locteron in SELECT-1. All other side effects were predominantly mild and were comparable with other interferon products. Joost Holthuis, CEO of OctoPlus, says: "We are very excited to be able to present these promising results, which show the potential of Locteron to be a convenient and effective hepatitis C therapy with less side effects than its competitor products. We look forward to starting the next development phase, a Phase IIb study with Locteron, in 2008". Biolex and OctoPlus plan to commence SELECT-2, a Phase IIb study of Locteron in 2008 after assessment of the final results from the SELECT-1 Phase IIa study in the fourth quarter of 2007. The 12-week results of the Phase IIb trial will be used as the basis for dose selection for the commencement of the Phase III development program. Conference call OctoPlus will hold a conference call today at 10 AM CET. If you would like to participate in the conference call, please request the details from Ms. Rianne Roukema at OctoPlus, telephone number +31 (71) 524 1071. During the conference call Joost Holthuis, CEO of OctoPlus, will comment on the results of the Phase IIa study and will be available to answer questions. For further information, please contact: Rianne Roukema, Corporate Communications: +31 (71) 524 1071 Notes to editors: About Locteron Locteron is designed to be a best-in-class therapeutic for patients with chronic hepatitis C, with the potential to induce less side effects, improve patient compliance and provide a more convenient once every two week dosing schedule compared with current therapies. The need for improved patient tolerability will become even greater with the emergence of new oral anti-viral products. These emerging antiviral products are associated with additional side effects, further adding to the opportunity for Locteron to be the interferon of choice for future combination therapy as a result of its potential for improved tolerability. Locteron combines OctoPlus' proprietary PolyActive(TM) drug delivery technology with BLX-883, a recombinant alfa interferon produced by OctoPlus' co-development partner Biolex Therapeutics in its patented LEX System(SM). Locteron is produced in OctoPlus' cGMP manufacturing facilities in Leiden, the Netherlands. About hepatitis C More than four million people in the United States, and more than 200 million people worldwide, are currently infected with hepatitis C. The standard treatment for patients with chronic hepatitis C is pegylated interferon alfa administered in combination with the anti-viral drug ribavirin. The currently available pegylated alfa interferon products require administration once per week for up to 48 weeks and are associated with substantial side effects, particularly during the period following each administration. Independent market research predicts that modified interferons will continue to be a key component of combination therapy for hepatitis C patients and is expected to be complementary with new agents under development. These sources estimate that total interferon sales for the treatment of hepatitis C will exceed $5 billion by 2014. About OctoPlus OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines. Our pipeline consists of 5 products in preclinical and clinical development. Our lead product is Locteron, a sustained-release formulation of interferon alfa for the treatment of chronic hepatitis C, which we are co-developing with Biolex Therapeutics. Locteron is in Phase IIa clinical development. Furthermore, our pipeline comprises a product for the treatment of chronic middle ear infection also in Phase II development, a sustained-release formulation of growth hormone in Phase I and two preclinical single-shot vaccines. In addition, OctoPlus is a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. The earnings and expertise that we derive from rendering formulation and manufacturing services help to support our own drug development programs. OctoPlus is listed on Euronext Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl. This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.


 

Gouda, The Netherlands, 26 July 2007 - Imtech (technical services provider in Europe) announces that Imtech Care & Cure, in which Imtech has gathered knowledge and know-how of health care in the Netherlands, is making good progress. Recently, orders were obtained worth a total of more than 55 million euro. An important order is concerned with the complete electrical engineering and part of the security facilities in the Jeroen Bosch Hospital in Den Bosch which will be partly new construction and partly renovation. With an area of almost 170,000 m2, this hospital will be one of the largest in the Netherlands. Imtech is also supplying the new ICT (Information and Communications Technology) communications infrastructure for care provider Florence, a merger of five care providers in the Haaglanden region. This structure, which is based on IP (Internet Protocol), makes it possible to reduce operating costs, improve manageability, and introduce new services such as Telemedicine (digital ordering and distribution of medicines), ICT support for meal services and an interactive social alarm system. A future-proof infrastructure for a wireless ICT network will be realised for the Martini Hospital in Groningen. Virtually all the technical solutions for a clinical chemical haematological laboratory and a new general practitioners' post will be realised by Imtech at the Sint Franciscus Hospital in Rotterdam. Imtech will also provide part of the technology in the new Orbis Medical Park, a modern care boulevard in Sittard. Technology (a combination of electrical engineering, ICT and mechanical engineering) is becoming more and more important in health care. Operating costs have to be reduced, manageability must be improved, and maintenance must become more professional. The importance of ICT is also increasing rapidly. Technical solutions have to mesh seamlessly with the care process. Imtech has gathered its knowledge and know-how of health care in Imtech Care & Cure, which forms a single contact point for complete and integral technological solutions. The integration of all technological solutions is Imtech's answer to cost and management problems in health care, including ICT, data and telecommunication, electrical engineering, mechanical engineering (energy, air and climate technology), maintenance management & maintenance services, access technology and (fire) security technology. Imtech is concentrating on the following current topics: strengthening strategic alliances with hospitals and care facilities and suppliers of medical equipment, the complete technological exploitation of care buildings, integral security, sustainable use of energy, integration of ICT, and the development of innovative technological concepts (for example applications of RFID, Radio Frequency Identification, technology based on radio waves). In the health care sector, Imtech applies RFID to patient and chain logistics, such as identification, localisation, tracing, telemetry and security. 0-0-0-0-0-0-0-0-0-0-0-0 Further information Imtech N.V. Pieter Koenders Manager Corporate Communications Telephone: +31 182 54 35 28 E-mail: pieter.koenders@imtech.eu www.imtech.eu Imtech Profile Imtech N.V. is a European technical services provider in the fields of electrical engineering, ICT (information and communication technology) and mechanical engineering. With approximately 17,000 employees, Imtech realises annual revenue of 3 billion euro. Imtech holds strong positions in the buildings, industry, infrastructure and telecom markets in Belgium, Germany, Luxembourg, the Netherlands, Eastern Europe, Spain and the UK and in the global maritime market. Imtech provides services to a total of 12,000 clients. Imtech offers added value in the form of integrated and multidisciplinary total solutions that lead to improved operating processes and higher yields for clients and their clients in return. Imtech also provides solutions that contribute to a sustainable, liveable society, for example in the field of energy, mobility, safety and the environment. Imtech shares are listed on the Euronext Stock Exchange (Amsterdam), where Imtech is included in the Amsterdam SmallCap Index (AScX) and the Next 150 index.


 

Die Schweizer Wettbewerbskommission hat Jelmoli informiert, den geplanten Verkauf der Elektrohaushalt- und Multimedia-Sparte an Coop intensiver zu prüfen. Diese vertiefte Prüfung der Transaktion kann bis zu vier Monate in Anspruch nehmen und stellt keine Vorwegnahme einer endgültigen Entscheidung dar. Jelmoli ist zuversichtlich, dass die Transaktion nach Abschluss der vertieften Prüfung durch die Wettbewerbskommission zu einem erfolgreichen Abschluss kommt --- End of Message --- Jelmoli -----------------------------------------<Br><b>Jelmoli über WAP:<Br> wap.huginonline.com</b><Br>----------------------------------------- <Br>St. Annagasse 18 Zürich WKN: 851225; ISIN: CH0000668464; Index: SMCI, SPI, SPIEX; Listed: Main Market in SWX Swiss Exchange;


 

BRUSSELS, BELGIUM--(Marketwire - July 26, 2007) - Global Green Solutions Inc. (OTCBB: GGRN) - Vertigro and SGCEnergia, the biofuels division of the SGC Group of Portugal, have agreed to form a joint venture company to produce Vertigro algae biodiesel feedstock. Vertigro is jointly owned by Global Green Solutions Inc. (GGRN) and Valcent Products Inc. (VCTPF). The agreement calls for SGCEnergia to build and operate a Vertigro pilot plant near Lisbon, Portugal which will also serve as a research and development facility for Vertigro technology applications and projects in Europe. "The Vertigro-SGCEnergia joint venture provides an excellent platform for commercialization of the Vertigro technology within Europe," said Doug Frater, President and CEO of GGRN, the Vertigro venture operator. "According to recent Frost and Sullivan research, approximately 9.5 million tonnes (224 million gallons) per year of biodiesel will be required to meet the European Union's directives that biodiesel become 5.75% of transport fuels. Our algae oil is the ideal solution to Europe's growing demand for biofuel feedstock." "We are excited to team up with one of the world's leading providers of algae-to-biodiesel feedstock technology," said Vianney Vales, CEO of SGCEnergia. "This agreement is a significant milestone for SGCEnergia's planned production of second generation biofuels." Construction of the pilot plant is slated to begin in late 2007. Under the terms of the agreement, SGC is committed to building additional large commercial-scale facilities in Portugal as well as other countries in Europe. Plants will also be built in Africa. As Vertigro algae thrives on the absorption of carbon dioxide, significantly reducing greenhouse gases, the plants will be constructed near major sources of carbon dioxide emissions. Global Green Solutions Inc. (www.globalgreensolutionsinc.com) develops and implements ecotechnology solutions for renewable energy and reduction of greenhouse gas emissions. Global Green Solutions Inc. is a U.S. public traded company (OTCBB: GGRN) with offices in Vancouver, San Diego, El Paso, New York, London, Brussels, Caracas and Johannesburg. Safe Harbor for Forward Looking Statements: Except for historical information contained herein, the contents of this press release contain forward-looking statements that involve risks and uncertainties, including but not limited to economic, competitive, governmental and technological factors affecting the company's operations, markets, products and prices as well as other factors addressed in the company's filings with the Securities and Exchange Commission. Contacts: Global Green Solutions Inc. Steve McGuire Investor Relations 1-800-408-0153 or 1-800-877-1626 Global Green Solutions Inc. Bob Faris Investor Relations 1-800-408-0153 or 1-800-877-1626 Website: www.globalgreensolutionsinc.com Vorticom Public Relations Nancy Tamosaitis Media Relations (212) 532-2208 Email: Nancyt@vorticom.com McCloud Communications, LLC Marty Tullio (949) 553-9748 Email: marty@mccloudcommunications.com


 

25 July 2007, Godalming, UK. Sinclair Pharma plc ("Sinclair") (SPH.L) announces that the following Directors have today been granted Performance Share Awards ("Awards") under the Sinclair Pharma plc 2003 Executive Incentive Plan: Director Awards Dr Michael Flynn 242,009 Jerry Randall 194,521 The Awards are granted over ordinary 1p shares in Sinclair and are based on a share price of 109.5p per share. The awards have a three year vesting period and vesting is subject to certain share price performance criteria over the period. No amount was payable by the Directors on the grant of these Awards. An exercise price of 1p is payable in respect of each Award exercised. Dr Flynn and Mr Randall notified Sinclair of their respective interests in these shares on 25 July 2007. Ends For further information please contact: Sinclair Pharma plc Tel: +44 (0)1483 410 600 Dr Michael Flynn, CEO Jerry Randall, CFO Zoe McDougall, Director of investorrelations@sinclairpharma.com Communications Capital MS&L Mary Clark Tel +44 (0)20 7307 5340 Halina Kukula ---END OF MESSAGE---


 

Chrysalis VCT plc 25 July 2007 Chrysalis VCT plc announces that on 25 July 2007 the Company purchased 44,100 Ordinary shares of 1p each for cancellation representing approximately 0.13% of the issued Ordinary share capital at a price of 80.0p per share. Following the above transaction the Company's capital consists of 33,165,988 Ordinary shares of 1 pence each, 536,072 'D' Ordinary share of 1 pence each and 601,376 'E' Ordinary shares of 1 pence each. The Company does not hold any shares in treasury. Therefore the total number of voting rights in Chrysalis VCT plc is 34,303,436. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Chrysalis VCT plc under the FSA's Disclosure and Transparency Rules. ---END OF MESSAGE---


 

Oslo, 25 July 2007 - In contrast to the volatile market conditions of Q1, the second quarter saw solid and consistent market performance and continued strength in corporate activity. Nordic markets were again the best performers of all developed market regions and ABGSC achieved a higher market share of Nordic traded volume. While domestic client business levels dropped modestly from the first quarter, international client activity grew further such that overall Equities Division revenues increased in the period. Robust M&A and ECM activity allowed another significant increase in Corporate Finance revenues. Results from the expanded bonds team had a marked positive contribution in both the quarter and first half. First Half Highlights * First Half Earnings Per Share were NOK 0.93 versus NOK 0.83 last year, an increase of 12 %. Second quarter EPS were 0.44 vs. 0.42. * Global and Nordic region market conditions were far less volatile during Q2 despite concerns about credit market excesses. As a result, most markets extended their earlier gains on the back of continued corporate profit growth, wider profit margins and intense merger activity. The Nordic region markets as a group remained the best performing developed market region in the world for both Q2 and the first half of 2007. * ABGSC Corporate Finance continues to produce outstanding results despite tough comparisons. Revenues increased by 35% in the first half with ECM business making an especially strong contribution in Q2. Real estate and bond issues were also prominent contributors in the period. * Revenues from Stockbroking services increased slightly for Q2 and 13% for the first half. The firm's overall Nordic market share rose and results were positively impacted by our strong international client position during a period when domestic investor activity diminished somewhat. ECM transactions continued to benefit Equities Division's results as well. * ABGSC traded volume has risen faster than the overall market so far in 2007. * The firm's newly re-structured Board of Directors was announced during the second quarter.


 

Airline will offer a two-class interior in the Q400 aircraft TORONTO, ONTARIO--(Marketwire - July 25, 2007) - Bombardier Aerospace announced today that Lagos, Nigeria-based Arik Air has placed a firm order for four Q400 high-speed turboprop airliners. The value of the contract, based on the list price of the Q400 airliner, is approximately $104 million U.S. Arik Air will offer a two-class interior in its Q400 airliners by configuring its aircraft with 10 seats at 34-inch (86.4 cm) pitch and 62 economy class seats at 31 inches (78.7 cm). Arik Air's current fleet includes four Bombardier CRJ900 regional jets with 10 business class seats and 65 economy class seats in a spacious cabin. It also operates three CRJ200 regional jets. The airline currently serves seven routes in Nigeria which will rise to eleven before introducing African West Coast and Intercontinental destinations later this year. "We require the Q400 airliner especially for our Lagos-Port Harcourt service because of airstrip landing restrictions that eliminate the use of jet aircraft on this route," said Michael McTighe, Chief Executive Officer, Arik Air. "Equally important is that the Q400 will offer considerable operating cost savings on the route, while providing equivalent flight times because of its 360-knot (667 km/h) cruise speed." "Arik Air is another airline that sees value in operating a mixed fleet of jet and turboprop aircraft," said Steven Ridolfi, President, Bombardier Regional Aircraft. "The mix of CRJ200, CRJ900 and Q400 aircraft offers an ideal combination to meet the airline's capacity, stage length and operating cost requirements." Including the order announced today, Bombardier has now received a total of 254 orders for Q400 airliners. As of April 30, 2007, 152 of these had been delivered to airlines in Africa, the Asia-Pacific region, Europe, the Middle East and North America. About Arik Air, Wings of Nigeria Arik Air is a wholly owned Nigerian airline with a commitment to the people of Nigeria to deliver new standards in aviation. In October 2006 Arik Air introduced the first new commercial aircraft into Nigeria for over 20 years, flying domestic routes throughout the country before leading up to a full network of eleven destinations and three international routes on the African Continent. The airline also plans to commence intercontinental routes from Autumn 2007. About Bombardier A world-leading manufacturer of innovative transportation solutions, from regional aircraft and business jets to rail transportation equipment, systems and services, Bombardier Inc. is a global corporation headquartered in Canada. Its revenues for the fiscal year ended Jan. 31, 2007, were $14.8 billion US, and its shares are traded on the Toronto Stock Exchange (BBD). News and information are available at www.bombardier.com. Bombardier, CRJ200, CRJ900 and Q400 are trademarks of Bombardier Inc. or its subsidiaries. Notes to Editors An image of an Arik Air Q400 aircraft is available in our Multimedia Library at: www.aero.bombardier.com/htmen/F15.jsp Contacts: Bombardier Aerospace Marc Duchesne 514-855-7989 www.bombardier.com


 

Bethesda, MD - July 25, 2007 - Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced that the company will conduct a conference call and audio webcast on Wednesday, August 8, 2007, at 9:00am Eastern Time (03:00pm Central European Time) in conjunction with the release of its financial results for the second quarter ended June 30, 2007. Micromet anticipates releasing its financial results at 7:00am, Eastern Time (01:00pm Central European Time) on Wednesday, August 8, 2007. To participate in this conference call, dial 866-713-8310 (U.S.) or 617-597-5308 (international), passcode: 97082649. The audio webcast can be accessed via the company's website at: www.micromet-inc.com. A replay of the call will be available from 12:00pm Eastern Time on August 9, 2007 (06:00pm Central European Time) through Thursday, August 16, 2007. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 82626657. About Micromet, Inc. (www.micromet-inc.com ) Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Three product candidates are currently in clinical trials. MT103/MEDI-538, which is the first product candidate based on Micromet's novel BiTE® product development platform, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. The BiTE product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system. We are developing MT103 in collaboration with MedImmune, Inc. Our second clinical stage product candidate is adecatumumab (MT201), a recombinant human monoclonal antibody which targets EpCAM expressing tumors. Adecatumumab has completed two phase 2a clinical trials, one in patients with breast cancer and the other in patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of adecatumumab in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. We are developing adecatumumab in collaboration with Merck Serono. Our third clinical stage product candidate is D93/TRC093, a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. This product candidate is in phase 1 clinical trials and is being developed by TRACON Pharmaceuticals, Inc. for the treatment of patients with cancer and Age-Related Macular Degeneration (AMD) pursuant to a license agreement under which we have granted TRACON the worldwide rights to develop and commercialize D93. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which may be important in the treatment of inflammatory diseases, such as rheumatoid arthritis. # # # Contact Information: Company: Investors: Media: Christopher Schnittker, SVP & CFO Susan Noonan Patricia Garrison (240) 752-1421 (212) 966-3650 (917) 322-2567 christopher.schnittker@micromet-inc.com susan@sanoonan.com pgarrison@rxir.com


 

Plant Expected to Be Completed Before Year End GENEVA--(Marketwire - July 25, 2007) -- SES Solar Inc. (OTCBB: SESI), a European-based developer of cost-effective, high productivity solar panels and solar roof tiles, is pleased to announce that it has commenced construction of its new manufacturing facility in Plan-les-Ouates, Geneva, Switzerland. The new facility will produce solar panels, solar modules and solar tiles and is expected to be completed before December 31, 2007. "We are very pleased that construction has begun on our state-of-the-art manufacturing facility," said Jean-Christophe Hadorn, chief executive officer and president at SES Solar Inc. "We will be able to compete with foreign producers because we are applying new module assembly processes that will minimize the amount of manpower required." SES Solar's facilities are located in the heart of an industrial park that features Geneva's high technology sector. SES Solar's production plant will be a technological showcase, with its architectural design integrating high-performance photovoltaic elements in the roof and façade. About SES Solar Inc. SES Solar's wholly owned subsidiary, SES Switzerland, was incorporated under the laws of Switzerland on March 26, 2001. Its principle business is the production of solar photovoltaic modules and roof tiles from silicon cells. SES Switzerland's proprietary products are based upon integrating unique architecture on commercially available high-performance modules and solar tiles. SES Switzerland services global market integrators and resellers as well as its own clientele and is positioned as one of the few manufacturers in Europe that can also produce customized solar photovoltaic modules that are larger than three square meters. Additionally, SES Switzerland's patented industrial production process yields photovoltaic modules in Europe at Asian manufacturing costs. Of great importance in today's world is that SES Switzerland's photovoltaic technology turns solar energy directly into useable electricity without releasing carbon dioxide. For additional information please visit www.sessolar.com Safe Harbor Except for historical information, the matters set forth herein, which are forward-looking statements, involve certain risks and uncertainties that could cause actual results to differ. Potential risks and uncertainties include, but are not limited to, additional unforeseen expenses that the company incurs in implementing its growth strategy; the failure by the company to operate effectively in a highly competitive industry with many participants; the company's ability to keep pace with technological advances and correctly identify and invest in the technologies that become commercially accepted; the company's ability to protect its intellectual property rights and exposure to infringement claims by others; the company's ability to operate efficiently, without work stoppages, labor disputes, equipment/mechanical break-downs and in compliance with current and new governmental regulations; the company's ability to generate revenues, and the company's ability to obtain financing to build the manufacturing facility as well as if and when necessary to meet cash requirements. Media Contact: Standard Atlantic +41-22-548-0135 Investor Contact: Michael Noonan +1-512-687-3457


 

WALTHAM, Mass. -- July 25, 2007-- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported financial results for the quarter ended June 30, 2007 and provided an update on its oncology and ophthalmology drug development programs. Dr. Richard Chin, President and Chief Executive Officer of OXiGENE, commented that, "We have made great strides in the second quarter, including entering into a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration. This is a major milestone for OXiGENE, and we believe it significantly enhances the prospects for approval based on the ongoing pivotal registration study for ZYBRESTAT(TM) in anaplastic thyroid cancer. In addition, we executed very well against tight timelines and initiated the pivotal registration study, with site initiation and initial patient recruitment and screening underway less than 6 weeks after receiving the SPA." Accomplishments for Q2 2007 The Company indicated that it achieved a number of important milestones during the quarter: Clinical Oncology: * Formally agreed to a Special Protocol Assessment with the U.S. Food and Drug Administration for a pivotal registration study of ZYBRESTAT in anaplastic thyroid cancer. * At the June 2007 American Society of Clinical Oncology (ASCO) annual meeting, reported data from a Phase II study of ZYBRESTAT in combination with paclitaxel and carboplatin in patients with advanced imageable malignancies. This triple-drug combination was well-tolerated and demonstrated both anti-tumor activity, as determined by RECIST criteria, as well as significant reductions in tumor blood-flow as assessed by DCE-MRI imaging. * At the ASCO meeting, reported initial results from a Phase I dose-escalating study of OXi4503, our novel, dual-mechanism, vascular disrupting agent (VDA). These interim results demonstrated that OXi4503 is well-tolerated with no dose-limiting toxicities observed at any dose tested to date, and that the drug appears to have biological activity, as evidenced by reductions in tumor blood-flow as measured by PET and DCE-MRI imaging. Ophthalmology: * At the May 2007 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, presented positive results from a Phase II study of ZYBRESTAT in patients with myopic macular degeneration. The Company believes that these positive results provide initial human proof-of-concept for ZYBRESTAT in macular degeneration and other eye diseases, and also provide support for developing a convenient and patient-friendly topical ophthalmology formulation of the drug. In addition, on July 9, the Company announced the initiation of the ZYBRESTAT pivotal registration study. Corporate * Added two new Directors with relevant business, health care and medical / regulatory experience to OXiGENE's Board of Directors. Financial Results The net loss for the three months ended June 30, 2007 was $5.4 million, or $0.19 per share, compared with a net loss of $5.0 million, or $0.18 per share, in the second quarter of 2006. For the six-month period ended June 30, 2007, the net loss was $9.3 million, or $0.33 per share, compared to a net loss of $8.3 million, or $0.30 per share, for the comparable period in 2006. At June 30, 2007, OXiGENE had cash, cash equivalents and marketable securities of approximately $38.0 million compared with approximately $45.8 million at December 31, 2006. Cash utilization from operations for the first six months of 2007 was approximately $7.3 million. Clinical Update - ZYBRESTAT Oncology: Anaplastic Thyroid Cancer (ATC) ZYBRESTAT Pivotal Registration Study Initiated The Company announced on May 31 that it had reached agreement with the FDA on a Special Protocol Assessment for its planned pivotal registration study with ZYBRESTAT in anaplastic thyroid cancer. Subsequent to the end of the second quarter, the Company announced initiation of this study, which is expected to enroll approximately 180 patients with ATC. Two-thirds of the patients will receive intravenous ZYBRESTAT plus carboplatin and paclitaxel, and the other third will receive carboplatin and paclitaxel alone. The primary endpoint will be a statistically significant difference in the overall survival rate between the two treatment arms, as determined by a log-rank analysis of Kaplan-Meier survival curves at times when pre-determined numbers of study events (patient deaths) are reached. The study design incorporates a planned interim analysis for efficacy and safety, which will be overseen by an Independent Data Monitoring Committee. Approximately 40 clinical trial sites worldwide are expected to participate in the study. ZYBRESTAT has been granted Fast Track status by the FDA and Orphan Drug status by both the FDA and the European Agency for the Evaluation of Medicinal Products (EMEA). Non-small Cell Lung Cancer Randomized, Controlled Phase II Study of ZYBRESTAT In Combination with Bevacizumab (AVASTIN®) On Track to Begin in Fall 2007. The Company currently plans to initiate a randomized comparative Phase II study with ZYBRESTAT in combination with the widely utilized anti-angiogenic drug, bevacizumab (AVASTIN) with chemotherapy, in the second half of 2007, contingent on the final results from our ongoing Phase I study with this combination. Scientific support for the combination of ZYBRESTAT and anti-angiogenic drugs comes, in part, from (i) work published by the Company's collaborators and published in the journal Science in September 2006 (See Science 313, 1785, 2006 and the Company's press release dated September 21, 2006); and (ii) from data emerging from the ongoing Phase Ib study of ZYBRESTAT and bevacizumab that suggest that this drug combination is safe and well-tolerated. The Company believes that the Phase II study, the design of which is under review by the Company and lung cancer key opinion leaders, will represent the first controlled clinical study of a vascular disrupting agent in combination with an anti-angiogenic agent. Ovarian Cancer Initial Data From ZYBRESTAT Phase II Ovarian Cancer Study Expected by Year End The Company has an ongoing Phase II study of ZYBRESTAT, administered in combination with carboplatin and paclitaxel, in patients with platinum-resistant ovarian cancer. This study is a modified Simon two-stage design, and the primary endpoint is observance of a specific number of durable responses (as determined by RECIST criteria) in the first 18 patients. With achievement of an adequate number of responses in the first stage of the study, the study design provides for an expanded phase to further evaluate efficacy. The Company currently anticipates that initial results from the first stage of this study will be available to report by the end of 2007. Ophthalmology Human Proof-of-Concept Established for ZYBRESTAT in Macular Degeneration with Intravenous-Route Formulation; Topical Formulation Development Program Proceeding with IND Anticipated in Q1 2008. At the May 2007 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, investigators presented data in poster form from a Phase II study of ZYBRESTAT in myopic macular degeneration. All twenty-three patients receiving intravenous-route ZYBRESTAT in this study achieved the primary endpoint, maintenance of vision at 3 months. The Company believes these results demonstrate human proof-of-concept for the application of ZYBRESTAT in age-related macular degeneration and other ophthalmological diseases which are characterized by the presence and development of abnormal vasculature in the eye. Preliminary preclinical data suggest that topical delivery of ZYBRESTAT to the back of the eye is feasible, and the Company is currently working to develop a convenient and patient-friendly topical ophthalmology formulation of ZYBRESTAT suitable for broad use in age-related macular degeneration (AMD), diabetic retinopathy and other eye diseases. Importantly, the Company believes a topical formulation of ZYBRESTAT would be compatible with and complementary to current intravitreal-route, anti-VEGF therapies and has the potential to deliver substantial clinical benefits to patients by (i) prolonging the interval between administration of anti-VEGF drugs via intravitreal injections; and (ii) providing a prophylactic treatment alternative for certain AMD patients who may not be candidates for treatment of intravitreal-route anti-VEGF drugs yet are at risk for loss of vision. OXiGENE expects to report preclinical biodistribution and pharmacokinetic data for a potential topical formulation of ZYBRESTAT in the second half of 2007, and the Company currently anticipates filing an IND by the first quarter of 2008 for a topical formulation of ZYBRESTAT for use in the treatment of AMD. AMD is a leading cause of blindness in people over 55 years of age. According to the U.S. National Institute of Health's National Eye Institute, the disease currently affects approximately 1.5% of the adult population in the U.S. over age 40, or 1.75 million people; this figure is projected to nearly double to 3 million people by the year 2020 as a result of the population aging. Clinical Update - OXi4503 The Phase I, dose-escalation study of OXi4503, our novel, dual-mechanism, vascular disrupting agent (VDA), continues. Interim results reported at the June ASCO meeting demonstrated that OXi4503 is well-tolerated, with no dose-limiting toxicities observed to date in the study. Observed reductions in tumor blood-flow, as measured by PET and DCE-MRI imaging, provide evidence of biological activity, and escalation to higher doses will continue, per the protocol, until a maximum tolerated dose is identified. In collaboration with investigators and clinical / scientific advisors, the Company is developing a protocol to evaluate OXi4503 in combination with bevacizumab in solid tumor patients. The Company anticipates that this study will be an open-label, dose escalation study with a two-arm dose expansion phase to assess the safety, tolerability, biological and anti-tumor activity of the combination in subjects with advanced solid tumors. Planned Events for second half of 2007 * Initiate a Phase II study of ZYBRESTAT in combination with bevacizumab in non-small cell lung cancer and chemotherapy. * Announce initial results from our ongoing Phase I dose-escalation study of OXi4503 in patients with advanced solid tumors. * Announce initial results from our ongoing Phase Ib study of ZYBRESTAT in combination with bevacizumab in patients with advanced solid tumors. * Announce initial data from the first stage of Phase II study of ZYBRESTAT in ovarian cancer. * Announce preclinical biodistribution and pharmacokinetic data for a topical ophthalmological formulation of ZYBRESTAT in 2007. Planned Events for first half of 2008 * Initiate Phase I study with ZYBRESTAT for age-related macular degeneration by early 2008. About OXiGENE, Inc. OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients. Safe Harbor Statement This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, including with respect to the timing and results of its clinical trials involving ZYBRESTAT and OXi4503, may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's Form 10-Q, 8-K and 10-K reports. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2006 for a description of these risks. CONTACT: OXiGENE, Inc. Shari Annes, 650-888-0902 Investor Relations, 781-547-5900 The full report including tables can be downloaded from the following link:


 

SimCorp announces that a large European finance group has licensed SimCorp Dimension.


 

Revenues of $43.8 Million and Net Income of $11.4 Million; Entered Into $1 Billion Credit Facility for Aircraft Acquisitions; Signed Agreements for the Purchase and Leaseback of 4 New Aircraft SHANNON, Ireland, July 25, 2007 (PRIME NEWSWIRE) -- Genesis Lease Limited (NYSE:GLS) today announced its financial results for the second quarter ended June 30, 2007. For the quarter, revenues were $43.8 million, compared to $36.5 million for same period in 2006, an increase of 20.1%. Net income was $11.4 million, compared to $7.1 million for the same period last year, an increase of 59.0%. For the six months ended June 30, 2007, revenues were $86.0 million, compared to $72.4 million for the same period last year, an increase of 18.8%. Net income was $22.4 million, compared to $14.2 million for the same period last year, an increase of 57.1%. Increases in both year-over-year revenues and net income reflect primarily the acquisition of additional aircraft during 2006. For the quarter ended June 30, 2007, EBITDA was $38.9 million, compared to $35.7 million for the same period in 2006, an increase of 9.0%. For the six months ended June 30, 2007, EBITDA was $77.3 million, compared to $69.2 million for the same period last year, an increase of 11.8%. Genesis defines EBITDA as net income before provision for income taxes, interest and depreciation and amortization. EBITDA is a key measure of Genesis's operating performance and liquidity that management uses to focus on consolidated operating results exclusive of expenses that relate to the financing and capitalization of its business. Please read "Reconciliation of Non-GAAP Financial Measure -- EBITDA" for a description of EBITDA and a reconciliation of net income to EBITDA. John McMahon, Chief Executive Officer of Genesis, said, "During the second quarter, Genesis executed successfully against our business plan, signing separate agreements with Air Deccan and IndiGo Airlines to purchase four new Airbus A320 aircraft. These recent agreements are excellent examples of how the carriers are utilizing sale and lease-back arrangements to finance new additions to their fleets. We are encouraged with this activity and foresee additional opportunities to carry out similar transactions." Mr. McMahon continued, "The overall demand for commercial aircraft remains robust, with particular interest in the narrow-body aircraft that constitute a majority of our lease portfolio. The major commercial aircraft manufacturers are under tremendous pressure to meet worldwide demand for aircraft and are currently operating at capacity through 2011. We believe this situation bodes well for and will benefit the aircraft leasing industry." In line with its dividend policy, Genesis anticipates paying a dividend, subject to board approval, for the second quarter in August 2007 in an amount of $0.47 per share. This will be the second dividend payment since the initial public offering. On May 10, 2007, Genesis paid a dividend of $0.53 per share for the period from the completion of the initial public offering on December 19, 2006 to March 31, 2007. That dividend reflected the quarterly dividend of $0.47 per share, plus an incremental amount of $0.06 to reflect the slightly longer period. Aircraft Acquisition and Leasing Activities The following table presents the number of aircraft included in Genesis's initial portfolio of 41 aircraft and the number of those aircraft that were owned by its predecessor as of each of the following dates: Date Aircraft December 31, 2005 37 March 31, 2006 37 June 30, 2006 38 September 30, 2006 40 December 31, 2006 41 June 30, 2007 41 As of June 30, 2007, all 41 leases were performing and generating rents, as expected under the respective lease agreements. In April and June 2007, Genesis signed agreements to purchase four new Airbus A320 aircraft -- two from Air Deccan and two from IndiGo Airlines, both of India. Genesis took delivery of two of these aircraft (one from each of Air Deccan and IndiGo) in July 2007, and the remaining two will be delivered in September 2007. All four aircraft are subject to long-term leases to Air Deccan and IndiGo. During the first quarter, Genesis executed a new long-term lease agreement on a Boeing 737-800 with Sun Express of Turkey. The aircraft was delivered to Sun Express in June 2007. The portfolio contains no further scheduled lease expiries in 2007. Genesis also secured a long-term lease for a Boeing 737-800 expiring in 2008 with a new customer, leaving only two aircraft to be remarketed in 2008. Revolving Credit Facility As previously reported, on April 5, 2007, a subsidiary of Genesis entered into a $1 billion senior secured credit facility with a syndicate of lenders. The credit facility permits initial loans in an aggregate principal amount of up to $250 million, with an option for Genesis to increase the aggregate principal amount of available loans by an additional amount of up to $750 million during the first 18 months following the closing date of the credit facility, for a total commitment amount of up to $1 billion. Genesis made its first borrowings under the credit facility in July 2007 in connection with the deliveries of aircraft from Air Deccan and IndiGo. About Genesis Lease Limited Genesis Lease Limited is a global commercial aircraft leasing company that is headquartered in Shannon, Ireland. Genesis acquires and leases modern, operationally efficient passenger and cargo jet aircraft to a diverse group of airlines throughout the world. Genesis leverages the worldwide platform of GE Commercial Aviation Services Limited, or GECAS, to service its portfolio of leases, allowing management to focus on executing its growth strategy. Genesis's common shares, in the form of American Depositary Shares, are listed on the New York Stock Exchange under the symbol "GLS." On December 19, 2006, Genesis completed its initial public offering ("IPO") and issued 27,860,000 shares at a public offering price of $23.00 per share. On December 19, 2006, Genesis also issued 3,450,000 shares to an affiliate of General Electric Company ("GE"), in a private placement for a price of $23.00 per share, and issued $810 million of floating-rate aircraft lease-backed notes in a securitization transaction. Genesis used the net proceeds of the IPO, the private placement of shares to GE and the securitization to finance the acquisition of a portfolio of 41 aircraft from affiliates of GE. On January 16, 2007, Genesis sold an additional 4,179,000 shares after the underwriters of its initial public offering exercised their over-allotment option in full, as well as 517,500 additional shares in a private placement to GE, for aggregate additional proceeds of $108.0 million. References to amounts raised in offerings or other sales of securities are gross proceeds and do not reflect discounts and commissions paid to the underwriters or initial purchasers of those securities. Financial statements for periods prior to the IPO reflect the results of operations and financial condition of Genesis's predecessor. The predecessor's financial statements reflect the combination of the 41 aircraft in Genesis's portfolio from the date that each such aircraft was acquired by an affiliate of General Electric Company ("GE"). Conference Call and Webcast Genesis will host a conference call and webcast for investors and analysts to discuss its results for the quarter on Wednesday, July 25, 2007, at 2:00pm (GMT) / 9:00am (Eastern time) / 6:00am (Pacific time). Participants should call (877) 502-9276 (United States/Canada) or (913) 981-5591 (International) and request the Genesis call or utilize the confirmation code 6154885. A telephonic replay will be available for anyone unable to participate in the live call. To access the replay, call (888) 203-1112 or (719) 457-0820 and enter confirmation code 6154885. The recording will be available from Wednesday, July 25, 2007 until Wednesday, August 1, 2007 at 11:59 p.m. (Eastern Time). A live broadcast of the earnings conference call will also be available via the Internet at http://www.genesislease.com under Investor Relations. The webcast will be archived on the site for one year. The Genesis Lease Limited logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3178 Cautionary Statement Regarding Forward-Looking Statements This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "will," or words of similar meaning and include, but are not limited to, statements regarding the outlook for the company's future business and financial performance. Forward-looking statements are based on management's current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially due to global political, economic, business, competitive, market, regulatory and other factors and risks, including the lack of an independent operating history upon which to assess the company's prospects or ability to pay dividends to its shareholders; the possibility that the company's subsidiaries may have unknown contingent liabilities; the company's inability to pay or maintain dividends on its shares; reliance on subsidiaries to provide funds necessary to meet the company's financial obligations and pay dividends; unforeseen difficulties and costs associated with the acquisition and/or management of the company's aircraft portfolio; the need for additional capital to finance the company's growth; the death, incapacity or departure of senior management; the company's obligations to comply with reporting and corporate governance requirements; an inability to refinance the company's indebtedness on favorable terms or at all; operational restrictions imposed by the company's indebtedness; exposure to interest rate fluctuations; dependence on GECAS; limitations on the company's opportunities to purchase additional aircraft; potential conflicts of interests between the company and GECAS and its affiliates; competition with GECAS for acquisitions and dispositions of aircraft; limitations on remedies against GECAS for unsatisfactory performance; reliance on third-party service providers for certain administrative, accounting and other services; variability of supply and demand for aircraft and other aviation assets that could depress lease rates and the value of the company's leased assets; a decline in aircraft values and achievable lease rates; the possibility that the company may be required to substitute some of the aircraft in its portfolio; past damage to some of the aircraft in the company's portfolio; the advent of superior aircraft technology that could cause the company's existing aircraft portfolio to become outdated and therefore less desirable; increased operational costs as the company's aircraft age; concentration of aircraft types in the company's aircraft portfolio; competition for investment opportunities in aircraft and other aviation assets; an inability to expand due to limited demand for leased aircraft; possible depreciation expenses and impairment charges; the effect of aircraft liens on the company's ability to repossess, re-lease or resell its aircraft; failure by lessees to comply with the registration requirements in the jurisdiction where they operate; compliance with government regulations; difficulty to obtain title to one of the aircraft in the company's portfolio; an inability to re-lease or sell aircraft on favorable terms as leases expire; reliance on lessees' continuing performance of their lease obligations; difficulties in collecting lease payments from airlines; potential restructuring of leases with lessees that encounter financial difficulties; economic and political risks faced by lessees that operate in emerging markets; the possibility that the company may have to purchase repossession insurance if GECAS re-leases aircraft to lessees located in certain jurisdictions; potential lease defaults; an inability by lessees to fund their maintenance requirements on the company's aircraft; failure by lessees to pay certain operational costs that could result in grounding of aircraft; inadequate insurance coverage maintained by lessees; failure by lessees to obtain certain required licenses, consents and approvals; early termination rights contained in some leases; the concentration of lessees in certain geographical regions; a deterioration in the financial condition of the commercial airline industry; airline reorganizations that could impair lessees' ability to comply with lease payment obligations; the effect of high fuel prices on the profitability of the airline industry; the effects of terrorist attacks and geopolitical conditions on the airline industry; the effects of pandemic diseases on the airline industry; dependence on aircraft and engine manufacturers' continuing financial stability; the company's tax status as a passive foreign investment company; failure to qualify for tax treaty benefits and U.S. statutory tax exemptions; and exposure to potential taxation in jurisdictions in which the company's aircraft operate, where its lessees are located or where it perform certain services. Genesis expressly disclaims any obligation to update or revise any of these forward-looking statements, whether because of future events, new information, a change in its views or expectations, or otherwise. PLEASE NOTE: The financial tables accompanying this release have been attached as a Word (.doc) for your convenience. CONTACT: Genesis Lease Limited Alan Jenkins, Chief Financial Officer +353-61-233300 alan.jenkins@genesislease.com KCSA Worldwide Jeffrey Goldberger, Managing Partner +1-212-896-1249 jgoldberger@kcsa.com


 

Straumur Investment Bank hf. will announce its results for Q2 2007 on Thursday, 26 July 2007. A presentation for market participants will be held on Thursday, 26 July, in the banks headquarters, Borgartun 25, in the reception room on the 8th floor. William Fall, CEO, will present the results. The presentation will start at 8.30 am. Refreshments will be served from 8.00 am. A live broadcast of the presentation will be available on the website of Straumur www.straumur.net. Both the presentation and results will be available on the website of Straumur and the News System of the Iceland Stock Exchange www.omx.is after the meeting.


 

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | AXA Investment Managers UK | | | Limited/AXA Framlington | | | Investment Management Limited | |----------------------------------+--------------------------------| | Company dealt in | Quintain Estates & Development | |----------------------------------+--------------------------------| | Class of relevant security to | Ordinary shares | | which the dealings being | | | disclosed relate (Note 2) | | |----------------------------------+--------------------------------| | Date of dealing | 24/07/07 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------------------------------+ | | Long | Short | | | | | |---------------+--------------------------+------------------------------------------------| | |Number |Number | | | (%) | (%) | |---------------+--------------------------+------------------------------------------------| |(1) Relevant |2,178,593 (1.68%) | | |securities | | | | | | | |---------------+--------------------------+------------------------------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+--------------------------+------------------------------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+--------------------------+------------------------------------------------| |Total |2,178,593 (1.68%) | | | | | | +-------------------------------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +--------------------------------------------------------------------------+ |Class of | Long | Short | |relevant | | | |security: | | | | | | | |---------------+----------------------------+-----------------------------| | |Number |Number | | | (%) | (%) | |---------------+----------------------------+-----------------------------| |(1) Relevant | | | |securities | | | | | | | |---------------+----------------------------+-----------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+----------------------------+-----------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+----------------------------+-----------------------------| |Total | | | | | | | +--------------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | Sell | 8,075 | 9.55p | | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short (Note | Number of securities | Price per | | name, | 6) | (Note 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------------+------------------------+------------| | | | | | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 25/07/2007 | |---------------------------------------------------+---------------| | Contact name | Maria Mauro | |---------------------------------------------------+---------------| | Telephone number | 0207 003 2812 | |---------------------------------------------------+---------------| | If a connected EFM, name of offeree/offeror with | N/A | | which connected | | |---------------------------------------------------+---------------| | If a connected EFM, state nature of connection | N/A | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Novae Group plc Q2 2007 syndicate forecasts and current trading Correct: The run off year of Syndicate 1241 was inadvertently stated as being in respect of Syndicate 2147. The forecasts for Syndicate 2147 relate solely to the later years (2005 and 2006). The full corrected version of the release is set out below. Novae Syndicates Limited, the Lloyd's managing agency owned by Novae Group plc, today announces updated forecasts for its managed syndicates for the 2005 and 2006 underwriting years and for the 2002 and prior run off years. * Forecasts either unchanged or improved * Utilisation of provision for discontinued units in first half 2007 £4 million (first half 2006: £7 million) * Rating environment remains competitive consistent with our expectations (underlying overall rate reduction around 5%) 2005 year of account +-------------------------------------------------------------------+ | Syndicate | Capacity | Aligned | Current | Previous | | | £m | % | forecast | forecast | | | | | % | % | |-----------+----------+---------+----------------+-----------------| | | | | | | |-----------+----------+---------+----------------+-----------------| | 2147 | 286.0 | 100.0 | (12.5) - (7.5) | (12.5) - (7.5) | |-----------+----------+---------+----------------+-----------------| | | | | | | |-----------+----------+---------+----------------+-----------------| | 1007 | 151.0 | 81.6 | 11.0 - 16.0 | 10.0 - 15.0 | +-------------------------------------------------------------------+ The forecast for Syndicate 2147 continues to reflect the severity of windstorm losses during the year, as well as the transfer of certain business to the Group's insurance company. The net incurred loss ratio at 30 months is 109% (2004 55%; 2003 32%). In the case of Syndicate 1007 the forecast reflects the more favourable claims experience for Specialty classes, evident in a net incurred loss ratio at 30 months of 22% (2004 27%; 2003 12%). 2006 year of account +-------------------------------------------------------------------+ | Syndicate | Capacity | Aligned | Current | Previous | | | £m | % | forecast | forecast | | | | | % | % | |-----------+----------+---------+-----------------+----------------| | | | | | | |-----------+----------+---------+-----------------+----------------| | 2147 | 240.0 | 100.0 | 9.0 - 14.0 | 7.5 - 15.0 | |-----------+----------+---------+-----------------+----------------| | | | | | | |-----------+----------+---------+-----------------+----------------| | 1007 | 120.0 | 81.6 | 10.0 - 15.0 | 7.5 - 15.0 | +-------------------------------------------------------------------+ For the 2006 year, the more benign claims experience is evident within Syndicate 2147 from a net incurred loss ratio at 18 months of 23% (2005 105%; 2004 33%). For Syndicate 1007 early experience has been satisfactory, with an overall net incurred loss ratio of 12% (2005 10%; 2004 11%). Consistent with normal practice we have narrowed the forecast ranges at this stage. 2002 run off year of account +-------------------------------------------------------------------+ | Syndicate | Capacity | Aligned | Current | Previous | | | £m | % | forecast | forecast | | | | | % | % | |-----------+----------+---------+-----------------+----------------| | | | | | | |-----------+----------+---------+-----------------+----------------| | 1007 | 150.8 | 55.4 | (15.0) - (5.0) | (15.0) - (5.0) | |-----------+----------+---------+-----------------+----------------| | | | | | | |-----------+----------+---------+-----------------+----------------| | 1241 | 168.9 | 99.7 | (95.0) - (80.0) | (95.0) - | | | | | | (80.0) | +-------------------------------------------------------------------+ Progress continues to be made in dealing with legacy issues. The population of open claims on business led by the Group, which fell by 25% in 2006, fell by a further 18% in the first half of 2007, equivalent to a further 14% reduction by value. For the first half of 2007 utilisation of the provision for discontinued units was £4 million (H1 2006: £7 million). The pace of slowdown in utilisation of the provision has continued into 2007 and £9 million of the provision remains unutilised. Transactional solutions to the run off book consistent with the best interests of shareholders remain under permanent consideration, whether via a single transaction or large individual commutations. Current trading and prospects Some 12 months ago we highlighted the length of time that markets had remained favourable, and sounded a note of caution. A year on the softening of rates continues. In the first six months of 2007 rate reductions on renewal business across the Group averaged 3%. If weighted by business plan this would be of the order of a 5% reduction, albeit from high levels. Our response to the softening rating environment, whereby premium income of existing classes is generally reduced and complementary teams of new underwriters are added, was set out in detail in the annual report. This remains the Group's strategy in a challenging market. The most notable feature of claims experience so far in 2007 is the extensive flooding seen in England. It is too early to arrive at an accurate quantification of the cost to Novae but, based on information available at this stage and subject to other aspects of claims experience in the balance of the year, our current assessment is that this does not imply any material change to the likely outcome envisaged for the year as a whole. ENDS For further information: Matthew Fosh - Novae Group plc 020 7903 7300 Nick Miles - M:Communications 020 7153 1535 ---END OF MESSAGE---


 

MARIANA RESOURCES Ltd AIM and PLUS code: MARL 25 July 2007 DRILLING UPDATE- EXPLORADORA AND CHARANGO PROJECTS, CHILE Mariana Resources Ltd (Mariana) has completed a 2,755m reverse circulation percussion drill programme at the Exploradora and Charango properties targeting both porphyry copper-gold mineralisation and gold-silver epithermal veins. The properties are located along a major porphyry copper belt in the El Salvador Region of Northern Chile, approximately 50km northeast of Codelco's El Salvador porphyry copper mine Mariana's Exploradora Project is immediately south of the Exploradora porphyry copper-gold deposit owned by Codelco for which a geological resource of approximately 100Mt @ 0.3% Cu and 0.2g/t Au has been published in the Society of Economic Geologists, Special Publication 11 (2004, pp 97-111). At Exploradora, Mariana's target was secondary enrichment zones related to potential extensions of the porphyry system east of an area drilled previously by Anglo American. This drilling had intersected zones of secondary copper enrichment (best results of 4m @ 0.8% Cu, 34m @ 0.3% Cu and 20m @ 0.7% Cu). A number of gold-silver polymetallic epithermal veins were also tested on the Exploradora property. At Charango, the target was high-grade silver veins extending east from the adjacent Juncal silver mining district. At Exploradora, all 5 holes drilled in the East Sector intersected leached zones of variable thickness with hematite and subordinate jarosite in boxworks and veinlets. Two of the holes, EXM1 and EXM2, intersected substantial zones of anomalous (low grade) copper mineralization over downhole intervals of 188m and 168m respectively, assaying 0.2% Cu. In EXM1 a 30m zone from 260m to 300m was intersected assaying 0.26%Cu. In EXM2, a 48m zone from 172m to 220m averaged 0.25% Cu. The Primary zone was only weakly mineralized. No zones of higher grade secondary copper mineralisation were present within these broad envelopes. Narrow zones of anomalous gold were noted in EXM1, eg 4m @ .82 g/t Au and EXM3 (0.11-0.16 g/t Au over intervals of 8 to 30m). No strong veining was intersected in the 4 holes drilled to test peripheral vein targets. At Charango, no zones of strong quartz veining were intersected, however, Hole CHM3 intersected an 8m anomalous zone of quartz veinlets from 88m averaging 19.9 g/t Ag, 0.19% Pb and 0.26% Zn. Table 1: Significant intersections +---------------------------------------------------------+ | Hole No. | From | To | Interval | Assay | |----------------+-------+------+----------+--------------| | EXM-1 | 44m | 48m | 4m | 0.82 g/t Au | |----------------+-------+------+----------+--------------| | Including | 112m | 300m | 188m | 0.19% Cu | |----------------+-------+------+----------+--------------| | | 260m | 300m | 40m | 0.26% Cu | |----------------+-------+------+----------+--------------| | | 234m | 242m | 8m | 0.16g/t Au | |----------------+-------+------+----------+--------------| | EXM-2 | 142m | 300m | 158m | 0.22% Cu | |----------------+-------+------+----------+--------------| | Including | 172m | 220m | 48m | 0.25% Cu | |----------------+-------+------+----------+--------------| | EXM-4 | 160m | 198m | 38m | 0.16% Cu | |----------------+-------+------+----------+--------------| | EXM5 | 260m | 282m | 22m | 0.14% Cu | |----------------+-------+------+----------+--------------| | CHM3 | 88m | 96m | 8m | 0.18 g/t Au, | | | | | | 19.9 g/t Ag | | | | | | 0.19% Pb, | | | | | | 0.26% Zn | +---------------------------------------------------------+ Table 2: Drill hole details +-------------------------------------------------------------------------+ | | Drill | | | | | | | |Area | Hole | Azimuth | Dip | Length |East UTM | North UTM | Level | | | Name | | | | | | | |----------+-------+---------+-----+--------+---------+-----------+-------| |Anglo | | | -70 | | | | | |American | EXM-1 | 330 | | 300 | 475.645 | 7.144.229 | 3,728 | |----------+-------+---------+-----+--------+---------+-----------+-------| | Porphyry | EXM-2 | 200 | -60 | 300 | 475.567 | 7.144.605 | 3,681 | |----------+-------+---------+-----+--------+---------+-----------+-------| | | EXM-3 | 305 | -55 | 306 | 475.796 | 7.144.402 | 3,681 | |----------+-------+---------+-----+--------+---------+-----------+-------| | | EXM-4 | 305 | -55 | 288 | 476.104 | 7.144.252 | 3,727 | |----------+-------+---------+-----+--------+---------+-----------+-------| | | EXM-5 | 000 | -55 | 342 | 475.400 | 7.143.895 | 3,780 | |----------+-------+---------+-----+--------+---------+-----------+-------| |Bautizo | BZM-1 | 020 | -55 | 109 | 475.220 | 7.137.403 | 3,556 | |----------+-------+---------+-----+--------+---------+-----------+-------| | | BZM-2 | 005 | -75 | 178 | 475.220 | 7.137.403 | 3,556 | |----------+-------+---------+-----+--------+---------+-----------+-------| |Veta Sol | SOM-1 | 250 | -57 | 209 | 477.892 | 7.142.647 | 3,968 | |----------+-------+---------+-----+--------+---------+-----------+-------| |Charango | CHM-1 | 335 | -72 | 210 | 455.231 | 7.160.383 | 3,096 | |----------+-------+---------+-----+--------+---------+-----------+-------| | | CHM-2 | 010 | -59 | 165 | 455.292 | 7.159.149 | 2,939 | |----------+-------+---------+-----+--------+---------+-----------+-------| | | CHM-3 | 000 | -60 | 174 | 456.595 | 7.160.488 | 2,944 | |----------+-------+---------+-----+--------+---------+-----------+-------| | | CHM-4 | 000 | -60 | 174 | 455.211 | 7.160.354 | 2,941 | +-------------------------------------------------------------------------+ A more detailed assessment of the results is in progress, including whether there are possible structural targets in the vicinity of the broad zones of strongly anomalous copper in Holes EXM 1and 2, however at this stage no further drilling is being planned. Exploradora and Charango are held in joint venture with EMMB, a subsidiary of Anglo American PLC whereby Mariana can earn a 70% interest by spending US$3M over 3 years, subject to back-in rights. Other projects that were subject to the joint venture including Miel and Grillo were not drilled by Mariana and, under the terms of the joint venture agreement, will be returned to EMMB. For more information: +-------------------------------------------------------------------+ | Mariana Resources Limited | RFC Corporate Finance | | | Limited (Nomad) | | | | |--------------------------------------+----------------------------| | John Horsburgh | +61 2 9437 | Rob Adamson | +61 2 9250 | | (Chairman) | 4588 | Glen Parsons | 0041 | | John Sutcliffe (MD) | +593 2 298 | | +61 2 9250 | | | 6464 | | 0036 | |-------------------------------------------------------------------| | | |-------------------------------------------------------------------| | Conduit PR Limited (Public | Haywood Securities (UK) | | Relations) | Limited (Broker) | | | | |--------------------------------------+----------------------------| | Laurence Read | +44 20 7429 | Daniel Brooks | +4420 7031 | | | 6605 | | 8000 | | | +44 797 | | | | | 9955 923 | | | |------------------------+-------------+---------------+------------| | Ed Portman | +44 20 7429 | | | | | 6667 | | | | | +44 773 | | | | | 3363 501 | | | +-------------------------------------------------------------------+ Or visit website at www.marianaresources.com ADDITIONAL INFORMATION The drill programme was supervised by the Company's Managing Director Mr John Sutcliffe. Analytical work was carried out at the ALS Chemex laboratory in Santiago, Chile, using conventional fire assay technique for gold and silver. Exploration information in this announcement has been compiled by John Sutcliffe who is a Fellow of the Geological Society of London, a Chartered Engineer and a Member of the Institute of Mining and Metallurgy. Mr Sutcliffe has sufficient experience relevant to the style of mineralisation and types of copper and gold-silver deposit under consideration and to the activity that he is undertaking to qualify as a Competent Person as defined in the JORC Code. ---END OF MESSAGE---


 
Hitt og þetta
25. júlí 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |-------------------------------------------------+-----------------| | Company dealt in | Freeport Plc | |-------------------------------------------------+-----------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |-------------------------------------------------+-----------------| | Date of dealing | 24th July 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 2,500 | 347p | 347p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 0 | | | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +------------------------------------------------------------------+ | Date of disclosure | 25th July 2007 | |----------------------------------------------+-------------------| | Contact name | Edward Hodge | |----------------------------------------------+-------------------| | Telephone number | 0207 991 6661 | |----------------------------------------------+-------------------| | Name of offeree/offeror with which connected | Freeport Plc | |----------------------------------------------+-------------------| | Nature of connection (Note 6) | Connected Advisor | +------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Seadrill has agreed to sell the 1981-built jack-up West Titania for US$146.5 million to the Nigerian drilling contractor SeaWolf Oil Services Limited. The unit is at present operating in Tunisia for Ecumed under a three well contract that is expected to run until November 2007. The unit will thereafter be transferred to SeaWolf upon completion of the contract. As such, Seadrill will receive income from the three-well assignment in addition to the agreed sale price. Mr. Kjell E Jacobsen, CEO of Seadrill Management AS, said: "The Company-mission is to create a leading offshore driller with worldwide activities focused on new and modern drilling assets. The sale of the jack-up West Titania is in line with this strategy." A representative of SeaWolf Oil Services Limited, said: "This is a win-win for both SeaWolf and Seadrill. SeaWolf's strategy is to establish a first class truly indigenous Nigerian drilling contractor which is well supported by this acquisition as well as our acquisition of the two Mosvold jack-ups." Analyst contact Jim Daatland VP Investor Relations Seadrill Management AS +47 51 30 99 19 Media contact: Alf C Thorkildsen Chief Operating Officer Seadrill Management AS +47 51 30 99 19 Seadrill Limited Hamilton, Bermuda July 25, 2007


 

Addex raised CHF137 million in IPO ADX10059 shows efficacy in GERD & Migraine Conference call & webcast at 15:30 CEST (9:30am EDT) Corrected version English Release (PDF) German Release (PDF) French Release (PDF) Geneva, Switzerland, 25 July 2007 - Allosteric modulation company Addex Pharmaceuticals Ltd. (SWX:ADXN) reported today its financial results for the first half of 2007 and provided a product pipeline update. * CHF137 million ($111 million / ¤83 million) raised in Swiss IPO in May * CHF159 million ($129 million / ¤96 million) in cash as of 30 June 2007 * ADX10059 met the primary efficacy endpoint in a Phase IIa GERD trial * ADX10059 met the primary efficacy endpoint in a Phase IIa migraine trial * ADX10059 Phase IIa anxiety data due around the end of the year * ADX10061 Phase IIa smoking cessation data due around the end of 3Q07 "In terms of financial and clinical milestones, the first half of 2007 has been the most exciting period in the five year history of Addex," said Vincent Mutel, CEO. "The success of our IPO provides us the opportunity to advance our entire pipeline and realize our goal of diversifying our product portfolio into metabolic diseases and inflammation." In May, Addex raised CHF137 million through the issue of 1,875,000 new shares at CHF73 per share in initial public offering on the SWX Swiss Exchange. The company now has 5,862,492 shares outstanding. The free float is 32%. As of June 30th, Addex held CHF159 million in cash and cash equivalents. The loss per share was CHF4.55 for the first half of 2007 compared to CHF3.65 in the first half of 2006. Net loss for the first half of 2007 was CHF19.5 million compared to CHF9.6 million of the same period in 2006. Research and development expenses were CHF12.6 million in the first half of 2007 compared to 10.6 million for the same period in 2006. Tim Dyer, CFO, gave guidance: "We expect 2007 full year operating cash burn to be in the range of CHF35-40 million and CAPEX cash burn to be in the range of CHF3-4 million." Conference call & webcast Title: Addex Pharmaceuticals First Half 2007 Financial Results Conference Call Date: 25 July 2007 Time: 15.30 ~ 16.30 CEST (9:30 ~ 10:30am EDT) Dial-in numbers: +41 91 610 56 00 (Europe) +44 207 107 0611 (UK) +1 866 291 4166 (USA) The webcast and slides will be available at: www.addexpharma.com A replay and transcript will be made available in the investor relations section of our website. Clinical results review Addex reported in April that in a French Phase IIa trial in 24 patients, ADX10059, a negative allosteric modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5), met the primary endpoint of 24-hour esophageal pH control that was significantly better than placebo. In the 2-day trial, patients received placebo on day 1 and either 50 mg or 250 mg of ADX10059 on day 2. Results for the 50 mg dose were not statistically significant.Patients receiving 250 mg of ADX10059 had an esophageal pH <4 for 3.5% of a 24-hour period compared with 7.2% for placebo (p=0.014). The compound also significantly reduced the duration of acid reflux episodes vs. placebo over 24 hours (p=0.013) and during nighttime (p=0.0021). Finally, the 250 mg dose of ADX10059 significantly reduced the number and duration of patient reported symptomatic episodes vs. placebo (p=0.031 for both). Also in April Addex reported that in a Phase IIa trial in 129 patients, ADX10059 met the primary endpoint of significantly more patients than placebo who were pain-free 2 hours after dosing. In the double-blind, U.K. and German trial, 16.1% of ADX10059 patients were pain-free at 2 hours vs. 4.5% of placebo patients (p=0.039). The percent improvement was similar to that seen with triptans, the leading drugs for migraine. ADX10059 had better pain improvement than placebo at all time points up to 2 hours, although the differences were not statistically significant. Addex decided, with input from migraine thought leaders that since ADX10059 is thought to address the underlying mechanism involved in migraine, that it would pursue migraine prophylaxis in Phase IIb studies. Pipeline update Addex is preparing the trial designs for Phase IIb testing of ADX10059 in both GERD and migraine and is on track to complete the regulatory submissions for both programs around the end of the first quarter of 2008. The first patients are expected to be treated around the middle of 2008 in both indications. Data from the Phase IIb trials are expected in 2009. We will announce timing for the ADX10059 Phase IIb anxiety trial after analyzing the Phase IIa anxiety data. Enrollment of 148 patients has been completed in the placebo-controlled U.S. Phase IIa trial of ADX10061 for smoking cessation. The primary endpoint is four weeks continuous abstinence from the start of treatment week four. Addex will announce top line data from the double-blind study around the end of the third quarter. Enrollment is ongoing in the placebo-controlled EU Phase IIa trial of ADX10059 to treat acute anxiety in about 50 dental patients. The primary endpoint is the comparison of VAS-Anxiety score at 60 minutes post dose, immediately before a dental procedure. Addex will announce data from the double-blind study around the end of the year. Addex completed an initial Phase I trial of ADX48621. In this first-in-man single ascending dose study, the orally administered product was well tolerated. Additional Phase I studies of ADX48621 are planned once the galenic formulation of the compound has been completed. The Phase I program will be completed in 2008. Despite academic research suggesting that the molecular target of ADX48621, metabotropic glutamate receptor 5 (mGluR5), could be an interesting target for pain, Addex found that ADX48621 was not efficacious in two separate preclinical acute pain models. Addex will continue development of ADX48621 and believes it may have potential in multiple indications including depression and anxiety. ADX48621 also could play a role as a backup compound for ADX10059 in GERD and migraine. ADX63365, a positive allosteric modulator (PAM) of mGluR5, with potential for the treatment of schizophrenia and cognitive impairment, is in late preclinical testing and is on track to start Phase I testing in 2008. A clinical candidate has been selected from the ADX1 series. The compound, ADX71441, a PAM of GABA b, will now enter Phase 0 testing. We plan to start Phase I testing of ADX71441 next year. Additions to the Board In the first half of 2007 Addex added two new members to its board of directors: Jacques Theurillat and Beat E. Lüthi. Mr. Theurillat is the former deputy CEO and SVP Corporate Strategic Development at Serono. Mr. Lüthi is a member of the Management Board of Mettler Toledo (NYSE:MTD) and is head of its largest division, Laboratory Balances and Analytical Instruments. About Us Addex Pharmaceuticals Ltd. discovers and develops allosteric modulators, a small molecule therapeutic agent that may offer more sophisticated ways to normalize biological signaling compared to classical "orthosteric" agonist or antagonist drugs. "Allosteric", literally translated from its Greek roots, means: "other site". Thus, allosteric modulators bind receptors at sites that are distinct from the binding sites of classical small molecule "orthosteric" agonist and antagonist drugs. In May 2007, Addex completed an initial public offering on the SWX Swiss Exchange, raising CHF137 million ($111 million / ¤83 million). The IPO was the largest biotech IPO in Europe in three years. The most advanced drug candidate, ADX10059, a negative allosteric modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5), recently demonstrated clinically and statistically significant efficacy in separate Phase IIa clinical trials in gastroesophageal reflux disease (GERD) patients and migraine headache patients. Another phase IIa clinical trial of ADX10059 in acute anxiety is scheduled to finish in the second half of 2007. Data from a U.S. Phase IIa trial of ADX10061, an inlicensed orthosteric dopamine D1 receptor antagonist, for smoking cessation are due in the second half of 2007. The Addex discovery capability has been validated through a collaboration with Ortho-McNeil, a Johnson & Johnson company. The deal is limited to discovery and development of allosteric modulators of metabotropic glutamate receptor 2 (mGluR2). Forward-looking statements This publication contains specific forward-looking statements, e.g., statements including terms like "believe", "assume", "expect" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the Company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. Contact Chris Maggos Katia Spartalli Head of Investor Relations & Executive Secretary Communications Addex Pharmaceuticals Addex Pharmaceuticals Tel: +41 22 884 15 11 Tel. + 41 22 884 15 99 chris.maggos@addexpharma.com katia.spartalli@addexpharma.com www.addexpharma.com


 

Weak second quarter but strong inflow of orders - Net sales for the quarter amounted to SEK 107.6 (103.9). Net sales for the period amounted to SEK 210.4 (206.0) million. - Profit/loss for the quarter amounted to SEK -127.8 (-29.7) million. Profit/loss for the period amounted to SEK -214.5 (-45.3) million. - Earnings per share for the quarter amounted to SEK -2.21 (-1.03). Earnings per share for the period amounted to SEK -4.77 (-1.82). - The result for the second quarter was charged with SEK 85.7 million for the write-down of capitalised expenditures for development work. - Inflow of orders for the quarter amounted to SEK 160.4 (97.3) million. Inflow of orders for the period amounted to SEK 345.4 (155.3) million. - On 2 July, it was announced that Teligent, subject to the approval of the extraordinary general meeting of shareholders on 6 August 2007, will execute a secured preferential rights issue of SEK 231.3 million before transaction costs. Questions regarding this interim report may be directed to: Tomas Duffy, President and CEO, +46 8 410 172 76, Jan Bengtsson, CFO, +46 8 410 171 52 or Jan Rynning, Chairman of the Board, +46 733 11 72 76.


 

Sittard/Leiden, The Netherlands, July 25, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a non-exclusive PER.C6® research licensing agreement with Paris, France-based LFB Biotechnologies. LFB Biotechnologies will use Crucell's technology to develop undisclosed antibodies. No financial details were disclosed. During the research license period, Crucell and LFB Biotechnologies will also evaluate a joint collaboration in the field of enhancing sugar structures, described as glycosylation patterns, on recombinant antibodies using LFB's in-house developed technology. About the PER.C6® Technology Platform Crucell's and DSM's PER.C6® technology platform has been developed for the large-scale manufacture of biopharmaceutical products including vaccines. Compared to conventional production technologies, the strengths of the PER.C6® technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. About LFB Group The LFB Group's mission is to develop, manufacture and market plasma-derived medicinal products and biotherapeutic proteins. Created in 1994, LFB is a public limited company with the French state as a majority shareholder. Based in France, the LFB is the 3rd pharmaceutical group supplying drugs to hospitals in France. LFB SA is a French pharmaceutical company comprised of a holding company and two operating subsidiaries: - LFB BIOMEDICAMENTS, 1100 employees, produces and markets a wide range of plasma-derived medicinal products. - LFB BIOTECHNOLOGIES, 200 employees, is dedicated to the group's biotechnological activities and new medicinal products Research & Development. LFB S.A. currently has three foreign subsidiaries: LFB Hemoderivados in Brazil, LFB Biopharmaceuticals Ltd in the United Kingdom and LFB GmbH in Germany. The LFB is ideally placed to become a driving force in new technological and therapeutic fields. LFB focuses its discovery and development activities on monoclonal antibodies and therapeutic proteins for rare and severe diseases mixing and synergising different technologies: plasma purification, cell culture, transgenic production. LFB uses Emabling®, its technology platform, to develop highly functionally optimized antibodies while its R & D portfolio contains high-potential projects calling on innovative technology. For more information about the LFB Group, you can visit http://www.lfb.fr About Crucell Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, Sanofi Aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com. About DSM Biologics DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technology and services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6® human cell line as a production platform for recombinant proteins and monoclonal antibodies. DSM Biologics' FDA-approved facility in Groningen, The Netherlands, was established in 1986 and has a strong track record in using a broad range of cell lines (PER.C6®, CHO, hybridoma, etc.) in biopharmaceutical manufacturing, and has a wide range of experience using multiple manufacturing (batch, fed-batch and continuous perfusion) and purification techniques. The combination of the PER.C6® human cell line and DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. For more information, please visit www.dsmbiologics.com About DSM DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named Vision 2010 - Building on Strengths, focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over ¤8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com. Forward-looking statements This press release contains forward-looking statements that involve inherent risks and uncertainties. These statements are based on current expectations, estimates and projections of the management of DSM and Crucell and information currently available to both companies. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM and Crucell do not guarantee that their expectations will be realized. Furthermore, DSM and Crucell have no obligation to update the statements contained in this press release. Crucell has identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to the Form 20-F, as filed by Crucell with the U.S. Securities and Exchange Commission on June 13, 2007, and the section entitled "Risk Factors". Crucell prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS). For further information please contact: DSM Pharmaceutical Products Terry Novak Crucell N.V. Chief Marketing Officer Leonard Kruimer DSM Pharmaceuticals Inc. and Chief Financial Officer Biologics Tel. +31-(0)71 519 9100 Tel. +1 973 257 8471 Leonard.Kruimer@crucell.com Terry.Novak@dsm.com DSM Biologics Crucell N.V. Marcel Lubben Barbara Mulder Vice President Director Corporate Communications Marketing, Sales & NBD Tel: 31-(0) 71 519 7346 (+31) 46 47 73343 barbara.mulder@crucell.com marcel-m.lubben@dsm.com For Crucell in the US: LFB SA Redington, Inc. Sandrine Charrières Thomas Redington Corporate Communications Director Tel. +1 212-926-1733 Tel: +33 (0)1 69 82 72 80 tredington@redingtoninc.com charrieres@lfb.fr Marc Pennacino Business Development Director Tel : +33 (0)1 69 82 56 04 pennacino@lfb.fr Bertrand Mérot Chief Operating Officer Tel : +33 (0)1 69 82 88 22 merotb@lfb.f


 

Vancouver, Canada, July 24, 2007: Mr. Bill Wagener, COO of Northland Resources Inc., is pleased to announce that the Company's Annual General Meeting will be held on Tuesday, September 18, 2007 in the Rococo Room at the Grand Hotel in Oslo, Norway at 2:00 p.m. (Norwegian time). The formal meeting will be followed by refreshments as well as an opportunity to have informal discussions with the Company's executives and directors. "With approximately 80 percent of our shares held by European investors, we felt it was important that we give these investors an opportunity to attend our Annual General Meeting closer to where they live. This event will also provide the shareholders an opportunity to meet the Company's directors and management team in both a formal and informal setting," said Buck Morrow, President of Northland. About Northland Northland, www.northlandresourcesinc.com, is a well-structured, debt free junior exploration company with a portfolio of high quality iron, gold, and base metal exploration projects in Sweden and Finland. ON BEHALF OF THE BOARD "Bill Wagener" NORTHLAND RESOURCES INC. The TSX Venture Exchange has not reviewed and does not take responsibility for the accuracy of this release. CONTACT INFORMATION Northland Resources Inc. Buck Morrow, President Tel: 303-663-7829 Ralph Rushton, Investor Relations Tel: 604-408-7965 Toll Free: 1-866-719-8962 Gabriella Roos 44-791-286-9936


 

* First worldwide approval for new anti-cancer therapy designed to more potently and preferentially target the cause of chronic myeloid leukemia * Data show Tasigna to be generally well-tolerated with high response rates and manageable safety profile in patients who are resistant or intolerant to Glivec * US and EU regulatory decisions expected in 2007 with filing in Japan completed during the second quarter * Rapid development of Tasigna demonstrates commitment to speeding innovative medicines to patients with unmet medical need Basel, July 25, 2007 - Switzerland has granted the first worldwide approval for Tasigna® (nilotinib), a potent and novel targeted cancer therapy for patients with a form of the life-threatening blood cancer chronic myeloid leukemia (CML) who are resistant or intolerant to treatment with Glivecâ (imatinib)[1] - the leading therapy for CML patients also developed by Novartis. The approval of Tasigna came after an accelerated review by the Swiss health authority Swissmedic based on positive findings from a pivotal Phase II trial, Trial results showed high response rates in these patients with a generally well-tolerated, manageable safety profile. Taken twice-daily, Tasigna inhibits production of cancer cells containing an abnormal chromosome by targeting the Bcr-Abl protein. This protein, which is produced by cells containing the abnormal Philadelphia chromosome, is recognized as the key driver of the overproduction of cancer-causing white blood cells in patients with CML. In clinical trials, Tasigna reduced or eliminated this abnormal chromosome in 42% of Glivec-resistant patients with Philadelphia chromosome-positive (Ph+) CML in the chronic phase of the disease, as well as in 31% of patients in the accelerated phase of the disease. "While over 90% of patients on Glivec survive after five years, we focused on helping the small percentage of patients who developed resistance or intolerance to Glivec, which led to the discovery of Tasigna," said Dr. Daniel Vasella, Chairman and CEO of Novartis. "I am pleased that we set a record of less than five years from synthesis to market, rapidly bringing Tasigna - our second-generation, more selective and more potent Bcr-Abl tyrosine kinase inhibitor - to those patients who need it." Additional regulatory decisions on Tasigna are expected in the US and Europe later this year, while a regulatory submission was completed in Japan during the second quarter of 2007. In the US, the Food and Drug Administration requested on July 16 a three-month extension in the regulatory review period. Also planned for 2007 are Phase III studies involving Tasigna in CML patients responding sub-optimally to other therapies as well as newly-diagnosed CML patients. A registration study is already underway in patients with gastrointestinal stromal tumors (GIST), which can also be treated with Glivec in certain countries. Recent landmark clinical trial results for Glivec showed that nearly 90% of newly-diagnosed chronic phase Ph+ CML adults patients treated with Glivec were alive after five years[2], but some develop resistance or cannot tolerate this therapy. Applying key learnings from Glivec, a team of Novartis scientists created Tasigna in August 2002, just a year after the launch of Glivec. Tasigna was specifically designed to target Bcr-Abl more potently and preferentially without adding new mechanisms of action that might cause additional side effects. Tasigna moved from synthesis to its first regulatory approval in less than five years. "The speed of developing Tasigna reflects our passion to help cancer patients," said David Epstein, President and CEO of Novartis Oncology. "A designer cancer treatment, Tasigna also highlights our leadership in targeted therapies." Chronic myeloid leukemia is one of the four most common types of leukemia, responsible for about 15% of all leukemia cases worldwide[3], and caused by an overproduction of immature white blood cells. Approximately 95% of CML patients have the Philadelphia chromosome. Approval based on impressive Phase II results Tasigna has been approved for use in the treatment of chronic or accelerated phase of Ph+ CML patients resistant to, or experiencing significant toxicity during treatment with Glivec. The Swiss filing was based on an open-label Phase II study designed to evaluate the safety and efficacy of Tasigna in Glivec-resistant or -intolerant patients with Ph+ CML in chronic and accelerated phase. Efficacy was measured by cytogenetic response, i.e. reduction or elimination of the Ph+ chromosome, and hematologic response, i.e. normalization of white blood cell counts.. Among 132 patients with chronic phase disease, major cytogenetic response was observed in 55 patients (42%) after a median of 7.7 months' treatment. Among 64 patients with accelerated phase disease, major cytogenetic response was observed after a median of five month' follow-up in 20 (31%). Longer-term data from this pivotal Phase II trial presented last month at the American Society of Clinical Oncology annual meeting showed even further positive results. Tasigna safety information The safety of Tasigna was studied in 438 patients. The most frequent Grade 3 or 4 adverse events for Tasigna were primarily hematological in nature and included neutropenia and thrombocytopenia. Elevations were seen in bilirubin, liver function tests, lipase enzymes and blood sugar, which were mostly transient and resolved over time. These cases were easily managed and rarely led to discontinuation. Pancreatitis was reported in less than 1% of cases. The most frequent non-hematologic drug-related adverse events were rash, pruritus, nausea, fatigue, headache, constipation, and diarrhea. Most of these adverse events were mild to moderate in severity. Tasigna should be used with caution in patients who have or may develop prolongation of QTc. These include patients with abnormally low potassium or magnesium levels, patients with congenital long QT syndrome, patients taking anti-arrhythmic medicines or other drugs that may lead to QT prolongation, and cumulative high-dose anthracycline therapy. Low levels of potassium or magnesium must be corrected prior to Tasigna administration. The bioavailability of Tasigna is increased by food. Tasigna should not be taken in conjunction with food and should be taken two hours after a meal. No food should be consumed for at least one hour after the dose is taken. About Glivec Glivec is approved in more than 90 countries including the US, EU and Japan for the treatment of all phases of Ph+ CML. Glivec is also approved in the EU, US and other countries for the treatment of patients with Kit (CD117)-positive gastrointestinal tumors (GIST), which cannot be surgically removed and/or have already spread to other parts of the body (metastasized). Glivec has also been approved in various countries for use in treating patients with certain rare types of cancer. The majority of patients treated with Glivec in clinical trials experienced adverse events at some time. Most events were of mild to moderate grade and treatment discontinuation was not necessary in the majority of cases. Rare/serious adverse reactions include: sepsis, pneumonia, depression, convulsions, cardiac failure, thrombosis/embolism, ileus, pancreatitis, hepatic failure, exfoliative dermatitis, angioedema, Stevens-Johnson syndrome, renal failure, fluid retention, edema (including brain, eye, pericardium, abdomen and lung), hemorrhage (including brain, eye, kidney and gastrointestinal tract), diverticulitis, gastrointestinal perforation, tumor hemorrhage/ necrosis, hip osteonecrosis/avascular necrosis. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated. Cardiac screening should be considered in patients with HES/CEL, and patients with MDS/MPD with high level of eosinophils (echocardiogram, serum troponin level). Disclaimer The foregoing release contains forward-looking statements that can be identified by terminology such as "expected," "should," "planned" or similar expressions, or by express or implied discussions regarding potential regulatory approvals for Tasigna or potential future sales of Glivec or Tasigna, or regarding the long-term impact of a patient's use of Glivec or Tasigna. Such forward-looking statements reflect the current views of Novartis regarding future events and involve known and unknown risks, uncertainties and other factors that may cause actual results with Glivec or Tasigna to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Tasigna will be approved for any indications in any market, that Tasigna will brought to market in Switzerland or any additional markets or that Glivec or Tasigna will reach any particular level of sales. There can also be no guarantee regarding the long-term impact of a patient's use of Glivec or Tasigna. In particular, management's expectations regarding Glivec and Tasigna could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including additional analysis of clinical data, or new clinical data; competition in general; government, industry, and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; and other risks and factors discussed in Novartis' Form 20-F on file with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. About Novartis Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ more than 100,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com. References [1] Known as Gleevec® (imatinib mesylate) tablets in the US, Canada and Israel. [2] Druker, B. et al. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. N Engl J Med 2006;355:2408-17. [3] Faderl S; Talpaz M; Estrov Z; O'Brien S; Kurzrock R; Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999 Jul 15;341(3):164-72. # # # Novartis Media Relations Corinne Hoff Geoff Cook Novartis Global Media Relations Novartis Oncology +41 61 324 9577 (direct) +1 862 778 2675 (direct) +41 79 248 5717 (mobile) +1 973 652 7927 (mobile) corinne.hoff@novartis.com geoffrey.cook@novartis.com e-mail: media.relations@novartis.com Novartis Investor Relations International North America Ruth Metzler-Arnold Ronen Tamir +1 212 830 2433 Katharina Ambuehl Jill Pozarek +1 212 830 2445 Nafida Bendali Edwin Valeriano +1 212 830 2456 Pierre-Michel Bringer Jason Hannon Thomas Hungerbuehler Richard Jarvis Central phone number +41 61 324 79 44 e-mail: investor.relations@novartis.com --- End of Message --- Novartis International AG Posfach Basel WKN: 904278; ISIN: CH0012005267; Index: SLCI, SMI, SPI, SLIFE; Listed: Main Market in SWX Swiss Exchange, ZLS in BX Berne eXchange;


 

Addex raised CHF137 million in IPO ADX10059 shows efficacy in GERD & Migraine Conference call & webcast at 15:30 CEST (9:30am EDT) English Release (PDF) German Release (PDF) French Release (PDF) Geneva, Switzerland, 25 July 2007 - Allosteric modulation company Addex Pharmaceuticals Ltd. (SWX:ADXN) reported today its financial results for the first half of 2007 and provided a product pipeline update. * CHF137 million ($111 million / ¤83 million) raised in Swiss IPO in May * CHF159 million ($129 million / ¤96 million) in cash as of 30 June 2007 * ADX10059 met the primary efficacy endpoint in a Phase IIa GERD trial * ADX10059 met the primary efficacy endpoint in a Phase IIa migraine trial * ADX10059 Phase IIa anxiety data due around the end of 3Q07 * ADX10061 Phase IIa smoking cessation data due around the end of the year "In terms of financial and clinical milestones, the first half of 2007 has been the most exciting period in the five year history of Addex," said Vincent Mutel, CEO. "The success of our IPO provides us the opportunity to advance our entire pipeline and realize our goal of diversifying our product portfolio into metabolic diseases and inflammation." In May, Addex raised CHF137 million through the issue of 1,875,000 new shares at CHF73 per share in initial public offering on the SWX Swiss Exchange. The company now has 5,862,492 shares outstanding. The free float is 32%. As of June 30th, Addex held CHF159 million in cash and cash equivalents. The loss per share was CHF4.55 for the first half of 2007 compared to CHF3.65 in the first half of 2006. Net loss for the first half of 2007 was CHF19.5 million compared to CHF9.6 million of the same period in 2006. Research and development expenses were CHF12.6 million in the first half of 2007 compared to 10.6 million for the same period in 2006. Tim Dyer, CFO, gave guidance: "We expect 2007 full year operating cash burn to be in the range of CHF35-40 million and CAPEX cash burn to be in the range of CHF3-4 million." Conference call & webcast Title: Addex Pharmaceuticals First Half 2007 Financial Results Conference Call Date: 25 July 2007 Time: 15.30 ~ 16.30 CEST (9:30 ~ 10:30am EDT) Dial-in numbers: +41 91 610 56 00 (Europe) +44 207 107 0611 (UK) +1 866 291 4166 (USA) The webcast and slides will be available at: www.addexpharma.com A replay and transcript will be made available in the investor relations section of our website. Clinical results review Addex reported in April that in a French Phase IIa trial in 24 patients, ADX10059, a negative allosteric modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5), met the primary endpoint of 24-hour esophageal pH control that was significantly better than placebo. In the 2-day trial, patients received placebo on day 1 and either 50 mg or 250 mg of ADX10059 on day 2. Results for the 50 mg dose were not statistically significant.Patients receiving 250 mg of ADX10059 had an esophageal pH <4 for 3.5% of a 24-hour period compared with 7.2% for placebo (p=0.014). The compound also significantly reduced the duration of acid reflux episodes vs. placebo over 24 hours (p=0.013) and during nighttime (p=0.0021). Finally, the 250 mg dose of ADX10059 significantly reduced the number and duration of patient reported symptomatic episodes vs. placebo (p=0.031 for both). Also in April Addex reported that in a Phase IIa trial in 129 patients, ADX10059 met the primary endpoint of significantly more patients than placebo who were pain-free 2 hours after dosing. In the double-blind, U.K. and German trial, 16.1% of ADX10059 patients were pain-free at 2 hours vs. 4.5% of placebo patients (p=0.039). The percent improvement was similar to that seen with triptans, the leading drugs for migraine. ADX10059 had better pain improvement than placebo at all time points up to 2 hours, although the differences were not statistically significant. Addex decided, with input from migraine thought leaders that since ADX10059 is thought to address the underlying mechanism involved in migraine, that it would pursue migraine prophylaxis in Phase IIb studies. Pipeline update Addex is preparing the trial designs for Phase IIb testing of ADX10059 in both GERD and migraine and is on track to complete the regulatory submissions for both programs around the end of the first quarter of 2008. The first patients are expected to be treated around the middle of 2008 in both indications. Data from the Phase IIb trials are expected in 2009. We will announce timing for the ADX10059 Phase IIb anxiety trial after analyzing the Phase IIa anxiety data. Enrollment of 148 patients has been completed in the placebo-controlled U.S. Phase IIa trial of ADX10061 for smoking cessation. The primary endpoint is four weeks continuous abstinence from the start of treatment week four. Addex will announce top line data from the double-blind study around the end of the third quarter. Enrollment is ongoing in the placebo-controlled EU Phase IIa trial of ADX10059 to treat acute anxiety in about 50 dental patients. The primary endpoint is the comparison of VAS-Anxiety score at 60 minutes post dose, immediately before a dental procedure. Addex will announce data from the double-blind study around the end of the year. Addex completed an initial Phase I trial of ADX48621. In this first-in-man single ascending dose study, the orally administered product was well tolerated. Additional Phase I studies of ADX48621 are planned once the galenic formulation of the compound has been completed. The Phase I program will be completed in 2008. Despite academic research suggesting that the molecular target of ADX48621, metabotropic glutamate receptor 5 (mGluR5), could be an interesting target for pain, Addex found that ADX48621 was not efficacious in two separate preclinical acute pain models. Addex will continue development of ADX48621 and believes it may have potential in multiple indications including depression and anxiety. ADX48621 also could play a role as a backup compound for ADX10059 in GERD and migraine. ADX63365, a positive allosteric modulator (PAM) of mGluR5, with potential for the treatment of schizophrenia and cognitive impairment, is in late preclinical testing and is on track to start Phase I testing in 2008. A clinical candidate has been selected from the ADX1 series. The compound, ADX71441, a PAM of GABA b, will now enter Phase 0 testing. We plan to start Phase I testing of ADX71441 next year. Additions to the Board In the first half of 2007 Addex added two new members to its board of directors: Jacques Theurillat and Beat E. Lüthi. Mr. Theurillat is the former deputy CEO and SVP Corporate Strategic Development at Serono. Mr. Lüthi is a member of the Management Board of Mettler Toledo (NYSE:MTD) and is head of its largest division, Laboratory Balances and Analytical Instruments. About Us Addex Pharmaceuticals Ltd. discovers and develops allosteric modulators, a small molecule therapeutic agent that may offer more sophisticated ways to normalize biological signaling compared to classical "orthosteric" agonist or antagonist drugs. "Allosteric", literally translated from its Greek roots, means: "other site". Thus, allosteric modulators bind receptors at sites that are distinct from the binding sites of classical small molecule "orthosteric" agonist and antagonist drugs. In May 2007, Addex completed an initial public offering on the SWX Swiss Exchange, raising CHF137 million ($111 million / ¤83 million). The IPO was the largest biotech IPO in Europe in three years. The most advanced drug candidate, ADX10059, a negative allosteric modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5), recently demonstrated clinically and statistically significant efficacy in separate Phase IIa clinical trials in gastroesophageal reflux disease (GERD) patients and migraine headache patients. Another phase IIa clinical trial of ADX10059 in acute anxiety is scheduled to finish in the second half of 2007. Data from a U.S. Phase IIa trial of ADX10061, an inlicensed orthosteric dopamine D1 receptor antagonist, for smoking cessation are due in the second half of 2007. The Addex discovery capability has been validated through a collaboration with Ortho-McNeil, a Johnson & Johnson company. The deal is limited to discovery and development of allosteric modulators of metabotropic glutamate receptor 2 (mGluR2). Forward-looking statements This publication contains specific forward-looking statements, e.g., statements including terms like "believe", "assume", "expect" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the Company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. Contact Chris Maggos Katia Spartalli Head of Investor Relations & Executive Secretary Communications Addex Pharmaceuticals Addex Pharmaceuticals Tel. + 41 22 884 15 99 Tel: +41 22 884 15 11 katia.spartalli@addexpharma.com chris.maggos@addexpharma.com www.addexpharma.com


 

Stockholm - Wednesday, July 25, 2007 - Tele2 AB ("Tele2") (OMX Nordic Exchange: TEL2 A and TEL2 B), Europe's leading alternative telecom operator, today announced its consolidated results for the second quarter 2007. - Operating revenue for Q2 2007 grew by 6 percent to SEK 13,110 (12,386) million - EBITDA in Q2 2007 increased by 40 percent to SEK 1,737 (1,237) million - EBIT in Q2 2007 increased by 110 percent to SEK 604 (288) million excluding one-off items of SEK -520 (52) million related to the sale of Alpha Telecom and Calling Card Company (C3) operations. Including one-off items EBIT decreased by 75 percent to SEK 84 (340) million - Net profit/loss from continuing operations for Q2 2007 amounted to SEK 108 (136) million excluding one-off items of SEK -520 (52) million - Earnings per share from continuing operations, after dilution, for Q2 2007 amounted to SEK 0.32 (0.41) excluding one-off items of SEK -520 (52) million - Operating revenue for H1 2007 grew by 5 percent to SEK 25,947 (24,629) million - Net profit/loss for H1 2007 amounted to SEK 190 (279) excluding, and SEK -330 (331) million including, one-off items of SEK -520 (52) million - Earnings per share, after dilution, for H1 2007 amounted to SEK 0.60 (0.81) excluding, and SEK -0.57 (0.92) including, one-off items of SEK -520 (52) million - Mobile revenues in Q2 2007 increased by 25.5 percent to SEK 5.8 billion - Continued excellent performance in Russian mobile operations with EBITDA margin of 33 percent in Q2 2007. Russia now has a customer base in excess of 7.9 million - Solid broadband intake during Q2 2007, adding a total of 221,000 new broadband customers - Fixed telephony EBITDA margin at 12 (9) percent in Q2 2007 Lars-Johan Jarnheimer, President and CEO of Tele2 AB comments: "Tele2's realignment process remains on track and is proving successful. As stated previously, a more infrastructure-based strategy will lead to higher margins. These quarterly results prove that we really are on the right track. Our focus on core business in mobile and broadband services is showing key results. EBITDA grew 40 percent, compared to Q2 2006. However, we're aiming even higher. Therefore we have introduced a financial hurdle to keep us on our toes. We have set a minimum EBITDA target of 20 percent for each of Tele2's geographies, and they must stride over this hurdle in the medium term. This is a sign of our dedication, focus and concentration. Our performance in mobile services is strong. Russia has once again proved star qualities with an EBITDA margin at a record-high 33 percent. Competition is tough in the Russian mobile services market, but we are certain of our ability to master the current situation. The Baltic region produced impressive revenue growth, with a year-on-year increase of 18 percent. We see promising development, especially in the corporate segment. The Nordic area is showing a good balance between revenue growth and EBITDA development in absolute terms. Our broadband business continues to show progress with a total customer intake of 221,000 new customers in Q2 2007. Italy accomplished its strongest direct access & LLUB intake ever, adding 107,000 customers during the quarter. EBITDA in direct access & LLUB was negatively impacted by start-up costs - this time in the German operations. However, I am pleased to see that Southern Europe has turned the corner when it comes to operational performance. Tele2's fixed line customer base still offers opportunities in cross-selling broadband services. Dispite a high level of competition, our fixed line operations are developing according to plan. We strive to maximize value through an extremely cost-conscious regime and broadband cross-selling." Further information can be obtained from: Lars-Johan Jarnheimer, President and CEO Tele2 AB, Telephone: +46 8 5626 4000 Lars Nilsson, CFO Tele2 AB, Telephone: +46 8 5626 4000 Lars Torstensson, Investor Inquiries, Telephone: +46 702 73 48 79 Visit us at our website: http://www.tele2.com PRESENTATION DETAILS A presentation to discuss the results will be held at 06.45 am UK time (07.45 am CET) at Hilton Stockholm Slussen, Guldgränd 8, Stockholm. The presentation will be web-cast on Tele2's website www.tele2.com, along with the presentation material. CONFERENCE CALL DETAILS A conference call to discuss the results will be held at 16.00 (CET) / 15.00 (UK time) / 10.00 am (New York time), on July 25, 2007. The dial-in number is: +44 (0)20 7806 1956 or US: +1 718 354 1388. Please dial in 10 minutes prior to the start of the conference call to allow time for registration. A recording of the conference call will be available for 10 days after the call on: +44 (0)20 7806 1970 or US: +1 718 354 1112 with access code 3024007#. The conference call will be web-cast on Tele2's website www.tele2.com, with the possibility to enter questions online. Tele2 is Europe's leading alternative telecom operator Tele2's mission is to provide cheap and simple telecoms for everyone in Europe. Tele2 always strives to offer the market's best prices. We have 29 million customers in 21 countries. Tele2 offers fixed and mobile telephony, broadband, data network services and cable TV. Ever since Jan Stenbeck founded the company in 1993, it has been a tough challenger to the former government monopolies and other established providers. Tele2 has been listed on OMX Nordic Exchange since 1996. In 2006 we had operating revenue of SEK 50.3 billion and we reported an operating profit (EBITDA) of SEK 5.7 billion.


 

Martinsried/Munich (Germany) and Princeton, N.J., July 25, 2007 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) today announced that the Oncologic Drugs Advisory Committee (ODAC) for the U.S. Food and Drug Administration (FDA) recommended (12-0) that the FDA should wait for the final survival analysis of the SPARC trial before deciding whether the satraplatin application is approvable for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed. The FDA is not bound by the recommendations of advisory committees but will consider their advice when reviewing an applicant's NDA. The Company said that, due to a recent slowing in the reported rate of deaths in the SPARC trial, final overall survival results could take longer than the previously communicated timeframe of the fall of this year. Conference call scheduled As previously announced, the Company has scheduled a conference call to which participants may listen via live webcast, accessible through the GPC Biotech Web site at www.gpc-biotech.com or via telephone. A replay will be available via the Web site following the live event. The call, which will be conducted in English, will be held tomorrow, July 25th at 7:00 CET/1:00 AM ET, prior to the opening of the German markets. The dial-in numbers for the call are as follows: Participants from Europe: +49 (0)89 9982 99910 or +44 (0)20 7806 1950 Participants from the U.S.: 1-718-354-1385 END OF AD HOC ANNOUNCEMENT This ad hoc release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech AG, including statements about the status of the FDA review process. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this ad hoc release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2006 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Satraplatin has not yet been approved by the FDA in the U.S., the EMEA in Europe or any other regulatory authority and no conclusions can or should be drawn regarding its safety or effectiveness. Only the relevant regulatory authorities can determine whether satraplatin is safe and effective for the use(s) being investigated. For further information, please contact: GPC Biotech AG Martin Braendle Director, Investor Relations & Corporate Communications Phone: +49 (0)89 8565-2693 ir@gpc-biotech.com In the U.S.: Laurie Doyle Director, Investor Relations & Corporate Communications Phone: +1 609 524 5884 usinvestors@gpc-biotech.com Additional Media Contacts: In Europe: Maitland Brian Hudspith Phone: +44 (0)20 7379 5151 bhudspith@maitland.co.uk In the U.S.: Russo Partners, LLC David Schull Phone: +1 212 845 4271 david.schull@russopartnersllc.com --- End of Message --- GPC Biotech AG Fraunhoferstr. 20 Martinsried WKN: 585150; ISIN: DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX, HDAX, TECH All Share; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Geregelter Markt in Frankfurter Wertpapierbörse;


 

NEWS RELEASE DATE: July 24, 2007 FOR IMMEDIATE RELEASE TRADING SYMBOLS: TSX-V (Canada): WGP.V FRANKFURT: WE6.F WESTERN GEOPOWER ANNOUNCES RESIGNATION OF DIRECTOR VANCOUVER, Canada, July 24, 2007, TSX Venture Exchange Trading Symbol: WGP - Western GeoPower Corp., (the "Company"), today announced that the Board of Directors of the Company has accepted the resignation of Murray Sinclair as a director of the Company. The Board has expressed its gratitude to Mr. Sinclair for his service and his assurance that he will continue to support Western GeoPower's efforts to become a leading geothermal energy company. Corporate Overview Western GeoPower Corp. is a renewable energy company dedicated to the development of geothermal energy projects for the delivery of clean, baseload electricity generation. The Company is developing the 25.5 Megawatt (net) geothermal power plant at The Geysers Geothermal Field in Sonoma County, California, United States. The Company is also developing the South Meager Geothermal Project in British Columbia, Canada. On behalf of Western GeoPower Corp. "Kenneth MacLeod" Kenneth MacLeod, President & CEO Cautionary Note Regarding Forward-Looking Statements Statements in this release that are forward-looking are subject to various risks and uncertainties concerning the specific factors identified above that reflect the Company's expectations and projections about its future results. The Company has tried whenever possible to identify these forward-looking statements which include but are not limited to, words such as "anticipates," believes," "estimates," "expects," "plans," "intends," "potential," and similar expressions. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in the forward-looking statements. The Company disclaims any obligation or intention to update or to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Such information contained herein represents management's best judgment as of the date hereof based on information currently available. This news release is not for dissemination in the United States of America or to United States of America news services. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. For more information or to be put on our email list, please contact our office: (604) 662-3338 or US/Canada Toll Free: 1-866-662-3322, email: info@geopower.ca Investor Relations: IR@geopower.ca --- End of Message --- Western GeoPower Corp. 837 West Hastings Street Suite 411 Vancouver, BC<br>V6C 3N6 Canada WKN: 254049; ISIN: CA95827Q1037; ;


 

- Shareholders fully approve the growth strategy pursued by the Board of Directors - Resolutions in favor of a capital increase out of capital reserves - Annual prognosis for 2007 supported by current business developments Regensburg, July 24, 2007. Today at the GENEART AG Shareholders' Meeting in Regensburg, the shareholders adopted all agenda items by a large majority and expressed broad approval for the company's sustained growth strategy. The Board of Directors and the Supervisory Board had also proposed a capital increase using company funds. The Shareholders' Meeting adopted this proposal by resolution. The measure is similar to a stock split. GENEART will implement this resolution after registering it with the commercial registry. In all likelihood, this will be in the beginning of September 2007. The Shareholders' Meeting also decided to grant formal approval for the actions of the Board of Directors and the Supervisory Board, to adapt the bylaws and to select the annual auditor for the business year 2007. The shareholders further confirmed the current Supervisory Board for five more years and set up new remuneration rules for the members of the controlling body. In a presentation and later in a general debate with the shareholders, the GENEART AG Board of Directors expressed satisfaction with the business development in recent months and projected further strong growth in 2007. With yearly turnover growth rates of more than 70% since 2000 and a growing staff of now more than 120 coworkers the world market leader in the field of gene synthesis and specialist in the synthetic biology has emerged as one of the few profitable German biotechnology enterprises. The GENEART AG will publish its financial data for the first 6 months and the 2nd Quarter 2007 on August 9, 2007. For further inquiries, please contact: Bernd Merkl Frank Ostermair GENEART AG Haubrok Investor Relations GmbH Josef-Engert-Str. 11 Maximilianstraße 45 D-93053 Regensburg 80538 München Germany Germany Tel.: +49-(0)941-942 76 - 638 Tel: 089-21027-204 Fax: +49-(0)941-942 76 - 711 Fax: 089-21027-298 ir@geneart.com f.ostermair@haubrok.de www.geneart.com Legal Information This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results. Background information: About GENEART AG GENEART was founded in 1999. Today, the company ranks as the leading global specialist in gene synthesis for research institutions, the pharmaceutical industry and for enterprises in biotechnology and chemistry. GENEART offers integrated product systems based on gene synthesis for the development of innovative drugs, in particular for DNA- and protein-based therapeutics and vaccines, and for the identification of improved industrial enzymes. Service offerings range from synthesizing artificial genes according to DIN EN ISO 9001:2000, via constructing gene libraries in the field of combinatorial biology, to the production and development of DNA-based active components. The team of more than 80 employees in Regensburg and with the subsidiary GENEART Inc. in Toronto/Canada reached break even in 2005. Since May 2006 GENEART AG is listed at the German Stock Exchange.


 

Reykjavik/Oslo/Stockholm/Helsinki - 24 July 2007 - Glitnir was the third largest equity broker in the Nordic Capital Market (OMX + Oslo Stock Exchange) in the first six months of 2007 in terms of market turnover*. Glitnir and FIM's combined market share YTD 2007 was 24.4% in Iceland, 6.1% in Finland, 6.1% in Sweden, 5.8% in Norway, 3.2% in Denmark, 6.3% for OMX and 6.2% for the Nordics (OMX+Oslo). In June Glitnir/FIM was the second largest broker in the Nordics with a market share of 6.4%. "Through strong growth in recent years Glitnir has established itself as one of the largest Nordic brokerage houses. We have increased our market share since Q1 in a market that continues to see turnover records. The strong position in brokerage supports our position as a leading financial service provider in the Nordics", says Lárus Welding, CEO, Glitnir. Glitnir Market share June YTD Nordics 6.37% 6.16% OMX 6.44% 6.26% Stockholm 7.00% 6.13% Helsinki 5.42% 6.12% Oslo 6.10% 5.81% Reykjavik 23.06% 24.43% Copenhagen 3.27% 3.23% Largest brokers Nordics YTD June YTD 1 Skandinaviska Enskilda Banken AB 7.08% 7.11% 2 Morgan Stanley & Co. International Ltd 6.13% 6.36% 3 Glitnir/FIM 6.37% 6.16% 4 Merrill Lynch International 4.30% 4.42% 5 Carnegie Investment Bank AB 4.49% 4.38% 6 Lehman Brothers International 4.11% 4.19% 7 Svenska Handelsbanken AB 3.78% 3.85% 8 Goldman Sachs International 3.56% 3.61% 9 UBS Limited 3.40% 3.52% 10 Danske Bank A/S 3.75% 3.47% "Glitnir has built a strong position in the equity markets in the Nordics. An important element of our strategy is to deliver top quality research to investors. We are doing research on 220 listed companies in Iceland, Norway, Sweden, Finland and Russia and we are steadily growing our research team in the Nordics in order to maintain and further strengthen our position", says Almar Gudmundsson, Glitnir, Head of Nordic Research" About Glitnir The financial group Glitnir offers universal banking and financial services. Glitnir is a leading niche player in three global industry segments; seafood/food, sustainable energy, and offshore services vessels. Services include retail, corporate and investment banking, stock trade/brokerage and capital management. Glitnir considers Iceland and Norway its home markets. The Glitnir group has operations in Iceland, Norway, Sweden, Denmark, Finland, the UK, Luxembourg, Russia, Canada and China and plans to open a US office in New York in the fall of 2007. Glitnir is listed on the Icelandic Stock Exchange. For more information: www.glitnirbank.com For more information: Frank O. Reite, Executive Vice President, Nordic & Markets, mobile +47 915 80 604 Almar Gudmundsson, Glitnir, Head of Nordic Research, mobile +354 844 4944, e-mail: almar.gudmundsson@glitnir.is Bjørn Richard Johansen, Managing Director, Corporate Communication, Glitnir, e-mail: brj@glitnir.no, mobile +47 47 800 100 For more photos: akj@glitnir.no *Based on statistics published by OMX and Oslo Børs Please note: Presentation of Glitnir Bank's Second Quarter Results Glitnir will host the following presentations and webcasts in relation to the publication of its second quarter results for 2007. An English version of the presentation will be available on www.glitnirbank.com as of its publishing midday on 31 July. Presentation in Reykjavík, Iceland Lárus Welding, CEO, will present Glitnir's second quarter results for 2007 to shareholders and market participants on Tuesday, 31 July, at 1.30 p.m. at Nordica Hotel, room H, in Reykjavík. Presentation and web cast in London, UK Lárus Welding, CEO, will present Glitnir's second quarter results for 2007 to shareholders and market participants on Wednesday, 1 August, at 11 a.m. at The Great Eastern Hotel, Liverpool Street, EC2M 7QN, London. Lunch will be offered after the presentation. A live broadcast of the meeting can be accessed on Glitnir's web: www.glitnirbank.com, where questions can be sent to the meeting via the web cast. You can also participate with questions by telephone by dialling +44 (0) 208 817 9301. Attendance should register with Vala Pálsdóttir, Head of Investor Relations, by e-mail at ir@glitnir.is or by calling +354 440 4989. Media interviews bookings To book media interviews, please contact Bjørn Richard Johansen, Managing Director, Corporate Communication, by sending an e-mail message to brj@glitnir.no or by calling mobile +47 47 800 100.


 

` FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | DEEPHAVEN CAPITAL | | | MANAGEMENT LLC | |-----------------------------------------------+-------------------| | Company dealt in | EMI Group Plc | |-----------------------------------------------+-------------------| | Class of relevant security to which the | 14p Ordinary | | dealings being disclosed relate (Note 2) | | |-----------------------------------------------+-------------------| | Date of dealing | 23 July 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------+ | | Long | Short | | | | | |-------------------------------------+--------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (2) Derivatives (other than | 0 | 0 | | | | options) | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | Total | 0 | 0 | | | | | | | | | +-------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +-------------------------------------------------------------------+ | Class of relevant security: | Long | Short | | | | | |-------------------------------------+--------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (2) Derivatives (other than | | | | | | options) | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | Total | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short | Number of securities | Price per unit | | name, | (Note 6) | (Note 7) | (Note 5) | | e.g. CFD | | | | |----------+------------+--------------------------+----------------| | | | | | | CFD | SHORT | 3,760,000 | 261.87000 | | CFD | SHORT | 3,500,000 | 261.93800 | | CFD | SHORT | 4,000,000 | 261.95767 | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 24th July 2007 | |--------------------------------------------------+----------------| | Contact name | James Feast | |--------------------------------------------------+----------------| | Telephone number | 0207 469 1901 | |--------------------------------------------------+----------------| | If a connected EFM, name of offeree/offeror with | | | which connected | | |--------------------------------------------------+----------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

2nd quarter 2007 webcast and conference call information Stavanger, Norway Ocean Rig will release its 2nd quarter 2007 results on July 31, 2007, in connection with a webcast and conference call to be held by Mr. Trygve Arnesen, CEO, and Mr. Jan Rune Steinsland, CFO, at 2:00 p.m. (CET). The sound and presentation material will be broadcasted live through Ocean Rig ASA's website www.ocean-rig.com. To connect, please activate the link on the website's front page. The broadcast will also be available through Oslo Stock Exchange Webcast. A recorded version of the webcast will be available on the company's website after the presentation has concluded. To participate in the conference call, please call one of the numbers below: From Norway, call free of charge, 8001 9395 From the US, call free of charge, 1866 966 9444 From the UK, call free of charge, 0800 694 2370 International callers, +44 (0) 1452 552 510 Please call 10 minutes in advance to register for the conference call. The conference call ID-number is 4416339. Ocean Rig owns and operates two of the world's largest and most modern drilling rigs, built for ultra deep waters and extreme weather conditions. The units are currently operating offshore Angola and in the US Gulf of Mexico. NOTE: This press release contains forward-looking statements (within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended) which reflect the Company's current views with respect to certain future events and financial performance. Actual events or results may differ materially from those projected or implied in such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information or otherwise. The following important factors, among other, could cause actual results to differ materially from those projected or implied in any forward-looking statements: (i) our results of operation and financial conditions in the future; (ii) the performance of our rigs, including the sufficiency of their design and their ability to prevent discharges of hazardous materials and pollutants; (iii) our ability to generate sufficient cash-flow to meet our debt service requirements; (iv) our ability to retain existing contracts and secure future drilling contracts for our rigs at attractive day rates; (v) our ability to perform our operations in accordance with our plans; (vi) the impact of changed conditions in the oil and gas industry; (vii) the occurrence of any accidents involving the Company or its assets; (viii) changes in governmental regulations, particularly with respect to environmental matters; (ix) increased competition or the entry of new competitors into the Company's markets; and (x) unforeseen occurrences in any of the areas in which the Company may conduct its operations, such as war, expropriation, nationalization, renegotiation or nullification of existing licenses or treaties, taxation and resource development policies, foreign exchange restrictions, changing political conditions and other risks relating to foreign governmental sovereignty over certain areas in which the Company will conduct operations. Due to such uncertainties and risks, investors are cautioned not to place undue reliance upon such forward-looking statements. For further information, please contact Finance Manager Andreas Lian Kvam, tel +47 5196 9000. Stavanger, July 24, 2007 Ocean Rig ASA


 

ANNOUNCEMENT DATED 24 JULY 2007 Bear Stearns Global Asset Holdings, Ltd. Issue of up to SEK 500,000,000 Notes Linked to the a Basket Of Currencies due 2009 (the "Notes") ISIN Code: SE0002046714 under the U.S.$30,000,000,000 Euro Medium Term Note Programme NOTICE OF ISSUE AMOUNT The offer period for the Notes (described above) ended at 5:00pm (Central European Time) on 29 June 2007. Pursuant to the Prospectus for the issue of the Notes dated 23 May 2007, the Aggregate Nominal Amount of the Notes to be issued on 26 July 2007 will be SEK 384,570,000. Enquiries: Transaction Management Group Bear, Stearns International Limited One Canada Square London E14 5AD Tel: +44 20 7516 6817 Fax: +44 20 7516 5001 ---END OF MESSAGE---


 

Bombardier Shows Continued Commitment to Polish Market BERLIN--(Marketwire - July 24, 2007) - Bombardier Transportation has received an order to supply 37 new generation double-deck coaches for the suburban rail network operated by Koleje Mazowieckie in the Mazovia region of Poland. The contract is valued at approximately 55 million euros ($76 million US). The funding for this new order is shared by the customer, the Mazovia Region and the EIB (European Investment Bank). Delivery of the coaches is scheduled to be completed in 2008. Commenting on this contract, Stephane Rambaud-Measson, President Mainline & Metros, Bombardier Transportation said: "We have always been committed to the Polish market and are delighted to offer our best products, incorporating the latest technology and environmental advantages to one of the most dynamic operators in Central Europe, Koleje Mazowieckie. We see a very strong future for our spacious, high capacity double-deck coaches in Poland and are confident they will create the same positive impact that they have in other European countries." Janusz Kucmin, Chief Country Representative of Bombardier Transportation in Poland added: "Through our strong local presence, Bombardier Transportation has been a major supporter of Poland's rail infrastructure modernization and a strong player in the mass transportation market. We are committed to increasing our participation in supporting the country's development and we are very proud to play an important role in the future development of the Polish rail industry". The new generation of double-deck coaches to be delivered to Poland is also enjoying increasing popularity among passengers in other countries, including Germany, Luxembourg, Denmark and Israel. Around 2000 double-deck coaches were running over the last 13 years. In Germany alone, over 1600 Bombardier double-deck coaches are successfully transporting passengers on a daily basis. During the 2006 InnoTrans global trade fair in Berlin, Bombardier Transportation was awarded Deutsche Bahn's special award for the outstanding quality and reliability of its double-deck coaches. The coaches include full climate control and smooth and quiet ride characteristics to optimize passenger comfort. Spacious multi- purpose compartments wide entrances and convenient low floor height in the intermediate coaches facilitate access for people with special needs. In addition, electronic passenger information systems ensure a pleasant and contemporary travel experience, encouraging people to travel by rail. Note to editors: Useful company background facts and contact details follow. Photography is available at: http://www.transportation.bombardier.com/photography.jsp Background facts and figures About Bombardier Transportation in Poland Bombardier Transportation's commitment to the Polish market manifests itself through long-term investments in four production sites. Today, the company employs more than 1300 people at Wroclaw, Lodz, Katowice and Warszawa. The wide scope of activities covers manufacturing of steel bodies, bogie frames and electrical equipment for rolling stock in Wroclaw, design and manufacture of rail traffic control systems in Warszawa and Katowice as well as electrical device servicing in Lodz. Bombardier Transportation Polska (formerly Pafawag) has played a major role in equipping the Polish railways with rolling stock ever since the foundation of the company in 1838. For example, since 1945, fully 70 % of all electrical locomotives and all Electric Multiple Units currently in operation have been delivered by the Wroclaw factory. About Bombardier Transportation Bombardier Transportation has its global headquarters in Berlin, Germany with a presence in over 60 countries. It has an installed base of over 100,000 vehicles worldwide. The Group offers the broadest product portfolio and is recognized as the leader in the global rail sector. About Bombardier A world-leading manufacturer of innovative transportation solutions, from regional aircraft and business jets to rail transportation equipment, systems and services, Bombardier Inc. is a global corporation headquartered in Canada. Its revenues for the fiscal year ended Jan. 31, 2007, were $14.8 billion US and its shares are traded on the Toronto Stock Exchange (BBD). News and information are available at www.bombardier.com. FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Forward- looking statements generally can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "anticipate", "plan", "foresee", "believe" or "continue" or the negatives of these terms or variations of them or similar terminology. By their nature, forward-looking statements require Bombardier Inc. (the "Corporation") to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause the Corporation's actual results in future periods to differ materially from forecasted results. While the Corporation considers its assumptions to be reasonable and appropriate based on current information available, there is a risk that they may not be accurate. For additional information with respect to the assumptions underlying the forward-looking statements made in this press release, please refer to the respective sections of the Corporation's aerospace segment ("Aerospace") and the Corporation's transportation segment ("Transportation") in the Management's Discussion and Analysis of the 2006-2007 Annual Report on the Corporation's Web site at www.bombardier.com. Certain factors that could cause actual results to differ materially from those anticipated in the forward-looking statements include risks associated with general economic conditions, risks associated with the Corporation's business environment (such as the financial condition of the airline industry, government policies and priorities, and competition from other businesses), operational risks (such as regulatory risks and dependence on key personnel, risks associated with doing business with partners, risks involved with developing new products and services, warranty and casualty claim losses, legal risks from legal proceedings, risks relating to the Corporation's dependence on certain key customers and key suppliers, risks resulting from fixed term commitments, human resource risks and environmental risks), financing risks (such as risks resulting from reliance on government support, risks relating to financing support provided on behalf of certain customers, risks relating to liquidity and access to capital markets, risks relating to the terms of certain restrictive debt covenants and market risks, including currency, interest rate and commodity pricing risks). For more details, please see the Risks and uncertainties section in the Management's Discussion and Analysis of the 2006-2007 Annual Report on the Corporation's Web site at www.bombardier.com. Readers are cautioned that the foregoing list of factors that may affect future growth, results and performance is not exhaustive and undue reliance should not be placed on forward-looking statements. The forward-looking statements set forth herein reflect the Corporation's expectations as at this date and are subject to change after such date. Unless otherwise required by applicable securities laws, the Corporation expressly disclaims any intention, and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts: Americas David Slack + 1 450 441 3190 Germany, Austria Jurgen Scheunemann + 49 30 986 07 1135 Switzerland Fiona Flannery +41 44 318 29 91 Central and Eastern Europe Vicki Luther + 49 30 986 07 1139 Russia Alexander Bocharov + 7 495 775 1830 UK, Ireland, Nordic Countries, Australia, New Zealand, other countries Neil Harvey + 44 1332 266470 Benelux and France Anne Froger + 33 6 07 78 95 38 Spain, Portugal, Italy, Greece, Turkey, India Luis Ramos + 35 1 919 693 728


 

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first half 2007 results on 30 July, 2007 at 7:30 a.m. CEST. At 10:00 a.m. CEST, the Management Board of MorphoSys AG will host a public conference call to present MorphoSys's financial results for the first six months of 2007 and provide further details on the Company's latest developments. Dial-in numbers (listen only): Germany: +49 (0)69 9897 2623 United Kingdom: +44 (0)20 7138 0843 In the late afternoon of the same day, an audio replay of the conference will be available on www.morphosys.com/conferencecalls In case of any further questions please contact: Dr. Claudia Gutjahr-Löser Senior Director Corporate Communications Tel: +49 89 899 27-122 Fax: + 49 89 899 27-5122 gutjahr-loeser@morphosys.com Mario Brkulj Manager Public Relations Tel: +49 (0) 89 / 899 27-454 Fax: +49 (0) 89 / 899 27-5454 brkulj@morphosys.com About MorphoSys: MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing agreements and/or research collaborations with Astellas (Japan), Bayer-Schering (USA/Germany), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (USA), Centocor Inc. (USA), Daiichi Sankyo & Co., Ltd. (Japan), GPC Biotech AG (Germany), Hoffmann-La Roche AG (Switzerland), ImmunoGen Inc. (USA), Merck & Co., Inc. (USA), Novartis AG (Switzerland), Novoplant GmbH (Germany), OncoMed Pharmaceuticals, Inc. (USA), Pfizer Inc. (USA), ProChon Biotech Ltd. (Israel), Schering-Plough (USA), Shionogi & Co., Ltd. (Japan), Xoma Ltd. (USA) and others. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit was founded in 2003 for the purpose of exploiting the MorphoSys non-therapeutic antibody markets. MorphoSys' activities in the research antibody segment were significantly strengthened through the acquisition of the U.K. and U.S.-based Biogenesis Group in January 2005 and Serotec Group in 2006. For further information please visit the corporate website at: http://www.morphosys.com/ Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the prospectus relating to the company's recent public offering.


 

In connection to the release of the results for Q2 2007 Storebrand invites to the following events: Wednesday 8 August 08.00 CET Release of stock exchange notification. Press release, quarterly report and analyst presentation will be available. 09:00 CET Combined press and analyst conference (in Norwegian) in Oslo at Felix Conference Centre, Bryggetorget 3, Oslo. To attend, please contact Anne-S. Wilhelmsen, tel. +47 22 31 26 20 or e-mail:aw3@storebrand.no Web-TV The 09.00 presentation will be available on Web-TV (live and demand) 15.00 CET Analyst conference call in English. To participate in the conferance Call please register at least 10 minutes before the presentation starts, dial: +47 80080119 (from Norway) or +47 23000400 (from Norway or abroad) If you are unable to attend the presentation, we offer you two options: To access replay of conference call dail +47-67894091 account.no:1292 followed by # (pound sign) press 1 conference no: 292 followed by # (pound sign) press 1 to play Thursday 9 August: 14.00 GMT: Analyst conference in London in the Ostler Suite at the Chartered Insurance Institute, 20 Aldermanbury, London. To attend please contact Scandinavian Financial Communications Ltd, tel. 01263 861715 or e-mail: pauls@sfc.u-net.com. Press release and quarterly report will be available 8 August at 0800 CET. Oslo, 25 July 2007 Egil Thompson Nils Robert Hodnesdal Director of Corporate Communications Vice President, Investor Relations & Corporate Finance


 

In connection to the release of the results for Q2 2007 Storebrand invites to the following events: Thursday 8 August: 08.00 CET Release of stock exchange notification. Press release, quarterly report and analyst presentation will be available. 09:00 CET Combined press and analyst conference (in Norwegian) in Oslo at Felix Conference Centre, Bryggetorget 3, Oslo. To attend, please contact Anne-S. Wilhelmsen, tel. +47 22 31 26 20 or e-mail:aw3@storebrand.no Web-TV The 09.00 presentation will be available on Web-TV (live and demand) 15.00 CET Analyst conference call in English. To participate in the conferance Call please register at least 10 minutes before the presentation starts, dial: +47 80080119 (from Norway) or +47 23000400 (from Norway or abroad) If you are unable to attend the presentation, we offer you two options: To access replay of conference call dail +47-67894091 account.no:1292 followed by # (pound sign) press 1 conference no: 292 followed by # (pound sign) press 1 to play Friday 9 August: 14.00 GMT: Analyst conference in London in the Ostler Suite at the Chartered Insurance Institute, 20 Aldermanbury, London. To attend please contact Scandinavian Financial Communications Ltd, tel. 01263 861715 or e-mail: pauls@sfc.u-net.com. Press release and quarterly report will be available 8 August at 0800 CET. Oslo, 25 July 2007 Egil Thompson Nils Robert Hodnesdal Director of Corporate Communications Vice President, Investor Relations & Corporate Finance


 

Wilh. Wilhelmsen ASA will present the results for first half 2007 for analysts, investors and media on Wednesday 1 August 2007 at 08.00 CET in Wilh. Wilhelmsen`s offices at Strandveien 20, Lysaker. Light refreshments will be served from 07.30. The presentations will be given in English by group CEO Ingar Skaug and deputy CFO Benedicte B. Agerup. ------------------------------------------ The presentation will be broadcasted live on WW Internet (www.wilhelmsen.com) at 08.00 CET and the presentation material will simultaneously be made available on WW Internet and www.newsweb.no. The presentation will end with a Q&A session. It will be possible to ask questions via webcast. In addition, participants can ask questions via telephone: International Dial In: +44 (0) 1452 552 510 Norway Free Call: 800 193 95 UK Free Call: 0800 694 2370 US Free Call: 1866 966 9444 Conference ID: 7130515 Please notify Wilh. Wilhelmsen corporate communications of your intention to participate via e-mail to ww@wilhelmsen.com


 

Six-monthly report January-June 2007 +-----------------------------------------------------------+ | | Jan-Jun 2007 | Jan-Jun 2006 | |----------------------------+---------------+--------------| | Net sales, SEK M | 9,218 | 8,250 | |----------------------------+---------------+--------------| | Operating income, SEK M | 883 | 596 | |----------------------------+---------------+--------------| | Return on capital employed | 16% | 11% | +-----------------------------------------------------------+ Södra has shown strong profit development during the first half-year. Despite non-recurring costs for Hurricane Per and a write-down at Tofte (see below), operating profit after non-recurring items has increased from SEK 596 M to SEK 883 M and return on capital employed has increased from 11 to 16 per cent. "Despite Hurricane Per we can see that we've managed to keep up our productivity work in the mills, where we're on track to achieve our long-term objective of 2 per cent annual productivity improvement. During the first half-year we have implemented 532 improvement proposals. During the same period we have also invested SEK 695 M (598) in assuring our long-term competitiveness," says Södra President and CEO Leif Brodén. Record volumes have been achieved in all core businesses. For Södra Timber, the market continues to be strong with increasing prices. Production has reached record levels with 911,000 cubic metres (788,000) of goods produced and an increase in planing to 62 per cent (61). During the period, Baro Wood AB in Åtvidaberg was acquired and in conjunction with this the Mönsterås sawmill has gone down to two shifts and now specialises in whitewood. In early May a fire occurred on one of the barkers at the Långasjö sawmill and a new barker already in operation by early June. Södra Cell has had strong production during the first half-year. The price level for softwood sulphate pulp increased to almost USD 800 per tonne towards the end of the period, but this price increase is set off against a falling dollar. The average gross price for delivered softwood pulp in Europe was SEK 5,220 (4,740) per tonne during the first half-year. Total pulp production was 1,000,000 tonnes (979,000). In conjunction with a strategic overview of the Södra Cell Tofte pulp mill in Norway and an associated impairment test, a write-down of NOK 160 M, equivalent to SEK 186 M, has been made. Gapro is also experiencing a strong market for interior wood products. The strong trend is however offset by increased raw material costs. During the period the Lona moulding mill in Norway and Sund's parquet in Denmark were acquired. During the first half-year Södra Skog has focussed on managing the consequences of Hurricane Per in late January. Prior to mid-year, a total of 6.9 million m3fub storm wood has been processed of the estimated total of 7.5 m3fub that Södra has contracted. The processing has been assisted by some 130 extra trucks and 100 extra felling groups. "In total we have taken costs of SEK 91 M into this report for increased transport costs and for range variation in conjunction with Hurricane Per," says Leif Brodén. Address questions to: President and CEO Leif Brodén, +46 70 558 94 26 CFO Mikael Staffas, +46 70 511 64 97 Communications Director Per Braconier, +46 70 534 51 66


 

TM Software hlaut nýverið samstarfsgráðuna Cisco Premier partner en Cisco er leiðandi aðili í búnaði fyrir netkerfi, bæði nærnet og víðnet. Í tilkynnigu segir að þetta er í takti við aðrar þekkingargráður sem starfsmenn TM Software hafa sótt sér en fyrirtækið hefur haft það sem hluta af sinni markmiðasetningu að starfsmenn séu með fullgildar þekkingargráður frá helstu og fremstu fyrirtækjum heims á sviði upplýsingatækni.Netvinna er einn stærsti þátturinn í daglegum rekstri nútíma fyrirtækja, hvort sem þau eru stór eða smá, og er búnaður frá Cisco notaður til að búa til netlausnir sem gera samskipti yfir netið möguleg og auðveldar þar með alla upplýsinganálgun, innan sem utan fyrirtækisins.Til að mynda er allt kjarnanetkerfi TM Software byggt á Cisco búnaði og því nauðsynlegt að tryggja að starfsmenn búi yfir rekstrarþekkingu á þeim búnaði sem og hafi aðgengi að bestu fáanlegu sérfræðingum á hverjum tíma.Í tilkynningunni segir að TM Software er eitt af fáum fyrirtækjum á Íslandi sem hlotið hafa Cisco partner vottun og er það mikill heiður að geta bætt henni við hóp annarra þekkingarviðurkenninga fyrirtækisins.?Cisco og lausnir þeirra eru með yfirburða markaðsstöðu í netlausnum og -kerfum. Markmið TM Software er að halda áfram á þessari braut og efla enn frekar þekkingu starfsmanna og fá hana vottaða, viðskiptavinum sínum til hagsbóta. Starfsmenn TM Software hafa lengi búið að mikilli netþekkingu og fer áhugi fyrirtækja á að sækja þessa þekkingu vaxandi en TM Software er óháður aðili á markaðnum. En þetta er vonandi bara byrjunin á okkar samstarfi við Cisco.? sagði Árni Jón Eggertsson, yfirmaður búnaðarlausnasviðs TM Software, eftir að vottunin leit dagsins ljós.


 
Hitt og þetta
24. júlí 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |--------------------------------------------+----------------------| | Company dealt in | C.I. Traders Limited | |--------------------------------------------+----------------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |--------------------------------------------+----------------------| | Date of dealing | 23rd July 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 322 | 97.78p | 97.78p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 0 | | | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +-------------------------------------------------------------------+ | Date of disclosure | 24th July 2007 | |--------------------------------------------+----------------------| | Contact name | Edward Hodge | |--------------------------------------------+----------------------| | Telephone number | 0207 991 6661 | |--------------------------------------------+----------------------| | Name of offeree/offeror with which | C.I. Traders Limited | | connected | | |--------------------------------------------+----------------------| | Nature of connection (Note 6) | Connected Advisor | +-------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 
Hitt og þetta
24. júlí 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |-----------------------------------------+-------------------------| | Company dealt in | Atrium Underwriting Plc | |-----------------------------------------+-------------------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note | | | 1) | | |-----------------------------------------+-------------------------| | Date of dealing | 23rd July 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price paid | | securities | (Note 3) | (Note 3) | | purchased | | | |--------------------------+--------------------+-------------------| | 27,364 | 358p | 356.76p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 17,950 | 358p | 358p | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +-------------------------------------------------------------------+ | Date of disclosure | 24th July 2007 | |-----------------------------------------+-------------------------| | Contact name | Edward Hodge | |-----------------------------------------+-------------------------| | Telephone number | 0207 992 16661 | |-----------------------------------------+-------------------------| | Name of offeree/offeror with which | Atrium Underwriting Plc | | connected | | |-----------------------------------------+-------------------------| | Nature of connection (Note 6) | Connected Advisor | +-------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

On 14 May 2007 Schibsted ASA announced an offer to acquire the remaining shares in Stavanger Aftenblad ASA in accordance with mandatory bid rules. The bid price was NOK 234.33 per share. The bid period lasted between 25 June 2007 and 23 July 2007 at 16.30 CET. After the end of the bid period, shareholders representing a total number of 1548708 shares in Stavanger Aftenblad have accepted Schibsted's mandatory bid. Including these shares, Schibsted holds 5424078 shares in Stavanger Aftenblad, corresponding to 74.1 % of the total share capital in the company. Settlement is intended to occur no later than 14 days after the end of the bid period. Oslo, 24 July, 2007 Schibsted ASA --- End of Message --- Schibsted Apotekergt 10, Pb 1178 Sentrum Oslo Norway ISIN: NO0003028904; ;


 

KESKO CORPORATION STOCK EXCHANGE NOTIFICATION 24.07.2007 AT 09.00 1(2) A total of 4,500 new Kesko Corporation B shares have been subscribed for with the stock options marked with symbols 2003D and 2003E in Kesko Corporation's 2003 stock option scheme. The corresponding increase in the share capital, ¤9,000, has been entered in the Trade Register today. The new B shares will be included in the main list of the Helsinki Stock Exchange with the old B shares for public trading on Wednesday, 25 July 2007. A total of 500 new B shares were subscribed for with Kesko Corporation's year 2003 stock options marked with symbol 2003D and 4,000 new B shares with stock options marked with symbol 2003E. The book counter value of a B share is ¤2.00. In accordance with the terms and conditions of the stock option scheme, the subscription price of the shares with options marked with symbol 2003D is ¤3.03 per share and with options marked with symbol 2003E ¤10.59 per share. In consequence of these subscriptions, Kesko Corporation's registered share capital increases by ¤9,000 to a total of ¤195,480,598. After this increase, the total number of Kesko Corporation's shares has risen to 97,740,299, of which 31,737,007 are A shares and 66,003,292 are B shares. Each A share entitles the holder to ten votes and each B share to one vote. After the increase, the number of votes carried by Kesko Corporation shares is 383,373,362. The new B shares carry the right to dividend and other shareholder rights with effect from today. The stock options marked with symbols 2003D, 2003E and 2003F are based on the decision made by Kesko Corporation's Annual General Meeting on 31 March 2003 to offer stock options to the management of the Kesko Group. A total of 1,800,000 stock options were issued in the 2003 stock option scheme. The stock options were marked with symbols 2003D, 2003E and 2003F in such a way that each unit had 600,000 stock options. Each stock option entitles to subscribe for one Kesko Corporation B share until the end of the subscription period, the stock options marked with symbol 2003D until 30 April 2008, the stock options marked with symbol 2003E until 30 April 2009 and the stock options marked with symbol 2003F until 30 April 2010. After this increase in the share capital, the stock options marked with symbol 2003D entitle to further subscribe for a total of 67,012 B shares, which correspond to an increase of ¤134,024 in the share capital, the stock options marked with symbol 2003E entitle to further subscribe for a total of 430,633 B shares, which correspond to an increase of ¤861,266 in the share capital, and the stock options marked with symbol 2003F entitle to further subscribe for a total of 500,761 B shares, which correspond to an increase of ¤1,001,522 in the share capital. The shares can be subscribed for at the offices of Nordea Bank Finland Plc. The terms and conditions of the year 2003 stock option scheme were published in a stock exchange release on 31 March 2003. Further information is available from Corporate Counsel Jarkko Karjalainen, tel. +358 1053 22602. Kesko Corporation Harri Utoslahti Communications Manager DISTRIBUTION Helsinki Stock Exchange Main news media


 

24 July 2007, Godalming, UK. Sinclair Pharma plc (SPH.L), the specialty pharmaceutical company, today provides a pre-close period update ahead of its preliminary results, which will be announced on 25 September 2007. Revenues for the year ended 30 June 2007 are expected to be approximately £24.1m, an increase of 108% on the previous year (2006: £11.6m). This increase in revenues has been driven both by acquired and organic growth. A full year's contribution from Sinclair's French operation, CS Dermatologie, and the acquisition in September 2006 of Ashbourne Pharmaceuticals in the UK, mean that revenue from the Company's own sales and marketing operations is expected to grow 161% from £5.4m in 2006 to £14.1m in 2007. In addition, Sinclair is expected to achieve organic growth of revenues through marketing partners of 61% to £10.0m (2006: £6.2m). Sinclair's eczema product Atopiclair has contributed strongly to this growth following launch in its EU territories as has the gum disease product Decapinol, as Sinclair delivered stock to OraPharma, Inc. for its US launch. As the board expected, the second half of the year ended 30 June 2007 generated the first profitable half-year since IPO. This brings the company much closer to profitability, from a half year EBITDA loss figure before exceptionals of £2.4m. Commenting on today's announcement, Dr Michael Flynn, Chief Executive of Sinclair, said: "Sinclair has more than doubled its revenues since the last financial year and the second half of the year saw strong progress towards profitability. Our flagship products are at the start of their growth curve, with Atopiclair recently achieving launch across the major mainland EU territories and Decapinol entering the US. We are also focused on preparing Sebclair for market entry in the major territories. Synergies with our own sales and marketing operations are also developing following the recent launch of Atopiclair by our French operation CS Dermatologie and its forthcoming launch in the UK by Ashbourne Pharmaceuticals. We are still very focused on Germany to complete the European jigsaw and fulfil our goal of an integrated European specialty salesforce." In addition to the trading update, Sinclair advises that the Company was involved in preparing for a major acquisition in July 2007. Sinclair was substantially outbid in this transaction; exceptional costs of approximately £400,000 were incurred which will fall into the financial year July 2007 - June 2008. Ends For further information please contact: Sinclair Pharma plc Dr Michael Flynn, CEO Jerry Randall, CFO Tel: +44 (0) 1483 410 600 Zoe McDougall, Director of Communications investorrelations@sinclairpharma.com Capital MS&L Mary Clark Halina Kukula Tel +44 (0)20 7307 5340 Notes to editors: Sinclair Pharma plc Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 65 countries. Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short time frame. The company focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health. In April 2007, Sinclair completed a dual listing on the Official List of the London Stock Exchange and Euronext Paris. Atopiclair(TM) Atopiclair(TM) is a non-steroidal cream, registered as a medical device in the US and EU, for the management of symptoms of atopic dermatitis and contact dermatitis. It is sold through Sinclair's sales and marketing team in France and Italy, and is also sold in the US, Germany, Spain, Austria, Portugal, Turkey, Indonesia, Israel and Jordan. It will be launched in the UK soon. For further product information please visit www.atopiclair.com. Atopic dermatitis (also known as eczema) is one of the most common dermatological complaints and accounts for a large number of physician consultations. It is known to affect approximately 20% of school aged children[i], [ii], [iii]. The prevalence in adults is estimated at 1-3%[iv],[v]. The atopic dermatitis market is estimated at more than $2 billion. Decapinol® Gingivitis is an inflammation of the gum surrounding the teeth. Periodontitis is a more advanced and severe condition that may result in bone or tooth loss. Both conditions are associated with dental plaque bacteria. The market for anti-gingivitis rinses is estimated at more than $1.5bn, and the anti-gingivitis toothpaste market a further $4bn. Current treatment of gingivitis may involve the use of an oral rinse, alongside 'scaling and planing' (mechanical cleaning of the teeth by a dental professional). Decapinol has advantages over existing products, which may cause semi-permanent tooth staining. While other leading products work by killing oral bacteria indiscriminately, Decapinol® specifically targets the 'bad' bacteria associated with gum disease. Decapinol® therefore promotes a healthy balance of oral bacteria. Decapinol is already cleared for sale in the USA by the FDA, as a medical device, where Sinclair's marketing partner OraPharma, Inc has exclusive rights to the product as a prescription-only mouthwash. It is also approved in the EC and sold in Italy by Dompe. In March 2006, Decapinol® Oral Rinse was awarded the 2006 Oral and Dental Care Product of the Year by Frost & Sullivan in the US. "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward- looking statements due to a variety of factors. [i] Yura A, Shimizu T. . Trends in the prevalence of atopic dermatitis in school children: longitudinal study in Osaka Prefecture, Japan, from 1985 to 1997 Br J Dermatol 2001; 145 (6): 966-73 [ii] Tay YK, Kong KH, Khoo L et al. The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. Br J Dermatol 2002; 146 (1): 101-6 [iii] Mortz CG, Lauritsen JM, Bindslev-Jensen C, Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. Br J Dermatol 2001; 144 (3): 523-32 [iv] Schultz-Larsen F, Hanifin JM. Epidemiology of Atopic Dermatitis. Immunol Allergy Clin North Am 2002; 22: 1-24 [v] Ellis CN, Drake LA, Prendergast MM. Cost of Atopic Dermatitis and eczema in the United States. J Am Acad Dermatol 2002; 46 (3): 361-70 ---END OF MESSAGE---


 

comdirect bank at the end of H1 2007: record profit of EUR 47.4m - further intensified growth planned Quickborn/Frankfurt/Main, 24 July 2007. comdirect bank (www.comdirect.de) generated a record pre-tax profit of EUR 47.4m in the first six months of the year, exceeding even the EUR 46.9m of the previous year. "After an excellent start to financial year 2007, business activities also developed very well in the second quarter. For the year as a whole, we aim to achieve pre-tax profit of more than EUR 75m," said Andre Carls, CEO of comdirect bank. On the earnings side, a record value of EUR 134.7m was achieved in the first half of the year, representing a rise of 17.3% on the first six months of 2006. This was triggered by the development in net interest income before provisions, which at EUR 58.0m significantly outstripped the previous year's figure (EUR 40.9m) as a result of the sharp rise in the deposit volume since the start of the year (up by more than EUR 2.2bn). With a slight increase in the number of orders executed to 5.16 million in the first half of 2007, at EUR 77.1m, net commission income remained at a high level (previous year: EUR 76.6m). The total number of customers rose in the second quarter by 50,658 to 888,056, up by around 83,000 overall since the start of the year. On 30 June 2007, total assets under custody reached a new record high of EUR 19.6bn - an increase of 36.9% on the previous year. This was due to strong growth in the deposit volume as well as the success of our Tagesgeld PLUS ("call money plus") account. Launched in November 2006, the product was being used by 253,000 customers by the middle of this year, which is 93,000 more than at the end of the first quarter. "The figures show that this year we are successfully continuing our strong growth course from the previous year," explained Carls. As planned, increased earnings were countered by higher administrative expenses under the comvalue growth programme. In the first half of 2007 these were up 28.4% year-on-year to EUR 87.3m (previous year: EUR 68.0m). The majority of these costs were attributable to other administrative expenses, which rose by 34.5% to EUR 63.5m due to the costs of the intensified market and product offensive. Personnel costs increased as a result of the rise in the number of employees from EUR 16.1m to EUR 19.1m. This also pushed up the cost/income ratio from 58.5% in the first half of 2006 to 64.5%. Given the positive trend in earnings, comdirect bank intends to further intensify and increase the costs for the comvalue growth programme in the second half-year. The overall planned growth budget from 2007 to 2009 is up to EUR 150m. Up to EUR 50m is to be made available for comvalue in 2007. "We will boost comvalue even further in the second half of the year and are therefore reinforcing our investment in a comprehensive market and product offensive as well as in the expansion of our customer services and IT infrastructure," added Carls. Continuing, he explained that the bank aims to gain new customers for the entire range of products and services, with a focus on banking. Despite the additional costs for the growth programme, the target for financial year 2007 as a whole is to achieve pre-tax profit of more than EUR 75m. Overview +---------------------------------------------------------------------+ |EUR thousand | Q2/06| Q1/07| Q2/07| H1/06| H1/07| H1/07| | | | | | | | vs| | | | | | | | H1/06| |--------------------------+------+------+------+------+------+-------| |Net interest income before|21,910|28,567|29,413|40,927|57,980| 41.7%| |provisions | | | | | | | |--------------------------+------+------+------+------+------+-------| |Provisions | -417| -495| -231|-1,271| -726|- 42.9%| |--------------------------+------+------+------+------+------+-------| |Net commission income |37,544|39,073|37,998|76,595|77,071| 0.6%| |--------------------------+------+------+------+------+------+-------| |Other income |-2,717| 1,100| -761|-1,412| 339| -| |--------------------------+------+------+------+------+------+-------| |Administrative |34,628|42,382|44,884|67,952|87,266| 28.4%| |expenses | | | | | | | |--------------------------+------+------+------+------+------+-------| |Pre-tax profit |21,692|25,863|21,535|46,887|47,398| 1.1%| |--------------------------+------+------+------+------+------+-------| |After-tax profit |13,982|16,837|14,161|30,131|30,998| 2.9%| +---------------------------------------------------------------------+ Length: 3,177 characters incl. spaces, excl. table Press contact: Johannes Friedemann, comdirect bank AG, Tel.: +49 4106-704 3402, e-mail: presse@comdirect.de Note for editors: All press releases are available at http://www.comdirect.de/pr If you no longer wish to receive press releases, please send an e-mail to this effect to presse@comdirect.de --- End of Message --- comdirect bank AG Pascalkehre 15 Quickborn WKN: 542800; ISIN: DE0005428007; Index: CDAX, CLASSIC All Share, Prime All Share, SDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Geregelter Markt in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;


 

Share photos, video and other media through virtually any connected device Espoo, Finland - Nokia and Twango today announced that Nokia has acquired substantially all assets of Twango (www.Twango.com). Twango provides a comprehensive media sharing solution for organizing and sharing photos, videos and other personal media. By acquiring Twango, Nokia will be able to offer people an easy way to share multimedia content through their desktop and mobile devices. In addition to key assets, through this transaction Nokia is bringing on a seasoned team with strong social media and Web services expertise. "The Twango acquisition is a concrete step towards our Internet services vision of providing seamless access to information, entertainment, and social networks - at anytime, anywhere, from any connected device, in any way that you choose. We have the most complete suite of connected multimedia experiences including music, navigation, games, and - with the Twango acquisition - photos, videos, and a variety of document types," said Anssi Vanjoki, Executive Vice President and General Manager, Multimedia, Nokia. "When you combine a Nokia Nseries multimedia computer that is always on, always connected, and always with you together with a rich media sharing destination like Twango, people will have exciting new ways to create and enjoy rich media experiences in real time." Twango, a privately-owned company founded by former Microsoft veterans, is headquartered in Redmond, Washington, USA. Twango's versatile platform makes organizing, sharing, and republishing media such as photos, videos and audio clips easy. Unlike many other social media services, Twango supports multiple media types and offers a comprehensive array of options for people to manage, share, and repurpose their personal media content. Twango offers a great destination experience on desktop computers and mobile devices, as well as a powerful platform that allows developers to create companion applications, connect with mobile devices, and integrate with other Web services. "Nokia's unique vision for social media aligns perfectly with Twango," said Twango co-founder, Jim Laurel. "It's really exciting to imagine what we can achieve by combining our social media experience with the resources of a company that has played such a major role in shaping the mobile landscape. Now, we will have the resources to deliver on our vision to enable people to capture and enjoy their personal media on mobile devices, desktop computers and in all the other places that are important to them." Twango co-founder, Serena Glover, adds "As a result of this acquisition, we will aggressively build out our team in the Seattle area, allowing us to deliver a superior global media sharing service." Equipped with high-quality megapixel cameras and mobile broadband connections, Nokia devices have revolutionized the way people create content, blog and participate in online communities. In 2006, Nokia sold over 140 million connected cameras, and its devices are rapidly becoming the world's primary source of images and videos. Nokia offers people new media sharing experiences, such as combining GPS-based location information with photos and videos. Notes to editors: High resolution photos of Twango service can be found at: www.nokia.com/press/photos For further information, please see Frequently Asked Questions (FAQ) at: www.nokia.com/NOKIA_COM_1/Press/Materials/NokiaTwangoFAQ.pdf About Nokia Nokia is the world leader in mobility, driving the transformation and growth of the converging Internet and communications industries. Nokia makes a wide range of mobile devices and provides people with experiences in music, navigation, video, television, imaging, games and business mobility through these devices. Nokia also provides equipment, solutions and services for communications networks. www.nokia.com About Twango Twango is a next generation social media sharing service that offers a comprehensive, integrated solution for people to organize, share, and republish all their personal media, publicly or privately, Twango enables people to share all media types such as pictures, videos, audio clips, and a variety of documents types - more than 110 file types in all. For more information, visit www.Twango.com. It should be noted that certain statements herein which are not historical facts, including, without limitation, those regarding: A) the timing of product, services and solution deliveries; B) our ability to develop, implement and commercialize new products,services, solutions and technologies; C) expectations regarding market growth, developments and structural changes; D) expectations regarding our mobile device volume growth, market share, prices and margins; E) expectations and targets for our results of operations; F) the outcome of pending and threatened litigation; and G) statements preceded by "believe," "expect," "anticipate," "foresee," "target," "estimate," "designed," "plans," "will" or similar expressions are forward-looking statements. These statements are based on management's best assumptions and beliefs in light of the information currently available to it. Because they involve risks and uncertainties, actual results may differ materially from the results that we currently expect. Factors that could cause these differences include, but are not limited to: 1) competitiveness of our product portfolio; 2) our ability to identify key market trends and to respond timely and successfully to the needs of our customers; 3) the extent of the growth of the mobile communications industry, as well as the growth and profitability of the new market segments within that industry which we target; 4) the availability of new products and services by network operators and other market participants; 5) our ability to successfully manage costs; 6) the intensity of competition in the mobile communications industry and our ability to maintain or improve our market position and respond successfully to changes in the competitive landscape; 7) the impact of changes in technology and our ability to develop or otherwise acquire complex technologies as required by the market, with full rights needed to use; 8) timely and successful commercialization of complex technologies as new advanced products, services and solutions; 9) our ability to protect the complex technologies, which we or others develop or that we license, from claims that we have infringed third parties' intellectual property rights, as well as our unrestricted use on commercially acceptable terms of certain technologies in our products and solution offerings; 10) our ability to protect numerous Nokia patented, standardized, or proprietary technologies from third party infringement or actions to invalidate the intellectual property rights of these technologies; 11) our ability to manage efficiently our manufacturing and logistics, as well as to ensure the quality, safety, security and timely delivery of our products and solutions; 12) inventory management risks resulting from shifts in market demand; 13) our ability to source quality components and sub-assemblies without interruption and at acceptable prices; 14) Nokia's and Siemens' ability to successfully integrate the operations, personnel and supporting activities of their respective businesses as a result of the merger of Nokia's networks business and Siemens' carrier-related operations for fixed and mobile networks forming Nokia Siemens Networks; 15) whether, as a result of investigations into alleged violations of law by some current or former employees of Siemens, government authorities or others take actions against Siemens and/or its employees that may involve and affect the carrier-related assets and employees transferred by Siemens to Nokia Siemens Networks, or there may be undetected additional violations that may have occurred prior to the transfer, or ongoing violations that may occur after the transfer, of such assets and employees that could result in additional actions by government authorities; 16) the expense, time, attention and resources of Nokia Siemens Networks and our management to detect, investigate and resolve any situations related to alleged violations of law involving the assets and employees of Siemens carrier-related operations transferred to Nokia Siemens Networks; 17) any impairment of Nokia Siemens Networks customer relationships resulting from the ongoing government investigations involving the Siemens carrier-related operations transferred to Nokia Siemens Networks; 18) developments under large, multi-year contracts or in relation to major customers; 19) general economic conditions globally and, in particular, economic or political turmoil in emerging market countries where we do business; 20) our success in collaboration arrangements relating to development of technologies or new products and solutions; 21) the success, financial condition and performance of our collaboration partners, suppliers and customers; 22) any disruption to information technology systems and networks that our operations rely on; 23) exchange rate fluctuations, including, in particular, fluctuations between the euro, which is our reporting currency, and the US dollar, the Chinese yuan, the UK pound sterling and the Japanese yen, as well as certain other currencies; 24) the management of our customer financing exposure; 25) allegations of possible health risks from electromagnetic fields generated by base stations and mobile devices and lawsuits related to them, regardless of merit; 26) unfavorable outcome of litigations; 27) our ability to recruit, retain and develop appropriately skilled employees; and 28) the impact of changes in government policies, laws or regulations; as well as the risk factors specified on pages 12-24 of the company's annual report on Form 20-F for the year ended December 31, 2006 under "Item 3.D Risk Factors." Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Nokia does not undertake any obligation to update publicly or revise forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required. Media Enquiries: Nokia Communications Tel. +358 7180 34900 Email: press.office@nokia.com Nokia Communications, Americas Media Relations Tel. +1 972 894 4573 Email: communication.corp@nokia.com Investor Contacts: Nokia Investor Relations, Europe Tel. +358 7180 34289 Nokia Investor Relations US Tel. +1 914 368 0555 Twango Michele Mehl Buzz Builders Tel. +1 425 205 9444 Email: michele@buzzbuilders.net Deanna Leung Buzz Builders Tel. +1 206 915 0512 Email: deanna@buzzbuilders.net www.nokia.com --- End of Message --- NOKIA P.O. Box 226<br>FIN-00045 NOKIA GROUP Espoo WKN: 870737; ISIN: FI0009000681; Index: DJ STOXX Large 200, DJ STOXX 50; Listed: Nordic list (Large Cap) in THE HELSINKI STOCK EXCHANGE;


 

Ericsson (NASDAQ:ERIC), the world's leading telecom supplier, and Texas Instruments Incorporated (TI) (NYSE:TXN), the global leader in silicon solutions for wireless communications, today announce that the companies will form a strategic technology engagement to develop custom solutions for new Open OS enabled 3G devices. Solutions from the technology created by the two companies will combine small and power efficient 3G modems from Ericsson Mobile Platforms with high-performance OMAP(TM) applications processors from TI. Solutions from the joint engagement will include OMAP, custom basebands and connectivity technologies and will be capable of supporting the major Open OS, which offer easy access to a rich array of applications and services. The result of this joint effort will enable all device manufacturers to offer advanced Open OS handsets for both the high-end and the rapidly growing mid-range market. The collaboration between Ericsson and TI will enable handset manufacturers to deliver the exciting mobile entertainment and multimedia experiences that consumers around the world are increasingly demanding. Ericsson's access technology leadership, current HSPA-enabled platforms, and future HSPA evolution and LTE technologies, combined with the cutting-edge multimedia performance enabled by TI's OMAP 2, OMAP 3 and future generations of OMAP processors, will continue to push the performance boundaries of mobile devices and mobile entertainment features. By leveraging TI's OMAP platform with Open OS support for Windows® Mobile, Symbian S60, Symbian UIQ and Linux®, these solutions will provide OEMs and operators with a robust and flexible architecture for applications and services deployment, enabling easier delivery and management of services and content. This enables handset manufacturers and mobile operators to differentiate their products through rich, easy-to-use and customizable user interfaces, and through a robust and flexible application architecture. The result of the joint effort will bring to market an evolving portfolio of wireless technology platforms with Open OS support to reduce complexity, investment and time-to-market for device manufacturers. The solutions, which seamlessly integrate the modem and applications processor, will be presented in one pre-verified and tested platform reference design. This approach will drastically reduce development and verification efforts previously undertaken by device manufacturers, enabling customers to rapidly bring highly advanced yet competitively priced products to market. The joint solutions will also benefit from the Ericsson Mobile Platforms IOT program, one of the industry's most extensive interoperability testing processes, guaranteeing full compliance with operator requirements, speeding up time to market and securing an easy roll-out of products. Greg Delagi, senior vice president of TI's Wireless Terminals Business Unit, says: "It's a tribute to the long-standing collaborative relationship between EMP and TI that we can tap into and combine each company's unique wireless expertise in order to deliver the most timely, targeted solutions to the market. TI's broad, proven product portfolio and advanced manufacturing capabilities have continued to adjust to the demanding requirements of EMP's customer base. We believe that today's announcement will build on what TI can bring to EMP and what both companies together can bring to this vital, dynamic industry." Robert Puskaric, head of Ericsson's mobile platforms' unit, says: "Ericsson is clear in its commitment to design and offer a portfolio of flexible, innovative mobile platforms that address the requirements of the rapidly evolving mobile device market. We are pleased to work closely with TI to combine the finest of each company's core wireless know-how - EMP's access technology and platform size leadership with TI's innovative OMAP application processors in order to provide the most capable Open OS platforms on the market today." Handsets based on these solutions are expected to be available on the market in the second half of 2008. Notes to editors: Robert Puskaric's photo and resume: www.ericsson.com/solutions/mobile_platforms/info.shtml Greg Delagi's photo and resume: www.ti.com/corp/docs/company/history/delagi.shtml Ericsson is shaping the future of Mobile and Broadband Internet communications through its continuous technology leadership. Providing innovative solutions in more than 140 countries, Ericsson is helping to create the most powerful communication companies in the world. Read more at http://www.ericsson.com FOR FURTHER INFORMATION, PLEASE CONTACT Ericsson Media Relations Phone: +46 8 719 6992 E-mail: press.relations@ericsson.com Texas Instruments Media Relations Renée Fancher (U.S.) Phone: +1 214 567 7447 Email: rfancher@ti.com Daniela Koeppe (EMEA) Phone: +33 49 322 2947 Email: koe@ti.com Trademarks OMAP is a registered trademark of Texas Instruments. All registered trademarks and other trademarks belong to their respective owners


 

Munich, 23 July 2007 (Interhyp AG) - The financial services company MLP and mortgage broker Interhyp will engage in a joint venture. "MLP Hyp" will provide MLP consultants with access to Interhyp's product and system platform for residential mortgages as well as with dedicated support by mortgage specialists. MLP customers will benefit from an independent selection from a wide range of products combined with a high level of service provided by the individualized MLP consulting approach. The interest rates on offer will be significantly below those offered by traditional branch banks. In future MLP will conduct its residential mortgage business through the new company. The joint venture will be based near Heidelberg and will commence operations at the end of the year. Interhyp will hold 50.2 per cent of the capital in MLP Hyp GmbH, while MLP will hold 49.8 per cent. The company will be operationally managed by Interhyp AG. Additional information: ISIN: DE 0005121701 Security identification number: 512 170 Listing: Official market (Prime Standard) of the Frankfurt Stock Exchange Registered head office of the company: Munich, Germany Contact: Interhyp AG Florian Prabst Head of Investor Relations Parkstadt Schwabing Marcel-Breuer-Str.18 80807 Munich Germany Phone +49 (89) 20 30 7 13 02 Fax +49 (89) 20 30 75 13 02 E-mail: florian.prabst@interhyp.de --- End of Message --- Interhyp AG Marcel-Breuer-Str. 18 Munich Germany WKN: 512170; ISIN: DE0005121701; Index: CDAX, CLASSIC All Share, Prime All Share, GEX, SDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Amtlicher Markt in Frankfurter Wertpapierbörse;


 

Irish Continental Group plc Results Of Annual General Meeting At the Annual General Meeting of Irish Continental Group plc held today, Monday 23rd July 2007, all resolutions proposed were duly passed by the shareholders. The full text of each resolution was included in the Notice of Annual General Meeting circulated to shareholders on 28th June, 2007. __________________________ Tom Corcoran Company Secretary 23rd July 2007 ---END OF MESSAGE---


 

Notifying Parties: COFRA Holding AG, Zug, Switzerland; Good Energies Investments (Luxembourg) S.à r.l., Luxembourg, Grand Duchy of Luxembourg; Good Energies Investments B.V., Amsterdam, The Netherlands; Entrepreneurs Fund B.V., Amsterdam, The Netherlands; Voorspring Holding B.V., Amsterdam, The Netherlands; Good Energies (Solar Investments) S.á r.l., Luxembourg, Grand Duchy of Luxembourg. Issuer: Name: Q-Cells AG Address: Guardianstraße 16, 06766 Thalheim, Germany Voting rights announcement: Release of a voting rights announcements pursuant to sections 21, 22 WpHG (Securities Trading Act) 1. COFRA Holding AG, Zug, Switzerland has voluntarily informed us that Entrepreneurs Fund Holding AG, Zug, Switzerland, has merged with COFRA Holding AG on 16 May 2007 and that therefore the shares which conveyed 23,466,513 of the voting rights in Q-Cells AG, corresponding to 29.90 % of the total number of voting rights, have been transferred to COFRA Holding AG. With its termination, the Entrepreneurs Fund Holding AG does not hold any voting rights in Q-Cells AG anymore and therefore does not exceed any threshold pursuant to WpHG. 2. Good Energies Investments (Luxembourg) S.à r.l., Luxembourg, Grand Duchy of Luxembourg, has notified us that on 17 July 2007 they exceeded the thresholds of 3 %, 5 %, 10 %, 15 %, 20 % and 25 % of the voting rights in Q-Cells AG and at that time held 29.63 % of the voting rights in Q-Cells AG, corresponding to 23,466,513 of the total number of 79,201,475 voting rights. All of these voting rights were attributed to them pursuant to section 22 sub-sec. 1 sentence 1 no. 1 WpHG. All of these voting rights were attached to shares held by Good Energies Investments B.V., Amsterdam, The Netherlands, and were attributed to Good Energies Investments (Luxembourg) S.à r.l. pursuant to section 22 sub-sec. 1 sentence 1 no.1 WpHG through Entrepreneurs Fund B.V., Amsterdam, The Netherlands, which is controlled by them. 3. Good Energies Investments B.V., Amsterdam, The Netherlands, has notified us that on 18 July 2007 their holding in voting rights in Q-Cells AG fell below the thresholds of 25 %, 20 %, 15 %, 10 %, 5 % and 3 % and that they do no longer hold any voting rights in Q-Cells AG. 4. Entrepreneurs Fund B.V., Amsterdam, The Netherlands, has notified us that on 18 July 2007 their holding in voting rights in Q-Cells AG fell below the thresholds of 25 %, 20 %, 15 %, 10 %, 5 % and 3 % and that they do no longer hold any voting rights in Q-Cells AG. 5. Voorspring Holding B.V., Amsterdam, The Netherlands, has notified us that on 18 July 2007 they exceeded the thresholds of 3 %, 5 %, 10 %, 15 %, 20 % and 25 % of the voting rights in Q-Cells AG and at that time held 29.63 % of the voting rights in Q-Cells AG, corresponding to 23,466,513 of the total number of 79,201,475 voting rights. They hold all 23,466,513 voting rights in Q-Cells AG by themselves. 6. Good Energies (Solar Investments) S.á r.l., Luxembourg, Grand Duchy of Luxembourg, has notified us that on 18 July 2007 they exceeded the thresholds of 3 %, 5 %, 10 %, 15 %, 20 % and 25 % of the voting rights in Q-Cells AG and at that time held 29.63 % of the voting rights in Q-Cells AG, corresponding to 23,466,513 of the total number of 79,201,475 voting rights. All of these voting rights were attributed to them pursuant to section 22 sub-sec. 1 sentence 1 no. 1 WpHG. All of these voting rights attributed to them pursuant to section 22 sub-sec. 1 sentence 1 no. 1 WpHG were attached to shares held by Voorspring Holding B.V., Amsterdam, The Netherlands, which is controlled by them. Q-Cells AG Guardianstraße 16, 06776 Thalheim, Germany --- End of Message --- Q-Cells AG Guardianstr. 16 Thalheim Germany WKN: 555866; ISIN: DE0005558662; Index: CDAX, GEX, Prime All Share, TecDAX; Listed: Amtlicher Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Stuttgart;


 
Hitt og þetta
23. júlí 2007

Final Results

THE AIM DISTRIBUTION TRUST PLC UNAUDITED PRELIMINARY ANNOUNCEMENT OF RESULTS FOR THE YEAR ENDED 31 MARCH 2007 FINANCIAL SUMMARY Unaudited Audited Year Year ended ended 31 March 31 March 2007 2006 Pence pence Net asset value (per share) 64.1 70.0 Cumulative distributions paid since launch 53.8 51.8 Total return (net asset value plus cumulative 117.9 121.8 distributions paid) Interim distribution paid (per share) 2.0 2.0 The statement to shareholders by the Chairman, Sir Aubrey Brocklebank, includes the following comments: Performance of your Company over the year ended 31 March 2007 has been a little disappointing, although the second half of the year has seen an increase in NAV after the fall that was experienced in the first half. Net Asset Value At 31 March 2007, the Net Asset Value per share ("NAV") stood at 64.1p. This represents a decrease of 3.9p or 5.5% since the previous year-end after adjusting for the 2p dividend paid in March 2007, although is an increase of 0.6p (0.9%) per share since the half year date also after adjusting for the dividend paid. VCT investments The Company has been effectively fully invested throughout the year, so investment activity has been relatively low. There were however two follow-on investments made at a total cost of £175,000. A number of realisations occurred during the year, which produced cash proceeds of £2.3 million. The most significant was that of Neutec Pharma, which was the subject of a cash offer and produced a realised gain of £512,000 in the year from an investment with an original cost of £210,000. As I highlighted in my statement with the interim results, the Company's performance has been held back by the poor performance of a small number of investments. Cellcast, Chariot (UK), Hill Station and PM Group were the most notable poor performers. The holding in PM Group has now been sold and Chariot (UK) has effectively failed, however Hill Station and Cellcast have reacted to the difficulties they faced earlier in the year and there are now prospects for at least a partial recovery for both businesses. Overall the investment portfolio showed net realised gains of £546,000 and net unrealised losses of £1.2 million. Results and Dividend The loss on ordinary activities after taxation was £786,000 (2006 profit: £862,000), comprising a revenue profit of £18,000 and a capital loss of £804,000. An interim dividend of 2p per share (2006: 2p per share) was paid on 29 March 2007. The Directors are not proposing to declare any further dividends in respect of the year to 31 March 2007. Fixed interest securities During the year, the Company's fixed interest securities realised a small loss of £6,000 against cost. At the year end, the Company continued to hold one fixed interest security, which had a value of £661,000. Share buybacks The Board is conscious that the Company's share price is affected by the illiquidity of its shares in the market. In line with widespread practice amongst VCTs, the Company has a policy of purchasing its own shares. During the year, the Company acquired 2,378,417 shares at an average price of 59.4p per share. This unusually high level of buybacks resulted from a sizeable disposal by a group of institutional investors. Although this transaction absorbed a significant amount of the Company's liquid funds, the fact that it was undertaken at approximately a 10% discount to NAV meant that the transaction resulted in a small uplift in NAV for remaining shareholders. The Board intends to continue with the policy of buying in shares at approximately a 10% discount to the latest published NAV (subject to regulatory and other restrictions) and a special resolution to that end is proposed for the forthcoming AGM. Future of the Company It is now five years since Shareholders voted for the Company to continue as a VCT. In accordance with Article 26 of the Company's Articles of Association, a resolution will again be put to Shareholders as to whether the Company should continue for another 5 years. The Board have given consideration to options available, paying particular attention to the situations of many Shareholders. As winding up the Company is likely to crystallise a capital gains tax liability for many Shareholders, the Board is firmly of the opinion that the Company should continue as a VCT, and recommend that Shareholders vote in favour of resolution 6 at the forthcoming Annual General Meeting. Annual General Meeting The Annual General Meeting of the Company will be held at Port of Liverpool Building, Pier Head, Liverpool, L3 1NW at 12 noon on 10 September 2007. Outlook The number of investments showing significant falls in the first half of the year was a concern for the Board, however the slightly improved performance in the second half provides evidence that the Company's diversified portfolio includes some investments with good growth prospects that can deliver improved performance as they mature. UNAUDITED INCOME STATEMENT for the year ended 31 March 2007 Unaudited Audited Year ended 31 March 2007 Year ended 31 March 2006 Revenue Capital Total Revenue Capital Total £'000 £'000 £'000 £'000 £'000 £'000 Income 220 - 220 168 - 168 (Losses)/gains on - (686) (686) - 1,014 1,014 investments 220 (686) (466) 168 1,014 1,182 Investment (39) (118) (157) (39) (117) (156) management fees Other expenses (163) - (163) (164) - (164) Return on ordinary 18 (804) (786) (35) 897 862 activities before tax Tax on ordinary - - - - - - activities Return attributable to 18 (804) (786) (35) 897 862 equity shareholders Return per share 0.1p (5.3p) (5.2p) (0.2p) 5.3p 5.1p The revenue and capital movements in the year relate to continuing operations. The total column within the Income Statement represents the profit and loss account of the Company. A Statement of Total Recognised Gains and Losses has not been prepared as all gains and losses are recognised within the Income Statement as noted above. RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS for the year ended 31 March 2007 Unaudited Audited Year ended Year ended 31 March 2007 31 March 2006 £'000 £'000 Opening shareholders' funds 11,602 10,831 Issue of shares - 611 Share issue costs - (53) Purchase of own shares (1,421) (313) Total recognised (losses)/gains for the (786) 862 year Distributions paid (287) (336) Closing shareholders' funds 9,108 11,602 BALANCE SHEET Unaudited Audited at 31 March 2007 2007 2006 £'000 £'000 £'000 £'000 Fixed assets Investments 7,848 11,638 Current assets Debtors 276 51 Cash at bank and in hand 1,153 47 1,429 98 Creditors: amounts falling due within (169) (134) one year Net current assets/(liabilities) 1,260 (36) Net assets 9,108 11,602 Capital and reserves Called up share capital 3,551 4,145 Capital redemption reserve 860 266 Share premium 348 348 Special reserve - 1,176 Capital reserve - unrealised (1,730) (812) Capital reserve - realised 6,049 6,467 Revenue reserve 30 12 Equity shareholders' funds 9,108 11,602 Net asset value per share 64.1p 70.0p CASH FLOW STATEMENT for the year ended 31 March 2007 Unaudited Audited Year ended Year 31 March ended 2007 31 March 2006 £'000 £'000 £'000 £'000 Net cash outflow from operating (150) (120) activities Capital expenditure Purchase of investments (231) (2,807) Sale of investments 3,106 1,159 Net cash inflow/(outflow) from 2,875 (1,648) capital expenditure Equity distributions paid (287) (336) Net cash inflow/(outflow) 2,438 (2,104) before financing Financing Applications for share issue - 271 Share issue costs - (22) Purchase of own shares (1,332) (335) Net cash outflow from financing (1,332) (86) Increase/(decrease) in cash in 1,106 (2,190) the year NOTES TO THE UNAUDITED PRELIMINARY ANNOUNCEMENT for the year ended 31 March 2007 1. Accounting policies Basis of accounting The Company has prepared its financial statements under UK Generally Accepted Accounting Practice ("UK GAAP") and in accordance with the Statement of Recommended Practice "Financial Statements of Investment Trust Companies" revised December 2005 ("SORP"). The financial statements are prepared under the historical cost convention except for the revaluation of certain financial instruments. Presentation of Income Statement In order to better reflect the activities of a Venture Capital Trust and in accordance with guidance issued by the Association of Investment Companies ("AIC"), supplementary information which analyses the income statement between items of a revenue and capital nature has been presented alongside the Income Statement. The net revenue is the measure the Directors believe appropriate in assessing the Company's compliance with certain requirements set out in Section 842 Income and Corporation Taxes Act 1988. Investments Venture capital investments are designated as "fair value through profit or loss" assets and are initially measured at cost. Thereafter the investments are measured at subsequent reporting dates at fair value. Listed fixed income investments, investments quoted on AIM and those traded on the PLUS Market (formerly OFEX) are measured using bid prices with marketability discounts applied where deemed appropriate, in accordance with the International Private Equity and Venture Capital Valuation Guidelines. In respect of unquoted instruments, fair value is established by using International Private Equity and Venture Capital Valuation Guidelines. Where no reliable fair value can be estimated for such unquoted equity investments they are carried at cost, subject to any provision for impairment. Where an investee company has gone into receivership or liquidation the investment, although not physically disposed of, is treated as being realised. Gains and losses arising from changes in fair value are included in the income statement as a capital item and transaction costs on acquisition or disposal of the investment expensed. It is not the Company's policy to exercise either significant or controlling influence over investee companies. Therefore the results of these companies are not incorporated into the revenue account except to the extent of any income accrued. Income Dividend income from investments is recognised when the shareholders' rights to receive payment has been established, normally the ex dividend date. Interest income is accrued on a timely basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount, and only where there is reasonable certainty of collection. Expenses All expenses are accounted for on an accruals basis. In respect of the analysis between revenue and capital items presented within the income statement, all expenses have been presented as revenue items except as follows: * Expenses which are incidental to the disposal of an investment are deducted from the disposal proceeds of the investment. * Expenses are split and presented partly as capital items where a connection with the maintenance or enhancement of the value of the investments held can be demonstrated and accordingly the investment management fee and finance costs have been allocated 25% to revenue and 75% to capital, in order to reflect the Directors' expected long-term view of the nature of the investment returns of the Company. Taxation The tax effects on different items in the Income Statement are allocated between capital and revenue on the same basis as the particular item to which they relate using the Company's effective rate of tax for the accounting period. Due to the Company's status as a Venture Capital Trust and the continued intention to meet the conditions required to comply with Section 842AA of the Income and Corporation Taxes Act (1988), no provision for taxation is required in respect of any realised or unrealised appreciation of the Company's investments which arises. Deferred taxation is provided in full on timing differences that result in an obligation at the balance sheet date to pay more tax, or a right to pay less tax, at a future date, at rates expected to apply when they crystallise based on current tax rates and law. Timing differences arise from the inclusion of items of income and expenditure in taxation computations in periods different from those in which they are included in the accounts. 2. Return per share Revenue return per ordinary share is based on the net revenue return after taxation of £18,000 (2006: loss £35,000) in respect of 15,229,480 ordinary shares (2006: 16,881,512), being the weighted average number of ordinary shares in issue during the year. Capital return per ordinary share is based on the net capital loss for the financial year of £804,000 (2006: profit £897,000) in respect of 15,229,480 ordinary shares (2006: 16,881,512), being the weighted average number of ordinary shares in issue during the year. As the Company has not issued any convertible securities or share options, there is no dilutive effect on return per ordinary share. The return per share disclosed therefore represents both basic and diluted return per ordinary share. 3. Net asset value per ordinary share 2007 2006 Net asset Net asset value value per share Net asset per share Net asset value value pence £'000 pence £'000 Ordinary 64.1 9,108 70.0 11,602 shares Net asset value per ordinary share is based on net assets at the year-end, and on 14,203,875 ordinary shares (2006: 16,582,292), being the number of ordinary shares in issue at the year-end. As the Company has not issued any convertible securities or share options, there is no dilutive effect on net asset value per ordinary share. The net asset value per share disclosed therefore represents both basic and diluted net asset value per ordinary share. 4. Reconciliation of net revenue return before taxation to net cash flow from operating activities 2007 2006 £'000 £'000 Revenue/(loss) return on ordinary activities before tax 18 (35) Expenses charged to capital (118) (117) (Increase)/decrease in prepayments and accrued income (45) 13 (Decrease)/increase in accruals and deferred income (5) 19 Net cash outflow from operating activities (150) (120) 5. Analysis of changes in cash during the period 2007 2006 £'000 £000 Beginning of year 47 2,237 Net cash inflow/(outflow) 1,106 (2,190) End of year 1,153 47 Announcement based on unaudited accounts The financial information set out in the announcement does not constitute the Company's statutory accounts in accordance with section 240 Companies Act 1985 for the year ended 31 March 2007. The statutory accounts for the year ended 31 March 2007 will be finalised on the basis of the financial information presented by the Directors in this preliminary announcement and will be delivered to the Registrar of Companies following the Company's Annual General Meeting. The statutory accounts for the year ended 31 March 2006 have been delivered to the Register of Companies and received an Auditor's Report which was unqualified and did not contain statements under s237 (2) and (3) of the Companies Act 1985. A copy of the full annual report and financial statements for the year ended 31 March 2007 will be printed and posted to shareholders. Copies will also be available to the public at the registered office of the Company at Kings Scholars House, 230 Vauxhall Bridge Road, London, SW1V 1AU. The financial information contained within this Preliminary Announcement was approved by the Board on 23 July 2007. ---END OF MESSAGE---


 

Liguori assumes this new role on August 1st 2007, as the successor of Urs Stulz Swiss WorldCargo, the air cargo division of Star Alliance carrier Swiss International Airl Lines, announced today that Adolfo Liguori has been appointed Director Cargo Switzerland. As the successor of Urs Stulz, who was recently promoted Managing Director Cargo Europe, Liguori assumes this new role as of August 1st, 2007. A veteran within the organisation, Liguori (47) is currently the head of Product Management. Throughout his career, which started back in 1984 at Swissair, he has held several other management positions in Revenue Management, Sales and Product Management at Swissair Cargo, Swisscargo and, more recently, at Swiss WorldCargo, where he especially performed to the highest standards. Married with two children, Liguori has a dual Swiss and Italian citizenship; As a native speaker of German and Italian and as a fluent speaker of French and English, with experience of and respect for the different Swiss cultures and mentalities, Liguori is very well suited to take on this challenge. Urs Stulz says: "With his strong assets, his in-depth know-how and extensive experience, and his clearly expressed willingness to further develop and strengthen the leading role of Swiss WorldCargo in the multicultural and multifaceted home market, I am convinced that Adolfo will be very successful in this position." Swiss WorldCargo is the airfreight division of Swiss International Air Lines Ltd. With a worldwide network serving more than 150 destinations in more than 80 countries and abroad spectrum of services, Swiss WorldCargo earns genuine added-value for its customers and makes a substantial contribution to the earnings of SWISS. Note to editors: For further information about Swiss WorldCargo, pictures and interview requests please contact: Bernd Maresch Senior Manager Marketing, PR & Strategy bernd.maresch@swiss.com Phone +41 44 564 50 50 Please visit swissworldcargo.com Please click the following links for the media release in pdf and a photograph of Adolfo Liguori:


 

` FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | DEEPHAVEN CAPITAL | | | MANAGEMENT LLC | |-----------------------------------------------+-------------------| | Company dealt in | EMI Group Plc | |-----------------------------------------------+-------------------| | Class of relevant security to which the | 14p Ordinary | | dealings being disclosed relate (Note 2) | | |-----------------------------------------------+-------------------| | Date of dealing | 20 July 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------+ | | Long | Short | | | | | |------------------------------+---------------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |------------------------------+------------+--------+--------+-----| | (1) Relevant securities | | | | | | | | | | | |------------------------------+------------+--------+--------+-----| | (2) Derivatives (other than | 11,260,000 | 1.3882 | | | | options) | | | | | | | | | | | |------------------------------+------------+--------+--------+-----| | (3) Options and agreements | | | | | | to purchase/sell | | | | | | | | | | | |------------------------------+------------+--------+--------+-----| | Total | 11,260,000 | 1.3882 | | | | | | | | | +-------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +-------------------------------------------------------------------+ | Class of relevant security: | Long | Short | | | | | |-------------------------------------+--------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (2) Derivatives (other than | | | | | | options) | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | Total | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short | Number of securities | Price per | | name, | (Note 6) | (Note 7) | unit (Note 5) | | e.g. CFD | | | | |----------+------------+---------------------------+---------------| | | | | | | CFD | LONG | 1,160,000 | 262.3800 | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 23rd July 2007 | |-------------------------------------------------+-----------------| | Contact name | James Feast | |-------------------------------------------------+-----------------| | Telephone number | 0207 469 1901 | |-------------------------------------------------+-----------------| | If a connected EFM, name of offeree/offeror | | | with which connected | | |-------------------------------------------------+-----------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

BILTHOVEN, The Netherlands - July 30, 2007 - ASM International N.V. (NASDAQ: ASMI and Euronext Exchange in Amsterdam: ASM) will report operating results for the 2007 second quarter and six months ended June 30, 2007, on Monday, July 30, 2007 at approximately 18:00 Continental European time (12:00 p.m. US Eastern Time). ASM International will host an investor conference call and web cast on Tuesday, July 31, 2007 at 15:00 Continental European time (09:00 a.m. US Eastern Time). The teleconference dial-in numbers are as follows: United States - +1 866.356.4281 International - +1 617.597.5395 The participant pass code is 259 91 047 A simultaneous audio web cast will be accessible at www.asm.com. The teleconference will be available for replay, beginning one hour after completion of the live broadcast through August 14, 2007. The replay dial-in numbers are: United States - +1 888.286.8010 International - + 1 617.801.6888 The participant pass code is 565 30 577 About ASM International ASM International N.V. and its subsidiaries design and manufacture equipment and materials used to produce semiconductor devices. The company provides production solutions for wafer processing (Front-end segment) as well as assembly and packaging (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International's common stock trades on NASDAQ (symbol ASMI) and the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's web site at www.asm.com. Contact: Lies Rijnveld - + 31 30 229 8506, or Mary Jo Dieckhaus - +1 212 986 2900


 

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | Elliott Advisors (UK) | | | Ltd. | |-------------------------------------------+-----------------------| | Company dealt in | EMI Group PLC | |-------------------------------------------+-----------------------| | Class of relevant security to which the | Convertible Bonds | | dealings being disclosed relate (Note 2) | | |-------------------------------------------+-----------------------| | Date of dealing | 19 July 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------------------------------------------------+ | | Long | Short | | | | | |---------------+------------------------------------------+--------------------------------------------------| | |Number |Number (%)| | |(%) | | |---------------+------------------------------------------+--------------------------------------------------| |(1) Relevant |33,988,000 13.9672% | | |securities | | | | | | | |---------------+------------------------------------------+--------------------------------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+------------------------------------------+--------------------------------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+------------------------------------------+--------------------------------------------------| |Total |33,988,000 13.9672% | | | | | | +-------------------------------------------------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +------------------------------------------------------------------------------------------------------------------+ |Class of relevant | Long | Short | |security: Convertible | | | |Bonds 2010 | | | | | | | | | | | |------------------------+------------------------------------------+----------------------------------------------| | |Number |Number | | |(%) |(%) | |------------------------+------------------------------------------+----------------------------------------------| |(1) Relevant | | | |securities | | | | | | | | | | | |------------------------+------------------------------------------+----------------------------------------------| |(2) Derivatives (other |12,955,800 1.5973% | | |than options) | | | | | | | |------------------------+------------------------------------------+----------------------------------------------| |(3) Options and | | | |agreements to | | | |purchase/sell | | | | | | | |------------------------+------------------------------------------+----------------------------------------------| |Total |12,955,800 1.5973% | | | | | | +------------------------------------------------------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | Buy | 6,500,000 | 216.50 | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short (Note | Number of securities | Price per | | name, | 6) | (Note 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------------+------------------------+------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |Date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) YES/NO +-------------------------------------------------------------------+ | Date of disclosure | 20 July 2007 | |--------------------------------------------------+----------------| | Contact name | Philippa Rowan | |--------------------------------------------------+----------------| | Telephone number | 0207 518 1818 | |--------------------------------------------------+----------------| | If a connected EFM, name of offeree/offeror with | | | which connected | | |--------------------------------------------------+----------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Glitnir will host the following presentations and webcasts in relation to the publication of its second quarter results for 2007. An English version of the presentation will be available on www.glitnirbank.com as of its publishing midday on 31 July. Presentation in Reykjavík, Iceland Lárus Welding, CEO, will present Glitnir's second quarter results for 2007 to shareholders and market participants on Tuesday, 31 July, at 1.30 p.m. at Nordica Hotel, room H, in Reykjavík. Presentation and web cast in London, UK Lárus Welding, CEO, will present Glitnir's second quarter results for 2007 to shareholders and market participants on Wednesday, 1 August, at 11 a.m. at The Great Eastern Hotel, Liverpool Street, EC2M 7QN, London. Lunch will be offered after the presentation. A live broadcast of the meeting can be accessed on Glitnir's web: www.glitnirbank.com, where questions can be sent to the meeting via the web cast. You can also participate with questions by telephone by dialling +44 (0) 208 817 9301. Attendance should register with Vala Pálsdóttir, Head of Investor Relations, by e-mail at ir@glitnir.is or by calling +354 440 4989. Media interviews bookings To book media interviews, please contact Bjørn Richard Johansen, Managing Director, Corporate Communication, by sending an e-mail message to brj@glitnir.no or by calling mobile +47 47 800 100.


 

Highlights * The consolidated result after tax for the January-June period was a profit of SKr 21.7 million (loss 9.1). The result for Q2 2007 was a profit of SKr 46.9 (loss 23.4). * Earnings per share for the January-June period amounted to SKr 5.10 (loss 1.05). Earnings per share for the second quarter of 2007 amounted to SKr 10.75 (loss 4.70). * The result of Management of Securities was a profit of SKr 42.1 million (23.8), of which changes in value accounted for SKr 31.1 million (13.7). The result for Q2 2007 was a profit of SKr 18.6 million (loss 34.3). * Industrial Operations' turnover amounted to SKr 436.5 million (388.6). Turnover in Q2 2007 amounted to SKr 346.1 million (310.8). * Industrial Operations' operating result, which tends to be weak during the first half-year owing to seasonal factors, was a loss of SKr 5.2 million (loss 28.8). The operating profit for Q2 2007 amounted to SKr 47.3 million (27.5). * Industrial Operations' operating profit for 2007 as a whole is expected to be better than in 2006, when it was SKr 38.6 million. * The return on Geveko's Series "B" shares for the January-June 2007 period, including dividends paid and redemption of shares, was 32%. The SIX Return Index rose by 13% during the same period. * During the first half of 2007, by way of dividend and redemption of shares, SKr 86 per share was repaid to Geveko's shareholders. After the end of the period At the beginning of July two Polish road marking companies - Technom and GIK - with an aggregate turnover of some SKr 46 million in 2006, were acquired. The companies will be integrated with Cleanosol's business in Poland. Forthcoming information, 2007-2008 Interim report, January-September 26 October 2007 Year-end release 2007 25 February 2008 Annual Report 2007 April 2008 Interim Report, January-March 2008 24 April 2008 Annual General Meeting 2008 24 April 2008 AB GEVEKO (publ) co. reg. no.: 556024-6844 Box 2137, S-403 13 Göteborg, Sweden. +46 31 172945 info@geveko.se www.geveko.se The full report with tables can be downloaded from the following link:


 

ALMA MEDIA CORPORATION PRESS RELEASE 23 JULY 2007 OLLI-PEKKA MOLLBERG NOMINATED MANAGING DIRECTOR FOR MONSTER OY Olli-Pekka Mollberg (45), Bachelor in Marketing, has been nominated Managing Director for Monster Oy, which publishes Monster.fi, the leading online recruitment service in Finland. Mollberg starts in his position in 20 August 2007 and reports to Raimo Mäkilä, Senior Vice President, Head of Marketplaces. "Monster.fi is growing strongly and is the best in its field in Finland. This position was an opportunity that I had to take. Online recruiting advertising is a young business that has a lot of potential", comments Olli-Pekka Mollberg, who previously worked as Field Manager in Suomen Varamiespalvelu Oy. Monster.fi is Finland's leading online recruitment service. It has continuously increased its market share and in 2006 the number of job vacancies on its pages grew by more than 50% compared to the previous year. Some 220,000 different job applicants visit the Monster.fi pages every month. Monster is owned by Alma Media Corporation (75 %) and Monster Inc. (25 %). More information: Raimo Mäkilä, Senior Vice President, Head of Marketplaces, tel. +35840 546 1892. Distribution: Principal media Alma Media is a profitably growing and internationally expanding company that invests in the future of newspapers and the online media. Its best known products are Aamulehti, Iltalehti, Kauppalehti and Etuovi.com. Net sales in 2006 totalled EUR 302 million and the operating margin was 16 %. The company's share is listed in the Mid Cap segment of the OMX Nordic Exchange's Nordic List, trading code ALN1V. More information at http://www.almamedia.fi/home


 

In keeping with its niche strategy for its European business, Nationale Suisse is selling its French subsidiary Nationale Suisse Assurances SA to AXA France Assurance SAS. As part of its European business strategy, Nationale Suisse will concentrate primarily on profitable niche business. As its French subsidiary writes virtually only bulk business and has no prospects of realising a promising niche strategy with good profit potential in the medium term, its life business was already sold in 2006. Through this second transaction, Nationale Suisse is now exiting the French non-life market. The divested French subsidiary is a multiline insurer with a strong focus on motor insurance business (50.2% of premiums). It wrote a premium volume of EUR 101.5 million in 2006 and currently has a workforce of 125. Both parties agreed not to disclose details of the transaction. The company expects to receive the approval of the supervisory authorities during the course of the next few months to enable it to successfully conclude the transaction by the end of this year. Brief profile Nationale Suisse is an innovative, The headquarters of international Swiss insurer providing Nationale Suisse is in first-rate risk and pension solutions and Basel. Nationale Suisse tailored niche products. The Group has gross is listed on the SWX premiums of CHF 1.74 billion, approximately Swiss Exchange (NATN). 35% of which come from subsidiaries in On 31 December 2006 the Germany, France, Italy, Belgium, Spain and Group employed 2,013 Liechtenstein. persons (1,884 FTEs). Downloads Disclaimer You can access this media release and the new Any forward-looking advertisement on our website statements contained in www.nationalesuisse.ch. this article consist of estimates, assessments and forecasts. The influence of uncertain and unforeseeable circumstances and certain risks may mean that actual performance deviates significantly from our expectations. Contacts Sabrina Pagnetti Head of Information & Communication Tel. +41 61 275 22 33 Fax +41 61 275 22 21 sabrina.pagnetti@nationalesuisse.ch Nationale Suisse Steinengraben 41 4003 Basel www.nationalesuisse.ch --- End of Message --- Nationale Suisse Steinengraben 41 Basel WKN: 1081197; ISIN: CH0010811971; Index: SMCI, SPI, SPIEX; Listed: Main Market in SWX Swiss Exchange;


 
Hitt og þetta
23. júlí 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |-------------------------------------------------+-----------------| | Company dealt in | Freeport Plc | |-------------------------------------------------+-----------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |-------------------------------------------------+-----------------| | Date of dealing | 20th July 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 500 | 351p | 351p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 837 | 359p | 356.25p | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +------------------------------------------------------------------+ | Date of disclosure | 23rd July 2007 | |----------------------------------------------+-------------------| | Contact name | Edward Hodge | |----------------------------------------------+-------------------| | Telephone number | 0207 991 6661 | |----------------------------------------------+-------------------| | Name of offeree/offeror with which connected | Freeport Plc | |----------------------------------------------+-------------------| | Nature of connection (Note 6) | Connected Advisor | +------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 
Hitt og þetta
23. júlí 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |-------------------------------------------------+-----------------| | Company dealt in | Homeserve Plc | |-------------------------------------------------+-----------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |-------------------------------------------------+-----------------| | Date of dealing | 20th July 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price paid | | securities | (Note 3) | (Note 3) | | purchased | | | |--------------------------+--------------------+-------------------| | 283 | 1,840.10p | 1,840.10p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 0 | | | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +-------------------------------------------------------------------+ | Date of disclosure | 23rd July 2007 | |---------------------------------------+---------------------------| | Contact name | Edward Hodge | |---------------------------------------+---------------------------| | Telephone number | 0207 992 16661 | |---------------------------------------+---------------------------| | Name of offeree/offeror with which | Domestic & General Group | | connected | Plc | |---------------------------------------+---------------------------| | Nature of connection (Note 6) | Connected Advisor | +-------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Norwegian utility provider Lyse Gass (www.lyse.no) and I.M. Skaugen (IMS) join forces to create a unique LNG "small scale" supply chain for the Nordic markets. A natural gas liquefying plant with an annual production capacity of 300,000 tonnes of LNG will be built by Lyse, and its partners. It is expected to come on-stream in 2010, creating the North European market leader in LNG. I.M. Skaugen is currently engaged in a building program of up to ten sophisticated LNG carriers in China. Out of these 10 carriers one will initially be assigned to the joint venture, called Nordic LNG, full time from 2010. .The partners will jointly establish and own Nordic LNG AS that will be the company responsible for the logistic and sales of the LNG made by the liquefaction plant. Norwegian utility provider Lyse Gass (www.lyse.no) and I.M. Skaugen (IMS) join forces to create a unique LNG "small scale" supply chain for the Nordic markets. A natural gas liquefying plant with an annual production capacity of 300,000 tonnes of LNG will be built by Lyse, and its partners. It is expected to come on-stream in 2010, creating the North European market leader in LNG. I.M. Skaugen is currently engaged in a building program of up to ten sophisticated LNG carriers in China. Out of these 10 carriers one will initially be assigned to the joint venture, called Nordic LNG, full time from 2010. .The partners will jointly establish and own Nordic LNG AS that will be the company responsible for the logistic and sales of the LNG made by the liquefaction plant. IMS ambition in this new market has been not only to transport the LNG but also take an active part in the whole supply chain and up to the point of acting as a seller of LNG directly to the end-users. With the small-scale LNG concept, natural gas in the form of LNG can be supplied directly to end-users located outside the normal cover of pipeline systems. This will give these end-users the unique opportunity to switch to natural gas - an energy source with significantly lower emission levels of greenhouse gases. The Nordic LNG concept gives us the opportunity to be an early mover into an exciting new market currently under development around the globe - that of small-scale distribution of LNG. A move into this market needs to be scrutinized at every stage in the process and therefore, I.M. Skaugen has been working since 2002 to analyse the market potential and supply chain management of small-scale LNG in the Nordic region. Our objective has been to "demystify" the LNG concepts and build a robust supply chain concept based on well known and proven technologies. By this approach we can create an economical efficient supply chain with the aim of serving the customers in the most flexible way. The first result of these efforts is the partnership with Lyse Gass and the exploration of LNG based services for customers in Scandinavia. The decision in 2005 to commence a process to make our own-designed and own-built "Multigas" vessels and being the first of their kind - capable of carrying the more traditional cargoes of LPG and Ethylene, as well as LNG, makes it possible to switch between different gas cargoes. Furthermore, we will be able to gain access to a totally new market without the significant costs normally associated with the building of a dedicated large scale LNG fleet and with large scale re-gasification plants and receiving terminals. The environmental benefits to the companies and the society are considerable. The customer's shift from oil to gas will represent a reduction in CO2 emissions of 250.000 tonnes per year, corresponding to the yearly emissions from nearly 100.000 cars. Also the emissions of nitrous oxide (NOx) will be considerably reduced. The unique cooperation benefits from Lyse's gas and utility expertise and I.M. Skaugen's distribution and logistics capabilities. The partners will thus have under its own control the value chain from natural gas entering the processing plant in Norway to the product being delivered on the customer's doorstep. Nordic LNG AS, which is the Company entrusted with the sales and logistics of the distribution of the natural gas, will be owned 40% by IMS and 60% by Lyse and its partners. The Company will provide natural gas to a great number of industrial companies not having access to natural gas pipelines today. At the outset, Nordic LNG will focus on industrial customers in Norway and Sweden, but will also address the entire Northern European market. Nordic LNG's first customers have already signed on, among them AGA in Sweden. So far, almost 20 per cent of the plant's capacity is contracted. The partners in the Nordic LNG venture have decided on a business model where the investments made by each partner will be carried on its own balance sheets. These assets will then be pooled into an "EBITDA sharing pool" where the IMS share of the EBITDA from the business will be aprox 20% . The final share will depend on the size of the final investments made when the plant and the vessels are commissioned. The ¤ 120 million investment in the plant, to be made by Lyse and its partners Celsius Invest AS, will create one of Europe's largest producers of liquefied natural gas at Risavika just outside Stavanger. A step 2 development of the plant, increasing the capacity to 600,000 tonnes is already being assessed. The processing plant will be delivered by the German engineering company Linde, the contract to this effect was signed last week. Construction is expected to commence just after the summer break. Shell will be delivering natural gas from the Kårstø terminal via Lyse's pipeline to the processing plant. The gas contract includes 200 million cubic meters of natural gas annually; making it one of the largest such gas contracts ever in Norway. "Lyse's involvement in the production and distribution of LNG outside Norway is a natural expansion of our gas business. We see this as an attractive business opportunity and a substantial environmental contribution," said Lyse's CEO, Eimund Nygaard. "This project is now coming to its fruition after IM Skaugen and Lyse have worked on the project for quite a few years to ensure we have covered all angles. From a vision to reality to establish a first of its kind in the world; a profitable LNG supply chain based on a smaller scale plant and smaller scale logistics. The economics of this small scale will benefit the customers and ensure natural gas is brought to customers that otherwise would not get access to it due to cost" said I.M. Skaugen's CEO, Morits Skaugen". "The demand for gas is increasing all over Europe. Our LNG concept provides efficient access to gas also for companies not being close to pipelines. This enables a great number of companies to reduce energy costs and improve their environmental performance," said managing director of Nordic LNG, Håkan Werner. I.M. Skaugen ASA If you have any questions, please contact: Bente Flø, Chief Financial Officer, on telephone +47 23 12 03 30/+47 91 64 56 08 or by e-mail: bente.flo@skaugen.com. This press release is also available on the Internet at our website: http://www.skaugen.com. Listed on the Oslo Stock Exchange, I.M. Skaugen ASA (IMSK) - www.skaugen.com - is a Marine Transportation Service Company engaged in the hassle free transportation of petrochemical gases and LPG, ship-to-ship transfer of crude oil and LNG, as well as the design and construction of smaller and specialized high quality marine vessels. IMSK is a fully integrated shipping company that designs, builds, owns, mans and manages our own ships. IMSK customers are major international companies in the oil and petrochemical industry, whom we serve worldwide from our operations in Dubai (UAE), Freeport and Houston (Texas), Oslo (Norway), Singapore Sunderland (UK), Nanjing, Shanghai, Taizhou, Zhangjiagang and Wuhan (China). IMSK operates recruitment and training programmes in St. Petersburg (Russia) and Wuhan (China) for the crewing of vessels. IMSK employs approx. 1,500 people and currently operates 45 vessels worldwide. The fleet comprises petrochemical gas and LPG carriers, Aframax tankers, vessels and barges for the transportation of gases on the Yangtze River (China) and a small number of workboats for Skaugen PetroTrans (SPT). IMSK has a comprehensive newbuilding project in China where it has three LPG vessels of 3,200 cbm; three purpose designed combination carriers with LPG/Ethylene/VCM and Organic chemicals carrying capability and up to ten advanced 10,000 cbm LNG/LPG/Ethylene gas carriers are on order for Norgas for delivery from beginning 2007 and onwards. IMSK has invested in infrastructure with both a shipyard and a cargo plant maker in China to ensure innovative and flexible vessels at low cost. Six new, purpose designed and built "Aframax sized tankers", are on order for delivery to SPT on a long term Bareboat charter and for delivery from May 2007 until spring 2008.


 

Update July 16-20 Amsterdam (July 23, 2007) - Wolters Kluwer, a leading global information services and publishing company, today announces that in line with the launch of its ¤475 million share buy-back program on June 15, 2007, the company has repurchased 1,414,771 ordinary shares in the period July 16 until July 20, 2007. Shares were repurchased at an average price of ¤23.20 for a total amount of ¤32.8 million. For detailed information on the daily repurchased shares, see the Wolters Kluwer website at http://www.wolterskluwer.com/WK/Investors/Share+Information/Share+Buy-back+Program/ The total number of shares repurchased under this program to date is 5,536,619 ordinary shares for a total consideration of ¤126.0 million. About Wolters Kluwer Wolters Kluwer is a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal and regulatory sectors. Wolters Kluwer has annual revenues (2006) of ¤3.4 billion, employs approximately 18,450 people worldwide, and maintains operations across Europe, North America, and Asia Pacific. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its shares are quoted on the Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. For more information, visit www.wolterskluwer.com. Contact: Caroline Wouters Kevin Entricken Vice President, Vice President, Corporate Communications Investor Relations Wolters Kluwer nv Wolters Kluwer nv + 31 (0)20 6070 459 + 31 (0)20 6070 407 press@wolterskluwer.com ir@wolterskluwer.com Forward-looking Statements This press release contains forward-looking statements. These statements may be identified by words such as "expect," "should," "could," "shall," and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


 

Santalucía is one of the major players in the insurance sector in Spain. They have now decided to automate their invoice handling in order to improve processes within their SAP® system. To achieve this, they have chosen ReadSoft DOCUMENTS for Invoices to process the 40,000 invoices they receive every year. With a ¤921 million turnover, Santalucía is the biggest insurance company in Spain within the areas Life, Family Care, and Home Insurance. Each year, Santalucía protects and insures more than 7 million people. For a company of Santalucía's size, it is crucial to be able to process supplier invoices in an efficient way. Consequently, they started to look for a solution which could automatically process their incoming invoices inside their SAP® system. "It was a long process. We were comparing solutions for several months to be sure that we got the strongest and most complete solution on the market. Finally, we chose ReadSoft's Invoices business solution for SAP®. It guaranteed a seamless integration with our ERP system together with high-quality professional services," says José Abellán Collado, Finance Area Manager at Santalucía. Until now, the Finance Department at Santalucía processed all their paper invoices manually. This was very time-consuming and prevented staff from doing more valuable tasks. From now on, this process will be quicker and more efficient. Paper invoices will be scanned and ReadSoft's INVOICES product will capture the data automatically. INVOICE COCKPIT will integrate the captured information into Santalucía's SAP system and WEB CYCLE will create a workflow for automatic approval of invoices. Thus, the manual tasks will be reduced to a minimum and the whole process will be carried out with better control and accuracy. "This is a very important project for us on the Spanish market. Santalucía is one of the most important companies in the insurance sector in Spain and their decision to choose us strengthens our position as the leading supplier of invoice automation software for SAP®," says Jan Andersson, President and CEO of ReadSoft. ReadSoft DOCUMENTS for Invoices More than ten years of experience with electronic invoice processing has produced the most powerful, and by far the most popular (2,000 clients), system on the market. ReadSoft DOCUMENTS for Invoices is a highly profitable investment for just about any business. Fully implemented, electronic invoice processing lowers costs by 25-50%. Meanwhile, the invoicing process speeds up and employees can devote more time to tasks that take advantage of their individual skills. ReadSoft DOCUMENTS for Invoices captures, reads and classifies all incoming formats, whether paper or electronic. The solution, which is customised for simple linkage to leading international enterprise systems, is certified for both SAP and Oracle. ------------------------------------------------ For additional information, contact --------------------------------------- ReadSoft AB Jan Andersson, CEO Phone: +46 708376600 Jonna Opitz, Vice President Corporate Communications Phone: +46 733378668 jonna.opitz@readsoft.com ReadSoft is a world-leading supplier of software for document automation. The company develops and markets a complete software platform for document automation under the name of ReadSoft DOCUMENTS. The vision is to release businesses around the world from handling documents manually. Since starting in 1991, ReadSoft has grown to a worldwide Group with offices in 16 countries in Europe, North America, South America and Australia, as well as a large number of local and global partners. The head office is in Helsingborg, Sweden, which - along with Stockholm - also houses the Group's main research and development unit. The ReadSoft share is traded on the Nordic Stock Exchange Small Cap list. Find out more about the company at www.readsoft.com


 

Venlo, The Netherlands -- July 23, 2007 - QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced that its offer to exchange cash and stock for all outstanding shares of Digene Corporation (Nasdaq: DIGE) expired as scheduled at 11:59 p.m., New York City time, on Friday, July 20, 2007. All conditions of the exchange offer have either been satisfied or waived, and QIAGEN intends to accept all tendered shares. Preliminary tabulations indicate that the number of shares tendered constituted well in excess of 90% of the outstanding stock. Accordingly, QIAGEN intends to complete its acquisition of Digene by effectuating a merger without the approval of the Digene stockholders, as permitted under Delaware law, promptly after its acceptance of the shares. Pro-ration calculations will be announced when completed, and payment for the Digene shares will be made as soon as practicable. As previously announced, QIAGEN received the vote of the necessary percentage of its shareholders in favor of the acquisition of Digene at QIAGEN's Extraordinary General Meeting of Shareholders held on Friday, July 20, 2007, in The Netherlands. Additionally, the antitrust waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired at 11:59 pm EDT on July 16, with respect to the previously announced merger of the two companies. About QIAGEN QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such as pre-analytical sample preparation and assay solutions in research for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and target specific assays. The company's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 1,900 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. In this press release QIAGEN is using the term molecular diagnostics. The use of this term is in reference to certain countries, such as the United States, limited to products subject to regulatory requirements. Current QIAGEN molecular diagnostics products are 34 EU CE IVD assays, six EU CE IVD sample preparation products, one 510k PAX RNA product, nine China SFDA IVD assays and 98 general purpose reagents. Further information about QIAGEN can be found at www.qiagen.com. Forward-Looking Statements This communication contains certain forward-looking statements, including a statement concerning the month in which the parties expect to complete the transaction. These forward-looking statements are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, the risk that the conditions relating to the required minimum tender of Digene shares or regulatory clearance might not be satisfied in a timely manner or at all, risks relating to the integration of the technologies and businesses of QIAGEN and Digene, unanticipated expenditures, changing relationships with customers, suppliers and strategic partners, conditions of the economy and other factors described in the most recent reports on Form 20-F, Form 6-K and other periodic reports filed with or furnished to the Securities and Exchange Commission by QIAGEN and the most recent reports on Form 10-K, Form 10-Q, Form 8-K and other periodic reports filed by Digene with the Securities and Exchange Commission. Additional Information This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Digene. QIAGEN has filed a Registration Statement on Form F-4, as amended, and a Schedule TO, as amended, and Digene has filed a Solicitation/Recommendation Statement on Schedule 14D-9, as amended, with the Securities and Exchange Commission in connection with the transaction. QIAGEN and Digene have commenced an exchange offer and mailed a Prospectus, which is part of the Registration Statement on Form F-4, the Solicitation/Recommendation Statement on Schedule 14D-9 and related exchange offer materials, including a letter of election and transmittal, to shareholders of Digene. These documents contain important information about the transaction and should be read before any decision is made with respect to the exchange offer. Investors and stockholders may obtain free copies of these documents through the website maintained by the Securities and Exchange Commission at www.sec.gov. Free copies of these documents may also be obtained from QIAGEN, by directing a request to QIAGEN's IR department at QIAGEN Strasse 1, 40724 Hilden, Germany, or from Digene, by directing a request to Digene at 1201 Clopper Road, Gaithersburg, MD, 20878. In addition to the Registration Statement on Form F-4, as amended, the Schedule TO, as amended, Prospectus, Solicitation/Recommendation Statement on Schedule 14D-9, as amended, and related exchange offer materials, both QIAGEN and Digene file or furnish annual, quarterly and special reports, proxy statements and other information with the Securities and Exchange Commission. You may read and copy any reports, statements or other information filed or furnished by QIAGEN or Digene at the Securities and Exchange Commission's Public Reference Room at Station Place, 100 F Street, N.E., Washington, D.C. 20549. You can request copies of these documents by writing to the Securities and Exchange Commission and paying a fee for the copying cost. Please call the Securities and Exchange Commission at 1-800-SEC-0330 for more information about the operation of the Public Reference Room. QIAGEN's and Digene's SEC filings are also available to the public at the Securities and Exchange Commission's web site at http://www.sec.gov, or at their web sites at www.qiagen.com or www.digene.com. # # # --- End of Message --- Qiagen N.V. Spoorstraat 50 KJ Venlo Netherlands WKN: 901626; ISIN: NL0000240000; Index: HDAX, MIDCAP, Prime All Share, TECH All Share, TecDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;


 

ING announced today that, in line with the launch of its EUR 5.0 billion share buy back programme on 4 June 2007, the company has repurchased 2,939,058 (depositary receipts for) shares during the week of 16 July until 23 July. The (depositary receipts for) shares were repurchased at an average price of EUR 33.00 for a total amount of EUR 96,985,099.30. For detailed information on the daily repurchased shares, see the ING website at www.ing.com/investorrelations. The total number of (depositary receipts for) shares repurchased under this programme to date is 30,086,021 ordinary shares for a total consideration of EUR 987,013,652.14. To date approximately 19.7% of the repurchase programme has been completed. The repurchase programme is expected to run until June 2008. +-------------------------------------------------------------------+ | Press enquiries: | | Carolien van der Giessen, +31 20 541 6522, | | carolien.van.der.giessen@ing.com | +-------------------------------------------------------------------+ ING is a global financial institution of Dutch origin offering banking, insurance and asset management to over 60 million private, corporate and institutional clients in more than 50 countries. With a diverse workforce in excess of 120,000 people, ING comprises a broad spectrum of prominent companies that increasingly serve their clients under the ING brand.


 

Luxembourg, 23rd July 2007 - Metro International S.A. ("Metro") (MTROA, MTROB), today announced its financial results for the second quarter ended 30th June 2007. The Group's consolidated accounts have been prepared according to International Financial Reporting Standards (IFRS). HIGHLIGHTS FOR Q2 2007 * Net sales increased by 6.9% to US$ 119.8 million (2006: US$ 112.1 million). Excluding Bostad, other income and divested operations (Finland & Poland) the sales growth was 11.7%: in real terms sales growth was 4.5%. * Group operating profit of US$ 4.6 million (2006: US$ 6.5 million profit) is below 2006 due to reduced margins in Sweden, France and Denmark and investments in the US and Online. Q206 also benefited from advertising spend related to the Swedish parliamentary elections. * Contribution from subsidiary newspaper operations: operating profit of US$ 9.5 million (2006: US$ 11.3 million profit). * The average 12 month rolling EBIT margin on operations older than 3 years has fallen to 9.9% from 14% in Q107. This is due to lower margins in Sweden and the inclusion of New York for the first time. Excluding New York the Q207 margin would be 11.6%. * Net HQ costs of US$ 5.5 million (2006: US$ 5.6 million) excluding franchise income * Net profit of US$ 0.9m (2006: US$ 4.6 million profit). FIRST HALF RESULTS * 8.3% year- on- year increase in net sales to US$ 222.3 million (2006:US$205.3 million); flat in real terms due to the decline in Bostad and Sweden's Metro * Total operating loss of US$ 6.9 million ( 2006: profit US$2.6 million). * Loss before tax of US$ 8.8 million ( 2006: profit US$0.4 million). * Net loss of US$13.4 million ( 2006: net loss of US$ 1.1 million). Pelle Törnberg, President and CEO of Metro International, commented: "The second quarter is a seasonally strong quarter for Metro and this is no different in 2007 as we delivered a return to profit in Q2. However, as we stated in the Q1 release, the business issues identified in Sweden continue to affect the results in Q2 although their impact is lessened as we progress through the quarter. In real terms, owned operations net sales growth excluding Bostad and the divested operations in Finland and Poland, was 4.5% year-on-year. This result is not a complete surprise given the strong Q2 2006. Metro has shown strong sales growth in many markets including Holland, Italy, Portugal, and the US. However, price pressures in Spain, and low volumes in France and Sweden delivered modest growth in the quarter. In Sweden, Q2 has been a period of turnaround for the Swedish titles. Bostad, the real estate product in Stockholm and Malmo has been stabilised at break-even but real sales are 30% lower than 2006. Green Metro has made significant progress. Despite a 7% real drop in sales versus Q206, margins are not significantly lower due to a stronger focus on customer profitability and cost control. Sales for Sweden's Green Metro in May were close to 2006 levels and EBIT margin approached last year's level. However, Bostad remains at break-even, so in Q2 Sweden's EBIT variance is a negative $1.8m. Group EBIT from operations is $1.8m lower at $9.5m. Margins in Denmark, although still very strong, have declined due to competitive pressure; French margins are lower due to higher circulation costs and lower volumes following ad rate increases; and US margins are lower due to investments in the sales forces and marketing events that have driven sales growth of 13% in the US. Higher margins and good sales growth are features of many of our businesses including Holland, Greece, Portugal and Chile. New York's margins are gradually improving based on sales growth in excess of 20%. As we advised at the Q1 release, margins in the more than three year old editions for Q2 07 fall from 11.6% to 9.9% due to the inclusion of New York for the first time. We continue to develop the New York business to attract national advertising revenues. Metro's board recently confirmed our commitment to developing our Online business with pilot web sites in France and Spain. We will test a new interactive approach in Metro's metropolitan areas to strengthen links with our readers and to provide advertisers with a cost-effective route to our unique demographics. The 2007 investment is now forecast at less than $4m for the year. Further investments will be decided based on the performance of the pilots. Our existing websites will continue to be developed to test alternative concepts eg Metrobloggen in Sweden. Gross HQ costs are 6.6% higher than in Q206 at $6.7m. This is mainly due to the investment in Online. However, excluding Online and other business unit costs, the core HQ costs have remained flat at $5m. In real terms core HQ costs have declined by 7%. This is the result of an ongoing review of costs. The selection process for a new chief executive is progressing well. For confidentiality reasons, the board is not in a position to make an announcement today, but it hopes to confirm the appointment of a new chief executive shortly. For further information, please visit www.metro.lu, email info@metro.lu or contact: Pelle Törnberg, President & CEO tel: +44 (0) 20 7016 1300 Frank Mooty, CFO tel: +44 (0) 20 7016 1374 Birgitta Henriksson, Brunswick Group, IR tel: +46 708 12 86 39 contact Metro is the largest and fastest growing international newspaper in the world. Metro is published in over 100 major cities in 20 countries across Europe, North & South America and Asia. Metro has a unique global reach - attracting a young, active, well-educated Metropolitan audience of over 20 million daily readers. Metro's advertising sales have grown at a compound annual rate of 41% since the launch of the first edition in 1995. Metro International S.A. 'A' and 'B' shares are listed on the Stockholmsbörsen 'MID CAP-List' under the symbols MTROA and MTROB. CONFERENCE CALL The company will host a conference call today at 10.00 (CET). The call will also be webcast on Metro's website at www.metro.lu. To participate in the conference call, please dial in on the following numbers: UK / International: +44 (0)20 8817 9301 Sweden: +46 (0) 8 505 202 70 US: +1 718 354 1226 A replay facility will be available shortly after the conclusion of the call at www.metro.lu The full report with tables can be downloaded from the following link:


 

Milan, Italy, July 23, 2007 - BioXell S.p.A. (SWX: BXLN) today announced the start of a large Phase IIb clinical trial of its lead compound Elocalcitol in Overactive Bladder (OAB), a widespread symptom syndrome characterized by urinary urgency, with or without urge incontinence, usually with frequency and nocturia. The objective of this study, which will include a urodynamic evaluation, is to confirm the positive clinical effects found in a previous Phase IIa study. Results are expected in the second half of 2008. In May 2006 BioXell announced the results of the Phase IIa study of Elocalcitol in 114 patients with OAB. These results demonstrated clear efficacy signals on the primary endpoint (mean volume voided per micturition) and on symptoms, including frequency, nocturia and incontinence episodes. Elocalcitol was found to be extremely well tolerated, with an adverse event profile comparable to placebo. "A large body of safety and efficacy data exists for Elocalcitol. A state-of-the-art urodynamic trial setting should allow us to further demonstrate its efficacy and also further characterize its mechanism of action," remarked Enrico Colli, Chief Medical Officer and Head of R&D at BioXell. "Our objective is to confirm Elocalcitol's potential as the treatment of choice for OAB." "OAB is a highly prevalent symptom syndrome for which current treatments are suboptimal. As a consequence, it is necessary to identify drugs with novel mechanisms of actions if improvements are to be made in the management of this syndrome. As the existing anti-muscarinics on the market have already been subjected to urodynamic trials, the results with Elocalcitol can be directly compared with existing data," stated Professor Linda Cardozo of King's College in London, European coordinator of this study. In addition to the new Phase IIb trial in OAB, Elocalcitol is currently in a Phase IIb study for another urological indication, Benign Prostatic Hyperplasia (BPH). Total enrolment in this trial encompasses 541 patients, with results expected by the end of September 2007. Clinical trial design The Phase IIb study will be a urodynamic, multi-center, double-blind, placebo-controlled study in which 234 patients will be randomized in three groups (placebo, 75mcg, 150mcg) and treated daily for 4 weeks. The primary endpoint will be the volume at which the first involuntary contraction occurs, with the objective being to increase this value through administration of Elocalcitol. The secondary outcomes to be evaluated include additional urodynamic parameters, symptom severity and patient perception of bladder condition. The trial will be performed in 26 centers located in Italy, the UK and the Netherlands. Should the trial be positive, a Phase III trial could be initiated in the first half of 2009. Urodynamic studies measure the pressure/volume relationship of the bladder in order to provide objective and precise measurements of both storage and voiding phases. Additional advantages are that both the number of patients needed per arm and the trial duration can be substantially reduced. Performed in accordance with the International Continence Society (ICS) recommendations, this urodynamic trial will include centralized reading of the results. About OAB OAB is a symptom syndrome characterized by urgency, with or without urge incontinence, usually with frequency and nocturia. In 2005, approximately 68 million people were diagnosed with the disease in the 7 principal pharmaceutical markets, with over $1 billion spent on drug treatments. Currently, the main approach to treating the symptoms is with the anti-muscarinic class of agents. However, the side effect profile for these compounds tends to have a negative impact on patient compliance. Elocalcitol's novel mechanism of action may allow it to treat involuntary bladder contractions without causing any of the side effects commonly associated with currently available treatments. About BioXell BioXell (SWX: BXLN) is a biopharmaceutical company focused on the discovery and development of drugs that exploit novel mechanisms of action to treat important urological, inflammatory, and related disorders with significant unmet medical needs. The Company was founded in 2002 as a spin-out from Roche. BioXell's strategic goal is to become a fully integrated pharmaceutical company by maximizing the commercial potential of its product portfolio and leveraging existing platforms into profitable partnerships. BioXell's lead compound, Elocalcitol, derived from its proprietary VD3 (Vitamin D3) technology platform, is in Phase IIb clinical trials for Benign Prostatic Hyperplasia (BPH) and Overactive Bladder (OAB), with a third Phase IIa trial for Male Infertility scheduled for the second half of 2007. In addition, the Company has several follow-on programs based on both VD3 and other technological platforms. These include BXL746, to enter Phase II trials for Post-Surgical Adhesions in 2008, as well as MNAC13, an innovative new approach to the treatment of pain, and the TREM platform, with TREM-1 in development for the treatment of septic shock. In June 2006, BioXell listed its shares on the main segment of the SWX Swiss Exchange. BioXell currently employs 60 people and has sites in Milan, Italy and Nutley, NJ, USA. More information on BioXell can be found at: http://www.bioxell.com For further information, please contact: BioXell S.p.A Rochat & Partners Alvise Sagramoso/Angela Evans Christophe Lamps/Jonathan Leighton Tel: +39 (0)2 210 49 51 Tel: +41 22 718 37 46 Fax: +39 (0)2 210 49 529 Fax: +41 22 786 54 58 alvise.sagramoso@bioxell.com clamps@rochat-pr.ch angela.evans@bioxell.com jleighton@rochat-pr.ch DISCLAIMER This press release does not constitute or form part, or all, of any offer to sell or invitation to subscribe, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of this press release and any attached and/or referred material, if any, or their distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of BioXell, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of BioXell, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. BioXell disclaims any obligation to update these forward-looking statements to reflect future events or developments. --- End of Message --- bioXell S.p.A via Olgettina 58 Milan Italy WKN: A0J3MW; ISIN: IT0004069933 ; Listed: Main Market in SWX Swiss Exchange;


 

Basel, July 22, 2007 - Novartis has completed its fourth share repurchase program initiated on August 9, 2004, and during which 47,575,000 Novartis shares were repurchased for a total of CHF 3 billion. The average purchase price per share was CHF 63.05. A total of 25,400,000 shares repurchased in this program were cancelled following the Annual General Meetings in 2005 and 2006. The remaining 22,175,000 shares from this program will be cancelled following the approval of shareholders at the next Annual General Meeting in February 2008. Shares from this program correspond to 1.74% of the current Novartis share capital. # # # Novartis Media Relations John Gilardi Corinne Hoff Novartis Global Media Relations Novartis Global Media Relations +41 61 324 3018 (direct) +41 61 324 9577 (direct) +41 79 596 1408 (mobile) +41 79 248 5717 (mobile) john.gilardi@novartis.com corinne.hoff@novartis.com e-mail: media.relations@novartis.com Novartis Investor Relations International North America +41 61 324 79 44 Ronen Tamir +1 212 830 2433 Jill Pozarek +1 212 830 2445 Edwin Valeriano +1 212 830 2456 e-mail: investor.relations@novartis.com --- End of Message --- Novartis International AG Posfach Basel WKN: 904278; ISIN: CH0012005267; Index: SLCI, SMI, SPI, SLIFE; Listed: Main Market in SWX Swiss Exchange, ZLS in BX Berne eXchange;


 

* ODAC briefing documents now available online on FDA website Martinsried/Munich (Germany), Princeton, N.J., July 20, 2007 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) today announced that the Company will hold a conference call on July 25, 2007 at 7:00 AM CET/1:00 AM ET to discuss the recommendation of the Oncologic Drugs Advisory Committee (ODAC) relating to satraplatin for the treatment of patients with hormone-refractory prostate cancer whose disease has progressed after prior chemotherapy. The ODAC meeting will be held on Tuesday, July 24, 2007 and its outcome will be published in advance of the conference call. The Company also announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the ODAC meeting. Documents posted on the FDA website include briefs submitted by GPC Biotech and the FDA. The briefing documents can be accessed at http://www.fda.gov/ohrms/dockets/ac/cder07.htm#OncologicDrugs Dial-in information for GPC Biotech conference call on July 25th Participants may listen to the Company's conference call via live webcast, accessible through the GPC Biotech Web site at www.gpc-biotech.com or via telephone. A replay will be available on the Web site following the live event. The call, which will be conducted in English, will be held on July 25, 2007 at 7:00 AM CET/1:00 AM ET, prior to the opening of the German markets. The dial-in numbers for the call are as follows: Participants from Europe: +49 (0)89 9982 99910 or +44 (0)20 7806 1950 Participants from the U.S.: 1-718-354-1385 Please dial in 10 minutes before the beginning of the call. About GPC Biotech GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech's lead product candidate satraplatin is currently under review by the U.S. FDA for hormone-refractory prostate cancer patients whose prior chemotherapy has failed. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany), and has a wholly owned U.S. subsidiary headquartered in Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at www.gpc-biotech.com. This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech AG, including statements about the status of the FDA review process. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2006 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Satraplatin has not yet been approved by the FDA in the U.S., the EMEA in Europe or any other regulatory authority and no conclusions can or should be drawn regarding its safety or effectiveness. Only the relevant regulatory authorities can determine whether satraplatin is safe and effective for the use(s) being investigated. The ODAC will report to the FDA and make recommendations and we expect the report of the ODAC to the FDA on satraplatin to be an important element in the FDA's review of our NDA. However, views of the ODAC may differ from those of the FDA and there can be no guarantee that the FDA will follow the ODAC's recommendations. For further information, please contact: GPC Biotech AG Martin Braendle Director, Investor Relations & Corporate Communications Phone: +49 (0)89 8565-2693 ir@gpc-biotech.com In the U.S.: Laurie Doyle Director, Investor Relations & Corporate Communications Phone: +1 609 524 5884 usinvestors@gpc-biotech.com Additional Media Contacts: In Europe: Maitland Brian Hudspith Phone: +44 (0)20 7379 5151 bhudspith@maitland.co.uk In the U.S.: Russo Partners, LLC David Schull Phone: +1 212 845 4271 david.schull@russopartnersllc.com --- End of Message --- GPC Biotech AG Fraunhoferstr. 20 Martinsried WKN: 585150; ISIN: DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX, HDAX, TECH All Share; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Geregelter Markt in Frankfurter Wertpapierbörse;


 

Cargotec Corporation, Press Release, July 20, 2007 at 10:30 a.m. Finnish time Hiab, the business area providing load handling solutions within Cargotec, together with SAWO, Hiab's importer in Denmark, have secured a significant order for 133 hooklifts and 22 loader cranes from MAN. The hooklifts and the loader cranes will be installed by SAWO onto MAN trucks and supplied to the Danish Army. The high mobility trucks are designed for use by the military in extreme operating conditions and when equipped with MULTILIFT hooklifts the trucks are capable of loading, transporting and unloading both ISO containers and military flatracks. The HIAB loader cranes are swoppable and trucks can be equipped with them within one hour. The delivery of the hooklifts and the loader cranes will start in 2007, and continue into 2008. The order value will be booked evenly over the duration of the contract. The unit price of hooklifts for military use is EUR 30,000-60,000 depending on the delivery content. The unit price for a military loader crane in this size category is EUR 20,000-30,000 depending on the delivery content. Sender: Cargotec Corporation Kari Heinistö Senior Executive Vice President and CFO Eeva Mäkelä SVP, Investor Relations and Communications For further information, please contact: Pekka Vartiainen, President, Hiab, tel. +358 204 55 4264 Eeva Mäkelä, SVP, Investor Relations and Communications, tel. +358 204 55 4281 Cargotec is the world's leading provider of cargo handling solutions whose products are used in the different stages of material flow in ships, ports, terminals, distribution centers and local transportation. Cargotec Corporation's brands, Hiab, Kalmar and MacGREGOR, are market leaders in their fields and well-known among customers all over the world. Cargotec's sales are EUR 2.8 billion. The company employs over 10,000 people and operates in close to 160 countries. Cargotec's class B shares are quoted on the Helsinki Stock Exchange. www.cargotec.com


 

Koninklijke DSM N.V. maakt bekend dat zij in het kader van de op 27 april 2007 aangekondigde tweede fase van het aandelen inkoopprogramma, 521.335 eigen aandelen heeft ingekocht in de periode 12 juli 2007 tot en met 18 juli 2007 tegen een gemiddelde prijs van EUR 37,60. Het bedrag dat gemoeid is met de inkoop bedroeg EUR 19,6 miljoen. Het totaal aantal ingekochte aandelen onder de tweede fase van dit programma is tot dusver 8.124.654 aandelen voor een totaalbedrag van EUR 297,0 miljoen. DSM DSM is wereldwijd actief op het gebied van producten voor de voedingsindustrie en de farmaceutische industrie, hoogwaardige materialen en industriële chemicaliën. De onderneming ontwikkelt, produceert en verkoopt innovatieve producten en diensten die bijdragen aan de kwaliteit van het leven. DSM-producten worden gebruikt in een breed scala van eindmarkten en toepassingen, zoals voedings- en gezondheidsproducten voor mens en dier, cosmetica, geneesmiddelen, auto's en andere transportmiddelen, coatings en verf, producten voor de bouw en elektrotechnische en elektronica-producten. DSM's strategie, genaamd Vision 2010 - Building on Strengths, is gericht op versnelde winstgevende en innovatieve groei van de specialty-activiteiten van de onderneming. De pijlers van deze strategie zijn marktgedreven groei en innovatie en uitbreiding in opkomende economieën. DSM heeft een jaaromzet van ruim ¤8 miljard en biedt werk aan zo'n 22.000 mensen wereldwijd. DSM behoort met veel van zijn activiteiten tot de wereldtop. De onderneming heeft vestigingen in Europa, Azië, Afrika, Australië en Noord- en Zuid-Amerika. Het hoofdkantoor is gevestigd in Nederland. Meer informatie over DSM is te vinden op www.dsm.com Voor meer informatie: DSM Corporate Communications DSM Investor Relations Elvira Luykx Dries Ausems tel. +31 (0) 45 tel. +31 (0) 45 5782864 5782035 fax +31 (0) 45 5782595 fax +31 (0) 45 e-mail 5740680 investor.relations@dsm.com e-mail media.relations@dsm.com


 

CHELMSFORD, Mass., July 20, 2007 (PRIME NEWSWIRE) -- Airvana, Inc. (Nasdaq:AIRV) today announced the pricing of its initial public offering of 8,300,000 shares of common stock at a price to the public of $7.00 per share. All of the 8,300,000 shares being sold in the offering are being sold by Airvana. In addition, Airvana has granted the underwriters a 30-day option to purchase up to an additional 1,245,000 shares to cover over-allotments, if any. Airvana's common stock is expected to begin trading on the NASDAQ Global Market on Friday, July 20, 2007 under the symbol "AIRV." Morgan Stanley & Co. Incorporated acted as the sole book-running lead manager for the offering. Lehman Brothers Inc. acted as joint-lead manager, and Deutsche Bank Securities Inc. and UBS Investment Bank acted as co-managers for the offering. The offering is made only by means of a prospectus, copies of which may be obtained by contacting Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, New York 10014; Attention: Prospectus Department or by email at prospectus@morganstanley.com. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. ABOUT AIRVANA Airvana is a leading provider of network infrastructure products used by wireless operators to provide mobile broadband services. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and projections, management's beliefs, and certain assumptions made by us, all of which are subject to change. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," similar expressions, and variations or negatives of these words. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. CONTACT: Airvana, Inc. Laura Often (508) 887-3796 loften@airvana.com


 

Attached follows analyst presentation for second-quarter 2007. Hafslund ASA Oslo, 20 July 2007


 

Norgani has agreed with Akershaven AS to acquire the property Clarion Collection Hotel Bastion, Oslo, in Norway for NOK 128 million. The property consists of 99 rooms, conference and restaurant facilities and is leased to Choice Scandinavia to 2015. This is Norgani's third hotel in Oslo. The price per Room is NOK 1, 3 million. "This property is well located in Oslo, in good condition and operated by a good operator. The favorable location will improve further during the coming years with the opening of the Opera and the coming development of the neighborhood. The property will strengthen our position in the Oslo hotel market, which we believe is a hotel market with strong growth. We also believe that this part of Oslo will outperform the rest of the Oslo market." says CEO Eva Eriksson. For further information: please contact CEO Eva Eriksson, mobile phone +46 706443497 CFO Mats Sterner, mobile phone +46 706902009 With a portfolio of more than 70 hotels in the Nordic region, Norgani is Europe's fifth largest hotel property investor. Through size and specialization Norgani has knowledge of and insight in the hotel industry, creating a unique platform for development of hotel properties and business in cooperation with operators and brands. The share is listed on the Oslo Stock Exchange. Homepage www.norgani.no


 

Press Release - 20th July 2007 LONDON, United Kingdom: Crew Gold Corporation ("Crew" or "the Company") (TSX: CRU) (OSE: CRU) (Frankfurt: KNC) (OTC-BB-Other; CRUGF.PK) today announced:- Notification of Trade On July 19, 2007, Jan A Vestrum, President and Chief Executive Officer of Crew bought 4.7 million shares in Crew at NOK 15.50 fulfilling a previously announced forward contract, sold 5.0 million shares in Crew at NOK 11.68 and bought 2.0 million shares in Crew at NOK 11.87 by way of a new forward contract with maturity October 18th 2007 and bought 3.0 million shares in Crew Gold at NOK 11.84 by the way of a new forward contract with maturity October 9th, 2007. Mr Vestrum`s total exposure is 11,599,042 Crew shares, including common shares, convertible bonds, forward contracts and options. Jan A Vestrum President & CEO Safe Harbour Statement This news release contains forward-looking statements which reflect the expectations of management and the board of directors, and are made pursuant to applicable and relevant national legislation (including the Safe-Harbour provisions of the United States Private Securities Litigation Reform Act of 1995) in countries where Crew Gold Corporation is conducting business and/or investor relations. Forward looking statements typically contain words such as "believes", "anticipates", "continue", "could", "expects", "indicates", "plans", "will", "may", "projects", "would" or similar expressions suggesting future outcomes or events, although not all forward-looking statements contain these identifying words. Such forward-looking statements reflect the current beliefs of management and the board of directors based on information currently available to them. Forward-looking statements involve inherent risks and uncertainties, and Crew cautions readers not to place undue reliance on these statements as a number of important factors could cause Crew's actual results to differ materially from the beliefs and expectations expressed in such forward-looking statements. Factors that could cause actual results to differ materially from the results discussed in the forward-looking statements, include, but are not limited to, the factors discussed under the heading "Risks and Uncertainties" in Crew's Annual Information Form dated October 10, 2006, as filed on SEDAR at www.sedar.com. Although the forward-looking statements contained in this news release are based upon what management and the board of directors believes to be current and reasonable assumptions, Crew cannot assure readers that actual results will be consistent with these forward-looking statements. The forward-looking statements contained herein are made as of the date of this news release and are expressly qualified in their entirety by this cautionary statement. Crew undertakes no obligation to publicly update or revise these forward-looking statements to reflect subsequent events or circumstances. Cautionary Note to US Investors - The United States Securities and Exchange Commission permits US mining companies, in their filings with the SEC, to disclose only those mineral deposits that a company can economically and legally extract or produce. We use certain terms on this website (or press release), such as "measured", "indicated", and "inferred" "resources", which the SEC guidelines strictly prohibit US registered companies from including in their filings with the SEC. US Investors are urged to consider closely the disclosure from the SEC's website at http://www.sec.gov/edgar.shtml. --- End of Message --- Crew Gold Corporation Abbey House, Wellington Way, Weybridge Surrey United Kingdom WKN: 226534105 ; ISIN: CA2265301036; ;


 

20 July 2007 - Mark van Kemenade, together with Marijke Wellens and Jan van Rijt founder of Qurius in 1999, has decided to leave Qurius. He resigns from the Executive Board and will leave the company by the 1st of September 2007. ''Winning the global Microsoft Dynamics Partner of the Year is fantastic milestone and a crown on our work'', says van Kemenade, ''I look back on eight hectic years with pride and pleasure. The company is well-funded, and has a clear strategy so I am confident that Qurius will have a bright future''. ''We regret but respect Mark's choice, says Fred Hermans, CEO of Qurius, '' Mark and his co-founders have meant a lot to the company, we will miss their drive and competence''. Qurius N.V. Qurius provides architecture, realization and systems management of Microsoft technology based business and IT solutions, including infrastructures. Qurius has over 900 staff members; its headquarters are located in Zaltbommel, the Netherlands. Its offices in Belgium, Denmark, Germany, Italy, the Netherlands, Norway, Spain, Sweden and the United Kingdom serve over 2,300 clients. Qurius has been publicly listed on Euronext Amsterdam since 1998. Qurius was recognised by Micorosoft® as the 2007 global Microsoft Dynamics(TM) Partner of the Year. Contact Qurius, Fred Hermans: telefoon 0418 683 500 of Fred.Hermans@Qurius.com.


 

[Ericsson discloses the information provided herein pursuant to the Swedish Securities Exchange and Clearing Operations Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 07.30 CET, on July 20, 2007.] * Net sales SEK 47.6 (44.0) b. in the quarter, up 8%, SEK 89.8 (83.2) b. first six months 1) * Operating income SEK 9.3 (8.3) b. in the quarter, up 12%, SEK 17.4 (14.9) b. first six months * Operating margin 19.4% (18.4%) in the quarter, 19.4% (17.6%) first six months * Cash flow from operations SEK 4.2 (0.2) b. in the quarter, SEK 8.8 (2.6) b. first six months * Net income SEK 6.4 (5.7) b. in the quarter, up 12%, SEK 12.2 (10.3) b. first six months 2) * Earnings per share SEK 0.40 (0.36) in the quarter, up 11%, SEK 0.77 (0.65) first six months 2) CEO COMMENTS "We continue to outpace the market," said Carl-Henric Svanberg, President and CEO of Ericsson (NASDAQ:ERIC). "Sales showed an encouraging year-over-year increase this quarter, primarily driven by Asia Pacific. Europe, Middle East and Africa were softer while we see improving trends in the Americas. Margins were stable with improved cash generation. The total number of mobile subscriptions has now reached three billion, a milestone for our industry. GSM shipments reach new record levels every quarter and we continue to see growing demand for mobile and fixed broadband. We see dramatic data traffic increases in the HSPA networks that we monitor. We have strengthened our position through the recent acquisitions, and the announced IP broadband agreement with AT&T was a breakthrough in the North American market, confirming our strong offering in next-generation networks. Our services business continues to expand faster than the market and several managed services contracts will start to be revenue generating in coming quarters. We are in a start-up phase in multimedia, where sales and margins will vary. Tandberg Television is now part of our group and will add significant strength. On the handset side, Sony Ericsson had another quarter of strong performance and market share increase. In the ongoing industry consolidation we are expanding our footprint in mobile as well as fixed communications. Our scale advantage from over 40% market share in GSM and WCDMA is obvious and enables technology leading and affordable solutions to an expanding and increasingly demanding market," concluded Carl-Henric Svanberg. FINANCIAL HIGHLIGHTS Income statement and cash flow Second quarter First quarter Six months SEK b. 2007 2006 1) Change 2007 Change 2007 2006 1) Change Net sales, excl. divested operations 47.6 44.0 8% 42.2 13% 89.8 83.2 8% Net sales 47.6 44.8 6% 42.2 13% 89.8 84.3 6% Gross margin 43.0% 42.6% - 43.0% - 43.0% 43.0% - EBITDA margin 23.9% 22,3% - 23.8% - 23.8% 22.0% - Operating income 9.3 8.3 12% 8.2 14% 17.4 14.9 17% Operating margin 19.4% 18.4% - 19.3% - 19.4% 17.6% - Operating margin ex Sony Ericsson 16.4% 16.3% - 15.5% - 16.0% 15.7% - Income after financial items 9.3 8.3 12% 8.3 12% 17.5 15.0 17% Net income 2) 6.4 5.7 12% 5.8 10% 12.2 10.3 18% Cash flow from operations 4.2 0.2 - 4.6 - 8.8 2.6 - EPS, SEK 2) 0.40 0.36 11% 0.37 8% 0.77 0.65 18% 1)Excludes sales from the in 2006 divested defense business, Ericsson Microwave systems. 2)Attributable to stockholders of the parent company, excluding minority interest. The second quarter year-over-year sales increase of 8% was driven by organic growth and acquired sales. Organic growth amounted to 6%. The USD has continued to weaken and affected sales growth negatively. Gross margin was stable sequentially and up 0.4%-points year-over-year. The operating margin increased sequentially, excluding Sony Ericsson, as a result of increased sales and continued focus on operational excellence, including a completed streamlining of the former Marconi operations. Sony Ericsson's pre-tax profit was down sequentially but was flat when adjusted for increased royalty fees to the parent companies. Cash flow from operating activities reached SEK 4.2 (0.2) b., a year-over-year improvement. Balance sheet and other performance indicators Six months Three months Full year SEK b. 2007 2007 2006 Net cash 16.1 29.1 40.7 Interest-bearing provisions and liabilities 32.6 22.6 21.6 Trade receivables 55.3 52.4 51.1 Days sales outstanding 106 107 85 Inventory 24.6 24.1 21.5 Of which work in progress 14.1 14.9 14.2 Inventory turnover 4.4 4.2 5.2 Customer financing, net 3.7 3.8 3.7 Return on capital employed 24.2% 23.8% 27.4% Equity ratio 54.4% 56.6% 56.2% Deferred tax assets decreased in the quarter by SEK 1.4 b. to SEK 12.7 (14.1) b. Working capital increased by SEK 7.8 b. in the quarter. This increase reflects the continued growth of turnkey projects in emerging markets. During the quarter, approximately SEK 1.3 b. of provisions was utilized to cover costs incurred of which the majority was related to previously announced restructuring programs and ongoing product related commitments. New net provisions of SEK 0.1 b. have been made in the quarter. SEGMENT RESULTS Second quarter First quarter Six months 2007 2006 2007 2007 2006 SEK b. 1) 2) Change 1) Change 1) 2) Change Networks sales 33.7 31.4 7% 29.3 15% 63.0 59.5 6% Of which Network rollout 4.3 3.4 26% 3.8 15% 8.1 7.4 10% Operating margin 19% 19% - 17% - 18% 18% - Professional Services sales 10.3 9.2 11% 9.5 8% 19.8 17.5 13% Of which Managed services 2.9 2.4 21% 2.6 12% 5.5 4.7 16% Operating margin 15% 16% - 15% - 15% 15% - Multimedia sales 3.6 3.4 6% 3.4 8% 7.0 6.2 12% Operating margin 0% 1% - 8% - 4% 2% - Total sales 47.6 44.0 8% 42.2 13% 89.8 83.2 8% Of which Mobile systems 32.7 30.9 6% 28.4 15% 61.1 57.6 6% 1)Acquired companies are included from date of acquisition. 2)Excludes sales from the in 2006 divested defense business, Ericsson Microwave Systems. Networks The 7% year-over-year sales increase in Networks was driven by a 6% growth in mobile systems. Operating margin increased sequentially due to higher volumes and tight cost control. Fixed networks showed even higher growth, also excluding the acquisition of Redback. The supply chain restructuring of optical transmission is done, which completes the integration of former Marconi products. The demand for GSM continues with new delivery records and during the quarter Ericsson delivered its millionth GSM base station. Growth is primarily driven by new network deployments and capacity expansions in high-growth markets. Basically all WCDMA network rollouts are HSPA-enabled. Upgrades are ongoing in previously deployed WCDMA networks, laying the foundation for the accelerated migration to mobile broadband. The combination of Redback and Ericsson's global sales organization is generating considerable business opportunities and several new contracts have been announced. We have completed the first critical integration phase, including leveraging Ericsson's supply chain capabilities, and we are now entering the next phase, which includes the alignment of sales channels. Professional Services Sales in Professional Services grew by 11% year-over-year and continue to outpace the market. Growth in local currencies amounted to 14%. Growth was slower in network design and systems integration. The high activity level in previous quarters has now translated into increased network rollout activities, reported in Networks. Operating margin was stable. Managed services grew by 21%, or 24% in local currencies, and recent key wins confirm our strong lead. A new agreement with Oi in Brazil, as well as earlier announced agreements with Orange in the Netherlands and Belgium, Vodafone and KPN in the Netherlands, and the European-wide spare part contract with Vodafone, will start to contribute to sales in the third quarter. Ericsson is managing networks that together serve more than 135 million subscribers worldwide. Multimedia Growth was 6% year-over-year. We continue to build a strong position in this growing business segment. As previously indicated, Multimedia sales will vary between quarters. Sales, excluding Tandberg Television, were down sequentially, affected by timing of completion of several larger revenue management projects. Operating margin was negatively affected as a result. During the quarter, Mobeon and Drutt were acquired and a public offer was made for LHS, a world leader in post-paid billing systems. Tandberg Television is consolidated from May 2007. During the quarter, Tandberg secured new contracts from broadcasters and operators who are launching IPTV, HDTV and on-demand interactive video services. Sony Ericsson Mobile Communications For information on transactions with Sony Ericsson Mobile Communications, please see Financial statements and Additional information. Second quarter First quarter Six months EUR m. 2007 2006 Change 2007 Change 2007 2006 Change Number of units shipped (m.) 24.9 15.7 59% 21.8 15% 46.7 29.0 61% Average selling price (EUR) 125 145 -14% 134 -7% 129 147 -12% Net sales 3,112 2,272 37% 2,925 6% 6,037 4,264 42% Gross margin 29.5% 28.5% - 30.3% - 29.9% 27.4% - Operating margin 10.1% 8.9% - 11.8% - 11.0% 8.1% - Income before taxes 327 211 55% 362 -10% 689 362 90% Net income 220 143 54% 254 -13% 474 252 88% Sony Ericsson continued to show profitable growth and market share gains. The company continued to strengthen its product line by announcing a large number of new products across a variety of price points, including the K850, a HSPA, 5 mega-pixel, flag-ship, Cyber-shot phone, and the W960, a high-end Walkman phone with 8 GB of on-board storage. Sony Ericsson is building premium positions also in the low- and mid-tier segments. The volumes increased faster in these segments, resulting in a decline in average selling price. The underlying gross margin, when adjusted for increased parent company royalties, was stable. Ericsson's share in Sony Ericsson's income before tax was SEK 1.5 (1.0) b. in the quarter. REGIONAL OVERVIEW Second quarter First quarter Six months Sales, SEK b. 2007 2006 1) Change 2007 Change 2007 2006 1) Change Western Europe 12.4 12.4 0% 12.5 -1% 24.9 23.7 5% Central & Eastern Europe, Middle East & Africa 11.5 11.5 0% 11.0 4% 22.5 20.8 8% Asia Pacific 16.6 12.6 32% 12.3 36% 28.9 22.3 30% Latin America 4.1 3.8 7% 3.3 23% 7.4 7.5 -1% North America 3.0 3.7 -18% 3.1 -3% 6.1 8.9 -31% 1) Excludes sales from the in 2006 divested defense business, Ericsson Microwave Systems. The market in Western Europe was soft. This development is primarily a result of ongoing operator consolidation in Italy and shared networks discussions in UK, putting investment decisions on temporary hold. A 3G/HSPA contract was signed with Vodafone Spain. Other significant contracts were announced with Telefónica Deutschland and Wind in Italy. New managed services contracts were announced with Vodafone and KPN in the Netherlands. In Central and Eastern Europe, Middle East and Africa, the high business activity continues, but the large new network rollouts and expansion projects create sales fluctuations between quarters. A number of new contracts have been awarded in the quarter, especially in the Middle East, and major rollouts continue in sub-Sahara. GSM sales to Russia are lower while 3G preparations are ongoing. Asia Pacific's sales development was very strong and primarily driven by continued expansions in China, India, Bangladesh, Japan and South East Asia. A USD 1 billion GSM expansion agreement with China Mobile was signed. New GSM business with Orascom in Bangladesh was awarded. A USD 2 billion contract, Ericsson's largest to date, has been signed with Bharti Airtel for GSM/EDGE network infrastructure. Latin America is recovering as expected. Sales during the quarter were mainly driven by GSM rollouts and expansions in most markets, however, Brazil and Mexico are still slow. 3G rollouts are accelerating throughout the region. In North America, the sales gap versus last year is closing. HSPA is now available in more than 165 AT&T markets, the demand is strong and rollout continues. During the quarter, an agreement was reached with AT&T for their "U-verse" IP broadband rollout. This was a breakthrough for Ericsson in next-generation networks and a vote of confidence in our expanded product portfolio and capabilities. MARKET DEVELOPMENT Growth rates based on Ericsson and market estimates. Fixed and mobile traffic accelerates due to increased coverage, usage and new multimedia services. Operator investments in infrastructure equipment over the long-term should continue to grow along historical trends of mid- to high-single digits. Infrastructure investments vary over time and between regions depending on regulatory developments, license awards and new technology deployments. Mobile subscriptions grew with some 140 million in the quarter to 3 billion, ahead of previous estimates. 2.6 billion are GSM/WCDMA subscriptions. 135 million are WCDMA subscriptions, growing by 17 million in the quarter. There are 164 WCDMA networks in 73 countries, of which 117 are upgraded to HSPA services. Data traffic in mobile networks accelerates and HSPA has generated a dramatic step up in data traffic. In networks we monitor data traffic has doubled the last six months. In the twelve-month period ending March 31, 2007, fixed broadband connections grew by 17 million per quarter, to a total of approximately 300 million. Growth both within the mobile systems market and the fixed infrastructure market in the twelve-month period ending March 31, 2007 is estimated to have been mid-single digit. IP broadband and optical transmission related products showed the strongest development. The telecom services market in the twelve-month period ending March 31, 2007, is estimated to have shown good growth with managed services being the fastest growing area. Within the emerging multimedia market, growth has accelerated but with large variations between different market segments. MARKET OUTLOOK FOR MOBILE INFRASTRUCTURE AND SERVICES All estimates are measured in USD and refer to market growth compared to previous year. For 2007 we continue to believe that the GSM/WCDMA track within the global mobile systems market, measured in USD, will continue to show mid-single digit growth. We also continue to believe that the addressable market for professional services is expected to show good growth in 2007. With our technology leadership and global presence we are well positioned to take advantage of these market opportunities. PARENT COMPANY INFORMATION In accordance with new Swedish reporting requirements for listed companies, effective July 1, 2007, additional information for the parent company is to be included in the six- and twelve-month period reports. Net sales for the six-month period amounted to SEK 1.7 (1.3) b. and income after financial items was SEK 8.3 (6.6) b. Patent license fees have been included in net sales from 2007, instead of in other operating revenues, and 2006 has been restated accordingly. Major changes in the Parent Company's financial position for the six-month period include: increased investments in subsidiaries of SEK 27.6 b., mostly attributable to the Tandberg, Redback and Entrisphere acquisitions and the future acquisition of LHS; decreased other current receivables of SEK 3.2 b.; decreased cash and bank and short-term investments of SEK 17.4 b., mainly related to the acquisitions mentioned, payment of dividend for 2006 of SEK 7.9 b. to shareholders and cash from new non-current borrowings; increased notes and bond loans by SEK 11.1 b. through a new bond issue program; current and non-current liabilities to subsidiaries decreased by SEK 7.6 b. As per June 30, 2007, cash and bank and short-term investments amounted to SEK 36.6 (54.0) b. Major transactions and balances with related parties include the following with Sony Ericsson Mobile Communications: revenues of SEK 1,214 (448) m.; liabilities of SEK 933 (1) m.; dividend of SEK 2,561 (1,160) m. In accordance with the conditions of the Stock Purchase Plans and Option Plans for Ericsson employees, 4,059,795 shares from treasury stock were sold or distributed to employees during the second quarter. The holding of treasury stock at June 30, 2007 was 242,579,010 Class B shares. OTHER INFORMATION Extraordinary General Meeting At the Extraordinary General Meeting (EGM) on June 28, the EGM resolved to implement a long-term variable compensation program 2007 (LTV 2007). The LTV 2007 is based on the same principles as the long-term incentive plan 2006 and covers all employees through three different programs. Acquisitions and public offerings On June 5, Ericsson announced a voluntary public cash offer to acquire LHS AG for approximately EUR 310 m. The company employs around 550 people and has its headquarters in Frankfurt. Sales amounted to EUR 71.6 m. in 2006 with strong sales momentum. On June 27, the acquisition of Drutt Corporation was closed. Drutt is a leading provider of service delivery platform solutions with operations in Sweden, China, Canada and Mexico and employs around 85 people. Credit rating On May 14, Moody's Investors Service upgraded Ericsson's long-term debt ratings to Baa1 from Baa2 and affirmed the Company's Prime 2 short-term debt ratings. According to Moody's, the upgrade was based on Ericsson's growing track record of robust profitability and very conservative financial structure. On June 15, Standard & Poor's upgraded Ericsson's credit rating two notches to BBB+/A-2 from BBB-/A-3. The upgrade is predicated on Standard & Poor's expectations that Ericsson will continue to benefit significantly from the expansion of the global mobile systems market, thanks to its leading market positions in key second and third generation mobile network systems technologies and its low cost breakeven point. Standard & Poor's said that the rating reflects Ericsson's remarkably strong capital structure and liquidity position. Funding program In the quarter, Ericsson completed a multi-currency bond issue program of SEK 11.1 b. The proceeds of the offering are mainly intended for the re-financing of existing loans. On July 16, Ericsson signed a new seven-year USD 2 b. committed back-up facility with its core group of banks, which replaces the existing USD 1 b. five-year back-up facility. New information sections In accordance with new Swedish reporting requirements for listed companies, effective July 1, 2007, two additional sections have been added to the report for the six-month period; Assessment of risk environment and Board assurance. The full Board is also required to sign the six-month interim report. The same requirements apply to the report for the twelve-month period. Assessment of risk environment We have reviewed Ericsson's operational and financial risk factors and exposures as described under "Risk factors" in our 2006 Annual Report and have determined that the risk environment has not materially changed. However, the increased activities related to the new Multimedia segment may result in a more volatile quarterly sales pattern. Specific additional risks for the near term are associated with the acquisitions made during 2007, as a timely and effective integration of these is essential to make them accretive as planned. Risk factors and exposures in focus for the Parent Company and the Ericsson Group for the forthcoming six-month period include: changes in foreign exchange rates, in particular a continued weakness or further deterioration of the USD/SEK rate; increases in interest rates and the potential effect on our customers' willingness to invest in network development; effects of the ongoing industry consolidation among our customers as well as between our largest competitors; an increased volume of turn-key projects, which may result in working capital build-up which in turn puts pressure on our cash conversion rate. Ericsson conducts business in certain countries subject to trade restrictions or which are focused on by certain investors. We stringently follow all relevant regulations and trade embargos applicable to us in our dealings with customers operating in such countries. Moreover, Ericsson operates globally in accordance with Group level policies and directives for ethics and conduct. In no way should our business activities in these countries be construed as supporting a particular political agenda or regime. We have activities in such countries mainly due to certain customers with multi-country operations puts demands on us to support them in all of their markets. Please further refer to Ericsson's Annual report 2006 to learn more about our risks and uncertainties along with our strategies and tactics to mitigate the risk exposures or limit unfavorable outcomes which remains valid also for 2007. BOARD ASSURANCE The Board of Directors and the CEO certify that the half-yearly financial report gives a fair review of the performance of the business, position and profit or loss of the Company and the Group, and describes the principal risks and uncertainties that the Company and the companies in the Group face. Stockholm, July 20, 2007 Telefonaktiebolaget LM Ericsson (publ) Org. Nr. 556016-0680 Sverker Martin-Löf Michael Treschow Marcus Wallenberg Deputy chairman Chairman Deputy chairman Nancy McKinstry Sir Peter L. Bonfield Anders Nyrén Member of the board Member of the board Member of the board Börje Ekholm Ulf J. Johansson Katherine Hudson Member of the board Member of the board Member of the board Torbjörn Nyman Monica Bergström Jan Hedlund Member of the board Member of the board Member of the board Carl-Henric Svanberg Member of the board and President and CEO REVIEW REPORT We have reviewed this report for the period January 1 to June 30, 2007, for Telefonaktiebolaget LM Ericsson (publ). The board of directors and the CEO are responsible for the preparation and presentation of this interim financial information in accordance with IAS 34 and the Annual Accounts Act. Our responsibility is to express a conclusion on this interim financial information based on our review. We conducted our review in accordance with the Standard on Review Engagements SÖG 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by FAR. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing in Sweden, RS, and other generally accepted auditing practices. The procedures performed in a review do not enable us to obtain a level of assurance that would make us aware of all significant matters that might be identified in an audit. Therefore, the conclusion expressed based on a review does not give the same level of assurance as a conclusion expressed based on an audit. Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial information is not, in all material respects, in accordance with IAS 34 and the Annual Accounts Act. Stockholm, July 20, 2007 PricewaterhouseCoopers AB Bo Hjalmarsson Peter Clemedtson Authorized Public Accountant Authorized Public Accountant Lead partner Date for next report: October 25, 2007 EDITOR'S NOTE To read the complete report with tables, please go to: www.ericsson.com/investors/financial_reports/2007/6month07-en.pdf Ericsson invites media, investors and analysts to a press conference at the Ericsson headquarters, Torshamnsgatan 23, Stockholm, at 09.00 (CET), July 20. An analyst and media conference call will begin at 14.00 (CET). Live audio webcasts of the press conference and conference call as well as supporting slides will be available at www.ericsson.com/press and www.ericsson.com/investors FOR FURTHER INFORMATION, PLEASE CONTACT Henry Sténson, Senior Vice President, Communications Phone: +46 8 719 4044 E-mail: investor.relations@ericsson.com or press.relations@ericsson.com Investors Gary Pinkham, Vice President, Investor Relations Phone: +46 8 719 0000 E-mail: investor.relations@ericsson.com Susanne Andersson, Investor Relations Phone: +46 8 719 4631 E-mail: investor.relations@ericsson.com Glenn Sapadin, Investor Relations, North America Phone: +1 212 843 8435 E-mail: investor.relations@ericsson.com Media Åse Lindskog, Vice President, Head of Media Relations Phone: +46 8 719 9725, +46 730 244 872 E-mail: press.relations@ericsson.com Ola Rembe, Vice President Phone: +46 8 719 9727, +46 730 244 873 E-mail:press.relations@ericsson.com Telefonaktiebolaget LM Ericsson (publ) Org. number: 556016-0680 Torshamnsgatan 23 SE-164 83 Stockholm Phone: +46 8 719 00 00 www.ericsson.com Safe Harbor Statement of Ericsson under the Private Securities Litigation Reform Act of 1995; All statements made or incorporated by reference in this release, other than statements or characterizations of historical facts, are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by us. Forward-looking statements can often be identified by words such as "anticipates", "expects", "intends", "plans", "predicts", "believes", "seeks", "estimates", "may", "will", "should", "would", "potential", "continue", and variations or negatives of these words, and include, among others, statements regarding: (i) strategies, outlook and growth prospects; (ii) positioning to deliver future plans and to realize potential for future growth; (iii) liquidity and capital resources and expenditure, and our credit ratings; (iv) growth in demand for our products and services; (v) our joint venture activities; (vi) economic outlook and industry trends; (vii) developments of our markets; (viii) the impact of regulatory initiatives; (ix) research and development expenditures; (x) the strength of our competitors; (xi) future cost savings; (xii) plans to launch new products and services; (xiii) assessments of risks; (xiv) integration of acquired businesses; (xv) compliance with rules and regulations and (xvi) infringements of intellectual property rights of others. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements speak only as of the date hereof and are based upon the information available to us at this time. Such information is subject to change, and we will not necessarily inform you of such changes. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Important factors that may cause such a difference for Ericsson include, but are not limited to: (i) material adverse changes in the markets in which we operate or in global economic conditions; (ii) increased product and price competition; (iii) further reductions in capital expenditure by network operators; (iv) the cost of technological innovation and increased expenditure to improve quality of service; (v) significant changes in market share for our principal products and services; (vi) foreign exchange rate or interest rate fluctuations; and (vii) the successful implementation of our business and operational initiatives. The full report including tables can also be downloaded from the attached link.


 

TietoEnator Corporation Press Release 20 July 2007 at 08.00 am EET This is a press release without tables. You can download the complete version using this link (pdf): http://hugin.info/3114/R/1140616/215564.pdf Despite very good growth in net sales, TietoEnator's profitability declined in the second quarter of 2007. Net sales increased by 5% to EUR 434 million. Operating profit totalled EUR 9.9 (26.3) million. TietoEnator recorded capital losses of EUR 4.9 million in the second quarter compared to capital gains of EUR 3.5 million in 2006. The other main reasons of the profitability decline were higher personnel and subcontracting costs, loss-making delivery projects and high product development costs. TietoEnator's net sales grew 5% to EUR 434.2 (411.8) million. Organic growth of 8% was higher than total growth as divestments reduced net sales more than acquisitions added. The market for IT services and solutions is active. In most areas prices are either stable or slightly higher than the year before. For TietoEnator prices remained unchanged on average. The second-quarter operating profit totalled EUR 9.9 (26.3) million. TietoEnator recorded EUR 4.9 million of capital losses mainly from the divestment of parts of the German Banking & Insurance business. In the second quarter of 2006 TietoEnator recorded capital gains from divestments amounting to EUR 3.5 million. Excluding capital gains and losses operating margin was 3.4% (5.5). Restructuring expenses were lower than expected at EUR 3.3 (4.2) million. Underlying operating profit (excluding capital gains and losses and restructuring expenses) declined to EUR 18.1 million from EUR 26.9 million the year before. Higher personnel expenses and subcontracting costs together with unchanged average prices had negative impact on profitability. Banking & Insurance business area recorded operating loss for the quarter due to poor profitability in Germany, challenging delivery projects in the core banking area and higher product development costs. The weak performance of the healthcare business in Sweden, Norway and Germany continued. Lower operating profit was reflected in profit before taxes, which totalled EUR 8.9 (25.3) million and earnings per share amounting to EUR 0.07 (0.23). TietoEnator's Deputy CEO Åke Plyhm comments on the second quarter performance: "We cannot be satisfied with our latest quarterly results. There are several things that are pressuring our profitability at the moment, the weakness of Banking & Insurance's solutions business being new for this quarter. The profitability issues will be tackled and solved one by one. Growth continued to be strong and we will have to work on using that to turn profitability to positive direction in the future." TietoEnator expects its full-year organic growth in 2007 to be higher than the 2006 level of 2%. TietoEnator considers reaching the earlier communicated underlying operating profit guidance of over EUR 124 million difficult for 2007. TietoEnator's Q2 2007 report can be found as an attachment. For further information, please contact; Åke Plyhm, vice koncernchef, TietoEnator, tel. +46 705 65 8631, ake.plyhm@tietoenator.com Timo Salmela, CFO, TietoEnator, tel. +358 9 8626 2213, +358 400 434 974, timo.salmela@tietoenator.com Päivi Lindqvist, EVP, Communications and Investor Relations, TietoEnator, tel. +358 9 8626 3276, +358 40 708 5351, paivi.lindqvist@tietoenator.com Paula Liimatta, IR-chef, TietoEnator, tel. +358 9 8626 3113, +358 40 580 3521, paula.liimatta@tietoenator.com TIETOENATOR CORPORATION DISTRIBUTION Principal media TietoEnator is among the leading architects in building a more efficient information society and one of the largest IT services providers in Europe. TietoEnator specializes in consulting, developing and hosting its customers' business operations in the digital economy. The Group's services are based on a combination of deep industry-specific expertise and the latest information technology. TietoEnator has about 16 000 experts in close to 30 countries. www.tietoenator.com


 

QIAGEN will supply proven, ready-to-use screening sets to determine protein structures VENLO, The Netherlands / SAN DIEGO, CA, July 20, 2007 - QIAGEN N.V., the leading provider of sample and assay technologies for research in life sciences, molecular diagnostics and applied testing, today announced that it has entered a strategic agreement with the Joint Center for Structural Genomics (JCSG), one of the 4 PSI Structural Genomics Production Centers, providing protein crystallographers with a new set of proven crystallization screens that have been assembled from analysis of hundreds of thousands of crystallization experiments. Protein crystallography is a complex process used to determine the three-dimensional structure of proteins. By elucidating the structure of proteins, scientists can discover new drugs that more effectively target disease. To generate crystals, protein samples undergo a crystallization screening step, in which protein samples are combined in multiple reactions with different chemical solutions. This set of 384 conditions - split into four screens of 96 unique conditions - was previously provided by QIAGEN as a customized product and will be supplied to the wider market as The JCSG Core Suites I-IV. The new screens are the result of analyzing over 500,000 high-throughput crystallization experiments performed at the JCSG. The 384 crystallization conditions that provided the highest hit rates in initial screening were chosen to form the screens [Lesley SA, Wilson IA. "Protein production and crystallization at the Joint Center for Structural Genomics." J. Struct. Funct. Genom., 6: 71-79 (2005)]. "Improving initial sample preparation screens for crystallization is a continuous effort of the crystallographic community", said Kai te Kaat, Global Business Director Proteins at QIAGEN. "These new screens are the result of mining the vast database of crystallization experiments performed by the JCSG. We are proud to have been selected by the JCSG as their partner to commercialize these screens to the entire crystallographic community in QIAGEN's proprietary sample technology formats." The JCSG has chosen QIAGEN as their main supplier of crystallization screens for its proven quality and customer orientation in the development process. "I am delighted that QIAGEN markets these JCSG screens", said Professor Ian Wilson, Principal Investigator of the JCSG. "It enables the fruits of the NIH Protein Structure Initiative to become available to all structure biologists and allow them the opportunity to enhance their own individual success rates in protein crystallization." QIAGEN entered the market for sample preparation of proteins for crystallization in 2005. The objective behind all QIAGEN sample technologies for protein crystallization is to help reduce the time required for sample preparation to produce crystals and determine structures. The comprehensive product line aims to simplify and standardize sample preparation for protein crystallization using unique, ready-to-use kits that provide scientists with fast and easy experimental setups in manual and automatable formats. With the world's largest offering of protein crystallization screening conditions available in a wide range of formats - from highly innovative sample technologies for crystallization that make setup and screening easy and convenient to bulk formats for higher throughputs - QIAGEN products deliver unparalleled quality, convenience, and flexibility for sample preparation in protein crystallization. The precise chemical composition of every solution is recorded in a detailed production report that can be downloaded from the QIAGEN website, ensuring maximum reproducibility. About Protein Crystallography The human body contains around a million different proteins with essential roles in maintaining life. To learn how proteins function, scientists must understand a protein's structure. One way to achieve this is by x-ray crystallography, for which the protein must first be crystallized. Because there are no empirical rules governing which conditions individual proteins will crystallize, the complex process of preparing samples to obtain diffraction quality crystals requires screening of a large amount of conditions and can take from several weeks to several years. Once crystals are obtained, precise measurements of thousands of diffraction intensities from each crystal help scientists map the probable positions of the atoms within each protein molecule, and ultimately derive a 3D structure. With an improved understanding of the molecular structure and interactions of proteins, scientists are able to develop new drugs and treatments that target specific human, animal, and plant diseases. About the Joint Center of Structural Genomics Consortium (JCSG) The JCSG is funded by the National Institute for General Medical Sciences (NIGMS), as part of the Protein Structure Initiative (PSI) of the National Institutes of Health. Its initial mission was "to establish a robust and scalable protein structure determination pipeline that will form the foundation for a large-scale effective production center for structural genomics". A number of institutes make up the JCSG consortium, with major centers at The Scripps Research Institute (TSRI); the Genomics Institute of the Novartis Research Foundation (GNF); The University of California San Diego (UCSD); The Burnham Institute for Medical Research (Burnham); and the Stanford Synchrotron Radiation Laboratory (SSRL) at Stanford University. As part of the PSI program, North America's largest fully integrated crystallization platform has been established at TSRI using liquid handling and visualization instruments from Rigaku Automation (previously RoboDesign) with substantial support from IAVI (International AIDS Vaccine Initiative) and TSRI. More information can be obtained at http://www.jcsg.org . About QIAGEN QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such pre-analytical sample preparation and assay solutions in research for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and target specific assays. The company's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 2000 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. Further information about QIAGEN can be found at www.qiagen.com. Contacts: Dr. Thomas Theuringer Nicole York Manager Public Relations Marketing Communications Tel: 0049-2103-29-11826 Manager Email: thomas.theuringer@qiagen.com Tel.: 001-240-68-67660 Email: nicole.york@qiagen.com www.qiagen.com


 

* Study results show more patients receiving both Tekturna and Diovan reached target blood pressure goal compared to those taking either agent alone[1] * Tekturna, first new type of high blood pressure medicine in more than a decade, works well alone or in combination with other high blood pressure medicines * Tekturna provides significant blood pressure reductions for 24 hours and beyond with placebo-like tolerability * Strong need for new therapies like Tekturna since nearly 70% of patients with high blood pressure still not achieving treatment goals[2] Basel, July 20, 2007 - Results from a new study involving high blood pressure patients taking Tekturna® (aliskiren) and Diovan® (valsartan) were published today in The Lancet. The study, presented earlier this year at the American College of Cardiology congress, shows this combination provides patients with greater blood pressure reductions than either medicine alone and demonstrated tolerability comparable to placebo. Adding Tekturna to Diovan helped more patients reach their target blood pressure. Nearly half (49.3%) of the patients taking both Tekturna and Diovan reached the target blood pressure level of 140/90 mmHg, which is recommended by treatment guidelines. This proportion of patients was significantly more than with either drug alone (37.4% Tekturna, 33.8% Diovan). "We are encouraged by these results, because they demonstrate the value of complementary mechanisms of action when Tekturna and Diovan are used together," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "Most people need at least two medicines to effectively control their high blood pressure." Tekturna and Diovan work in different ways to target the Renin Angiotensin System, one of the body's key regulators of blood pressure. Tekturna targets renin, an enzyme responsible for triggering a process that can lead to high blood pressure. Diovan, an angiotensin receptor blocker (ARB) and one of the world's most-prescribed cardiovascular medicines, blocks a hormone later in this system that causes narrowing of blood vessels[3]. The study, involving almost 1800 patients, found that even at maximum doses of Tekturna and Diovan, the combination was safe and well-tolerated. A mild and transient increase in serum potassium levels above 5.5 mmol/L was seen in 4.2% of patients taking both Tekturna and Diovan compared to placebo (2.7%). However, there were fewer reports of serum potassium levels above 6.0 mmol/L in patients taking both medicines (0.5%), compared to 1.5% taking placebo, 1.0% taking Tekturna alone and 1.1% taking Diovan alone. While mild increases in serum potassium may be clinically important in rare situations, potentially life-threatening events associated with increases in serum potassium rarely occur unless the serum potassium concentration exceeds 7.0-7.5 mmol/L[4], levels which were not seen in this study. Commenting on an editorial in The Lancet, which questioned the safety of such a combination, the study's lead investigator Dr Suzanne Oparil, Professor of Medicine at the University of Alabama at Birmingham and President of the American Society of Hypertension said, "In our study, this combination was clearly shown by the data to be no more likely to increase potassium to unhealthy levels than either drug alone or even placebo. Mild increases in potassium are expected with agents that block the Renin Angiotensin System, including ACE inhibitors and angiotensin receptor blockers, the most-commonly used medicines to treat high blood pressure. Physicians have managed these mild increases in potassium very successfully for over 20 years." The need for new high blood pressure medicines, including using new combinations of medicines, is strong given that studies estimate that this condition may affect nearly one billion people globally and that more than 70% of patients with high blood pressure remain uncontrolled[5]. In fact, many require two or more medications to reach their target blood pressure goal[2],[6]. Uncontrolled high blood pressure can increase the risk of cardiovascular disease, the world's leading cause of death[6],[7]. Tekturna received approval in the US in March, 2007. Known as Rasilez outside the US, it received a positive CHMP opinion in June, 2007 recommending approval in the EU and was also recently approved in Switzerland. Tekturna was developed in collaboration with Speedel. Disclaimer The foregoing release contains forward-looking statements which can be identified by the use of terminology such as "can" or similar expressions, or by express or implied discussions regarding potential future regulatory filings, approvals or future sales of Tekturna/Rasilez or potential future sales of Diovan. Such statements reflect the current views of Novartis regarding future events and and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Tekturna/Rasilez will be approved for sale in any other market, or that Tekturna/Rasilez or Diovan will reach any particular sales levels. In particular, management's expectations regarding the approval and commercialization of Tekturna/Rasilez or Diovan could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data and new clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; increased government, industry, and general public pricing pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ more than 100,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com. References [1.] Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221-29 [2.] Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007; 49:69-75. [3.] Diovan Website. http://www.diovan.com/info/about/about_diovan.jsp. Accessed November 28, 2006. [4.] Harrisons Internal Medicine on line, Chapter 41, section 7, hyperkalemia. [5.] Rosamond W, Flegal K, Friday G, et al. for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update. A report from the American Heart Association Statistics Committee and Stroke Subcommittee. Circulation. 2007:115. [6.] Chobanian AV, Bakris GL, Black HR, et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003; 42:1206-1252. [7.] World Health Organization. "Main causes of death and global burden of disease (DALYs), world, all ages, projections for 2005." Available at: http://www.who.int/whosis/highlight05.png # # # Novartis Media Relations John Gilardi Peter Shelby Novartis Global Media Relations Novartis Pharma Communications +41 61 324 3018 (direct) +41 61 324 4470 (direct) +41 79 596 1408 (mobile) +41 79 597 6353 (mobile) john.gilardi@novartis.com peter.shelby@novartis.com e-mail: media.relations@novartis.com Novartis Investor Relations International North America Ruth Metzler-Arnold +41 61 324 7944 Ronen Tamir +1 212 830 2433 Katharina Ambühl +41 61 324 Jill Pozarek +1 212 5316 830 2445 Nafida Bendali +41 61 324 3514 Edwin +1 212 Valeriano 830 2456 Jason Hannon +41 61 324 2152 Thomas +41 61 324 8425 Hungerbuehler Richard Jarvis +41 61 324 4353 e-mail: investor.relations@novartis.com --- End of Message --- Novartis International AG Posfach Basel WKN: 904278; ISIN: CH0012005267; Index: SLCI, SMI, SPI, SLIFE; Listed: Main Market in SWX Swiss Exchange, ZLS in BX Berne eXchange;


 

Hamilton, Bermuda, July 19, 2007 Nordic American Tanker Shipping Ltd. (the "Company") today announced the pricing of an underwritten public offering of 3,000,000 common shares. On July 19, 2007, the closing price of the Company's common shares on the New York Stock Exchange was $42.85 per share. The common shares are being offered pursuant to the Company's effective shelf registration statement. Bear, Stearns & Co. Inc. and Morgan Stanley are acting as joint bookrunning managers. The Company expects to close the sale of the common shares on July 25, 2007, subject to customary closing conditions. The Company has granted the underwriters a 30-day option to purchase up to 450,000 additional shares to cover over-allotments. The net proceeds of the offering are expected to be used to repay indebtedness under the Company's revolving credit facility and to prepare the Company for further expansion. Today the Company also announced that it expects that its dividend in respect of the second quarter of 2007 will be in the region of $1.17 per share. The offering is being made only by means of a prospectus and related prospectus supplement. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. When available, copies of the prospectus and prospectus supplement relating to the offering may be obtained from the offices of Bear, Stearns & Co. Inc. at 383 Madison Avenue, New York, New York 10179, Attention: Prospectus Department, or by telephone to (866) 803-9204 and Morgan Stanley at 180 Varick Street, Second Floor, New York, New York 10014, Attention: Prospectus Department or by telephone to (212) 761-6775. About the Company The Company is an international tanker company that owns twelve modern double-hull Suezmax tankers. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words "believe," "anticipate," "intend," "estimate," "forecast," "project," "plan," "potential," "may," "should," "expect," "pending" and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand in the tanker market, as a result of changes in OPEC's petroleum production levels and world wide oil consumption and storage, changes in our operating expenses, including bunker prices, drydocking and insurance costs, the market for our vessels, availability of financing and refinancing, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessels breakdowns and instances of off-hire, failure on the part of a seller to complete a sale to us and other important factors described from time to time in the reports filed by the Company with the Securities and Exchange Commission, including the prospectus and related prospectus supplement, our Annual Report on Form 20-F, and our Reports on Form 6-K. Contacts: Scandic American Shipping Ltd Manager for: Nordic American Tanker Shipping Limited P.O Box 56, 3201 Sandefjord, Norway Tel: + 47 33 42 73 00 E-mail: nat@scandicamerican.com Rolf Amundsen, Investor Relations Nordic American Tanker Shipping Limited Tel: +1 800 601 9079 or + 47 908 26 906 Gary J. Wolfe Seward & Kissel LLP, New York, USA Tel: +1 212 574 1223 Herbjørn Hansson, Chairman and Chief Executive Officer Nordic American Tanker Shipping Limited Tel: +1 866 805 9504 or + 47 901 46 291 SK 01318 0002 793682 v3


 

* Once-daily patch offers novel approach to treating Alzheimer's disease, providing smooth and continuous delivery of drug over 24 hours[1] * Similar efficacy to highest doses of Exelon capsules with significant improvement in memory and ability to perform everyday activities compared to placebo[1] * Designed with compliance in mind and preferred by caregivers, helping them manage patient care and giving visual reassurance of treatment[2] * Minimizes gastrointestinal side effects seen with oral form of drug[1] Basel, July 19, 2007 - A patch that delivers Exelon®, an effective Alzheimer's disease medication, through the patient's skin has been recommended for approval in the European Union - the first time this technology has been applied to treat the disease in the EU. Exelon (rivastigmine transdermal patch) received a positive opinion for treating mild to moderately severe forms of Alzheimer's disease from the Committee for Medicinal Products for Human Use (CHMP), the body that reviews drug applications for all 27 EU member states as well as Iceland and Norway. This announcement comes on the same day that the CHMP recommended approval for two other Novartis medicines, Galvus® (vildagliptin) for type 2 diabetes and Aclasta® (zoledronic acid 5 mg) for postmenopausal osteoporosis. So far this year Novartis has received a total of seven product approvals and four positive opinions from the US and European regulatory authorities, providing innovative treatments to patients and creating a strong new growth platform. The European Commission generally follows the recommendation of the CHMP and is expected to issue a decision on Exelon patch within three months. The announcement comes a few weeks after this medicine was approved in the US. "Exelon patch offers unique therapeutic benefits because it maintains steady drug levels in the bloodstream, improves tolerability and allows a higher proportion of patients to receive therapeutic doses of medication," said Alexander Kurz, MD, Professor of Psychiatry and Head of the Centre for Cognitive Disorders at the Department of Psychiatry and Psychotherapy of Technische Universität München, Munich, Germany. "Coupled with the clear benefits for caregivers in terms of ease of administration, it represents a significant advance in the treatment of Alzheimer's disease. We look forward to the time when this important new therapy will be available throughout the EU," Dr. Kurz said. Alzheimer's disease is a progressive disorder that alters the brain, causing impaired memory, thinking and behavior, and is estimated to affect 18 million people worldwide[3]. The patch is applied to the back, chest or upper arm, and provides smooth and continuous delivery of medication through the skin over 24 hours with the potential for improved efficacy[1]. A key attribute of Exelon patch is a sharp reduction in gastrointestinal side effects commonly seen with the oral forms of this class of drugs called cholinesterase inhibitors. In a clinical trial these side effects were greatly reduced, with three times fewer reports of nausea and vomiting than with the capsule form of the drug[1]. Designed with compliance in mind, Exelon patch was preferred to capsules by more than 70% of caregivers in a clinical study as a method of drug delivery because it helped them follow the treatment schedule, interfered less with their daily life, and was easier to use overall than an oral medication[2]. "The positive recommendation in Europe, coming so soon after the US approval, highlights the tremendous importance of Exelon patch as an innovative way of delivering a proven medicine," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "The patch offers visual reassurance that the medication has been given, and helps caregivers cope with the daily challenges of looking after someone with this devastating disease." The EU positive opinion was based on results from the international IDEAL (Investigation of Transdermal Exelon in ALzheimer's disease) trial, which showed that patients receiving the Exelon patch demonstrated improved memory, overall functioning, and ability to perform everyday activities than those taking placebo[1]. Since 1997, Exelon (rivastigmine) has been used to treat mild to moderate Alzheimer's disease in more than 70 countries. Exelon is the only cholinesterase inhibitor to be approved for both mild to moderate Alzheimer's disease and Parkinson's disease dementia in both Europe and the US. The US Food and Drug Administration approved Exelon®Patch (rivastigmine transdermal system) on July 6 for the treatment of both mild to moderate Alzheimer's disease and Parkinson's disease dementia. Alzheimer's disease affects one in 10 people over the age of 65, making it the most common form of dementia and the third leading cause of death in this age group behind cardiovascular disease and cancer3. The global direct costs of dementia were estimated at USD156 billion in 2003[4]. Disclaimer This release contains certain forward-looking statements relating to the Novartis Group's business, which can be identified by the use of forward-looking terminology such as "generally follows", "potential", "expected", "look forward to the time", similar expressions, or express or implied discussions regarding potential future regulatory approvals or submissions with respect to, or future sales of, Exelon or the Exelon patch . Such forward-looking statements reflect the current views of Novartis regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance, or achievements expressed or implied by such statements. There can be no guarantee that the Exelon patch will be approved for sale in the EU or in any additional markets or that the Exelon patch will reach any particular sales levels. In particular, management's expectation regarding the Exelon patch could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, unexpected clinical trial results, including additional analysis of existing clinical data and new clinical data; government, industry, and general public pricing pressures; competition in general; the ability to obtain or maintain patent or other proprietary intellectual property protection and competition in general, as well as factors discussed in Novartis AG's Form 20-F filed with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Novartis is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. About Novartis Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ more than 100,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com. References [1] Winblad B, Cummings J, et al. A 6-Month Double-blind, Randomized, Placebo-Controlled Study of a Transdermal Patch in Alzheimer's Disease - Rivastigmine Patch versus Capsule. International Journal of Geriatric Psychiatry May 2007: 22: 5:485-491. [2] Winblad B, Cummings J, et al. Caregiver Preference For Rivastigmine Patch Relative to Capsule For Treatment of Probable Alzheimer's Disease. International Journal of Geriatric Psychiatry May 2007: 22: 5: 456-67. [3] Alzheimer's Association. Alzheimer's Disease Facts and Figures, 2007. [4] Wimo A, Jonsson L, Winblad B. An Estimate of the Worldwide Prevalence and Direct Costs of Dementia in 2003. Dementia and Geriatric Cognitive Disorders 2006; 21:175-181. # # # Novartis Media Contacts Corinne Hoff Julie Morrow Novartis Global Media Relations Novartis Pharma Communications +41 61 324 9577 (direct) +41 61 324 1135 (direct) +41 79 248 5717 (mobile) +41 79 596 4636 (mobile) corinne.hoff@novartis.com julie.morrow@novartis.com e-mail: media.relations@novartis.com Novartis Investor Relations International North America Ruth Metzler-Arnold +41 61 324 7944 Ronen Tamir +1 212 830 2433 Katharina Ambühl +41 61 324 Jill Pozarek +1 212 5316 830 2445 Nafida Bendali +41 61 324 3514 Edwin +1 212 Valeriano 830 2456 Jason Hannon +41 61 324 2152 Thomas +41 61 324 8425 Hungerbuehler Richard Jarvis +41 61 324 4353 e-mail: investor.relations@novartis.com --- End of Message --- Novartis International AG Posfach Basel WKN: 904278; ISIN: CH0012005267; Index: SLCI, SMI, SPI, SLIFE; Listed: Main Market in SWX Swiss Exchange, ZLS in BX Berne eXchange;


 

* Galvus delivers significant blood sugar reductions with good tolerability in a range of patients with type 2 diabetes * Recommended for use in combination with the most common oral diabetes medicines - broadest indication in Europe for new class of DPP-4 drugs * Estimated 28 million patients have type 2 diabetes in the European Union[1] Basel, July 19, 2007 - Novartis has received a positive opinion recommending European Union approval of Galvus® (vildagliptin) as a new once-daily oral medication for type 2 diabetes, a disease affecting an estimated 28 million patients in Europe[1]. The Committee for Medicinal Products for Human Use (CHMP), which reviews medicines for the European Commission, issued the positive opinion based on data from more than 5,700 patients in 13 clinical studies. This announcement comes on the same day that the CHMP recommended approval for two other Novartis medicines, Aclasta® (zoledronic acid 5 mg) for postmenopausal osteoporosis and Exelon® (rivastigmine transdermal patch) for Alzheimer's disease. So far this year Novartis has received a total of seven product approvals and four positive opinions from the US and European regulatory authorities, providing innovative treatments to patients and creating a strong new growth platform. The European Commission generally follows the CHMP's recommendations and is expected to issue a decision on Galvus within three months. The decision will apply in all 27 EU member states plus Iceland and Norway. The clinical trial program showed that Galvus delivered significant blood sugar reductions in a range of patients with type 2 diabetes[2],[3]. Furthermore, Galvus provided additional efficacy when added to the most commonly used oral diabetes medicines[4],[5],[6]. Galvus is recommended in the EU for use in combination with the most common oral diabetes medicines - metformin, a thiazolidinedione (TZD) or a sulfonylurea (SU) - the broadest proposed indication for any member of the new DPP-4 inhibitor class of drugs. When studied in combination with the most widely-used diabetes medicines, Galvus showed a positive safety and tolerability profile[4],[5],[6]. The most frequent side effects seen in the Galvus clinical program were stuffy nose, headaches and dizziness[7]. "Galvus is an important new treatment option for controlling type 2 diabetes because it provides beneficial blood sugar reductions without many of the side effects seen with other diabetes medications," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "Many type 2 diabetes patients need more than one treatment to bring their blood sugar levels under control, therefore the efficacy and tolerability of Galvus in combination with other medicines is especially significant." More than 21,000 patients have participated in the Galvus clinical trial program to date, including approximately 10,000 treated with Galvus. The recommended dose of Galvus is 100 mg once-daily when used in combination with metformin or a TZD, and 50 mg once-daily in combination with an SU. "The positive opinion and recommended label in Europe reflect the depth and breath of preclinical and clinical data for vildagliptin as one of the most widely studied DPP-4 inhibitors," said Bo Ahren, MD, Head of the Research Department at Lund University Hospital, Sweden. "The clinical trial program has shown vildagliptin to be safe, effective and well tolerated across a range of patients. This new treatment option has the potential to make a difference for the many millions of patients who suffer from type 2 diabetes and are still not achieving their blood sugar goals using existing treatments." Galvus is available in Brazil and Mexico. In February 2007, Novartis received an "approvable letter" from the US Food and Drug Administration. Novartis has submitted a proposal to the FDA for additional studies in renally impaired patients to also confirm good tolerability in this patient group. Skin lesions, as seen in monkeys, have not been seen either in healthy volunteers or in patients in the Galvus clinical trial program involving clinical studies lasting up to two years. As a member of the new class of DPP-4 inhibitors, Galvus works through a novel mechanism of action by targeting the dysfunction in the pancreatic islets that causes high blood sugar levels in people with type 2 diabetes. Islet dysfunction, along with insulin resistance, is a contributory factor to type 2 diabetes, a progressive disease in which control of blood sugar deteriorates over time. In most developed nations, diabetes is the fourth leading cause of death[8]. Controlling blood sugar levels is difficult even among patients receiving treatment, and more than half of patients with type 2 diabetes currently taking medicines are still not reaching their blood sugar goals[9]. When left untreated or not kept under control, type 2 diabetes can lead to heart and kidney disease, blindness, and vascular or neurological problems[8]. Disclaimer The foregoing press release contains forward-looking statements that can be identified by the use of forward-looking terminology such as "generally follows", "expected", "potential", or similar expressions, or by express or implied discussions regarding potential future regulatory filings or approvals with respect to, or future sales, of Galvus. Such forward-looking statements reflect the current views of Novartis and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Galvus will be approved for sale in the EU, the US or in any additional markets or that Galvus will reach any particular sales levels. In particular, management's expectation regarding Galvus could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, unexpected clinical trial results, including additional analysis of existing clinical data and new clinical data; government, industry, and general public pricing pressures; competition in general; the ability to obtain or maintain patent or other proprietary intellectual property protection and competition in general, as well as factors discussed in Novartis AG's Form 20-F filed with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Novartis is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. About Novartis Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ more than 100,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com. References [1] International Diabetes Federation (IDF) Diabetes Atlas estimates there are 31 million people with diabetes in the European Union. The IDF estimates that in developed nations, 85-95% of all cases of diabetes are type 2 diabetes. 90% of those with diabetes equates to 28 million with type 2 diabetes in the European Union. [2] Rosenstock J. et al. Consistent Efficacy and Safety of Vildagliptin Monotherapy Across Ethnicities Presented at ADA, 22-26 June 2006; (Abstract 2141-PO). [3] Pratley R. et al. Benefit/Risk Assessment of Vildagliptin in the Elderly; Pooled Analysis of 5 Monotherapy Studies. Presented at ADA, 22-26 June 2007; (Abstract 507-P). [4] Garber A. et al. Vildagliptin Added to Metformin Improves Glycemic Control and May Mitigate Metformin-Induced GI Side Effects in Patients with Type 2 Diabetes (T2DM). Presented at ADA, 9-13 June 2006; (Abstract 121-OR). [5] Garber A. et al. Efficacy and Tolerability of Vildagliptin Added to a Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM). Presented at ADA, 22-26 June 2007; (Abstract 501-P). [6] Rosenstock J. et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes, obesity & metabolism 2007; 9(2):175-85. [7] Novartis. Data on file. [8] International Diabetes Federation Diabetes Atlas. Third edition 2006: http://www.eatlas.idf.org/ [9] Saydah S. et al. Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes. JAMA 2004: 291(3): 335-342. # # # Novartis Media Relations Corinne Hoff Richard Booton Novartis Global Media Novartis Pharma Communications Relations +41 61 324 4356 (direct) +41 61 324 9577 (direct) +41 79 753 2593 (mobile) +41 79 248 5717 (mobile) richard.booton@novartis.com corinne.hoff@novartis.com e-mail: media.relations@novartis.com Novartis Investor Relations International North America Ruth Metzler-Arnold +41 61 324 7944 Ronen Tamir +1 212 830 2433 Katharina Ambühl +41 61 324 Jill Pozarek +1 212 5316 830 2445 Nafida Bendali +41 61 324 3514 Edwin +1 212 Valeriano 830 2456 Jason Hannon +41 61 324 2152 Thomas +41 61 324 8425 Hungerbuehler Richard Jarvis +41 61 324 4353 e-mail: investor.relations@novartis.com --- End of Message --- Novartis International AG Posfach Basel WKN: 904278; ISIN: CH0012005267; Index: SLCI, SMI, SPI, SLIFE; Listed: Main Market in SWX Swiss Exchange, ZLS in BX Berne eXchange;


 

(Munich, July 19, 2007) The members of the Executive Board and the Supervisory Board of Wacker Construction Equipment AG have today approved the construction of a new manufacturing facility for Ground Heaters, Inc. acquired in 2006. The construction of the new facilities in Korbach and Manila is already in progress. The facility should be completed in the second half of 2008. The capital expenditure will amount to approximately $ 10 million. If required, it will be possible to gradually expand the facility. The new manufacturing facility in Norton Shores, Michigan (U.S.A.) will allow for an increased production capacity for mobile hydronic heating equipment. Furthermore it is planned to manufacture mobile light towers for the utility business field at this new location and to make the production processes more efficient. Additional information about the Wacker Construction Equipment AG shares: ISIN: DE000WACK012 Securities Identification number: WACK01 Listing requested: Official Market / Prime Standard; Frankfurt Stock Exchange Registered office of the company: Germany Contact: Wacker Construction Equipment AG Imre Szerdahelyi Head of Corporate Communication Preußenstr. 41 80809 Munich, Germany Tel. + 49 - 89 - 354 02 - 251 E-mail: ir@eu.wackergroup.com Internet: www.wackergroup.com --- End of Message --- Wacker Construction Equipment AG Preußenstr. 41 München Deutschland WKN: WACK01; ISIN: DE000WACK012; Listed: Amtlicher Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse;


 

Downing Protected VCT IV plc Interim Statement for the six months ended 31 May 2007 PERFORMANCE SUMMARY 31 May 2007 30 Nov 2006 pence pence Net asset value per Ordinary share 95.6 95.7 Cumulative distributions per Ordinary share 1.0 - Total return per Ordinary share 96.6 95.7 CHAIRMAN'S STATEMENT The six-month period ended 31 May 2007 has seen your Company continue to make good progress in investing its funds as it moves towards the target of having 70% of its funds in VCT qualifying investments. Venture capital investments During the period the Company made two new investments of £1 million each in VCT qualifying businesses. Hoole Hall Country Club and Spa Limited is in the process of developing a Hotel near Chester. The Really Fine Leisure Company Limited owns and operates a health and leisure club near Marlow, Bucks. Both companies' have experienced management teams and, in both cases, your Company has been able to take first charges over the company's freehold assets. The Company found some further opportunities to make non-qualifying investments in several developer and other companies. In each case, these investments produce yields higher than fixed interest securities or bank deposits in exchange for a very small increase in risk, therefore the Board have welcomed such investments. There were a number of realisations during the period, although in all cases, these were redemptions of loan stock investments at par and, were either planned short-term investments, or funds being returned by companies which did not commence their original planned trades, as I mentioned in my statement within the last Annual Report. At the end of the period, the Board reviewed the portfolio and concluded that, generally, investments were performing to plan and that no provisions against the valuations were required. All investments have therefore been held at values equal to their original cost. Fixed interest portfolio The Company continues to hold a portfolio of eight corporate bonds with a total value of £3.9 million. The increase in interest rates has resulted in an unrealised loss on this portfolio of £68,000 being recorded over the period. Net Asset Value and Results At 31 May 2007, the Net Asset Value per share ("NAV") of the Company stood at 95.6p, a small increase of 0.9p (0.9%) since the previous year end of 30 November 2006 (after adjusting for the 1p dividend paid during the period). The profit on ordinary activities after taxation for the period was £196,000, comprising a revenue profit of £264,000 and a capital loss of £68,000. Share repurchase The Company operates a policy, subject to certain restrictions, of buying its own shares when any become available in the market. No shares were purchased in the period for cancellation. Outlook The Board remains satisfied with progress made by the manager in investing the Company's funds and is happy with the quality of investments made to date. The Board will continue to work closely with the manager to ensure that the investing phase is completed in a timely manner. Once the investing phase is complete, the Board will then be able to start to plan, with the manager, the detail of the Company's realisation and exit strategy, in order to deliver Shareholders a result in line with the objectives that were set at the Company's launch. Hugh Gillespie Chairman UNAUDITED INCOME STATEMENT for the six months ended 31 May 2007 Six months ended 31 May 2007 Revenue Capital Total £'000 £'000 £'000 Income 582 - 582 Losses on investments - (68) (68) 582 (68) 514 Investment management fees (104) - (104) Other expenses (88) - (88) Return on ordinary activities before 390 (68) 322 taxation Taxation (126) - (126) Return attributable to equity shareholders 264 (68) 196 Return per share 1.2p (0.3p) 0.9p Six months ended Year ended 31 May 2006 30 Nov 2006 Revenue Capital Total Total £'000 £'000 £'000 £'000 Income 209 - 209 706 Losses on investments - - - (21) 209 - 209 685 Investment management fees (42) - (42) (152) Other expenses (62) - (62) (146) Return on ordinary activities 105 - 105 387 before taxation Taxation (34) - (34) (133) Return attributable to equity 71 - 71 254 shareholders Return per share 0.5p - 0.5p 1.4p A Statement of Total Recognised Gains and Losses has not been prepared as all gains and losses are recognised in the Income Statement as noted above. UNAUDITED SUMMARISED BALANCE SHEET as at 31 May 2007 31 May 2007 31 May 2006 30 Nov 2006 £'000 £'000 £'000 Fixed assets Investments 19,532 11,000 19,950 Net current assets 1,210 9,579 813 Creditors: amounts falling due after more than one year (21) (20) (21) Net assets 20,721 20,559 20,742 Capital and reserves Called up share capital 217 217 217 Share premium - 20,271 20,271 Special reserve 20,271 - - Capital reserve - realised - - - Capital reserve - unrealised (89) - (21) Revenue reserve 322 71 275 Equity shareholders' funds 20,721 20,559 20,742 Net asset value per share 95.6p 94.8p 95.7p RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS for the six months ended 31 May 2007 31 May 2007 31 May 2006 30 Nov 2006 £'000 £'000 £'000 Opening shareholders' funds 20,742 - - Issue of shares - 21,680 21,680 Share issue costs - (1,192) (1,192) Dividends paid (217) - - Total recognised gains for 196 71 254 the period Closing shareholders' funds 20,721 20,559 20,742 UNAUDITED CASH FLOW STATEMENT for the six months ended 31 May 2007 31 May 31 May 2006 30 Nov 2007 2006 Note £'000 £'000 £'000 Cash inflow from operating activities and returns on 1 investments 407 65 152 Capital expenditure Purchase of investments (5,750) (11,000) (21,871) Proceeds from disposal of 6,100 - 1,900 investments Net cash inflow/(outflow) from 350 (11,000) (19,971) capital expenditure Equity dividends paid (217) - - Net cash inflow/(outflow) 540 (10,935) (19,819) before financing Financing Shares issued - 21,730 21,730 Redemption of preference shares - (50) (50) Share issue costs - (1,192) (1,192) Proceeds from issue of loan - - 21 notes Net cash inflow from financing - 20,488 20,509 Increase in cash 2 540 9,553 690 Notes to the cash flow statement: 1 Cash inflow from operating activities and returns on investments Net revenue before taxation 390 105 408 Decrease/(increase) in other 116 (78) (402) debtors (Decrease)/increase in other (99) 38 146 creditors Net cash inflow from operating 407 65 152 activities 2 Analysis of net funds Beginning of period 690 - - Net cash inflow 540 9,553 690 End of period 1,230 9,553 690 SUMMARY OF INVESTMENT PORTFOLIO as at 31 May 2007 % of Unrealised portfolio Cost Valuation gain/(loss) by value Venture Capital Investments (by value) £'000 £'000 £'000 £'000 VCT Qualifying Warwick Contracting Ltd 2,000 2,000 - 9.7% Heyford Contracting (North) Ltd 1,575 1,575 - 7.6% Heyford Contracting (South) Ltd 1,500 1,500 - 7.2% Cadbury House Hotel and Country Club Ltd 1,000 1,000 - 4.8% Hoole Hall Country Club and Spa Ltd 1,000 1,000 - 4.8% Nu Nu plc 1,000 1,000 - 4.8% The Really Fine Leisure Company Ltf 1,000 1,000 - 4.8% Richstone Contracting Ltd 642 642 - 3.1% 9,717 9,717 - 46.8% Non VCT Qualifying Green Mountain Contractors Ltd 1,000 1,000 - 4.8% Midlands Contracting Ltd 1,000 1,000 - 4.8% Vermont Development Ltd 1,000 1,000 - 4.8% Bowman Care Homes Ltd 600 600 - 2.9% Heyford Homes VCT Ltd 600 600 - 2.9% Gatewales Ltd 500 500 - 2.4% Property Solutions Ltd 500 500 - 2.4% OVL Banbury LLP 315 315 - 1.5% Sanguine Hospitality Ltd 250 250 - 1.2% Calthorpe Street Ltd 113 113 - 0.6% 5,878 5,878 - 28.3% Listed Fixed Interest Investments 4,026 3,937 (68) 19.0% Total 19,621 19,532 (68) 94.1% Cash at Bank 1,230 5.9% Total investments 20,762 100.0% SUMMARY OF INVESTMENT MOVEMENTS For the period ended 31 May 2007 Additions £'000 VCT Qualifying investments Hoole Hall Country Club and Spa Ltd 525 The Really Fine Leisure Company Limited 1,000 Non-qualifying investments Gatewales Ltd 500 Green Mountain Contractors Ltd 1,000 Property Solutions Ltd 500 Sanguine Hospitality Ltd 250 Vermont Development Ltd 1,500 5,275 Disposals Cost Proceeds Profit/(loss) £'000 £'000 £'000 Non-qualifying investments (All loan stock redemptions) Adam Pub Company Ltd 1,000 1,000 - Blackbush Pub Company Ltd 1,000 1,000 - Cadbury House and Hotel Limited 600 600 - Hattanman Contracting Ltd 1,000 1,000 - Manhattan Contractors Ltd 1,000 1,000 - Vermont Developments Ltd 500 500 - Windsor Garden Centres Ltd 1,000 1,000 - 6,100 6,100 - NOTES TO THE UNAUDITED FINANCIAL STATEMENTS 1. Basis of accounting The Company has prepared its financial statements under UK Generally Accepted Accounting Practice ("UK GAAP") and in accordance with the Statement of Recommended Practice "Financial Statements of Investment Trust Companies" revised December 2005 ("SORP"). Presentation of Income Statement In order to better reflect the activities of an investment trust company and in accordance with guidance issued by the Association of Investment Companies ("AIC"), supplementary information which analyses the income statement between items of a revenue and capital nature has been presented alongside the income statement. The net revenue is the measure the Directors believe appropriate in assessing the Company's compliance with certain requirements set out in Section 842 Income and Corporation Taxes Act 1988. Investments All investments are designated as "fair value through profit or loss" assets and are initially measured at cost, equivalent to their fair value. Listed fixed income investments are measured using bid prices in accordance with the International Private Equity and Venture Capital Valuation Guidelines. The Directors establish the fair value of unquoted investments by using an adjusted net asset valuation model, as they believe this best reflects the nature of the underlying investments and it is calculated in accordance with the International Private Equity and Venture Capital Valuation Guidelines. Where an investment has been held for less than one year, unless there are any indications to the contrary, fair value is assumed to be equal to the cost of the investment. The unrealised depreciation or appreciation arising on the valuation of investments and gains and losses arising on the disposal of investments are dealt with in the capital reserve. It is not the Company's policy to exercise significant influence over investee companies. Therefore the results of these companies are not incorporated into the income statement except to the extent of any income accrued. This is in accordance with the SORP that does not require portfolio investments to be accounted for using the equity method of accounting. Income Dividend income from investments is recognised when the shareholders' rights to receive payment has been established, normally the ex dividend date. Interest income is accrued on a timely basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount, and only where there is reasonable certainty of collection. Expenses All expenses are accounted for on accruals basis. In respect of the analysis between revenue and capital items presented within the income statement, all expenses have been presented as revenue items except as follows: * Expenses which are incidental to the disposal of an investment are deducted from the disposal proceeds of the investment. * Expenses are split and presented partly as capital items where a connection with the maintenance or enhancement of the value of the investments held can be demonstrated. The Company has adopted a policy of charging 100% of the Investment Management fees to the revenue account. Taxation The tax effects on different items in the Income Statement are allocated between capital and revenue on the same basis as the particular item to which they relate using the Company's effective rate of tax for the accounting period. Due to the Company's status as a Venture Capital Trust and the continued intention to meet the conditions required to comply with Section 842AA of the Income and Corporation Taxes Act (1988), no provision for taxation is required in respect of any realised or unrealised appreciation of the Company's investments which arises. Deferred taxation is provided in full on timing differences that result in an obligation at the balance sheet date to pay more tax, or a right to pay less tax, at a future date, at rates expected to apply when they crystallise based on current tax rates and law. Timing differences arise from the inclusion of items of income and expenditure in taxation computations in periods different from those in which they are included in the accounts. 2. All revenue and capital items in the Income Statement derive from continuing operations. 3. The Company has only one class of business and derives its income from investments made in shares, securities and bank deposits. 4. The comparative figures were in respect of the six-month period ended 31 May 2006 and the 12 month period ended 30 November 2006 respectively. 5. Return per share for the period has been calculated on 21,680,245 shares, being the weighted average number of shares in issue during the period. 6. Dividends paid 30 Nov 2006 31 May 2007 Revenue Capital Total Total £'000 £'000 £'000 £'000 Paid in period/year 2006 Final (1p paid 27 April 217 - 217 - 2007) 7. Reserves Share premium Special Capital reserve - Revenue account reserve unrealised reserve Total £'000 £'000 £'000 £'000 £'000 At 30 November 20,271 - (21) 275 20,525 2006 Losses on - - (68) - (68) investments Transfer (20,271) 20,271 - - - Dividends paid - - - (217) (217) Retained - - - 264 264 revenue At 31 May 2007 - 20,271 (89) 322 20,504 The Special Reserve was created on 6 December 2006 by the cancellation of the Share Premium account following court approval. The Special Reserve is available to the Company to enable the purchase of its own shares in the market without affecting its ability to pay capital distributions. The Special Reserve, Capital Reserve - Realised and Revenue Reserve are all distributable reserves. 8. The unaudited financial statements set out herein do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985 and have not been delivered to the Registrar of Companies. 9. Copies of the unaudited interim results will be sent to shareholders shortly. Further copies can be obtained from the Company's Registered Office and will be available for download from www.downing.co.uk. ---END OF MESSAGE---


 

Pursuant to Art. 20 of the Swiss Federal Act on Stock Exchanges and Securities Trading - BEHG, Deutsche Bank AG, Frankfurt, informed BB BIOTECH AG, Vordergasse 3, 8200 Schaffhausen, Switzerland on July 17, 2007 of a change in the group of persons in accordance with Article 15 par. 5 of the Stock Exchange and Securities Trading Ordinance of the Federal Banking Commission. Since July 12, 2007, Deutsche Bank Securities Inc., New York, does not hold any shares in BB BIOTECH AG anymore; the Group member companies now comprise the following: * Deutsche Bank AG Frankfurt, Taunusanlage 12, 60325 Frankfurt/Main * Deutsche Bank AG, London Branch, Winchester House, 1 Great Winchester Street, EC2N 2DB London * Deutsche Asset Management Investmentgesellschaft mbH, Mainzer Landstr. 178-190, 60327 Frankfurt am Main As at July 12, 2007 this Group held a total of 6.52% of voting rights. The voting rights comprise 1 205 910 bearer shares (5.05%), 211 112 voting rights from 1 200 000 long call warrants (0.88%) and 140 005 voting rights arising from 2 256 241 short put options (0.59%). For further information please contact: Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland Adrian Bruengger or Dr. Christian Lach, Tel. +41 44 267 67 00 --- End of Message --- BB BIOTECH AG Vordergasse 3 Schaffhausen Switzerland WKN: 888509; ISIN: CH0001441580; Index: SBIOM, IGSP, SLIFE; Listed: Investment Companies in SWX Swiss Exchange;


 

Zurich - Switzerland; Paris - France: Swiss WorldCargo, the air cargo division of Star Alliance carrier Swiss International Air Lines Ltd., has nominated Eric Schmid new Regional Manager Western Europe. Schmid, 50, has an extensive international experience in the air cargo business and has joined the organisation at the beginning of July succeeding Alain Guerin in this position. Married, father of three children, Schmid is a French and Swiss national. He has a proven track record in many areas of sales and marketing: Since 1979 he has held various management positions with KLM Cargo & Logistics Europe and, in the last three years, he was a Board Member & Consultant for the consulting firm Sahelian Management, where he developed the cargo commercial structure and business plan for a start-up airline company. As Regional Manager Western Europe for Swiss WorldCargo, based in Paris Charles de Gaulle, Schmid will be charged with ensuring the business further expansion and focused development in France, Spain & Portugal, and Benelux. With his broad view of the European air cargo market, he will surely bring fresh and expert insight and, therefore, great asset to Swiss WorldCargo and its customers. "Mr. Schmid brings a lot of industry know-how, great achievements and an expressed willingness to further develop and strengthen this important region and its different markets and countries", says Urs Stulz, Managing Director Cargo Europe. "In his new challenge, Mr. Schmid can count on the very solid ground prepared by his predecessor M.r Guerin and on the valuable support of the local sales management teams." Swiss WorldCargo is the airfreight division of Swiss International Air Lines Ltd. With a worldwide network serving more than 150 destinations in more than 80 countries and abroad spectrum of services, Swiss WorldCargo earns genuine added-value for its customers and makes a substantial contribution to the earnings of SWISS. Note to editors: For further information about Swiss WorldCargo, pictures and interview requests please contact: Bernd Maresch Senior Manager Marketing, PR & Strategy bernd.maresch@swiss.com Phone +41 44 564 50 50 Please visit swissworldcargo.com Please click the following links for the media release in pdf and a photograph of Eric Schmid:


 

Arnhem, the Netherlands, July 19, 2007 - Akzo Nobel has announced that Jo Lennartz (57) will become the company's new Director of Technology. Two further management changes resulting from his appointment have also been confirmed. Formerly General Manager of the company's Functional Chemicals business, Dutch-born Lennartz will officially take up his new position on September 1. He will be succeeded by Bob Margevich (50), currently General Manager of Akzo Nobel Polymer Chemicals. Alan Kwek (50) - presently Manager of the Powder Coatings activities in Asia Pacific - will in turn take over at Polymer Chemicals. "Jo Lennartz has been instrumental in successfully reshaping the Functional Chemicals business and he will bring to his new role a wealth of business and technology experience gained while working for a number of different Akzo Nobel businesses," said Akzo Nobel Board member Leif Darner. His new role will include establishing links and interacting with relevant external technology and science communities, as well as leading the development of the technology community within Akzo Nobel. Currently based in Chicago in the United States, Bob Margevich has almost 30 years of experience in the international chemicals business and has been General Manager of Akzo Nobel Polymer Chemicals since 2003. An American citizen, Margevich will move to Amersfoort in the Netherlands. Alan Kwek joined Akzo Nobel after the acquisition of Courtaulds in 1998, where he held a regional role for Marine and Protective Coatings in Asia. He will move from his native Singapore to the United States and will be based in Chicago. - - - Note to editors Akzo Nobel is a Fortune Global 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with coatings, chemicals and human and animal healthcare products. We employ around 62,000 people and conduct our activities in these four segments, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2006 totaled EUR 13.7 billion. The financial results for the second quarter will be published on July 24, 2007. Internet: www.akzonobel.com Not for publication - for more information Akzo Nobel nv Corporate Media Relations, tel. +31 26 366 43 43 Contact: Heleen van de Lustgraaf


 

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | Elliott Advisors (UK) | | | Ltd. | |-------------------------------------------+-----------------------| | Company dealt in | EMI Group PLC | |-------------------------------------------+-----------------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 2) | | |-------------------------------------------+-----------------------| | Date of dealing | 18 July 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------------------------------------------------+ | | Long | Short | | | | | |---------------+------------------------------------------+--------------------------------------------------| | |Number |Number (%)| | |(%) | | |---------------+------------------------------------------+--------------------------------------------------| |(1) Relevant | | | |securities | | | | | | | |---------------+------------------------------------------+--------------------------------------------------| |(2) Derivatives|12,955,800 1.5973% | | |(other than | | | |options) | | | | | | | |---------------+------------------------------------------+--------------------------------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+------------------------------------------+--------------------------------------------------| |Total |12,955,800 1.5973% | | | | | | +-------------------------------------------------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +---------------------------------------------------------------------------------------------------------------------+ |Class of relevant security:| Long | Short | |Convertible Bonds 2010 | | | | | | | | | | | |---------------------------+------------------------------------------+----------------------------------------------| | |Number |Number | | |(%) |(%) | |---------------------------+------------------------------------------+----------------------------------------------| |(1) Relevant |27,488,000 11.2960% | | |securities | | | | | | | | | | | |---------------------------+------------------------------------------+----------------------------------------------| |(2) Derivatives (other than| | | |options) | | | | | | | |---------------------------+------------------------------------------+----------------------------------------------| |(3) Options and agreements | | | |to purchase/sell | | | | | | | |---------------------------+------------------------------------------+----------------------------------------------| |Total |27,488,000 11.2960% | | | | | | +---------------------------------------------------------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short | Number of securities (Note | Price per | | name, | (Note 6) | 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------+------------------------------+------------| | CFD | Long | 3,000,000 | GBP 2.6256 | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |Date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ 7 (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if | | (Note 8) | | applicable) (Note 5) | | Convertible Bonds 2010 | | | |------------------------+------------+-----------------------------| | Buy | 11,000,000 | 217.27 | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) YES/NO +-------------------------------------------------------------------+ | Date of disclosure | 19 July 2007 | |--------------------------------------------------+----------------| | Contact name | Philippa Rowan | |--------------------------------------------------+----------------| | Telephone number | 0207 518 1818 | |--------------------------------------------------+----------------| | If a connected EFM, name of offeree/offeror with | | | which connected | | |--------------------------------------------------+----------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Chrysalis VCT plc 19 July 2007 Chrysalis VCT plc announces that on 19 July 2007 the Company purchased 40,100 Ordinary shares of 1p each for cancellation representing approximately 0.12% of the issued Ordinary share capital at a price of 80.0p per share. Following the above transaction the Company's capital consists of 33,210,088 Ordinary shares of 1 pence each, 536,072 'D' Ordinary share of 1 pence each and 601,376 'E' Ordinary shares of 1 pence each. The Company does not hold any shares in treasury. Therefore the total number of voting rights in Chrysalis VCT plc is 34,347,536. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Chrysalis VCT plc under the FSA's Disclosure and Transparency Rules. ---END OF MESSAGE---


 

Bombardier Vehicles Will be Moving Over 4 Million Passengers Daily in Delhi Metro's Extended Network Bombardier is One of the First Private Companies Chosen to Build Complete Rail Vehicles in India BERLIN, GERMANY--(Marketwire - July 19, 2007) - Bombardier Transportation announced today that it has won an order for 340 BOMBARDIER(i) MOVIA(i) metro cars from the Delhi Metro Rail Corporation Ltd (DMRC). The contract is valued at approximately 427 million Euros ($ 590 million US). Deliveries of the trains are scheduled to begin in the last quarter of 2008 with completion in 2010 to provide effective public transport during the Commonwealth Games that will be held in New Delhi in October 2010. In the phase II expansion of Delhi Metro, the modern BOMBARDIER MOVIA high-capacity vehicles will transport an impressive 4 million passengers every day, reducing their journey time and alleviating the heavy traffic congestion and pollution caused by more than 1 million cars that commute in New Delhi everyday. The phase II expansion extends the existing network by approximately 60 kilometers covering all major destinations in the East-West and North-South corridors of this remarkable city where almost 16 million people presently live. "Some of the greatest cities in the world, such as New York, Paris, London, Berlin, and Shanghai, have chosen Bombardier metros to provide modern mobility for their citizens while reducing traffic congestion and helping their cities breathe" said Andre Navarri, President, Bombardier Transportation. "We are very excited to be able to add the city of New Delhi as a new metro customer", Mr. Navarri added. "We've been an employer in India for over 35 years and we hope that this project will set the standard for other mass transit projects that we intend to pursue in New Delhi, Mumbai, Hyderabad, Bangalore, Kochi and Chandigarh and throughout India." Rajeev Jyoti, Managing Director, Bombardier Transportation India, said: "We are very proud to be one of the first private companies to have been chosen to build rail vehicles in India. Bombardier manufacturing and engineering sites in India, supported by our sites in Germany and Sweden, will deliver the new vehicles to Delhi Metro on time and with quality, meriting the trust that the public authorities in India have placed in us." The BOMBARDIER MOVIA metro vehicles are configured in 4 car sets with capacity for 1.480 passengers. The vehicles integrate the world's most advanced technologies in metro vehicle manufacture, such as stainless steel carbodies and the reliable BOMBARDIER(i) MITRAC(i) Propulsion and control system featuring IP technology. The MOVIA metros are developed from a standardized platform, which ensures a high degree of reliability, safety & maintainability while providing low life-cycle cost. This contract envisages a design approach that enables a high degree of localization and easy transfer of technology processes. To ensure successful localization, the carbodies, bogies and propulsion system for the first units will be manufactured by Bombardier sites in Germany and Sweden. Thereafter, the main production will be undertaken by Bombardier in India. The propulsion system for 60 four-car units will be produced by Bombardier's site in Baroda; 77 four-car units will be manufactured by other Bombardier sites in India. Key elements of the complete design will be undertaken at Bombardier's Indian engineering centre, Infotech, in Hyderabad in cooperation with Bombardier's site in Sweden. Note to editors: Useful market and company background facts and contact details follow. Photography is available at: http://www.transportation.bombardier.com/photography.jsp Background facts and figures Bombardier Metro vehicles Bombardier is the number one supplier of metro vehicles worldwide. More than 1,400 BOMBARDIER MOVIA metro cars have already been ordered from the company to date. Bombardier metros are vital elements for mobility in cities like New York, Montreal, Toronto, Paris, London, Berlin, Bucharest, Stockholm, Shanghai, Shenzhen, Guangzhou and many others. In Asia, Bombardier metro cars are in service with operators in Shanghai, Guangzhou, Shenzhen and Hong Kong. In Shanghai, Bombardier has participated in the supply of 16 metro trains (96 cars) for Line 1 and 37 trains (222 cars) for Line 2 of the city's metro system. In June 2006, Bombardier celebrated the delivery of its 1,000th metro car to customers in Guangzhou Province. Bombardier Transportation in India Bombardier Transportation has been present in India for over 35 years. It has supplied Indian Railways with technologically advanced rail products, such as the WAP5 and WAG9 electric locomotives for passenger and freight applications and the Mumbai Traffic Management System. This system controls the 60-km rail stretch around Mumbai - one of the world's heaviest rail commuter traffics - on which the Western Railways run on time and with safety an impressive number of 1,000 trains everyday. Bombardier Transportation is steadily ramping up its presence in India. Vadodara, Gujarat is home to its propulsion systems manufacturing facility and software development center for signalling and traction applications in India and for other Bombardier Transportation projects around the globe. The site is ISO 9001, ISO 14001 and OHSAS 18001 certified. In Hyderabad, Andhra Pradesh, Infotech Enterprises operates one of the most important engineering centers already sourcing key global projects for Bombardier Transportation. Potential manufacturing and project associations in India Bombardier is open to an association with Indian Railways under a Public Private Partnership approach to create a manufacturing facility to produce Bombardier locomotives in India, related to Indian Railways rail freight corridors project. In the Mass Transit sector Bombardier is developing associations with companies in India. About Bombardier Transportation Bombardier Transportation has its global headquarters in Berlin, Germany with a presence in over 60 countries. It has an installed base of over 100,000 vehicles worldwide. The Group offers the broadest product portfolio and is recognized as the leader in the global rail sector. About Bombardier A world-leading manufacturer of innovative transportation solutions, from regional aircraft and business jets to rail transportation equipment, systems and services, Bombardier Inc. is a global corporation headquartered in Canada. Its revenues for the fiscal year ended Jan. 31, 2007, were $14.8 billion US, and its shares are traded on the Toronto Stock Exchange (BBD). News and information are available at www.bombardier.com. Bombardier, MOVIA and MITRAC are trademarks of Bombardier or its subsidiaries. Contacts: Americas David Slack + 1 450 441 3190 Germany, Austria Jï¿¿rgen Scheunemann + 49 30 986 07 1134 Switzerland Fiona Flannery +41 44 318 29 91 Central and Eastern Europe Vicki Luther + 49 30 986 07 1139 Russia Alexander Bocharov + 7 495 775 1830 UK, Ireland, Nordic Countries, Australia, New Zealand, other countries Neil Harvey + 44 1332 266470 Benelux and France Anne Froger + 33 6 07 78 95 38 Spain, Portugal, Italy, Greece, Turkey, India Luis Ramos + 35 1 919 693 728


 

VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- 07/19/07 -- Buffalo Gold Ltd. (TSX VENTURE: BUF.U)(OTCBB: BYBUF)(FRANKFURT: B4K) ("Buffalo" or "the Company") is pleased to report that it has been informed by Kinbauri Gold Corp. (TSX VENTURE: KNB) ("Kinbauri") of positive drill results at the El Valle project in Spain. Buffalo holds a 25.4% strategic interest in Kinbauri as part of the Company's on-going strategy of aggressively adding value through investing in or acquiring projects and companies that offer considerable growth potential (see Buffalo news release July 4th, 2007). In a news release issued earlier today, Kinbauri reported: "...the first set of assay results from its drill program at El Valle. The objective of the on-going 7,000m drill program is to define resources to support six years of production, assuming reasonable conversion to reserves. Area 107 and Black Skarn North are being targeted for their continuity of gold and copper mineralization and proximity to existing mining infrastructure. Results from the first ten holes, drilled from the existing mine workings, are summarized in the table below. Thickness Zone(3) From To (2) Au Ag Cu ------- HOLE(1) (m) (m) (m) (g/t) (g/t) (%) Section -------------------------------------------------------------------------- 07KV1001 70.30 79.30 9.00 4.5 6.4 0.31 A107 including 73.20 79.30 6.10 5.6 8.1 0.39 ---- 07KV1001 80.80 85.30 4.50 2.1 9.3 0.85 10 -------------------------------------------------------------------------- A107 07KV1002 167.00 173.40 6.40 6.40 27.6 0.99 ---- including 169.35 173.40 4.05 8.90 36.6 0.91 9 -------------------------------------------------------------------------- NBS & A107 07KV1003 51.60 53.70 2.10 7.60 54.5 2.17 ---------- 07KV1003 64.50 69.00 4.50 2.20 6.7 0.69 10 -------------------------------------------------------------------------- 07KV1004 47.80 52.25 4.45 2.80 11.2 0.57 NBS 07KV1004 66.20 69.60 3.40 2.30 13.3 1.50 --- 07KV1004 105.20 109.40 4.20 7.30 9.1 1.07 6 -------------------------------------------------------------------------- 07KV1005 45.30 50.30 5.00 2.10 14.6 0.79 NBS including 45.30 46.50 1.20 2.37 20.0 1.58 --- 07KV1005 78.80 101.20 22.40 1.50 9.7 0.70 7 including 89.00 90.70 1.70 3.35 22 1.07 -------------------------------------------------------------------------- 07KV1006 83.25 89.15 5.90 3.60 5.0 0.19 NBS & A107 07KV1006 213.95 217.40 3.45 3.70 24.7 1.03 ---------- including 216.25 217.40 1.15 6.13 36.0 1.35 12 -------------------------------------------------------------------------- A107 07KV1007 151.10 152.90 1.80 4.33 7.0 1.16 ---- 07KV1007 157.70 166.00 8.30 5.90 102.4 7.68 8 -------------------------------------------------------------------------- A107 07KV1008 93.85 94.90 1.05 6.23 41.0 1.35 ---- 07KV1008 124.70 128.30 3.60 12.3 5.5 0.36 4 -------------------------------------------------------------------------- A107 07KV1009 65.1 137.1 72.00 5.10 22.9 1.40 ---- including 108.7 134.25 25.55 11.10 47 2.27 11 -------------------------------------------------------------------------- A107 07KV1010 150.00 154.20 4.20 6.9 18.1 0.98 ---- including 153.00 154.20 1.20 12.7 7.0 0.46 3 -------------------------------------------------------------------------- (1) See Schedule A for relative location (to view Schedule A please click on http://www.ccnmatthews.com/docs/buf0719map.pdf): (2) True thicknesses have not been calculated, pending confirmation of geological and mineralization geometry: (3) A107 - Area 107; NBS - Black Skarn North. These results extend the mineralization at Area 107 (beyond its defined resource area as of March 21, 2007) a minimum of 50m to the southeast, 150m to the west and 100m at depth. As noted in sections 10 and 12, high copper (sulphide) and gold values coincide with the apparent intersection of the Area 107 epithermal structure and the Black Skarn to the southeast. The results also suggest that Black Skarn North may be continuous with the Monica Zone some 350 metres to the south. As of March 21, 2007 Ore Reserves Engineering ("ORE") estimated (i) indicated resources of 12,000 ounces gold (38,000 tonnes at 9.8g Au/t) and inferred resources of 342,000 ounces gold (913,000 tonnes at 11.6g Au/t) for Area 107; (ii) inferred resources of 73,000 ounces gold and 5,000 tonnes copper (445,000 tonnes at 5.1g Au/t and 1% Cu) for Black Skarn North; and (iii) measured and indicated resources of 203,000 ounces gold and 19,000 tonnes copper (1,426,000 tonnes at 4.4g Au/t and 1.3% Cu) and inferred resources of 17,000 ounces gold and 2,000 tonnes copper (126,000 tonnes at 4.2g Au/t and 1.6% Cu) for the Monica Zone. The underground drill program is on-going and should be completed in September. It is being supervised by Mr. Santiago Gonzalez, Kinbauri Espana's senior geologist with quality control being provided by Dr. C. F. Gleeson, P.Eng., Kinbauri's Vice-President of Exploration: both qualified persons as defined by NI 43-101. Kinbauri has established an Analytical Quality Assurance Program to control and assure the analytical quality of assays. This program includes the systematic addition of a blank sample, a pulp duplicate and a standard to each batch of 20 samples. The samples are obtained from HQ core sawed in half, crushed, pulverized, homogenized and split in Kinbauri's on site facility at El Valle. Samples are sent to ITMA's laboratory in Oviedo, Spain for analyses. In addition 5% of the samples are sent to ALS Chemex's laboratory in Canada for check analyses. Gold assays are carried out on 30 gram splits using fire assay procedures with an atomic absorption finish. This press release was prepared by Dr. V.N. Rampton, P.Eng. in his capacity as a qualified person. About Kinbauri Kinbauri is a mineral exploration company focused on the development of mineral properties, primarily precious metal prospects in northwestern Spain, Nevada and Canada. Its immediate focus is to expand and upgrade resources to reserves at the El Valle property in Asturias, Spain with a view to re-starting operations at the mine and mill complex there, and to establish resources to support a mine and mill at Corcoesto in Galicia, Spain where it has an option to earn a 65 percent interest. It currently has 43,372,320 common shares issued and outstanding; 67,056,236, fully diluted. Effective July 16th, 2007, Kinbauri's classification as a mining company was upgraded to Tier 1 by the TSXV." For more information on Kinbauri Gold Corp., please see the company website: www.kinbauri-gold.com. About Buffalo Gold Buffalo's management is dedicated to maximizing shareholder value through growth strategies that emphasize careful opportunity assessment and vigilant project management. Buffalo is aggressively exploring at the Mt. Kare project in Papua New Guinea where the Company has defined a NI 43-101 compliant indicated resource of 1.4 million ounces of gold at a 1.0g/t gold equivalent cut-off (see Buffalo news release dated June 21st, 2007). Buffalo has a portfolio of gold exploration projects in producing and past-producing regions of Australia and recently vended the Company's Australian uranium properties into Australian uranium explorer Bondi Mining Ltd (ASX: BOM) for a 44% interest in that company. In July 2007, Buffalo announced a merger with Sargold Resource Corporation (TSX VENTURE: SRG), a junior gold miner with mining and exploration projects in Sardinia, Italy. On behalf of the Board of Directors of BUFFALO GOLD LTD. Damien Reynolds, Chair of the Board of Directors and Chief Executive Officer This press release contains certain forward-looking statements, which are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected. Buffalo undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change. The reader is cautioned not to place undue reliance on forward-looking statements. Cautionary Note to U.S. Investors - The United States Securities and Exchange Commission ("SEC") permits mining companies in filings with the SEC to disclose only those mineral deposits that a company can economically and legally extract or produce. The Company uses certain terms in this news release, such as "indicated resource", that the SEC guidelines strictly prohibit from including in filings with the SEC. U.S. investors are urged to consider closely the disclosure contained in the Company's Form 20-F Registration Statement, File No. 000- 30150. The Company's filings are available on the SEC's website at http://www.sec.gov/edgar.shtml. The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy of this press release.